Tumor-specific cleavable linkers

ABSTRACT

The present disclosure provides tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. The present disclosure also provides cleavage products of said drugs and prodrugs, and methods related to the use of the same.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. Provisional Application Ser. No. 63/118,585, filed Nov. 25, 2020; and 63/253,090, filed Oct. 6, 2021; each of which is incorporated herein by reference in its entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 737762003000SEQLIST.TXT, date recorded: Nov. 23, 2021, size: 961 KB).

FIELD

This invention relates to tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. This invention also relates to cleavage products of said drugs and prodrugs, and methods related to the use of the same.

BACKGROUND

Cancer is the second leading cause of death in the United States, accounting for more deaths than the next five leading causes (chronic respiratory disease, stroke, accidents. Alzheimer's disease and diabetes). While great strides have been made especially with targeted therapies, there remains a great deal of work to do in this space. Immunotherapy and a branch of this field, immuno-oncology, is creating viable and exciting therapeutic options for treating malignancies. Specifically, it is now recognized that one hallmark of cancer is immune evasion and significant efforts have identified targets and developed therapies to these targets to reactivate the immune system to recognize and treat cancer.

Cytokine therapy is an effective strategy for stimulating the immune system to induce anti-tumor cytotoxicity. In particular, aldesleukin, a recombinant form of interleukin-2 (IL-2), has been approved by the FDA for the treatment of metastatic renal cell carcinoma and melanoma. Unfortunately, cytokines that are administered to patients generally have a very short half-life, thereby requiring frequent dosing. For instance, the product label of aldesleukin, marketed under the brand name Proleukin, states that the drug was shown to have a half-life of 85 minutes in patients who received a 5-minute intravenous (IV) infusion. In addition, administration of high doses of cytokine can cause adverse health outcomes, such as vascular leakage, through systemic immune activation. These findings illustrate the need for developing therapeutics, such as cytokine therapeutics, that effectively target tumors without the side effects associated with systemic immune activation.

Prodrugs in which a cytokine therapeutic is masked by a masking moiety and in which the therapeutic is only active after cleavage of the masking moiety in the tumor cell environment are one way envisaged for addressing this need.

SUMMARY

This invention provides novel tumor-specific proteolytically cleavable peptide linkers comprising tumor-specific proteolytically cleavable peptides and their use in polypeptide drug constructs for delivering a therapeutic moiety to a tumor cell environment. The part of the construct other than the therapeutic moiety can be considered as a carrier moiety.

The tumor-specific proteolytically cleavable peptide acts as a substrate for protease(s) present in the tumor cell environment. The proteolytically cleavable peptide linker is positioned within the polypeptide drug construct so that the linker cleaves by protease action in the tumor cell environment, and the polypeptide drug construct separates to form cleavage products, one of which will comprise the therapeutic moiety. This invention also relates to cleavage products of said drug constructs, and methods related to the use of the same.

Provided herein is a polypeptide drug construct comprising (i) a therapeutic moiety; (ii) a carrier moiety and (iii) a proteolytically cleavable peptide linker comprising a tumor-specific proteolytically cleavable peptide having an amino acid sequence DLLAVVAAS or ISSGLLSGRS.

In some embodiments, the proteolytically cleavable peptide (CP) is flanked on both sides by a spacer domain (SD1 and SD2) as shown in formula:

SD1-CP-SD2.

In some embodiments, the spacer domains are rich in amino acid residues G, S and P.

In some embodiments, the proteolytically cleavable peptide linker is from 10 to 25 amino acids in length.

In some embodiments, the spacer domains only include amino acid residue types selected from the group consisting of G, S and P.

In some embodiments, the first spacer domain (SD1) is between 3 and 6 amino acids in length.

In some embodiments, the second spacer domain (SD2) is between 3 and 6 amino acids in length.

In some embodiments, SD2 comprises the amino acid sequence SGP.

In some embodiments, SD2 has the amino acid sequence SGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GGPSDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GSGPSDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GSSGGPDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GSPDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GSPGDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable peptide linker comprises sequence

GSGSPSDLLAVVAASSGP.

In some embodiments, the proteolytically cleavable linker comprises sequence

GGSSGGSPISSGLLSGRSSGPGSGS.

In some embodiments, the proteolytically cleavable linker comprises sequence

GPPSGSSPISSGLLSGRSSGGG.

In some embodiments, the proteolytically cleavable linker comprises sequence

GGSGGSISSGLLSGRSSGP.

In some embodiments, the proteolytically cleavable linker comprises sequence

GGSGGSGGSISSGLLSGRSSGP.

In some embodiments, the proteolytically proteolytically cleavable peptide linker is covalently bonded directly to the therapeutic moiety.

In some embodiments, the proteolytically cleavable peptide linker is located within the drug construct between the therapeutic moiety and the carrier moiety.

In some embodiments, the proteolytically cleavable peptide linker is located within the carrier moiety.

In some embodiments, the polypeptide drug construct comprises a single polypeptide chain. This means that the therapeutic moiety, the carrier moiety and the proteolytically cleavable peptide linker are present in the same polypeptide chain.

In some embodiments, the polypeptide drug construct comprises more than one polypeptide chain. In some embodiments, the proteolytically cleavable peptide linker is present in the same polypeptide chain as the therapeutic moiety. In some embodiments, the proteolytically cleavable peptide linker is present in a different polypeptide chain to the therapeutic moiety.

In some embodiments, the polypeptide drug construct is a prodrug. In some embodiments, where the polypeptide drug construct is a prodrug, the remainder of the molecule (away from which the therapeutic moiety separates after cleavage of the proteolytically cleavable peptide linker) comprises a masking moiety, which inhibits the biological activity of the therapeutic moiety in the prodrug such that the therapeutic moiety is biologically active only after cleavage of the proteolytically cleavable peptide linker in the tumor cell environment. In some embodiments, the masking moiety is present in the same polypeptide chain as the therapeutic moiety. In some embodiments, the masking moiety is present in a different polypeptide chain to the therapeutic moiety.

In some embodiments, the masking moiety is present in the same polypeptide chain as the therapeutic moiety.

In some embodiments, the masking moiety is present in a first polypeptide chain and the therapeutic moiety is present in a second polypeptide chain.

In some embodiments, the drug construct comprises a half-life extension moiety.

In some embodiments, the half-life extension moiety comprises an antibody or fragment thereof.

In some embodiments, the half-life extension moiety comprises first and second half-life extension moieties.

In some embodiments, the prodrug is a cytokine prodrug where the therapeutic moiety is a cytokine moiety.

In some embodiments, the masking moiety comprises a domain of the extracellular domain of the cytokine receptor.

A cytokine prodrug as described herein, where the therapeutic moiety is a cytokine moiety and the masking moiety comprises a domain of the extracellular domain of the cytokine receptor is referred to herein as a “masked cytokine”.

Provided herein, in some embodiments, is a masked cytokine comprising a masking moiety in a first polypeptide chain and a cytokine moiety thereof in a second polypeptide chain. Such masked cytokines may be referred to as ‘heterodimeric’ masked cytokines.

In some embodiments, the masked cytokine comprises a protein heterodimer comprising:

-   -   a) a first polypeptide chain comprising a masking moiety linked         to a first half-life extension moiety via a first linker; and     -   b) a second polypeptide chain comprising a cytokine moiety         thereof linked to a second half-life extension moiety via a         second linker,         wherein the first half-life extension moiety is associated with         the second half-life extension moiety, and wherein at least the         first linker or the second linker is a proteolytically cleavable         peptide linker comprising a proteolytically cleavable peptide         (CP) consisting of the amino acid sequence DLLAVVAAS or         ISSGLLSGRS.

In some embodiments, in the first polypeptide chain, the first half life extension domain is linked to the amino terminus of the first linker and the carboxy terminus of the first linker is linked to the amino terminus of the masking moiety and, in the second polypeptide chain, the second half life extension domain is linked to the amino terminus of the second linker and the carboxy terminus of the second linker is linked to the amino terminus of the cytokine moiety thereof.

In some embodiments, the first polypeptide chain comprises:

N′HL1-L1-MM C′

and the second polypeptide chain comprises:

N′HL2-L2-C C′

where HL1 is the first half life extension domain, L1 is the first linker, MM is the masking moiety, HL2 is the second half life extension domain, L2 is the second linker, and C is the cytokine moiety, wherein the first half-life extension moiety is associated with the second half-life extension moiety, and wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.

In some embodiments, the second linker is the proteolytically cleavable linker and the first linker is a non-cleavable linker. This arrangement is described herein as ‘Structure A’.

In some embodiments, the first polypeptide chain comprises:

N′HL1-non-cleavable L1-MM C′

and the second polypeptide chain comprises:

N′H1L2-cleavable L2-C C′

In some embodiments, the first linker is the proteolytically cleavable linker and the second is a non-cleavable linker. This arrangement is described herein as ‘Structure B’.

In some embodiments, the first polypeptide chain comprises:

N′HL1-cleavable L1-MM C′

and the second polypeptide chain comprises:

N′HL2-non-cleavable L2-C C′

Provided herein, in some embodiments, is a masked cytokine comprising a masking moiety and a cytokine moiety thereof linked in a single polypeptide chain. In some embodiments, the masked cytokine comprises a polypeptide chain comprising formula:

N′HL-L2-C-L1-MM C′

where HL is the half-life extension domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety, wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is non-cleavable. The non-cleavable linker may be as described anywhere herein.

In some embodiments, the masked cytokine comprises a polypeptide chain comprising formula:

N′HL-L2-MM-L1-C C′

where HL is the half-life extension domain, L1 is the first linker, MM is the masking moiety. L2 is the second linker, and C is the cytokine moiety thereof, wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is non-cleavable. The non-cleavable linker may be as described anywhere herein.

In some embodiments, the non-cleavable linker is between 3 and 25 amino acids in length.

In some embodiments, wherein the non-cleavable linker is rich in amino acid residues G, S and P.

In some embodiments, the non-cleavable linker comprises an amino acid sequence of SEQ ID NO: 14.

In some embodiments, the non-cleavable linker comprises an amino acid sequence of SEQ ID NO: 23.

In some embodiments, the half-life extension domain comprises a first half life extension domain and a second half life extension domain.

In some embodiments, the first half-life extension domain comprises a first Fc domain or a fragment thereof and the second Fc domain comprises an Fc domain or a fragment thereof.

In some embodiments, the first Fc domain comprises a CH3 domain or a fragment thereof and the second Fc domain comprises a CH3 domain or a fragment thereof.

In some embodiments, the first and second half-life extension domains are each an IgG1 Fc domain or fragment thereof.

In some embodiments, the first and/or second Fc domains each contain one or more modifications that promote the non-covalent association of the first and the second half-life extension domains.

In some embodiments, the first half-life extension domain comprises an IgG1 Fc domain or fragment thereof including the mutations Y349C; T366S; L38A; and Y407V to form a ‘hole’ in the first half-life extension domain and the second half-life extension domain comprises an IgG1 Fc domain or fragment thereof including the mutations S354C and T366W to form the ‘knob’ in the second half-life extension domain, numbered according to the Kabat EU numbering system.

In some embodiments, the first and second half-life extension domains are each an IgG1 Fc domain or fragment thereof and each comprise an amino substitution at position 297, numbered according to the Kabat EU numbering system.

In some embodiments, the first and second half-life extension domains are each an IgG1 Fc domain or fragment thereof and each comprise the amino substitution N297A, numbered according to the Kabat EU numbering system.

In some embodiments, the first and second half-life extension domains are each an IgG1 Fc domain or fragment thereof and each comprise an amino substitution at position 253, numbered according to the Kabat EU numbering system.

In some embodiments, the first and second half-life extension domains are each an IgG1 Fc domain or fragment thereof and each comprise the amino substitution I253A, numbered according to the Kabat EU numbering system.

In some embodiments, the first half-life extension domain comprises the amino acid sequence of SEQ ID NO: 9, and the second half-life extension domain thereof comprises the amino acid sequence of SEQ ID NO: 12.

In some embodiments, the first half-life extension domain comprises the amino acid sequence of SEQ ID NO: 10 and the second half-life extension domain thereof comprises the amino acid sequence of SEQ ID NO: 13.

In some embodiments, the half life extension domain (HL) comprises an Fc region of an antibody (i.e. the C-terminal region of an immunoglobulin heavy chain) or a fragment thereof comprising dimerized Fc domains (HL1-HL2). Although the boundaries of the Fc region of an immunoglobulin heavy chain might 30 vary, the human IgG heavy-chain Fe region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. In some embodiments, the dimerized Fc domains of an antibody (HL1-HL2) comprises a first half life extension domain and a second half life extension domain as described anywhere herein, where the first half-life extension moiety comprises a first Fc domain or a fragment thereof and the second half-life extension moiety comprises a second Fc domain or a fragment thereof. In some embodiments, HL2 is a component of the polypeptide chain and HL1 is dimerized to HL2.

In some embodiments, the first and second half-life extension moieties are each an IgG1 Fc domain or fragment thereof. In some embodiments, the first half-life extension moiety comprises an IgG1 Fc domain or fragment thereof including the mutation I253A and the second half-life extension moiety comprises an IgG1 Fc domain or fragment thereof including the mutation I253A. In some embodiments, the first and second half-life extension moieties are derived from the sequence for human IgG1 Immunoglobulin heavy constant gamma I having SEQ ID NO: 6 (the ‘parent sequence’), such that the first and second half-life extension moieties each comprise SEQ ID NO: 7 or fragment thereof, with one or more amino acid modifications. In some embodiments, the first and second half-life extension moieties comprise SEQ ID NO: 7 with amino substitutions to promote association of the first and second half-life extension moieties according to the ‘knob into holes’ approach. In some embodiments, the sequence SEQ ID NO: 7 contains mutations Y349C; T366S; L38A; and Y407V (numbered according to the Kabat EU numbering system) to form the ‘hole’ in the first half-life extension moiety and mutations S354C and T366W (numbered according to the Kabat EU numbering system) to form the ‘knob’ in the second half-life extension moiety.

In some embodiments, the first and second half-life extension moieties each further comprise amino substitution N297A, numbered according to the Kabat EU numbering system. In some embodiments, the first and second half-life extension moieties each further comprise the amino substitution I253A, numbered according to the Kabat EU numbering system. In some embodiments, the first and second half-life extension moieties each further comprise both the amino substitutions N297A and I253A, numbered according to the Kabat EU numbering system. In some embodiments, the first half-life extension moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of any one of SEQ ID NOs: 7, 8, 9 and 10. In some embodiments, the second half-life extension moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of any one of SEQ ID NOs: 7, 11, 12 and 13.

In some embodiments, the cytokine moiety comprises a wild-type cytokine moiety or variant cytokine moiety.

In some embodiments, the cytokine moiety is an IL-2 cytokine moiety as described anywhere herein.

In some embodiments, the IL-2 cytokine moiety comprises a wild-type IL-2 cytokine moiety or variant thereof.

In some embodiments, the IL-2 cytokine moiety comprises an IL-2 cytokine or fragment thereof.

In some embodiments, the IL-2 cytokine or functional fragment thereof is modified compared to the sequence of a mature IL-2 having SEQ ID NO: 2.

In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises modifications R38A, F42A, Y45A, and E62A relative to the sequence of a mature IL-2 having SEQ ID NO: 2.

In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises the modification C125A relative to the sequence of a mature IL-2 having SEQ ID NO: 2.

In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises R38A, F42A, Y45A, E62A and C125A relative to the sequence of a mature IL-2 having SEQ ID NO: 2.

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 3.

In some embodiments, the masking moiety comprises IL-2Rβ or a fragment, portion or variant thereof.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof comprises an amino acid sequence of SEQ ID NO: 4.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has a mutation at amino acid positions C122 as compared to IL-20 of SEQ ID NO: 4.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has a mutation at amino acid positions C168 as compared to IL-20 of SEQ ID NO: 4.

In some embodiments, the IL-2RH or a fragment, portion or variant thereof has mutations at amino acid positions C122 and C168 as compared to IL-20 of SEQ ID NO: 4.

In some embodiments, the IL-2R or a fragment, portion or variant thereof has mutations C122S and C168S as compared to IL-20 of SEQ ID NO: 4.

In some embodiments, wherein the IL-2Rβ or a fragment, portion or variant thereof comprises an amino acid sequence of SEQ ID NO: 5.

In some embodiments, the cytokine moiety is an IL-12 cytokine moiety as described anywhere herein.

In some embodiments, the IL-12 cytokine moiety comprises a wild-type IL-12 cytokine moiety or variant thereof.

In some embodiments, the IL-12 cytokine moiety comprises an IL-12 cytokine or fragment thereof.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an IL-12p40 polypeptide or functional fragment thereof covalently linked to an IL-12p35 polypeptide or functional fragment thereof.

In some embodiments, the IL-12p40-IL-12p35 linker is between 5 and 20 amino acids in length.

In some embodiments, the IL-12p40-IL-12p35 linker is rich in amino acid residues G and S.

In some embodiments, the IL-12p40-IL-12p35 linker comprises SEQ ID NO: 116 (GGGGSGGGGSGGGGS).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 204 (as shown in the IL-12 Cytokine Moieties table in the description) or an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 204 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 204 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises at least one amino acid modification to the GAG-binding domain (KSKREKKDRV) as compared to the amino acid sequence of SEQ ID NO: 204 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 205 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 206 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitution mutations as compared to the amino acid sequence of SEQ ID NO: 204 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 207 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 208 (as shown in the IL-2 Cytokine Moieties table in the description).

In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO: 209 (as shown in the IL-12 Cytokine Moieties table in the description) or an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 209 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO: 209 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 210 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 211 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 212 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 213 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 214 (as shown in the IL-12 Cytokine Moieties table in the description).

In some embodiments, the masking moiety comprises an IL-12 cytokine receptor, or a subunit or functional fragment thereof.

In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ1 or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12.

In some embodiments, the masking moiety comprises residues 24 to 237 of human IL-12Rβ1, namely a sequence having SEQ ID NO: 215 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises residues 24 to 545 of human IL-12Rβ1, namely a sequence having SEQ ID NO: 216 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ2 or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12.

In some embodiments, the masking moiety comprises residues 24 to 212 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 217 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises residues 24 to 222 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 218 (as shown in the IL-12 Masking Moieties table in the description), or the masking moiety comprises residues 24 to 227 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 222 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises residues 24 to 319 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 219 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises at least one amino acid modification as compared to the sequence of SEQ ID NO: 219 (as shown in the IL-12 Masking Moieties table in the description), optionally wherein said modifications are cysteine substitution mutations.

In some embodiments, the masking moiety comprises SEQ ID NO: 220 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises residues 24 to 622 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 221 (as shown in the IL-12 Masking Moieties table in the description).

In some embodiments, the cytokine moiety is an IL-15 cytokine moiety as described anywhere herein.

In some embodiments, the IL-15 cytokine moiety comprises a wild-type IL-15 cytokine moiety or variant thereof.

In some embodiments, the cytokine moiety is an IL-15 cytokine moiety and the masked cytokine further comprises a domain comprising an IL-15Rα subunit or a functional fragment thereof (‘IL-15Rα domain’). In some embodiments, the cytokine moiety is an IL-15 cytokine moiety and the masked cytokine further comprises a domain comprising an IL-15Rα subunit or a functional fragment thereof (‘IL-15Rα domain’), and the IL-15Rα domain and the IL-15 cytokine moiety are present in different polypeptide chains in the construct and the IL-15Rα domain is non-covalently linked to the IL-15 cytokine moiety.

The ‘IL-15Rα domain’ herein can consist of the sequence of the wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of the wild-type sushi domain sIL-15Rα with one or more e.g. 1, 2, 3 or 4 amino acid substitutions. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R26. In some embodiments, the IL-15Rα domain comprises amino acid substitution R26N. In some embodiments, the IL-15Rα domain comprises amino acid substitution R26S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R35. In some embodiments, the IL-15Rα domain comprises amino acid substitution R35Q. In some embodiments, the IL-15Rα domain comprises amino acid substitution R35S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at positions R26 and R35. In some embodiments, the IL-15Rα domain comprises amino acid substitutions R26S or R26N, and R35Q or R35S. In some embodiments, the IL-15Rα domain comprises amino acid substitutions R26N and R35Q.

In some embodiments, the IL-15 cytokine moiety comprises an IL-15 cytokine or fragment thereof.

In some embodiments, the IL-15 cytokine or fragment thereof comprises SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description) or a functional fragment thereof.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53, N71, N79, or N112 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71 and N79 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N79 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71. N79 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 225 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 226 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 227 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence 20 of SEQ ID NO: 228 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 229 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 230 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 233 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 234 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 235 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 236 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 237 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 238 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 239 (as shown in the IL-15 Cytokine Moieties table in the description).

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an additional mutation at position N71.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an additional mutation at position S73.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an additional mutation at one or more of amino acid positions N72, N79, V80, T81, and N112.

In some embodiments, the masking moiety comprises IL-15Rβ or a fragment or variant thereof.

In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 (as shown in the IL-15 Masking Moieties table in the description).

In some embodiments, the masking moiety comprises IL-15Rβ variant or a fragment thereof having an amino acid substitution at position C122.

In some embodiments, the masking moiety comprises IL-15Rβ variant or a fragment thereof having amino acid substitution C122S.

In some embodiments, the masking moiety comprises IL-15Rβ variant or a fragment thereof having an amino acid substitution at position C168.

In some embodiments, the masking moiety comprises IL-15Rβ variant or a fragment thereof having amino acid substitution C168S.

In some embodiments, the masking moiety comprises IL-15Rβ variant or a fragment thereof having an amino acid substitution at positions C122 and C168.

Provided herein is a cleavage product capable comprising an active therapeutic moiety, preparable by proteolytic cleavage of the proteolytically cleavable linker in the polypeptide drug constructs as described anywhere herein.

Provided herein is a nucleic acid encoding any one of the polypeptide drug constructs as described anywhere herein described herein.

Provided herein is a nucleic acid encoding one of the chains of any one of the polypeptide drug constructs as described anywhere herein described herein.

Provided herein is a vector comprising a nucleic acid described herein.

Provided herein is a vector comprising a nucleic acid encoding a polypeptide drug construct as described anywhere herein described herein.

Provided herein is a vector comprising a nucleic acid encoding one of the chains of a polypeptide drug constructs as described anywhere herein described herein.

Provided herein is a host cell comprising a nucleic acid described herein.

In one embodiment, the host cell is a HEK cell. In another embodiment, the host cell is a CHO cell.

Provided herein is a composition comprising any one of the polypeptide drug constructs as described anywhere herein described herein.

Provided herein is a pharmaceutical composition comprising any one of the polypeptide drug constructs as described anywhere herein described herein, and a pharmaceutically acceptable carrier.

Provided herein is a kit comprising any one of the polypeptide drug constructs as described anywhere herein, or the compositions, or the pharmaceutical compositions described herein.

Provided herein is a method of producing any one of the polypeptide drug constructs as described anywhere herein, comprising culturing a host cell described herein under a condition that produces the polypeptide drug construct.

Provided herein is a nucleic acid encoding any one of the cleavage products described herein.

Provided herein is a composition comprising any one of the cleavage products described herein.

Provided herein is a pharmaceutical composition comprising any one of the cleavage products described herein, and a pharmaceutically acceptable carrier.

Provided herein is a polypeptide drug construct as described herein for use in medicine.

Provided herein is a cleavage product as described herein for use in medicine.

Provided herein is a method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a polypeptide drug construct as described herein.

Provided herein is a method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a composition as described herein.

Provided herein is a method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described herein.

Provided herein is a method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a polypeptide drug construct as described herein, whereby the polypeptide drug construct is proteolytically cleaved in vitro to produce a cleavage product as described herein.

Provided herein is a method of treating or preventing cancer in a subject, the method comprising a step of producing a cleavage product in vivo that is capable of binding to its target protein, where the cleavage product is as described herein.

Provided herein is a polypeptide drug construct as described herein for use in treating or preventing cancer.

Provided herein is a polypeptide drug construct as described herein for use in a method of treating or preventing cancer, the method comprising administering to the subject an effective amount of the polypeptide drug construct, whereby the polypeptide drug construct is proteolytically cleaved in vivo to produce a cleavage product as described herein.

Provided herein is a cleavage product as described herein for use in treating or preventing cancer.

Provided herein is a cleavage product as described herein for use in treating or preventing cancer, the method comprising a step of administering a polypeptide drug construct as described herein to a patient, thereby producing the cleavage product by proteolytic cleavage of the masked cytokine in vivo.

Provided herein is a cleavage product as described herein for use in a method of treating or preventing cancer in a subject, the method comprising a step of producing the cleavage product by in vivo proteolytic cleavage from a polypeptide drug construct as described herein that has been administered to the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the structure of exemplary embodiments of a masked cytokine that includes a masking moiety, a cytokine or functional fragment thereof (“cytokine”), a half-life extension moiety, and a first linker that includes a first cleavable peptide (“ICP”), a first N-terminal spacer domain (“INSD”), and a first C-terminal spacer domain (“ICSD”). These exemplary embodiments also include a second linker that includes a second cleavable peptide (“2CP”), a second N-terminal spacer domain (“2NSD”), and a second C-terminal spacer domain (“2CSD”). As shown by the arrows, while the exemplary embodiments shows the masking moiety linked to the first linker, and the cytokine or functional fragment thereof is linked to the first linker and the second linker, the masking moiety and the cytokine or functional fragment thereof can be interchanged such that the cytokine or functional fragment thereof is linked to the first linker, and the masking moiety is linked to the first linker and the second linker. FIG. 1 shows the structure of an exemplary embodiment of a masked cytokine as a monomer.

FIG. 2 shows the structure of an exemplary embodiment of a masked cytokine that includes a masking moiety, a cytokine or functional fragment thereof (“cytokine”), a first half-life extension moiety, and a second half-life extension moiety. The exemplary embodiment shown in FIG. 2 also includes a first linker that includes a first cleavable peptide (“ICP”), a first N-terminal spacer domain (“INSD”), and a first C-terminal spacer domain (“ICSD”), and a second linker that includes a second cleavable peptide (“2CP”), a second N-terminal spacer domain (“2NSD”), and a second C− terminal spacer domain (“2CSD”). The exemplary first and second half-life extension moieties include “knobs into holes” modifications that promote the association of the first half-life extension moiety with the second half-life extension moiety, as shown by the “hole” in the first half-life extension moiety and the “knob” in the second half-life extension moiety. The first half-life extension moiety and the second half-life extension moiety are also shown as associating, at least in part, due to the formation of disulfide bonds. It is to be understood that although the “hole” is depicted as part of the first half-life extension moiety (linked to the masking moiety) and the “knob” is depicted as part of the second half-life extension moiety (linked to the cytokine), the “hole” and the “knob” can alternatively be included in the second half-life extension moiety and the first half-life extension moiety, respectively, so that the “hole” is a part of the second half-life extension moiety (linked to the cytokine) and the “knob” is part of the first half-life extension moiety (linked to masking moiety).

FIGS. 3A-B shows exemplary embodiments of masked cytokines prior to (left) and after (right) cleavage by a protease, such as at the tumor microenvironment. FIGS. 3A-B show exemplary embodiments of a masked IL-2 cytokine. Cleavage by a protease releases a masking moiety (e.g., IL-2Rβ, as shown in FIG. 38 ), or releases an IL-2 (FIG. 3A).

FIG. 4 shows SDS-PAGE analysis on flow-through (FT) samples (i.e., proteins that did not bind to the Protein A column) and the eluted (E) samples (i.e., proteins that bound to the Protein A column and were eluted from it) following production and purification of IL-2 constructs (AK304, AK305, AK307, AK308, AK309, AK310, AK311, AK312, AK313, AK314, and AK315).

FIG. 5A-D shows results from SPR analysis that tested the binding of an exemplary masked IL-2 polypeptide construct (AK168), or a rhIL-2 control, to CD25-Fc. FIG. 5A shows the interaction between AK168 and CD25-Fc, FIG. 5 shows the interaction between AK168 activated with MMP and CD25-Fc. and FIG. 5C shows the interaction between a recombinant human IL-2 (rhIL2) control and CD25-Fc. FIG. 5D provides a table summarizing the data obtained for the association constant (ka), dissociation constant (kd), equilibrium dissociation constant (KD), as well as the Chi2 value and U-value for each interaction.

FIGS. 6A-D shows results from SPR analysis that tested the binding of an exemplary masked IL-2 polypeptide constructs (AK111), or a rhIL2 control, to CD122-Fc. FIG. 6A shows the interaction between AK111 and CD122-Fc. FIG. 6B shows the interaction between AK111 activated with protease and CD122-Fc, and FIG. 6C shows the interaction between a recombinant human IL-2 (hIL-2) control and CD122-Fc. FIG. 6D provides a table summarizing the data obtained for the association constant (ka), dissociation constant (kd), equilibrium dissociation constant (KD), as well as the Chi2 value and U− value for each interaction.

FIG. 7A shows an exemplary embodiment of a masked cytokines prior to (left) and after (right) cleavage by a protease, such as at the tumor microenvironment. FIG. 7B shows SDS-PAGE analysis of an exemplary masked IL-2 polypeptide construct that was incubated in the absence (left lane) or presence (right lane) of the MMP10 protease, which demonstrates the release of IL-2 from the Fe portion.

FIGS. 8A-D shows STAT5 activation (%) in PBMCs treated with the construct AK032, AK035, AK041, or rhIL-2 as a control. The levels of STAT5 activation (%) are shown for NK cells. CD8+ T cells, effector T cells (Teff), and regulatory T cells (Treg), as determined following incubation with rhIL-2 (FIG. 8A), AK032 (FIG. 8B). AK035 (FIG. 8C), or AK041 (FIG. 8D).

FIGS. 9A-C shows STAT5 activation (%) in PBMCs treated with the construct AK081 or AK032. The AK081 construct with and without prior exposure to MMP10 was tested. An isotype control as well as a no IL-2 negative control was also tested. The levels of STAT5 activation (%) are shown for NK cells (FIG. 9A), CD8+ T cells (FIG. 9C), and CD4+ T cells (FIG. 9B).

FIGS. 10A-10D shows the results from STAT5 activation studies in PBMCs using constructs AK081 and AK111, as well as controls that included an rhIL-2 and anti-RSV antibody. A no-treatment control was also tested. EC50 (pM) is also shown for the rhIL-2, AK081, and AK111 treatments. STAT5 activation (%) is shown for CD4+FoxP3+CD25+ cells (FIG. 10A), CD8+ cells (FIG. 10B), and CD4+FoxP3−CD25− cells (FIG. 10C). FIG. 10D provides EC50 (pM) and fold-change data for the AK081, AK111 constructs, as well as the rhIL-2 control.

FIGS. 11A-D shows the results from STAT5 activation studies in PBMCs using constructs AK167 and AK168, as well as controls that included an rhIL-2 and anti-RSV antibody. A no-treatment control was also tested. EC50 (pM) is also shown for the rhIL-2, AK167, and AK168 treatments. STAT5 activation (%) is shown for CD4+FoxP3+CD25+ cells (FIG. 11A), CD8+ cells (FIG. 11B), and CD4+FoxP3−CD25− cells (FIG. 11C). FIG. 11D provides EC50 (pM) and fold-change data for the AK167 and AK168 constructs, as well as the rhIL-2 control.

FIGS. 12A-12D shows STAT5 activation (%) in PBMCs treated with the construct AK165 or AK166, or an isotype control or an IL-2-Fc control, that were (+MMP10) or were not previously exposed to the MMP10 protease. The key as shown in FIG. 12A also applies to FIG. 12B, and the key as shown in FIG. 12C also applies to FIG. 12D. STAT5 activation (%) is shown for CD4+FoxP3+T regulatory cells (FIG. 12A), CD4+FoxP3− T helper cells (FIG. 12B), CD8+ cytotoxic T cells (FIG. 12C), and CD56+NK cells (FIG. 12D).

FIGS. 13A-13C shows STAT5 activation (%) in PBMCs treated with the construct AK109 or AK1110, or an isotype control or an IL-2-Fc control, that were (+MMP10) or were not previously exposed to the MMP10 protease. The key as shown in FIG. 12B also applies to FIG. 13A. STAT5 activation (%) is shown for NK cells (FIG. 13A), CD8 cells (FIG. 13B), and CD4 cells (FIG. 17C).

FIGS. 14A-14D shows the results from STAT5 activation studies in PBMCs using the constructs AK211, AK235, AK253, AK306, AK310, AK314, and AK316, as well as an rhIL-2 control. STAT5 activation (%) is shown for CD3+CD4+FoxP3+ cells (FIG. 14A). CD3+CD4+FoxP3− cells (FIG. 14B), and CD3+CD8+ cells (FIG. 14C). FIG. 14D provides EC50 data for each of the tested constructs as well as the rhIL-2 control.

FIGS. 15A-15D shows the results from STAT5 activation studies in PBMCs using the constructs AK081, AK167, AK216, AK218, AK219, AK220, and AK223 that have been activated by protease, as well as an rhIL-2 control. STAT5 activation (%) is shown for CD4+FoxP3+CD25+ regulatory T cells (FIG. 15A), CD4+FoxP3−CD25− cells (FIG. 15B), and CD8+ cells (FIG. 15C). FIG. 15D provides EC50 data for each of the tested constructs as well as the rhIL-2 control.

FIGS. 16A-16C shows STAT5 activation (%) in PBMCs treated with the construct AK081, AK189, AK190, or AK210, or an anti-RSV control. The key as shown in FIG. 16A also applies to FIGS. 16B and 16C. STAT5 activation (%) is shown for regulatory T cells (FIG. 16A), CD4 helper T cells (FIG. 16B), and CD8 cells (FIG. 16C).

FIGS. 17A-17C shows STAT5 activation (%) in PBMCs treated with the construct AK167, AK191, AK192, or AK193, or an anti-RSV control. The key as shown in FIG. 17A also applies to FIGS. 17B and 17C. STAT5 activation (%) is shown for regulatory T cells (FIG. 17A), CD4 helper T cells (FIG. 17B), and CD8 cells (FIG. 17C).

FIGS. 18A-18D show results from pharmacokinetic studies carried out in tumor-bearing mice using the construct AK032, AK081, AK111, AK167, or AK168, or an anti-RSV control. FIG. 15A provides a simplistic depiction of the structure of each of the constructs tested. FIG. 18B shows Fc levels in plasma (μg/mL) by detecting human IgG, FIG. 18C shows Fc-CD122 levels in plasma (μg/mL) by detecting human CD122, and FIG. 18D shows Fc-IL2 levels in plasma (μg/mL) by detecting human IL-2. Prior to the detection step, an anti-human IG was used as the capture antibody.

FIGS. 19A-19D show results from pharmacokinetic studies carried out in tumor-bearing mice using the construct AK167, AK191 AK197, AK203, AK209, or AK211, or an anti-RSV control. FIG. 19A provides a simplistic depiction of the structure of each of the constructs tested. FIG. 19B shows Fc levels in plasma (μg/mL) by detecting human IgG, FIG. 19C shows Fc-IL2 levels in plasma (μg/mL) by detecting human IL-2, and FIG. 19D shows Fc-CD122 levels in plasma (μg/mL) by detecting human CD122. Prior to the detection step, an anti-human IG was used as the capture antibody.

FIGS. 20A-20L shows results from studies testing the in vivo responses of CD4, CDR. NK, and Treg percentages in spleen, blood, and tumor, using the AK032, AK081, AK111, AK167, or AK168 construct, or an anti-RSV IgG control. For spleen tissue,% CDR cells of CD3 cells (FIG. 20A), % CD4 of CD3 cells (FIG. 20B), % NK cells of CD3− cells (FIG. 20C). % FoxP3 of CD4 cells (FIG. 20D) is shown. For blood. % CD8 cells of CD3 cells (FIG. 20E), % CD4 of CD3 cells (FIG. 20F), % NK cells of CD3− cells (FIG. 20G), % FoxP3 of CD4 cells (FIG. 20H) is shown. For tumor tissue, % CDR cells of CD3 cells (FIG. 20I). % CD4 of CD3 cells (FIG. 20J), % NK cells of CD3− cells (FIG. 20K). % FoxP3 of CD4 cells (FIG. 20L) is shown.

FIGS. 21A-21L shows results from studies testing the in vivo responses of CD4. CD8, NK, and Treg percentages in spleen, blood, and tumor, using the AK167, AK168, AK191, AK197, AK203, AK209, or AK211 construct, or an anti-RSV IgG control. For spleen tissue, % CDR cells of CD3 cells (FIG. 21A), % CD4 of CD3 cells (FIG. 21B). % NK cells of CD3− cells (FIG. 21C), % FoxP3 of CD4 cells (FIG. 21D) is shown. For blood, % CD8 cells of CD3 cells (FIG. 21E), % CD4 of CD3 cells (FIG. 21F), % NK cells of CD3− cells (FIG. 21G). % FoxP3 of CD4 cells (FIG. 21H) is shown. For tumor tissue. % CD8 cells of CD3 cells (FIG. 21I). % CD4 of CD3 cells (FIG. 21J), % NK cells of CD3− cells (FIG. 21K), % FoxP3 of CD4 cells (FIG. 21L) is shown.

FIGS. 22A-22L shows results from studies testing the in vivo responses of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumor, using the AK235, AK191, AK192, AK193, AK210, AK189, AK190, or AK211 construct, or an anti-RSV IgG control. For spleen tissue, % CD8 cells of CD3 cells (FIG. 22A), % CD4 of CD3 cells (FIG. 22B). % NK cells of CD3− cells (FIG. 22C). % FoxP3 of CD4 cells (FIG. 22D) is shown. For blood, % CD8 cells of CD3 cells (FIG. 22E), % CD4 of CD3 cells (FIG. 22F), % NK cells of CD3− cells (FIG. 22G).% FoxP3 of CD4 cells (FIG. 22H) is shown. For tumor tissue, % CD8 cells of CD3 cells (FIG. 22I), % CD4 of CD3 cells (FIG. 22J), % NK cells of CD3− cells (FIG. 22K), % FoxP3 of CD4 cells (FIG. 22L) is shown.

FIGS. 23A-23I show results from in vivo T cell activation in spleen, blood, and tumor, using the AK235, AK191, AK192, AK193, AK210, AK189, AK190, or AK211 construct. T cell activation was measured as the mean fluorescence intensity (MFI) of CD25 in CD8+ T cells (FIG. 23A; FIG. 23I); FIG. 23G), CD4+ T cells (FIG. 23B; FIG. 23E; FIG. 23H), or Foxp3+ cells (FIG. 23C; FIG. 23F; FIG. 23I) in the spleen, blood, and tumor. Statistical analysis was performed using One-way ANOVA as compared to the non-cleavable AK211 construct.

FIG. 24A-24D show the results from studies testing the in vivo cleavage of the exemplary masked IL-2 polypeptide constructs AK168 (cleavable peptide sequence: MPYDLYHP; SEQ ID NO: 24) and AK209 (cleavable peptide sequence: VPLSLY; SEQ ID NO: 28). FIG. 24E shows results from a pharmacokinetic study of total plasma IgG concentration (μg/mL) for total levels of the AK167, AK168, and AK209 constructs, and for levels of non-cleaved forms of each construct.

FIGS. 25A-25D shows results from an in vivo study that assessed vascular leakage using the exemplary masked IL-2 polypeptide construct AK111 or AK168, or the non-masked IL-2 polypeptide construct AK081 or AK167, or an anti-RSV control. FIG. 25A shows the percentage (%) of body weight loss, and FIGS. 25B, 25C, and 25D shows the weight in grams of the liver, lung, and spleen, respectively, for each.

FIGS. 26A and 26B shows results from an in vivo study that assessed vascular leakage as indicated by measuring the extent of dye leakage into liver and lung tissue following administration of the AK081, AK111, AK167, or AK168 construct, or an anti-RSV control. The extent of dye leakage into liver (FIG. 26A) and lung (FIG. 26B) was measured based on absorbance at 650 nm.

FIGS. 27A and 27B shows results from an in vivo study that assessed vascular leakage as indicated by measuring the extent of mononuclear cell perivascular invasion into the liver and lung tissue following administration of the AK081, AK111, AK167, or AK168 construct, or an anti-RSV control. The average number of mononuclear cells in the liver (FIG. 27A) and the average number of mononuclear cells in the lung (FIG. 27B) depicted for each.

FIGS. 28A and 28B show results from a syngeneic tumor model study that assessed tumor volume and body weight over the course of treatment with the AK032, AK081, AK111, AK167, or AK168 construct, or an anti-RSV control. FIG. 28A shows data on tumor volume over the course of treatment, and FIG. 28B shows data on the percentage (%) change in body weight over the course of the treatment.

FIGS. 29A and 29B shows AK471 with I253A FcRn mutation induced robust CD8 T cells expansion in the TME while remaining inactive in the periphery.

FIGS. 30A-30C shows AK471 has slightly shorter half-life compared to a glyco-hIgG1 FIGS. 31A-31C shows there is no evidence of cleavage or decapitation with AK471 in the plasma FIGS. 32A and 32B show results of Example 5.

FIGS. 33A-33D show results of Example 5.

FIGS. 34A and 34B shows results of Example 6i. FIGS. 35A and 35B show results of Example 6ii. FIGS. 36A and 36B show results of Example 6iii. FIGS. 37A and 37B show results of Example 6iv. FIGS. 38A and 38B show results of Example 6v. FIGS. 39A and 39B show results of Example 6vi. FIGS. 40A-40D show results of Example 6vii. FIGS. 41A and 41B show results of Example 6viii. FIGS. 42A and 42B show results of Example 6ix. FIGS. 43A and 43B show results of Example 6x.

FIGS. 44A-D and FIG. 45A-F shows the results of a SDS-PAGE and HEK-Blue IL-2 bioassay using exemplary IL-15 constructs AK904 and AK910 that do not include a peptide substrate, and constructs AK932, AK938, AK930 and AK936 that do include a peptide substrate. FIGS. 44A-D shows the SDS-PAGE gel results. FIGS. 45A-F show the HEK-Blue IL-2 bioassay results.

FIGS. 46 to 54E show the results from Example 9.

FIG. 55 to 65 show the results from Example 10.

FIGS. 55A-D show results from pharmacokinetic studies carried out in CT26 tumor-bearing mice using the construct AK904, AK910, AK930 or AK936. FIG. 55A shows the percentage (%) of body weight loss.

FIG. 5B shows the volume in mm3 of tumor, and FIGS. 55C and D show the weight in grams of the lung and spleen, respectively, five days after treatment. Statistical analysis was performed using One-way ANOVA as compared to the vehicle group (*P<0.05; **P<0.01; *P<0.001; ****P<0.0001).

FIGS. 56A-C shows results from studies testing the in vivo responses of NK cells as percentages of CD45+ cells in blood, spleen, and tumor.

FIGS. 57A-C shows results from studies testing the in vivo responses of NK cell proliferation as MFI of Ki67 in blood, spleen, and tumor.

FIGS. 58A-C shows results from studies testing the in vivo responses of CD8 T cells as percentages of CD45+ cells in blood, spleen, and tumor.

FIGS. 59A-C shows results from studies testing the in vivo responses of CD8 T cell proliferation as MF1 of Ki67 in blood, spleen, and tumor.

FIGS. 64A-C shows results from studies testing the in vivo responses of CD8/Treg ratio in blood, spleen, and tumor.

FIGS. 61A-D show results from pharmacokinetic studies carried out in B16F10 tumor-bearing mice using the construct AK904, AK910, AK930 and AK936. FIG. 61A shows the percentage (%) of body weight loss, FIG. 60B shows the volume in mm3 of tumor, and FIGS. 61C and D show the weight in grams of the lung and spleen, respectively, five days after treatment. Statistical analysis was performed using One-way ANOVA as compared to the vehicle group (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

FIGS. 62A-D show results from pharmacokinetic studies carried out, as described Example 10, in B16F10 tumor-bearing mice using the construct AK904, AK910, AK930 and AK936. FIG. 62A shows Fc levels in plasma (ng/mL) by detecting human IgG. FIGS. 62B-D show the half-life, Cmax, and AUC(0-last) calculated by WinNonlin software from the results in FIG. 62A.

FIGS. 63A-C shows results from studies testing the in vivo responses of NK cells as percentages of CD45+ cells in blood, spleen, and tumor.

FIGS. 64A-C shows results from studies testing the in vivo responses of CD8 T cells as percentages of CD45+ cells in blood, spleen, and tumor.

FIGS. 65A-C shows results from studies testing the in vivo responses of CD8/Treg ratio in blood, spleen, and tumor.

FIGS. 66 and 67 shows results from Example 11.

FIG. 68 shows the constructs used in Example 4.

FIG. 69 shows the constructs used in Example 8.

FIG. 70 shows the flowchart for HEK-Blue IL-2 bioassay, as described in Example 8.

FIG. 71A-FIG. 71Q shows the constructs in Example 9.

FIG. 72 shows the flowchart used in ex vivo cleavage assay.

FIG. 73 shows schematic diagrams of positive controls unmasked AK904 (FIG. 73A) and cleavage control: masked, non-cleavable AK910 (FIG. 73B) as used in Example 10.

FIG. 74 shows schematic diagrams of masked cleavable molecules used in Example 10, cytokine-substrate construct: AK930 is shown in FIG. 74A, and mask-substrate construct: AK936 is shown in FIG. 74B.

FIG. 75 shows schematic diagram of the construct as used in Example 11.

FIG. 76A shows flowchart detailing the process of ex vivo human tumor cleavage assay. FIG. 76B shows flow-chart for evaluation of AK923 cleavage by various tumor cells.

DETAILED DESCRIPTION 1. Polypeptide Drug Constructs

This invention provides novel tumor-specific proteolytically cleavable peptide linkers and their use in polypeptide drug constructs for delivering a therapeutic moiety to a tumor cell environment. The proteolytically cleavable peptide linker is positioned within the polypeptide drug construct so that when the linker cleaves by protease action in the tumor cell environment, the polypeptide drug construct separates. This invention also relates to cleavage products of said drug constructs, and methods related to the use of the same.

Protease substrate amino acid sequences DLLAVVAAS and ISSGLLSGRS have been found to demonstrate very specific cleavage in the tumor cell environment compared to non-tumor cell environment. Thus, these proteolytically cleavable peptides advantageously can be used in proteolytically cleavable peptide linkers in polypeptide drug constructs, wherein any systemic side effects of the administered protein therapeutic may be reduced.

The proteolytically cleavable peptide linker may be bonded directly or indirectly to the therapeutic moiety within the polypeptide drug construct. Where the polypeptide drug construct comprises more than one polypeptide chain, the proteolytically cleavable peptide linker may be present in the same polypeptide chain as the therapeutic moiety or in a different polypeptide chain.

The part of the construct other than the therapeutic moiety can be considered as a carrier moiety. Where the proteolytically cleavable peptide linker is covalently bonded directly to the therapeutic moiety, the proteolytically cleavable peptide linker will be located within the drug construct between the therapeutic moiety and the carrier moiety. Alternatively, the proteolytically cleavable peptide linker may be located within the carrier moiety such that the molecule that separates away after cleavage comprises the therapeutic moiety and a part of the carrier moiety.

The polypeptide drug construct comprising the tumor-specific proteolytically cleavable peptide linkers may be a prodrug. Where the tumor-specific cleavable linker is used in a prodrug for delivering a therapeutic moiety to a tumor cell environment, the remainder of the molecule from which the therapeutic moiety separates away after cleavage may comprise a masking moiety, which inhibits the biological activity of the therapeutic moiety in the prodrug such that the therapeutic moiety is biologically active only after cleavage of the proteolytically cleavable peptide linker in the tumor cell environment. The masking moiety may be present in the same polypeptide chain as the therapeutic moiety. Alternatively, the masking moiety may be present in a first polypeptide chain and the therapeutic moiety may be present in a second polypeptide chain. The proteolytically cleavable peptide linker may be present in the first or second polypeptide chain.

By using a masking moiety, the systemic side effects of an administered protein therapeutic can be reduced by interfering with the binding capability of the therapeutic. By masking the therapeutic using a proteolytically cleavable peptide linker, the binding capability that is interfered with by using the masking moiety can be restored by cleavage of the proteolytically cleavable peptide linker at the tumor microenvironment. Thus, the prodrugs provided herein are engineered to precisely target pharmacological activity to the tumor microenvironment by exploiting one of the hallmarks of cancer, high local concentrations of active protease. This feature of the tumor microenvironment is used to transform a systemically inert molecule into a locally active molecules in the form of a cleavage product. Activation of the therapeutic moiety at the tumor microenvironment significantly reduces systemic toxicities that can be associated with drugs that are administered to a subject in active form.

In some embodiments, the drug construct provided herein comprises half-life extension moiety. A long half-life in vivo is important for therapeutic proteins. Unfortunately, therapeutics that are administered to a subject can have a short half-life since they are normally cleared rapidly from the subject by mechanisms including clearance by the kidney and endocytic degradation. Thus, in the drug constructs provided herein, a half-life extension moiety may be included for the purpose of extending the half-life of the therapeutic moiety in vivo.

Proteolytically Cleavable Peptide Linkers

The proteolytically cleavable peptide linkers described herein comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.

In some embodiments, the proteolytically cleavable peptide linker is from 9 to 25 amino acids in length.

In some embodiments, the proteolytically cleavable peptide linker is from 10 to 25 amino acids in length.

In some embodiments, the proteolytically cleavable peptide linker is from 12 to 18 amino acids in length.

In some embodiments, the proteolytically cleavable peptide linker comprises a proteolytically cleavable peptide (CP) flanked on both sides by a spacer domain (SD1 and SD2) as shown below:

SD1-CP-SD2

In some embodiments, the proteolytically cleavable peptide (CP) consists of the amino acid sequence DLLAVVAAS.

In some embodiments, the proteolytically cleavable peptide (CP) consists of the amino acid sequence ISSGLLSGRS.

A spacer domain may consist of one or more amino acids. The function of the spacer domains, where present, is to link the proteolytically cleavable peptide (CP) to the other functional components in the constructs described herein.

It will be understood that spacer domains do not alter the biological interaction of the proteolytically cleavable peptide with proteases in the tumor-cell environment or in non-tumor cell environment. In other words, even in the presence of spacer domains the inventive proteolytically cleavable peptides disclosed herein retain their advantageous tumor specificity.

In some embodiments, the spacer domains flanking the proteolytically cleavable peptide are different.

In some embodiments, the spacer domains are rich in amino acid residues G, S and P.

In some embodiments, the spacer domains only includes amino acid residue types selected from the group consisting of G, S and P.

In some embodiments, the first spacer domain (SD1) is between 3 and 10 amino acids in length. In some embodiments, the first spacer domain (SD1) is between 4 and 9 amino acids in length. In some embodiments, the first spacer domain (SD1) is between 3 and 6 amino acids in length.

Exemplary SD1 sequences are shown below:

Sequence of SDI GGPS GSGPS GSSGGP GSP GSGSPS

In some embodiments, the first spacer domain (SD1) has a sequence as shown in the table above.

In some embodiments, the C-terminus sequence of SD2 is −GP C′.

In some embodiments, the sequence of the C-terminus of SD2 is SEQ ID NO: 29.

In some embodiments, the second spacer domain (SD2) is between 3 and 6 amino acids in length.

In some embodiments, SD2 comprises the amino acid sequence SGP.

In some embodiments, SD2 has the amino acid sequence SGP.

Exemplary combinations of SD1 and SD2 in a cleavable linker are shown below:

Linker structure SD1 sequence SD2 sequence SD1-CP-SD2 GGPS SGP SD1-CP-SD2 GSGPS SGP SD1-CP-SD2 GSSGGP SGP SD1-CP-SD2 GSP SGP SD1-CP-SD2 GSGSPS SGP

In some embodiments, the second spacer domain (SD2) has a sequence as shown in the table above.

In some embodiments, the proteolytically cleavable linker comprises SD1-CP-SD2 where SD1 is a first S spacer domain, CP is a cleavable peptide having an amino acid sequence DLLAVVAAS, and SD2 is a second spacer domain. In some embodiments, the spacer domains are rich in amino acid residues G, S and P. In some embodiments, the spacer domains only include amino acid residue types selected from the group consisting of G, S and P. In some embodiments, SD2 has the amino acid sequence SGP.

In some embodiments, the proteolytically cleavable linker comprises SD1-CP-SD2 where SD1 is a first spacer domain, CP is a cleavable peptide having an amino acid sequence ISSGLLSGRS, and SD2 is a second spacer domain. In some embodiments, the spacer domains are rich in amino acid residues G, S and P. In some embodiments, the spacer domains only include amino acid residue types selected from the group consisting of G, S and P. In some embodiments, SD2 has the amino acid sequence SGP.

Exemplary cleavable linkers using the DLLAVVAAS cleavage peptide are shown below:

Cleavable linker sequence (cleavable peptide shown in bold) GGPSDLLAVVAASSGP GSGPSDLLAVVAASSGP GSSGGPDLLAVVAASSGP GSPDLLAVVAASSGP GSPGDLLAVVAASSGP GSGSPSDLLAVVAASSGP SGSDLLAVVAASSGPGSG SGSPSGDLLAVVAASSGPGSGSP

In some embodiments, the cleavable linker comprises sequence GGPSDLLAVVAASSGP.

In some embodiments, the cleavable linker comprises sequence GSGPSDLLAVVAASSGP.

In some embodiments, the cleavable linker comprises sequence GSSGGPDLLAVVAASSGP.

In some embodiments, the cleavable linker comprises sequence GSPDLLAVVAASSGP.

In some embodiments, the cleavable linker comprises sequence GSPGDLLAVVAASSGP.

In some embodiments, the cleavable linker comprises sequence GSGSPSDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GGPSDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GSGPSDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GSSGGPDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GSPDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GSPGDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence GSGSPSDLLAVVAASSGP.

In some embodiments, the cleavable linker has a sequence SGSDLLAVVAASSGPGSG.

In some embodiments, the cleavable linker has a sequence SGSPSGDLLAVVAASSGPGSGSP.

Exemplary cleavable linkers using the ISSGLLSGRS cleavage peptide are shown below:

Cleavable Sinker sequence (cleavable peptide shown in bold) GGSSGGSPISSGLLSGRSSGPGSGS GPPSGSSPISSGLLSGRSSGGG GGSGGSISSGLLSGRSSGP GGSGGSGGSISSGLLSGRSSGP

In some embodiments, the cleavable linker has a sequence GGSSGGSPISSGLLSGRSSGPGSGS.

In some embodiments, the cleavable linker has a sequence GPPSGSSPISSGLLSGRSSGGG.

In some embodiments, the cleavable linker has a sequence GGSGGSISSGLLSGRSSGP.

In some embodiments, the cleavable linker has a sequence GGSGGSGGSISSGLLSGRSSGP.

Linker combinations disclosed in exemplary AK molecules may be used with any cytokine moiety disclosed herein. Linker combinations disclosed in exemplary AK molecules may be used with any masking moiety disclosed herein disclosed herein. Linker combinations disclosed in exemplary AK molecules may be used with any half-life extension moieties. In other words, the linkers disclosed in exemplary AK molecules may be used in combinations with any cytokine moiety disclosed herein, masking moiety disclosed herein and/or half-life extension moiety disclosed herein.

Half-Life Extension Moieties

A long half-life in vivo is important for therapeutic proteins.

The term “half-life extension moiety” encompasses, for example, PEG, albumin, antibodies and antibody fragments.

The half-life extension moiety may comprise an antibody or fragment thereof.

An antibody or fragment thereof that is capable of FcRn-mediated recycling, can be reduce or otherwise delay clearance of the drug construct from a subject, thereby prolonging the half-life of the administered drug construct. In some embodiments, the antibody or fragment thereof is any antibody or fragment thereof that is capable of FcRn-mediated recycling, such as any heavy chain polypeptide or portion thereof (e.g., Fc domain or fragment thereof) that is capable of FcRn-mediated recycling.

The antibody or fragment thereof can be any antibody or fragment thereof. However, in some embodiments of a drug construct comprising a first half-life extension moiety and a second half-life extension moiety, either the first half-life extension moiety or the second half-life extension moiety may comprise an antibody or fragment thereof that does not bind to the FcRn receptor, such as a light chain polypeptide. For example, in some embodiments of the drug construct, a first half-life extension moiety comprises an antibody or fragment thereof that comprises a light chain polypeptide or portion thereof that does not directly interact with the FcRn receptor, but the drug construct nonetheless has an extended half-life due to comprising a second half-life extension moiety that is capable of interacting with the FcRn receptor, such as by comprising a heavy chain polypeptide. It is recognized in the art that FcRn-mediated recycling requires binding of the FcRn receptor to the Fc region of the antibody or fragment thereof. For instance, studies have shown that residues I253, S254, H435, and Y436 (numbering according to the Kabat EU index numbering system) are important for the interaction between the human Fc region and the human FcRn complex. See, e.g., Firan, M., et al., Int. Immunol. 13 (2001) 993-1002; Shields. R. L., et al, J. Biol. Chem. 276 (2001) 6591-6604). Various mutants of residues 248-259, 301-317, 376-382, and 424-437 (numbering according to the Kabat EU index numbering system) have also been examined and reported. Yeung, Y. A., et al. (J. Immunol. 182 (2009) 7667-7671.

In some embodiments, the antibody or fragment thereof comprises either a heavy chain polypeptide or a light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises a portion of either a heavy chain polypeptide or a light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises an Fc domain or fragment thereof. In some embodiments, the antibody or fragment thereof comprises a CH2 and CH3 domain or a fragment thereof. In some embodiments, the antibody or fragment thereof comprises the constant domain of the heavy chain polypeptide. In some embodiments, the antibody or fragment thereof comprises the constant domain of the light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises a heavy chain polypeptide or fragment thereof (e.g., an Fc domain or fragment thereof). In some embodiments, the antibody or fragment thereof comprises a light chain polypeptide.

In some embodiments, the first half-life extension moiety comprises a first Fc domain or a fragment thereof and the second half-life extension moiety comprises a second Fc domain or a fragment thereof.

In some embodiments, the first and/or second Fc domains each contain one or more modifications that promote the non-covalent association of the first and the second half-life extension moieties. In some embodiments, the first half-life extension moiety comprises an IgG1 Fc domain or fragment thereof including the mutations Y349C; T366S; L38A; and Y407V to form a ‘hole’ in the first half-life extension moiety and the second half-life extension moiety comprises an IgG1 Fc domain or fragment thereof including the mutations S354C and T366W to form the ‘knob’ in the second half-life extension moiety.

In some embodiments, the first and second half-life extension moieties are each an IgG1, IgG2 or IgG4 Fc domain or fragment thereof. In some embodiments, the first and second half-life extension moieties are each an IgG1 Fc domain or fragment thereof. Human IgG1 Immunoglobulin heavy constant gamma 1 has the sequence:

(SEQ ID NO: 6) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

In some embodiments, the first and second half-life extension moieties am derived from the sequence for human IgG1 Immunoglobulin heavy constant gamma I having SEQ ID NO: 6 (the ‘parent sequence’), such that the first and second half-life extension moieties each comprise SEQ ID NO: 6 or fragment thereof, with one or more amino acid modifications.

In some embodiments, the first and second half-life extension moieties each comprise the portion of SEQ ID NO: 6 shown in bold above, optionally with one or more amino acid modifications, i.e.:

(SEQ ID NO: 7) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG

In some embodiments, the first and second half-life extension moieties comprise SEQ ID NO: 7 with amino substitutions to promote association of the first and second half-life extension moieties according to the ‘knob into holes’ approach. In some embodiments, the sequence SEQ ID NO: 7 contains mutations Y349C; T366S; L38A; and Y407V (numbered according to the Kabat EU numbering system) to form the ‘hole’ in the first half-life extension moiety and mutations S354C and T366W (numbered according to the Kabat EU numbering system) to form the ‘knob’ in the second half-life extension moiety. These modified sequences have SEQ ID NOs 8 and 11 shown below:

First Half-Life Extension Moiety (Y349C; T366S; L38A; and Y407V) SEQ ID NO 8

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

Second Half-Life Extension Moiety (S354C and T366W) SEQ ID NO 11

DKTHTCPPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFWYVDGVEVHNKTKPREEQYNSTYRVVSVLTVLHQDW LVGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTK NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

In some embodiments, the first and second half-life extension moieties each further comprise amino substitution N297A, numbered according to the Kabat EU numbering system:

First Half-Lire Extension Moiety (Y349C; T366S; L38A; Y407V and N297A) SEQ ID NO 9

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

Second Half-Life Extension Moiety (S354C, T366W and N-297A) SEQ ID NO 12

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTK NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

In some embodiments, the first and second half-life extension moieties each further comprise the amino substitution I253A, numbered according to the Kabat EU numbering system.

In some embodiments, the first and second half-life extension moieties each further comprise both the amino substitutions N297A and I253A, numbered according to the Kabat EU numbering system:

First Half-Life Extension Moiety (Y349C; T366S; L38A; Y407V, N297A and I253A) SEQ ID NO 10

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG

Second Half-Life Extension Moiety (S354C, T366W, N297A and I253A) SEQ ID NO 13

DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG

In some embodiments, the first half-life extension moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of any one of SEQ ID NOs: 7, 8, 9 and 10.

In some embodiments, the second half-life extension moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of any one of SEQ ID NOs: 7, 11, 12 and 13.

In some embodiments, the first half-life extension moiety comprises an amino acid sequence having one or more modifications, such as one or more amino acid substitutions, additions, or deletions, as compared to the amino acid sequence of any one of SEQ ID NOs: 7, 8, 9 and 10. In some embodiments, the second half-life extension moiety comprises an amino acid sequence having one or more modifications, such as one or more amino acid substitutions, additions, or deletions, as compared to the amino acid sequence of any one of SEQ ID NOs: 7, 11, 12 and 13. The one or more modifications can be any modifications or alterations described herein, including, in some embodiments, any modifications or alterations disclosed herein that promote heterodimerization of polypeptide chains and/or suppresses homodimerization of polypeptide chains, alter effector function, or enhance effector function.

In some embodiments, the Fc domain or fragment thereof comprises one or more amino acid substitutions altering effector function. In some embodiments, the half-life extension moiety is an IgG1 Fc domain or fragment thereof and comprises one or more amino acid substitutions selected from the group consisting of N297A, N297G, N297Q, L234A, L235A, C220S, C226S, C229S, P238S, E233P, L234V, L234F, L235E, P331 S, S267E, L328F, D265A, and P329G, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extension moiety is an IgG2 Fc domain or fragment thereof and comprises the amino substitution(s): V234A and G237A; H268Q, V309L, A330S, and A331S; and/or V234A, G237A, P238S, H268A, V309L, and A330S, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extension moiety is an IgG2 Fc domain or fragment thereof and comprises one or more amino acid substitutions selected from the group consisting of V234A, G237A, H268Q, V309L, A330S, A331S, P238S, H268A, and V309L, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extension moiety is an IgG4 Fc domain or fragment thereof and comprises the amino substitution(s): L235A, G237A, and F318A; S228P, L234A, and L235A; H268Q, V309L, A330S, and P331S; and/or S228P and L235A, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extension moiety is an IgG2 Fc domain or fragment thereof and comprises one or more amino acid substitutions selected from the group consisting of L235A, G237A, E318A, S228P, L234A, H268Q, V309L, A330S, and P331S, numbered according to the Kabat EU numbering system.

In some embodiments, the half-life extension moiety comprises Fc domain or fragment thereof that comprises one or more amino acid substitutions enhancing effector function. In some embodiments, the half-life extension moiety is an IgG1 Fc domain or fragment thereof and comprises the amino acid substitution(s); S298A, E333A, and K334A; S239D and I332E; S239D, A330L, and I332E; P247I and A339D or A339Q; D280H and K290S; D280H, K290S, and either S298D or S298V; F243L, R292P, and Y300L; F243L, R292P, Y300L, and P396L; F243L, R292P, Y300L, V305I, and P396L; G236A, S239D, and I332E; K326A and E333A; K326W and E333S; K290E, S298G, and T299A; K290E, S298G, T299A, and K326E; K290N, S298G, and T299A; K290N, S298G, T299A, and K326E; K334V; 1235S, S239D, and K334V; K334V and Q331M, S239D, F243V, E294L, or S298T; E233L, Q311M, and K334V; L234I, Q311M, and K334V; K334V and S298T, A330M, or A330F; K334V, Q311M, and either A330M or A330F; K334V, S298T, and either A330M or A330F; K334V, S239D, and either A330M or S298T; L234Y, Y296W, and K290Y, F243V, or E294L; Y296W and either L234Y or K290Y; S239D, A330S, and I332E, V264I; F243L and V264I; L328M I332E; L328M and I332E; V264I and I332E; S239E and I332E; S239Q and I332E; S239E; A330Y; T32; L328I and I332E; L328Q and I332E; V264T; V240I; V266I; S239D; S239D and I332D; S239D and I332N; S239D and I332Q; S239E and 332D; S239E and I332N; S239E and I332Q; S239N and I332D; S239N and I332E; S239Q and I332D; A330Y and T332E; V264I, A330Y, and I332E; A330L and I332E; V264I, A330L, and I332E; L234E, L234Y, or L234I; L235D, L235S, L235Y, or L2351; S239T; V240M; V264Y; A330I; N325T; I332E and L328D, L328V, L328T, or L328I; V264I, I332E, and either S239E or S239Q; S239E, V264I, A330Y, and I332E; A330Y, I332E, and cither S239D or S239N; A330L, I332E, and either S239D or S239N; V264I, S298A, and I332E; S298A, I332E, and either S239D or S239N; S239D, V264I, and I332E; S239D, V264I, S298A, and I332E; S239D, V264I, A330L, and I332E; S239D, I332E, and A330I; P230A; P230A, E233D, and I332E; E272Y; K274T, K274E, K274R, K274L, or K274Y; F275W; N276L; Y278T; V302I; E318R; S324D, S324I or S324V; K326I or K326T; T335D, T335R, or T335Y; V240I and V266I; S239D, A330Y, I332E, and L234I; S239D, A330Y, I332E, and L235D; S239D, A330Y, I332E, and V240I; S239D, A330Y, I332E, and V264T; and/or S239D, A330Y, I332E, and either K326E or K326T, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extension moiety is an IgG1 Fc domain or fragment thereof and comprises one or more amino acid substitution(s) selected from the group consisting of: P230A, E233D. L234E, L234Y, L234I, L235D, L235S, L235Y, L2351, S239D, S239E, S239N, S239Q, S239T, V240I, V240M, F243L, V264I, V264T, V264Y, V266I. E272Y, K274T, K274E, K274R, K274L, K274Y, F275W, N276L, Y278T, V302I, E318R, S324D, S324I, S324V, N325T, K326I, K326T, L328M, L328I, L328Q, L328D, L328V, L328T, A330Y, A330L, A330I, I332D, I332E, I332N, I332Q, T335D, T335R, and T335Y.

In some embodiments, the half-life extension moiety comprises one or more amino acid substitution(s) that enhance binding of the half-life extension moiety to FcRn. In some embodiments, the one or more amino acid substitution(s) increase binding affinity of an Fc-containing polypeptide (e.g., a heavy chain polypeptide or an Fc domain or fragment thereof) to FcRn at acidic pH. In some embodiments, the half-life extension moiety comprises one or more amino acid substitution(s) selected from the group consisting of M428F; T250Q and M428F; M252Y, S254T, and T256E; P257I and N434H; D376V and N434H; P257I and Q311I; N434A; N434W; M428F and N434S; V259I and V308F; M252Y, S254T, and T256E; V259I, V308F and M428F; T307Q and N434A; T307Q and N434S; T307Q. E380A, and N434A; V308P and N434A; N434H; and V308P.

For manufacturing purposes, a signal peptide may be engineered upstream of the half life domain to improve secretion of the protein. The signal peptide is selected according to the cell line's requirements as is known in the art. It will be understood that the signal peptide is not expressed as part of the protein that will be purified and formulated as drug product.

1.1.1 Heterodimerization Modifications

The half-life extension moieties described herein may include one or more modifications that promote heterodimerization of two different half-life extension moieties. In some embodiments, it is desirable to promote heterodimerization of the first and second half-life extension moieties such that production of the drug construct in its correct heterodimeric form is produced efficiently. As such, one or more amino acid modifications can be made to the first half-life extension moiety and one or more amino acid modifications can be made to the second half-life extension moiety using any strategy available in the art, including any strategy as described in Klein et al. (2012), MAbs, 4(6): 653-663. Exemplary strategies and modifications are described in detail below.

1.1.2 Knobs-into-Holes Approach

One strategy for promoting heterodimerization of two different half-life extension moieties is an approach termed the “knobs-into-holes”.

In some embodiments, the drug construct comprises a first half-life extension moiety and a second half-life extension moiety, each of which comprises a CH3 domain. In some embodiments, the half-life extension moiety comprising a CH3 domain is a heavy chain polypeptide or a fragment thereof (e.g., an Fc domain or fragment thereof). The CH3 domains of the two half-life extension moieties can be altered by the “knobs-into-holes” technology, which is described in detail with several examples in, e.g., WO 1996/027011; Ridgway, J. B. et al, Protein Eng. (1996) 9(7): 617-621; Merchant, A. M., et al, Nat. Biotechnol. (1998) 16(7): 677-681. See also Klein et al. (2012), MAbs, 4(6): 653-663. Using the knob-into-holes method, the interaction surfaces of the two CH3 domains are altered to increase the heterodimerization of the two half-life extension moieties containing the two altered CH3 domains. This occurs by introducing a bulky residue into the CH3 domain of one of the half-life extension moieties, which acts as the “knob.” Then, in order to accommodate the bulky residue, a “hole” is formed in the other half-life extension moiety that can accommodate the knob. Either of the altered CH3 domains can be the “knob” while the other can be the “hole.” The introduction of a disulfide bridge further stabilizes the heterodimers (Merchant, A. M., et al, Nat. Biotechnol. (1998) 16(7); Atwell. S., et al. J. Mol. Biol. (1997) 270(1): 26-35) as well as increases yield.

It has been reported that heterodimerization yields above 97% can be achieved by introducing the S354C and T366W mutations in a heavy chain to create the “knob” and by introducing the Y349C, T366S, L368A, and Y407V mutations in a heavy chain to create the “hole” (numbering of the residues according to the Kabat EU numbering system). Caner et al. (2001), J. Immunol. Methods, 248: 7-15; Klein et al. (2012). MAbs, 4(6): 653-663.

In some embodiments comprising a first half-life extension moiety and a second half-life extension moiety, the first half-life extension moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) that comprises the amino acid mutations S354C and T366W (numbered according to the Kabat EU numbering system), and the second half-life extension moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) that comprises the amino acid mutations Y349C, T366S, L368A, and Y407V (numbered according to the Kabat EU numbering system).

In some embodiments comprising a first half-life extension moiety and a second half-life extension moiety, the first half-life extension moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) that comprises the amino acid mutations Y349C, T366S, L368A, and Y407V (numbered according to the Kabat EU numbering system), and the second half-life extension moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) that comprises the amino acid mutations S354C and T366W (numbered according to the Kabat EU numbering system).

Additional examples of substitutions that can be made to form knobs and holes include those described in US20140302037A1, the contents of which are herein incorporated by reference. For example, in some embodiments, any of the following amino acid substitutions can be made to a first half-life extension moiety (“first domain”) and a paired second half-life extension moiety (“second domain”) that each contain an Fc domain: (a) Y407T in the first domain and T366Y in the second domain; (b) Y407A in the first domain and T366W in the second domain; (c) F405A in the first domain and T394W in the second domain; (d) F405W in the first domain and T394S in the second domain; (c) Y407T in the first domain and T366Y in the second domain; (f) T366Y and F405A in the first domain and T394W and Y407T in the second domain: (g) T366W and F405W in the first domain and T394S and Y407A in the second domain; (h) F405W and Y407A in the first domain and T366W and T394S in the second domain: or (i) T366W in the first domain and T366S. L368A, and Y407V in the second domain, numbered according to the Kabat EU numbering system.

In some embodiments, any of the following amino acid substitutions can be made to a first half-life extension moiety (“first domain”) and a paired second half-life extension moiety (“second domain”) that each contain an Fc domain: (a) Y407T in the second domain and T366Y in the first domain; (b) Y407A in the second domain and T366W in the first domain; (c) F405A in the second domain and T394W in the first domain; (d) F405W in the second domain and T394S in the first domain; (e) Y407T in the second domain and T366Y in the first domain; (f) T366Y and F405A in the second domain and T394W and Y407T in the first domain: (g) T366W and F405W in the second domain and T394S and Y407A in the first domain; (h) F405W and Y407A in the second domain and T366W and T394S in the first domain; or (i) T366W in the second domain and T366S, L368A, and Y407V in the first domain, numbered according to the Kabat EU numbering system.

In embodiments comprising a first half-life extension moiety and a second half-life extension moiety that each comprise an Fc domain, any of the heterodimerizing alterations described herein can be used in the Fc domains to promote heterodimerization of any of the drug constructs described herein.

Therapeutic Moieties

Provided herein, in some embodiments, is a cytokine prodrug where the therapeutic moiety is a cytokine moiety. The masking moiety in the cytokine prodrug may comprise a domain of the extracellular domain of the cytokine receptor. The cytokine prodrug thus may be considered to be a masked cytokine.

The cytokine moiety may comprise a wild-type cytokine moiety or variant cytokine moiety.

Cytokines exemplified herein are IL-2. IL-12 and IL-15.

Cytokine Prodrugs

Cytokines play a role in cellular signalling, particularly in cells of the immune system. Provided herein is a cytokine moiety comprising a cytokine (e.g. IL-2, IL-15 or IL-12 cytokine) or functional fragment thereof for use in a masked cytokine or cleavage product thereof.

1.1 ‘Heteromdimeric’ Masked Cytokines

Provided herein, in some embodiments, is a masked cytokine comprising a masking moiety in a first polypeptide chain and a cytokine moiety thereof in a second polypeptide chain. Such masked cytokines may be referred to as ‘heterodimeric’ masked cytokines.

In some embodiments, the masked cytokine comprises a protein heterodimer comprising:

-   -   c) a first polypeptide chain comprising a masking moiety linked         to a first half-life extension moiety via a first linker; and     -   d) a second polypeptide chain comprising a cytokine moiety         thereof linked to a second half-life extension moiety via a         second linker,         wherein the first half-life extension moiety is associated with         the second half-life extension moiety, and         wherein at least the first linker or the second linker is a         proteolytically cleavable peptide linker comprising a         proteolytically cleavable peptide (CP) consisting of the amino         acid sequence DLLAVVAAS or ISSGLLSGRS.

In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is a non-cleavable linker, non-cleavable linker may be as described anywhere herein.

In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the second linker is a proteolytically cleavable peptide linker and the first linker is non-cleavable. The non-cleavable linker may be as described anywhere herein.

The proteolytically cleavable peptide linker may be as described anywhere herein.

The half-life extension moieties may be as described anywhere herein.

The combination of masking moiety and cytokine moiety may be as described anywhere herein.

In some embodiments, in the first polypeptide chain, the first half life extension domain is linked to the amino terminus of the first linker and the carboxy terminus of the first linker is linked to the amino terminus of the masking moiety and, in the second polypeptide chain, the second half life extension domain is linked to the amino terminus of the second linker and the carboxy terminus of the second linker is linked to the amino terminus of the cytokine moiety thereof.

In some embodiments, the first polypeptide chain comprises:

N′HL1-L1-MM C′

and the second polypeptide chain comprises:

N′HL2-L2-C C′

where HL1 is the first half life extension domain. L1 is the first linker, MM is the masking moiety, HL2 is the second half life extension domain, L2 is the second linker, and C is the cytokine moiety thereof.

In some embodiments, the second linker is the proteolytically cleavable linker and the first linker is a non-cleavable linker. This arrangement is described herein as ‘Structure A’. In some embodiments, the first polypeptide chain comprises:

N′HL1-non-cleavable L1-MM C′

and the second polypeptide chain comprises:

N′HL2-cleavable L2-C C′

In some embodiments, the first linker is the proteolytically cleavable linker and the second is a non-cleavable linker. This arrangement is described herein as ‘Structure B’. In some embodiments, the first polypeptide chain comprises:

N′HL1-cleavable L1-MM C′

and the second polypeptide chain comprises:

N′HL2-non-cleavable L2-C C′

1.2 ‘Linear’ Masked Cytokines

Provided herein. In some embodiments, is a masked cytokine comprising a masking moiety and a cytokine moiety thereof linked in a single polypeptide chain. In some embodiments, the masked cytokine comprises a polypeptide chain comprising formula:

N′HL-L2-C-L1-MM C′

where HL is the half life extension domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety thereof, wherein at least the first linker comprises a proteolytically cleavable peptide.

In some embodiments, the masked cytokine comprises a polypeptide chain comprising formula:

N′HL-L2-MM-L1-C C′

where HL is the half life extension domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety thereof, wherein at least the first linker comprises a proteolytically cleavable peptide. In some embodiments, the first linker is a cleavable linker as described anywhere herein. In some embodiments, the second linker is a non-cleavable linker as described anywhere herein. In some embodiments, the cytokine moiety thereof is as described anywhere herein. In some embodiments, the half life extension domain (HL) comprises an Fc region of an antibody (i.e. the C-terminal region of an immunoglobulin heavy chain) or a fragment thereof comprising dimerized Fc domains (HL1-HL2). Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. In some embodiments, the dimerized Fc domains of an antibody (HL1-HL2) comprises a first half life extension domain and a second half life extension domain as described anywhere herein, where the first half-life extension moiety comprises a first Fc domain or a fragment thereof and the second half-life extension moiety comprises a second Fc domain or a fragment thereof. In some embodiments, HL2 is a component of the polypeptide chain and HL1 is dimerized to HL2.

1.1 Cytokine Moieties and Masking Moeities

The cytokine moieties and masking moieties (e.g. IL-2, IL-12, and IL-15 cytokine moieties and masking moieties) disclosed herein may be used in any polypeptide drug construct disclosed herein.

The cytokine moieties and masking moieties disclosed herein may be used in a heterodimeric masked cytokine of Structure A as disclosed herein.

The cytokine moieties and masking moieties disclosed herein may be used in a heterodimeric masked cytokine of Structure B as disclosed herein.

The cytokine moieties and masking moieties disclosed herein may be used in a linear masked cytokine as disclosed herein.

1.1.1 IL-2 Cytokine Moieties and IL-2 Masking Moieties

(a) IL-2 Cytokine Moieties

In some embodiments, the therapeutic moiety comprises an IL-2 cytokine or functional fragment thereof.

IL-2 is an interleukin, which is a type of cytokine signalling molecule in the immune system that regulates activities of white blood cells.

In eukaryotic cells, naturally occurring IL-2 is synthesized as a precursor polypeptide of 153 amino acids, which has SEQ ID NO: 1. This is then processed into mature IL-2 by the removal of amino acid residues 1-20. This results in a mature form of IL-2 consisting of 133 amino acids (amino acid residues 21-153), which has SEQ ID NO: 2. “Functional fragments” of an IL-2 cytokine comprise a portion of a full length cytokine protein which retains or has modified cytokine receptor binding capability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the full length cytokine protein).

Cytokine receptor binding capability can be shown, for example, by the capability of a cytokine to bind to the cytokine's cognate receptor or a component thereof (e.g., one or more chain(s) of a heterotrimeric receptor complex).

In some embodiments, the IL-2 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-2) protein or modified variant thereof capable of binding to an interleukin-2 receptor, particularly the IL-2Rα chain. In the context of IL-2 cytokine binding, the target protein could be IL-2R (comprising the IL-2Rα, IL-2Rβ, and IL-2Rγ chains), the IL-2Rα chain, the IL-2Rβ chain, or the IL-2Rα/β dimeric complex. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence of amino acid residues 21-153 of SEQ ID NO: 1. In some embodiments, the IL-2 polypeptide or functional fragment thereof comprises the amino acid sequence of mature IL-2, SEQ ID NO: 2.

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 2. Each of the at least one amino acid modifications can be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 2.

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions as compared to the amino acid sequence of wild-type IL-2 of SEQ ID NO: 2 that reduces the affinity of the IL-2 peptide or functional fragment thereof for IL-2Rα (CD25). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions as compared to the amino acid sequence of SEQ ID NOs: 2, such that one or more of amino acid residues 38, 42, 45, and 62 is an alanine (A). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 2, such that amino acid residues 38, 42, 45, and 62 are an alanine (A).

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises amino acid sequence substitution C125A as compared to the amino acid sequence of SEQ ID NOs: 2.

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 2, such that amino acid residues 38, 42, 45, and 62 are an alanine (A) and amino acid residue 125 is a alanine (A). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid residues R38, F42, Y45, and E62 substituted for alanine in the amino acid sequence of SEQ ID NO: 2. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid residues R38, F42, Y45, and E62 substituted for alanine (A) and amino acid residue C125 substituted for alanine (A) in the amino acid sequence of SEQ ID NO: 2.

In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 3.

In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues e.g. residues 1-3 s removed as compared to the amino acid sequence of the mature IL-2 of SEQ ID 2, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues substituted as compared to the amino acid sequence of the mature IL-2 of SEQ ID 2, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues inserted, e.g. in the region of residues 1-3, as compared to the amino acid sequence of the mature IL-2 of SEQ ID 2, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-2 cytokine or functional fragment thereof does not have an O-glycosylation site within residues 1-3.

(b) IL-2 Masking Moieties

Provided herein is a masking moiety for use in masking a therapeutic moiety comprising an IL-2 cytokine or functional fragment thereof.

It will be understood that the masking moiety is cleaved from the masked cytokine to form the cleavage product thereof. The masking moiety masks the IL-2 cytokine or functional fragment thereof in the masked cytokine thereby reducing or preventing binding of the IL-cytokine or functional fragment thereof to its cognate receptor. In some embodiments, the masking moiety reduces or prevents binding of the IL-2 cytokine or functional fragment thereof to IL-2Rα (CD25). In some embodiments, the masking moiety as provided herein refers to a moiety capable of binding to, or otherwise exhibiting an affinity for the IL-2 cytokine or functional fragment thereof, such as an anti-IL-2 antibody or IL-2 cognate receptor protein. Methods for determining the extent of binding of a protein (e.g., cytokine) to a cognate protein (e.g., cytokine receptor) are well known in the art.

In some embodiments, the masking moiety comprises an IL-2 cytokine receptor, or a subunit or functional fragment thereof.

In some embodiments, the masking moiety comprises IL-2Rβ (also referred to as CD122) or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-2.

In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 4 with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has mutation at amino acid position C122 as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has mutation C122S at amino acid position 122 as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 4 with a C122 mutation.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 4 with a C122S mutation.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has mutation at amino acid position C168 as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has mutation C168S at amino acid position 168 as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 4 with a C168 mutation.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 4 with a C168S mutation.

In some embodiments, the IL-2Rβ or a fragment, portion or variant thereof has mutation at amino acid positions C122 and C168 as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the IL-2Rβ i or a fragment, portion or variant thereof has mutation C122S and C168S as compared to IL-2Rβ of SEQ ID NO: 4.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 5.

In some embodiments, when (i) the masked cytokine is a Structure A heterodimeric masked cytokine and (ii) the cytokine moiety is an IL-2 cytokine moiety, then the proteolytically cleavable peptide linker does not have the amino acid sequence GGSGTSSGLLSGRSSSGP or GISSGLLSGRSSSGP.

1.1.2 IL-12 Cytokine Moieties and IL-12 Masking Moieties

(a) IL-12 Cytokine Moieties

In some embodiments, the therapeutic moiety comprises an IL-12 cytokine or functional fragment thereof.

IL-12 is an interleukin, which is a type of cytokine signalling molecule in the immune system that regulates activities of white blood cells.

Endogenous IL-12 exists as two distinct molecules IL-12 p40 and IL-12p35, that dimerize in the cell during biosynthesis.

The full sequences of IL-12 p40 and IL-12p35 are (pro-peptides cleaved off during biosynthesis are shown) in bold):

IL-12 p40 subunit: MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMWLTC DTPEEDGITVVTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLS HSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTT ISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQED SACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKP LKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKT SATVICRKNASISVRAQDRYYSSSWSEWASVPCS IL-12 p35 subunit: MCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVS NMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLN SRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLM DPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLC ILLHAFRIRAVTIDRVMSYLNAS

The mature forms are as follows:

IL-12 p40 subunit: IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGS GKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVT CGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKL KYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHS YFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYS SSWSEWASVPCS IL-12 p35 subunit: RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDH EDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMM ALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQA LNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVT1DRVMSYLNA S

They are expressed as two chains that covalently dimerize during biosynthesis through a disulfide bound between the two subunits: Cysteine C199 of the p40 subunit associates with Cysteine C96 of the p35 subunit.

“Functional fragments” of an IL-12 cytokine comprise a portion of a full length cytokine protein which retains or has modified cytokine receptor binding capability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the full length cytokine protein). Cytokine receptor binding capability can be shown, for example, by the capability of a cytokine to bind to the cytokine's cognate receptor or a component thereof.

In some embodiments, the IL-12 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-12) protein or modified variant thereof capable of binding to an interleukin-12 receptor.

In some embodiments, the IL-12 polypeptide or functional fragment thereof comprises an IL-12p40 polypeptide or functional fragment thereof covalently linked to an IL-12p35 polypeptide or functional fragment thereof.

The IL-12p40 polypeptide or functional fragment thereof may be attached to the first half life extension domain such that the first polypeptide chain comprises formula:

N′HL1-L1-MM C′

and the second polypeptide chain comprises formula:

N′HL2-L2-[IL-12p401-linker-IL-12p35]C′

where ‘IL-12p40’ is the IL-12p40 polypeptide or functional fragment thereof and ‘IL-12p35’ is the IL-12p35 polypeptide or functional fragment thereof.

In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-I²p40 polypeptide comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below. Each of the at least one amino acid modifications can be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-A2 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below.

The IL-12p40 polypeptide comprises a glycosaminoglycan (GAG)-binding domain (KSKREKKDRV). GAGs, such as heparin and heparan sulphate, have been shown to bind numerous growth factors and cytokines, including IL-12. The physiological significance of this binding is two-fold. First, GAGs can serve as co-receptors on cell surfaces to maintain high, local concentrations of cytokines. Second. GAGs can regulate bioactivities of growth factors and cytokines through multiple mechanisms including dimerization and protection from proteolytic degradation.

The GAG-binding domain in the mature form of the IL-12 p40 subunit is shown below in bold:

IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGITWTLDQSSEVLGSG KTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQK EPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTC GAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLK YENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSY FSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSS SWSEWASVPCS

Modifications to the GAG-binding domain (KSKREKKDRV) has been shown herein to increase the PK profile of constructs comprising an IL-12 cytokine with a mutated GAG-binding domain, without any decrease in cytokine activity. Thus, in some embodiments, the IL-12p40 polypeptide comprises at least one amino acid modification to the GAG-binding domain. In some embodiments, the modification to the GAG-binding domain is a deletion mutation. In some embodiments, the modification to the GAG-binding domain is a deletion mutation and at least one substitution mutation.

In some embodiments, the GAG-binding domain comprises the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence SEQ ID NO: 205 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the GAG-binding domain comprises the amino acid sequence KDNTEGRV. In some embodiments, the it-12p40 polypeptide comprises the amino acid sequence SEQ ID NO: 206 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the GAG-binding domain consists of the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence SEQ ID NO: 205 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the GAG-binding domain consists of the amino acid sequence KDNTEGRV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence SEQ ID NO: 206 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitutions as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having an amino acid substitution at position C252 as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the amino acid substitution at position C252 is C252S. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence of SEQ ID NO: 207 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 207 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p40 polypeptide consists of an amino acid sequence of SEQ ID NO: 207 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitutions as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below, and at least one amino acid modification to the GAG-binding domain. In some embodiments, the IL-12p40 polypeptide comprises an amino acid substitution at position C252S as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below, and the GAG-binding domain comprises the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises an amino acid substitution at position C252S as compared to the amino acid sequence of SEQ ID NO: 204 shown in the IL-12 Cytokine Moieties table below, and the GAG-binding domain comprises the amino acid sequence KDNTEGRV. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence of SEQ ID NO: 208 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 208 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p40 polypeptide consists of an amino acid sequence of SEQ ID NO: 208 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO: 209 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12p35 polypeptide comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 209 shown in the IL-12 Cytokine Moieties table below. Each of the at least one amino acid modifications can be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 20) shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 209 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12p40-IL-12p35 linker is between 5 and 20 amino acids in length.

In some embodiments, the IL-12p40-IL-12p35 linker is rich in amino acid residues G and S.

In some embodiments, the IL-12p40-IL-12p35 linker only includes amino acid residue types selected from the group consisting of G and S.

In some embodiments, the IL-12p40-IL-12p35 linker includes [(G)_(n)S], where n=4 or 5.

In some embodiments, the IL-12p40-IL-12p35 linker includes a (GGGGS) repent.

In some embodiments, IL-12p40-IL-12p35 linker comprises SEQ ID NO: 116. (GGGGSGGGGSGGGGS)

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 210 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequences of SEQ ID NO: 204 and 209 shown in the IL-12 Cytokine Moieties table below. Each of the at least one amino acid modifications can be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions as compared to the amino acid sequences of SEQ ID NO: 204 and 209 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions as compared to the amino acid sequences of SEQ ID NO: 204 and 209 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 210 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 210 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 211 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 211 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 212. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 212 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 213 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 213 shown in the IL-12 Cytokine Moieties table below.

In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 214 shown in the IL-12 Cytokine Moieties table below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 214 shown in the IL-12 Cytokine Moieties table below.

TABLE IL-12 Cytokine Moieties: Component SEQ ID NO Sequence hIL12B IL-12 204 IWELKKDVYWELDWYPDAPGEMWLTCDTPEED p40 GITWTLDQSSEVLGSGKTLTIQVKEFGD subunit AGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKD QKEPKNKTFLRCEAKNYSGRFTCWWLTTI STDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGD NKEYEYSVECQEDSACPAAEESLPIEVMV DAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSR QVEVSWEYPDTWSTPHSYFSLTFCVQV QGKSKREKKDRVFTDKTSATVICR KNASISVRAQDRYYSSSWSEWASV PCS IL-12 205 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGITW p40 TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVL subunit SHSLLLLHKKEDGIWSTDILKDQ [KDNTERV] KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVK IL-12 SSRGSSDPQGVTCGAATLSAERV p40 RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHK subunit LKYENYTSSFFIRDIIKPDPPKN [KDNTEGRV] LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQ VQGKDNTERVFTDKTSATVICRKNASISVRAQDRYY SSSWSEWASVPCS IL-12 206 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGITW p40 TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSH subunit SLLLLHKKEDGIWSTDILKDQ {C252S] KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSR GSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLK YENYTSSFFIRDIIKPDPPKN LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQG KDNTEGRVFTDKTSATVICRKNASISVRAQDRYYSSSWS EWASVPCS 207 IWELKKDVYWELDWYPDAPGEMWLTCDTPEEDGITW TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHS LLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRF TCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLK YENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYP DTWSTPHSYFSLTFSVQVQGKSKREKKDRVFTDKTSATV ICRKNASISVRAQDRYYSSSWSEWASVPCS p40 208 IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW subunit TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLS [KDNTEGRV] + HSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYS [C25S] GRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLS AERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDA VHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEV SWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKTS ATVICRKNASISVRAQDRYYSSSWSEWASVPCS hIL12A IL-12 209 RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLE p35 FYPCTSEEIDHEDITKDKTSTVEACLPLE subunit LTKNESCLNSRETSF1TNGSCLASRKTSFMMALCLSSIYE DLKMYQVEFKTMNAKLLMDPKRQIFLDQ NMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCIL LHAFRIRAVTIDRVMSYLNAS Cytokine hIL12B- 210 IWELKKDVYWELDWYPDAPGEMWLTCDTPEEDGIT hIL12A WTLDQSSEVLGSGKTLTIQVKEFGD AGQYTCHKGGEVLSHSLLLLHKKEDGIWSTD1LKDQK EPKNKTFLRCEAKNYSGRFTCWWLT TISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDN KEYEYSVECQEDSACPAAEESLPIEV MVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKN SRQVEVSWEYPDTWSTPHSYFSLTF CVQVQGKSKREKKDRVFTDKTSATVICRKNASISVR AQDRYYSSSWSEWASVPCSGGGGS GGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVS NMLQKARQTLEFYPCTSEEIDHE DITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCL ASRKTSFMMALCLSSIYEDLKMYQVE FKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNS ETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS hIL12B- 211 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDG hIL12A ITWTLDQSSEVLGSGKTLTIQVKEFGD [KDNTERV] AGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDOK EPKNKTFLRCEAKNYSGRFTCWWLT TISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGD NKEYEYSVECQEDSACPAAEESLPIEV MVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLK NSRQVEVSWEYPDTWSTPHSYFSLTF CVQVQGKDNTERVFTDKTSATVICRKNASISVRAQD RYYSSSWSEWASVPCSGGGGS GGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAV SNMLQKARQTLEFYPCTSEEIDHE DITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSC LASRKTSFMMALCLSSIYEDLKMYQVE FKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNF NSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS hIL12B- 212 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGI hIL12A TWTLDQSSEVLGSGKTLTIQVKEFGD [KDNTEGRV] AGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQK EPKNKTFLRCEAKNYSGRFTCWWLT TISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGD NKEYEYSVECQEDSACPAAEESLPIEV MVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKN SRQVEVSWEYPDTWSTPHSYFSLTF CVQVQGKDNTEGRVFTDKTSATVICRKNASISVRAQD RYYSSSWSEWASVPCSGGGGS GGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAV SNMLQKARQTLEFYPCTSEEIDHE DITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSC LASRKTSFMMALCLSSIYEDLKMYQVE FKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNF NSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS hIL12B- 213 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGI hIL12A TWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGE [C252S] VLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCE AKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVT CGAATLSAERVRGDNKEYEYSVECQEDSACPAAEES LPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQL KPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQG KSKREKKDRWTDKTSATVICRKNASISVRAQDRYYS SSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPD PGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSE ETDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFI TNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTM NAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETV PQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS hIL12B- 214 IWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDG hIL12A ITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGE [KDNTEGRV] + VLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEA [C252S] KNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCG AATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIE VMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLK NSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTE GRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWAS VPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHH SQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKT STVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFM MALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQEFLDQ NMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLC ILLHAFRIRAVTIDRVMSYLNAS

In some embodiments, the IL-12 cytokine moiety has an amino acid sequence as shown by one of the sequences in the table above.

(b) IL-12 Masking Moieties

Provided herein is a masking moiety for use in masking a therapeutic moiety comprising an IL-12 cytokine or functional fragment thereof.

It will be understood that the masking moiety is cleaved from the masked cytokine to form the cleavage product thereof. The masking moiety masks the IL-12 cytokine or functional fragment thereof in the masked cytokine thereby reducing or preventing binding of the IL-cytokine or functional fragment thereof to its cognate receptor.

The IL-12 receptor, beta 1, or IL-12Rβ1 is a subunit of the IL-12 receptor complex. IL-12Rβ1 is also known as CD212. This protein binds to interleukin-12 (IL-12) with a low affinity. This protein forms a disulfide-linked oligomer, which is required for its IL-12 binding activity. The IL-12 receptor, beta 2, or IL-12Rβ2 is a subunit of the IL-12 receptor complex. The coexpression of IL-12Rβ1 and IL-12Rβ2 protein has been shown to lead to the formation of high-affinity IL-12 binding sites.

Methods for determining the extent of binding of a protein (e.g., cytokine) to a cognate protein (e.g., cytokine receptor) are well known in the art.

In some embodiments, the masking moiety comprises an extracellular domain of an IL-12 cytokine receptor, or a subunit or functional fragment thereof.

Interleukin-12 receptor subunit beta-1, also called CD212 has the sequence:

MEPLVTWVVPLLFLFLLSRQGAA CRTSECCFQDPPYPDADSGSASGPRD LRCYRISSDRYECSWQYEGPTAGVSHFLRCCLSSGRCCYFAAGSATRLQ FSDQAGVSVLYTVTLWVESWARNQTEKSPEVTLQLYNSVKYEPPLGDIK VSKLAGQLRMEWETPDNQVGAEVQFRHRTPSSPWKLGDCGPQDDDTESC LCPLEMNVAQEFQLRRRQLGSQGSSWSKWSSPVCVPPENPPQPQVRFSV EQLGQDGRRRLTLKEQPTQLELPEGCQGLAPGTEVTYRLQLHMLSCPCK AKATRTLHLGKMPYLSGAAYNVAVISSNQFGPGLNQTWHIPADTHTEPV ALNISVGTNGTTMYWPARAQSMTYCIEWQPVGQDGGLATCSLTAPQDPD PAGMATYSWSRESGAMGQEKCYYITIFASAHPEKLTLWSTVLSTYHFGG NASAAGTPHHVSVKNHSLDSVSVDWAPSLLSTCPGVLKEYVVRCRDEDS KQVSEHPVQPTETQVTLSGLRAGVAYTVQVRADTAWLRGVWSQPQRFSI EVQVSD WLIFFASLGSFLSILLVGVLGYLGL NRAARHLCPPLPTPCASS AIEFPGGKETW Q WINPVDF QEEASLQ EALVVEMSWDKGERTEPLEKTEL PEGAPELALDTELSLEDGDRCKAKM

Interleukin-12 receptor subunit beta-2 has the sequence:

MAHTFRGCSLAFMFIITWLLIKA KIDACKRGDVTVKPSHVILLGSTVNI TCSLKPRQGCFHYSRRNKLILYKFDRRINFHHGHSLNSQVTGLPLGTTL FVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQKGEQGTVACTWER GRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPESNF TAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLY WRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQI SSKLHLYKGSWSDWSESLRAQTPEEEPTGMLDVWYMKRHIDYSRQQISL FWKNLSVSEARGKILHYQVTLQELTGGKAMTQNITGHTSWTTVIPRTGN WAVAVSAANSKGSSLPTRINIMNLCEAGLLAPRQVSANSEGMDNILVTW QPPRKDPSAVQEYVVEWRELHPGGDTQVPLNWLRSRPYNVSALISENIK SYICYEIRVYALSGDQGGCSSILGNSKHKAPLSGPHINAITEEKGSILI SWNSIPVQEQMGCLLHYRIYWKERDSNSQPQLCIIPYRVSQNSHPINSL QPRVTYVLWMTALTAAGESSHGNEREFCLQGKAN WMAFVAPSICIAIIM VGIFST HYFQQKVFVLLAALRPQWCSREIPDPANSTCAKKYPIAEEKTQ LPLDRLLIDWPTPEDPEPLVISEVLHQVTPVFRHPPCSNWPQREKGIQG HQASEKDMMHSASSPPPPRALQAESRQLVDLYKVLESRGSDPKPENPAC PWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQHISLSVFP SSSLHPLTFSCGDKLTLDQLKMRCDSLML

The bold indicates the pro-peptide, the italics with underline indicates the extracellular domain, the italics indicates the transmembrane domain and the bold with underline indicates the cytoplasmic domain.

In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ1 or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12.

In some embodiments, the masking moiety comprises an amino acid sequence having an amino acid sequence of human IL-12Rβ1 with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having an amino acid sequence of human IL-12Rβ1 with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 237 of human IL-12Rβ1, namely a sequence having SEQ ID NO: 215 as shown in the IL-12 Masking Moieties table below or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12. In some embodiments, the masking moiety comprises IL-12Rβ1 having SEQ ID NO: 215 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 215 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 215 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 215 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 545 of human IL-12Rβ1, namely a sequence having SEQ ID NO: 216 as shown in the IL-12 Masking Moieties table below or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12. In some embodiments, the masking moiety comprises IL-12Rβ1 having SEQ ID NO: 216 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 216 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 216 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 216 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises the extracellular domain of human IL-12R02 or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-12. In some embodiments, the masking moiety comprises an amino acid sequence having an amino acid sequence of human IL-12Rβ2 with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having an amino acid sequence of human IL-12Rβ2 with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 212 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 217 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 217 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 217 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 217 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 222 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 218 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 218 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 218 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 218 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 319 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 319 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below, with one or more cysteine substitutions. In some embodiments, the masking moiety comprises residues 24 to 319 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 219 as shown in the IL-12 Masking Moieties table below, with an amino acid substitution at position C242. In some embodiments, the amino acid substitution is at position C242 is C242S. In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 220 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 9%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 220 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety consists of an amino acid sequence of SEQ ID NO: 220 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises residues 24 to 622 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 221 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 221 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 221 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 221 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises residues 24 to 227 of human IL-12Rβ2, namely a sequence having SEQ ID NO: 222 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequence of SEQ ID NO: 222 as shown in the IL-12 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 222 as shown in the IL-12 Masking Moieties table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 222 as shown in the IL-12 Masking Moieties table below, with one or two amino acid substitutions.

TABLE IL-12 Masking Moicties: SEQ ID Component NO Sequence Masking hCD212 215 CRTSECCFQDPPYPDADSGSASGPRDLRCYRISSDRYECSWQYE moiety (24-237) GPTAGVSHFLRCCLSS (MM) GRCCYFAAGSATRLQFSDQAGVSVLYTVTLWVESWARNQTEKS PEVTLQLYNSVKYEP PLGDIKVSKLAGQLRMEWETPDNQVGAEVQFRHRTPSSPWKLG DCGPQDDDTESCLC PLEMNVAQEFQLRRRQLGSQGSSWSKWSSPVCVPPENP hCD212 216 CRTSECCFQDPPYPDADSGSASGPRDLRCYRISSDRYECSWQYE (24-545) GPTAGVSHFLRCCLS SGRCCYFAAGSATRLQFSDQAGVSVLYTVTLWVESWARNQTEK SPEVTLQLYNSVKYEP PLGDIKVSKLAGQLRMEWETPDNQVGAEVQFRHRTPSSPWKLG DCGPQDDDTESCLCP LEMNVAQEFQLRRRQLGSQGSSWSKWSSPVCVPPENPPQPQVRF SVEQLGQDGRRRL TLKEQPTQLELPEGCQGLAPGTEVTYRLQLHMLSCPCKAKATRT LHLGKMPYLSGAAY NVAVISSNQFGPGLNQTWHIPADTHTEPVALNISVGTNGTTMYW PARAQSMTYCIEW QPVGQDGGLATCSLTAPQDPDPAGMATYSWSRESGAMGQEKC YYITIFASAHPEKLTL WSTVLSTYHFGGNASAAGTPHHVSVKNHSLDSVSVDWAPSLLS TCPGVLKEYVVRCRDE DSKQVSEHPVQPTETQVTLSGLRAGVAYTVQVRADTAWLRGV WSQPORFSIEVQVSD IL12RB2 217 KIDACKRGDYTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-212) ILYKFDRRINFHHGHSL NSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWE RGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSL GSSSSL ILI2RB2 218 KIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-222) ILYKFDRRINFHHGHSLN SQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSC IQKGEQGTVACTWER GRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGS SSSLPSTFTFLDIV ILI2RB2 219 KIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-319) ILYKFDRRINFHHGHSL NSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTW ERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTP ESPESNFTAKVTAVNSL OSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLYWRDEGLV LLNRLRYRPSNSRLWNM VNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSWSDWSESLR AQTPEE ILI2RB2 220 KIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-319) ILYKFDRRINFHHGHSL [C242S] NSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWER GRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLG SSSSLPSTFTFLDIVRPLPPWDIRIKPQKASVSRSTLYWRDEGLVL LNRLRYRPSNSRLWNM VNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSWSDWSESLR AQTPEE ILI2RB2 221 KIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-622) ILYKFDRRINFHHGHSLNS QVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKOEQOTVACTWERGR DTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPES NFTAKVTAVNSLGSSSSL PSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLYWRDEGLVLLNRL RYRPSNSRLWNMVNVTK AKORHDLLDLKPFTEYEFQISSKLHLYKGSWSDWSESLRAQTPE EEPTGMLDVWYMKRHID YSRQQISLFWKNLSVSEARGKILHYQVTLQELTGGKAMTQNITG HTSWTTVIPRTGNWAVA VSAANSKGSSLPTRINIMNLCEAGLLAPRQVSANSEGMDNILVT WQPPRKDPSAVQEYVVE WRELHPGGDTQVPLNWLRSRPYNVSALISENIKSYICYEIRVYAL SGDQGGCSSILONSKHKAP LSGPHINAITEEKGSILISWNSIPVQEQMGCLLHYRIYWKERDSNS QPQLCEIPYRVSQNSHPIN SLQPRVTYVLWMTALTAAGESSHGNEREFCLQGKAN ILI2RB2 222 KIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKL (24-227) ILYKFDRRINFHHGHSLNSQVTG LPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQKGE QGTVACTWERGRDTHLYTEYTL QLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPESNFTAKVTAV INSLOSSSSLPSTFTFLDIVRPLPP

In some embodiments, the IL-12 masking moiety has an amino acid sequence as shown by one of the sequences in the table above.

1.1.3 IL-15 Cytokine Moieties and IL-15 Masking Moieties

(a) IL-15 Cytokine Moieties

In some embodiments, the therapeutic moiety comprises an IL-15 cytokine or functional fragment thereof.

IL-15 is an interleukin, which is a type of cytokine signalling molecule in the immune system that regulates activities of white blood cells.

In eukaryotic cells, IL-15 is synthesized as a precursor polypeptide of 162 amino acids, which is then processed into mature IL-15 by the removal of amino acid residues 1-48. This results in a mature form of IL-15 consisting of 114 amino acids (amino acid residues 49-162) that is secreted in a mature, active form.

IL-15 precursor polypeptide: MRISKPHLRSISIQCYCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISKLKKIEDLIQSM HIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGC KECEELEEKNIKEFLQSFVHIVQMFINTS IL-15 mature polypeptide: NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENL IILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS

The term “IL-15” or “IL-15 polypeptide” as used herein refers to any interleukin-15 (IL-15) protein, or a functional fragment or variant thereof. The term encompasses any native IL-15 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., rats and mice). The term encompasses unprocessed IL-15 (e.g., a full length, precursor form of IL-15 that consists of amino acid residues 1-162) as well as any form of IL-15 that results from processing in the cell (e.g., a mature form of IL-15 that consists of amino acid residues 49-162). As such, the term encompasses a protein encoded by the amino acid sequence of SEQ ID NO:224 as shown in the IL-15 Cytokine Moieties table below, as well as sequence variants thereof. The term also encompasses naturally occurring variants of IL-15. The term also encompasses non-naturally occurring variants of IL-15, such as truncations, deletions, forms where IL-15 is linked to another molecule, and variants caused by at least one amino acid change to the amino acid sequence (e.g., by substitution, addition, or deletion). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g., a 50, 100, or 114 continuous amino acid portion) compared to a naturally occurring IL-15 polypeptide, such as an IL-15 polypeptide encoded by the amino acid sequence of SEQ ID NO: 223 or 224 as shown in the IL-15 Cytokine Moieties table below. As such, the term “IL-15” or “IL-15 polypeptide” includes an IL-15 protein comprising the amino acid sequence of SEQ ID NO: 223 or 224 as shown in the IL-15 Cytokine Moieties table below, including variants thereof, such as variants created by one or more amino acid substitutions to the amino acid sequence of SEQ ID NO: 223 or 224 as shown in the IL-15 Cytokine Moieties table below.

“Functional fragments” of an IL-15 cytokine comprise a portion of a full length cytokine protein which retains or has modified cytokine receptor binding capability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the full length cytokine protein). Cytokine receptor binding capability can be shown, for example, by the capability of a cytokine to bind to the cytokine's cognate receptor or a component thereof (e.g., one or more chain(s) of a heterotrimeric receptor complex).

In some embodiments, the IL-15 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-15) protein or modified variant thereof capable of binding to an interleukin-2 receptor, particularly the IL-15Rα chain.

In some embodiments, the IL-15 cytokine or fragment thereof comprises SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below or a functional fragment thereof.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-5 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below. Each of the at least one amino acid modifications can be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below. In some embodiments, the IL-cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53, N71, N79, N112 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position D22 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position E46 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position E53 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N7I as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N79 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N112 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions E46 and E53 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71 and N79 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N79 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71, N79 and N112 as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the amino acid substitution at position D22 is D22A.

In some embodiments, the amino acid substitution at position E46 is E46A.

In some embodiments, the amino acid substitution at position E46 is E46R.

In some embodiments, the amino acid substitution at position E46 is E46S.

In some embodiments, the amino acid substitution at position E53 is E53A.

In some embodiments, the amino acid substitution at position E53 is E53R.

In some embodiments, the amino acid substitution at position E53 is E53S.

In some embodiments, the amino acid substitution at position N71 is N71Q.

In some embodiments, the amino acid substitution at position N79 is N79Q.

In some embodiments, the amino acid substitution at position N112 is N112Q.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution D22A as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution E46A as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46A and E53A as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46R and E53R as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46S and E53S as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution E53A as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N71Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N79Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N12Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N71Q and N79Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N71Q and N112Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N79Q and N112Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution N71Q, N79Q and N112Q as compared to the amino acid sequence of SEQ ID NO: 224 as shown in the IL-15 Cytokine Moieties table below.

IL-15 Cytokine Moieties: SEQ Component ID NO Sequence DC hIL-15 223 MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEA (precursor) NWVN VISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVIS LESGD ASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQM FINTS hIL15 224 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK401 LQVISL AK402 ESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEF AK403 LQSFVH AK481 IVQMFINTS AK482 AK483 AK478 AK479 AK480 AK242 AK243 AK247 AK248 AK245 AK250 AK419 AK246 AK251 AK420 AK421 AK457 AK399 AK404 AK405 AK400 AK244 AK249 AK418 AK507 AK564 hIL15 225 NWVNVISDLKKIEDLIQSMHIAATLYTESDVHPSCKVTAMKCFLLE AK458 (D22A) LQVISLESGD ASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFINTS hIL15 226 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLA AK459 (E46A) LQVISLESGDA SIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVH IVQMFINTS hIL15 227 NWVNVISDIKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLA AK461 (E46A, E53A) LQVISLASGD AK527 ASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV AK506 HIVQMFINTS hL15 228 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLR not (E46R, E53R) LQVISLRSGD named ASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV yet- HIVQMFINTS 2 hIL15 229 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLS not (E46S, E53S) LQVISLSSGD named ASTHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV yet- HIVQMFINTS 1 hIL15 230 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK460 (E53A) LQVISLASGD ASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFINTS hIL15 231 NWVNVISDLKKIEDLIQS not (N-ter) named yet- 3 not named yet- 4 hIL15 232 KVTAMKCFLLELQVISLESGDASIHDTVENLILANNSLSSNGNVTE not (C-ter) SGCKECEELEE named KNIKEFLQSFVHIVQMFINTS yet- 3 not named yet- 4 IL-15 233 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK595 (N71Q) LQVISLESGD AK596 ASHIDTVENLIILAQNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFNTS hIL-15 234 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK901 (N79Q) LQVISLESGD AK907 ASIHDTVENLIILANNSLSSNGQVTESGCKECEELEEKNIKEFLQSFV HIVQMFINTS hIL-15 235 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK900 (N112Q) LQVISLESGD AK906 ASIHDTVLNLITLANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFIQTS hIL-15 236 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK904 (N71Q, LQVISLESGD AK910 N79Q) ASIHDTVENLITLAQNSLSSNGQVTESGCKECEELEEKNIKEFLQSFV AK929 HIVQMFINTS AK935 AK931 AK937 AK934 AK940 AK933 Ak939 hIL-15 237 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK903 (N71Q, LQVISLLSGD AK909 N112Q) ASIHDTVENLIILAQNSLSSNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFIQTS hIL-15 238 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK902 (N79Q, LQVISLESGD AK908 N112Q) ASIHDTVENLIILANNSLSSNGQVTESGCKECEELEEKNIKEFLQSFV HIVQMFIQTS hIL-15 239 NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLE AK905 (N71Q, LQVISLESGD AK911 N79Q, N112Q) ASIHDTVENLIILAQNSLSSNGQVTESGCKECEELEEKNIKEFLQSFV HIVQMFIQTS

In some embodiments, the IL-15 cytokine moiety has an amino acid sequence as shown by one of the sequences in the table above.

In some embodiments, an additional mutation may be included in any of the sequences above at position N71. In some embodiments, the mutation is N71A, N71R, N71W, N71F, N71P, N71M, N71L, N71T, N71S, or N71Y.

In some embodiments, an additional mutation may be included in any of the sequences above at position S73. In some embodiments, the mutation is S73A, S73W, S73V, or S73M.

In some embodiments, an additional mutation may be included in any of the sequences above at one or more of amino acid positions N72, N79, V80, T81, and N112. In some embodiments, one or more additional mutations selected from N72A, N79A, V80A, T81A and N112R may be included in any of the sequences above.

In some embodiments, an additional mutation may be included in any of the sequences above at one or more of amino acid positions N72, S73, N79, V80, T81, and N112. In some embodiments, one or more additional mutations N72A, S73A, N79A, V80A, T81A, and N112 may be included in any of the sequences above.

In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues e.g. residues 1-3 s removed as compared to the amino acid sequence of the mature IL-15 of SEQ ID 224 as shown in the IL-15 Cytokine Moieties table above, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues substituted as compared to the amino acid sequence of the mature IL-15 of SEQ ID 224 as shown in the IL-15 Cytokine Moieties table above, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues inserted, e.g. in the region of residues 1-3, as compared to the amino acid sequence of the mature IL-15 of SEQ ID 224 as shown in the IL-15 Cytokine Moieties table above, for the purpose of removing an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof does not have an O-glycosylation site within residues 1-3.

In some embodiments, the masked IL-15 cytokine further comprises a domain comprising an IL-15Rα subunit or a functional fragment thereof (‘IL-15Rα domain’), incorporating an ‘IL-15Rα domain’ into a masked IL-15 cytokine construct has been demonstrated to increase the potency of said cytokine in activating CD8 T cell and NK cells.

The IL-15Rα subunit (also referred to as CD215) is structurally similar to IL-2Rα; the ectodomain of IL-15Rα consists of a single protein-binding Sushi domain, a membrane-proximal proline-threonine-rich (PT) region, and a linker/hinge region that connects the sushi domain and the PT region. The IL-15Rα subunit specifically binds IL-15 with very high affinity and is capable of binding IL-15 independently of the β and γ subunits.

Interleukin (IL)-15 is a cytokine that acts on a wide range of cell types but is most crucial for the development, homeostasis, and function of a specific group of immune cells that includes CD8 T cells, NK cells. NKT cells, and CD8aa intraepithelial lymphocytes. IL-15 signals are transmitted through the IL-2/15Rβ and common γ (γC) chains; however, it is the delivery of IL-15 to these signalling components that is quite unique. As opposed to other cytokines that are secreted, IL-15 primarily exists bound to the high affinity IL-15Rα. When IL-15/IL-15Rα complexes are shuttled to the cell surface, they can stimulate opposing cells through the β/γC receptor complex. This novel mechanism of IL-15 delivery has been called trans-presentation (S. W. Stonier and K. S. Schluns, ‘Trans-presentation: a novel mechanism regulating IL-15 delivery and responses’, Immunol Lett Jan. 4 2010; 127(2): 85-92, the contents of which is incorporated herein by reference).

The IL-15Rα subunit comprises a conserved protein binding motif called a sushi domain. The sushi domain sIL-15Rα, which comprises amino acids 31 to 95 of the IL-15Rα subunit, is responsible for interacting with IL-15 and is essential for IL-15/IL-15Rα function (Wei X el al. ‘The Sushi Domain of Soluble IL-15 Receptor α Is Essential for Binding IL-15 and Inhibiting Inflammatory and Allogenic Responses In Vitro and In Vivo’, J Immunol Jul. 1, 2001; 167(1) 277-282, the contents of which is incorporated herein by reference).

The sequence of the wild-type IL-15Rα subunit is shown below, along with a breakdown of the main domains:

        10         20         30         40 MAPRRARGCR TLGLPALLLL LLLRPPATRG ITCPPPMSVE         50         60         70         80 HADIWVKSYS LYSRERYICN SGFKRKAGTS SLTECVLNKA         90        100        110        120 TNVAHWTTPS LKCIRDPALV HQRPAPPSTV TTAGVTPQPE        130        140        150        160 SLSPSKGEPA ASSPSSNNTA ATTAAIVPGS QLMPSKSPST        170        180        190        200 GTTEISSHES SHGTPSQTTA KNWELTASAS HQPPGVYPQG        210        220        230        240 HSDTTVAIST STVLLCGLSA VSLLACYLKS RQTPPLASVE        250        260      MEAMEALPVT WGTSSRDEDL ENCSHHL <sp|Q13261|1-30 (signal peptide MAPRRARGCRTLGLPALLLLLLLRPPATRG <sp|Q13261|31-205 (Extracellular domain) [Note: 31-95 is canonical “Sushi domain”] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVL NKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSP SGKEPAASSPSSNNTAATTAAIVPGS <sp|Q13261|206-225 (Transmembrane domain) VAISTSTVLLCGLSAVSLLACYL <sp|Q13261|229-267 (Cytoplasmic domain) KSRQTPPLASVEMEAMEALPVTWGTSSRDEDLENCSHHL

The ‘IL-15Rα domain’ herein can comprise the sequence of the extracellular domain of the wild-type IL-15Rα subunit or a variant thereof, such as the sequence of the extracellular domain of the wild-type IL-15Rα subunit with one or more e.g. 1, 2, 3 or 4 amino acid substitutions.

The ‘IL-15Rα domain’ herein can comprise the sequence of the wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of the wild-type sushi domain sIL-15Rα with one or more e.g. 1, 2, 3 or 4 amino acid substitutions.

The ‘IL-15Rα domain’ herein can consist of the sequence of the wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of the wild-type sushi domain sIL-15Rα with one or more e.g. 1, 2, 3 or 4 amino acid substitutions.

In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R26. In some embodiments, the IL-15Rα domain comprises amino acid substitution R26N. In some embodiments, the IL-15Rα domain comprises amino acid substitution R26S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R35. In some embodiments, the IL-15Rα domain comprises amino acid substitution R35Q. In some embodiments, the IL-15Rα domain comprises amino acid substitution R35S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at positions R26 and R35. In some embodiments, the IL-15Rα domain comprises amino acid substitutions R26S or R26N, and R35Q or R35S. In some embodiments, the IL-15Rα domain comprises amino acid substitutions R26N and R35Q.

Exemplary sequences for the IL-15Rα domain are shown below:

Component Sequence hCD215 ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLN KATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSP SGKEPAASSPSSNNTAATTAAIVPGSQLMPSKSPSTGTTEISSHESSH GTPSQTTAKNWELTASASHQPPGVYPQGHSDTT hCD215(1to66) ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNK ATNVAHWTTPSLKCIRD hCD215(1to66) ITCPPPMSVEHADIWVKSYSLYSRENYICNSGFKRKAGTSSLTECVLNK R26N ATNVAHWTTPSLKCIRD hCD215(1to66) ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKQKAGTSSLTECVLNK R35Q ATNVAHWTTPSLKCIRD hCD215(1to66) iTCPPPMSVEHADIWVKSYSLYSRESYICNSGFKRKAGTSSLTECVLNK R26S ATNVAHWTTPSLKCIRD hCD215(1to66) ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKSKAGTSSLTECVLNK R35S ATNVAHWTTPSLKCIRD hCD215(1to66) ITCPPPMSVEHADIWVKSYSLYSRENYICNSGFKQKAGTSSLTECVLNK R26N; R35Q ATNVAHWTTPSLKCIRD hCD215(Sushi) ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATN VAHWTTPSLKCIRDPALVHQRPAPP hCD215(Truncated) ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNV AHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAAS

In some embodiments, the IL-15Rα domain has an amino acid sequence as shown by one of the sequences in the table above.

(b) IL-15 Masking Moieties

Provided herein is a masking moiety for use in masking a therapeutic moiety comprising an IL-15 cytokine or functional fragment thereof.

It will be understood that the masking moiety is cleaved from the masked cytokine to form the cleavage product thereof. The masking moiety masks the IL-15 cytokine or functional fragment thereof in the masked cytokine thereby reducing or preventing binding of the IL-cytokine or functional fragment thereof to its cognate receptor. In some embodiments, the masking moiety reduces or prevents binding of the IL-cytokine or functional fragment thereof to IL-15Rα. In some embodiments, the masking moiety as provided herein refers to a moiety capable of binding to, or otherwise exhibiting an affinity for the IL-15 cytokine or functional fragment thereof, such as an anti-IL-15 antibody or IL-15 cognate receptor protein. Methods for determining the extent of binding of a protein (e.g., cytokine) to a cognate protein (e.g., cytokine receptor) are well known in the art.

In some embodiments, the masking moiety comprises an IL-15 cytokine receptor, or a subunit or functional fragment thereof.

In some embodiments, the masking moiety comprises IL-15Rβ (also referred to as CD122) or a fragment, portion, or variant thereof that retains or otherwise demonstrates an affinity to IL-15.

The wild type sequence of IL-15Rβ is shown in SEQ ID NO: 240 in the IL-15 Masking Moities table below.

In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below with one or two amino acid substitutions.

In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof, where the IL-15Rβ has an amino acid substitution at position C122.

In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), where the IL-15Rβ has amino acid substitution C122S.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has an amino acid substitution at position C122 as compared to IL-15Rβ of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has mutation C122S at amino acid position 122 as compared to IL-15β of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below with a C122 mutation.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below with a C122S mutation.

In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), where the IL-15Rβ has an amino acid substitution at position C168.

In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), where the IL-15Rβ has amino acid substitution C168S.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has mutation at amino acid position C168 as compared to IL-15Rβ of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has mutation C168S at amino acid position 168 as compared to IL-15Rβ of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below, with a C168 mutation.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 240 in the IL-15 Masking Moieties table below, with a C168S mutation.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has mutation at amino acid positions C122 and C168 as compared to IL-15Rβ of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the IL-15Rβ or a fragment, portion or variant thereof has mutation C122S and C168S as compared to IL-15Rβ of SEQ ID NO: 240 in the IL-15 Masking Moieties table below.

In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 241 in the IL-15 Masking Moieties table below.

TABLE IL-15 Masking Moieties: SEQ ID Component NO Sequence DC Masking hCD122 240 AVNGTSQFTCFYNSRANISCVWSQ AK247 moiety DGALQDTSCQVHAWPDRRRWNQTC AK248 (MM) ELLPVSQASWACNLILGAPDSQKL AK421 TTVDIVTLRVLCREGVRWRVMAIQ AK457 DFKPFENLRLMAPISLQVVHVETH AK249 RCNISWEISQASHYFERHLEFEAR AK418 TLSPGHTWEEAPLLTLKQKQEWIC AK250 LETLTPDTQYEFQVRVKPLQGEFT AK251 TWSPWSQPLAFRTKPAALGKD AK399 AK400 AK404 AK405 AK419 AK420 AK401 AK402 AK403 AK458 AK459 AK460 AK461 AK478 AK479 AK480 AK481 AK482 AK483 AK527 not named yet-3 not named yet-4 hCD122 241 AVNGTSQFTCFYNSRANISCVWSQ AK564 C122S, DGALQDTSCQVHAWPDRRRWNQTC AK596 C168S) ELLPVSQASWACNLILGAPDSQKL AK900 TTVDIVTLRVLCREGVRWRVMAIQ AK901 DFKPFENLRLMAPISLQVVHVETH AK902 RSNISWEISQASHYFERHLEFEAR AK903 TLSPGHTWEEAPLLTLKQKQEWIS AK904 LETLTPDTQYEFQVRVKPLQGEFT AK905 TWSPWSQPLAFRTKPAALGKD AK906 AK907 AK908 AK909 AK910 AK911 AK929 AK935 AK931 AK937 AK934 AK940 AK933 AK939

In some embodiments, the IL-15 masking moiety has an amino acid sequence as shown by one of the sequences in the table above.

1.2 Non-Cleavable Peptide Linkers

Provided herein are non-cleavable peptide linkers for use in drug construct or cleavage product thereof as described herein. A non-cleavable linker as provided herein refers to a peptide of two more amino acids that is used to link two functional components together in the masked cytokines described herein.

The masked cytokine comprises a first linker and a second linker, where at least the first linker or the second linker comprises a proteolytically cleavable peptide.

In some embodiments, the second linker comprises a proteolytically cleavable peptide (linker herein referred to as a ‘proteolytically cleavable linker’) and the first linker does not comprise a proteolytically cleavable peptide (linker herein referred to as a ‘non-cleavable linker’). This arrangement is described herein as ‘Structure A’. In In some embodiments, the first polypeptide chain comprises formula:

N′HL1-non-cleavable L1-MM C′

and the second polypeptide chain comprises formula:

N′HL2-cleavable L2-C C′

In some embodiments, the first linker comprises a proteolytically cleavable peptide (linker herein referred to as a ‘proteolytically cleavable linker’ or‘cleavable linker’) and the second linker does not comprise a proteolytically cleavable peptide (linker herein referred to as a ‘non-cleavable linker’). This arrangement is described herein as ‘Structure H’. In some embodiments, the first polypeptide chain comprises formula:

N′HL1-cleavable LM-MM C′

and the second polypeptide chain comprises formula:

N′HL2-non-cleavable L2-C C′

The non-cleavable linkers and cleavable linkers of some embodiments are described in more detail below.

In some embodiments, the non-cleavable linker is between 3 and 25 amino acids in length.

In some embodiments, the non-cleavable linker is between 3 and 18 amino acids in length.

In some embodiments, the non-cleavable linker is between 3 and 8 amino acids in length.

In some embodiments, the non-cleavable linker is between 4 and 6 amino acids in length.

In some embodiments, the non-cleavable linker is rich in amino acid residues G, S and P.

In some embodiments, the non-cleavable linker only includes amino acid residue types selected from the group consisting of G, S and P.

In some embodiments, the non-cleavable linker includes a ‘GS’ repeat.

In some embodiments, the non-cleavable linker includes an N′ terminal ‘P’ residue.

In some embodiments, the non-cleavable linker comprises an amino acid sequence PGSGS (SEQ ID NO: 14).

In some embodiments, the non-cleavable linker consists of the amino acid sequence PGSGS.

In some embodiments, the non-cleavable linker comprises an amino acid sequence GGSSPPGGGSSGGGSGP (SEQ ID NO: 23).

In some embodiments, the non-cleavable linker consists of the amino acid sequence GGSSPPGGGSSGGGSGP.

  GGSSPPGGGSSGGGSGP.

In some embodiments, wherein the second linker is a procolytically cleavable linker and the first linker is a non-cleavable linker, the non-cleavable linker comprises PGSGS. In some embodiments, wherein the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker, the non-cleavable linker consists of the amino acid sequence PGSGS.

In some embodiments, wherein the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, the non-cleavable linker comprises GGSSPPCGGGSSGGGSGP. In some embodiments, wherein the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, the non-cleavable linker consists of the amino acid sequence GGSSPPGGGSSGGGSGP.

In some embodiments, wherein the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker, the non-cleavable linker is between 3 and 8 amino acids in length. In some embodiments, the non-cleavable linker is between 4 and 6 amino acids in length. In some embodiments, the non-cleavable linker comprises an amino acid sequence as shown in SEQ ID NO: 14 (PGSGS).

In some embodiments, wherein the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, the non-cleavable linker is between 3 and 18 amino acids in length. In some embodiments, wherein the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, the non-cleavable linker is between 10 and 18 amino acids in length. In some embodiments, the non-cleavable linker comprises an amino acid sequence as shown in SEQ ID NO: 23 (GGSSPPGGGSSGGGSGP).

In some embodiments, it is desirable for the first and second polypeptide chains to be of the same or a similar length to facilitate the first half life extension domain associating with the second half life extension domain and the masking moiety masking the cytokine or functional fragment thereof in the assembled construct. As such where the masking moiety is a shorter amino acid sequence than the cytokine or functional fragment thereof, the difference in length may be compensated fully or in part by using a longer linker L1.

In some embodiments, the first polypeptide chain comprises formula:

N′HL1-non-cleavable L1-MM C′

and the second polypeptide chain comprises formula:

N′HL2-SD1-CP-SD2-C C′

In some embodiments, the first polypeptide chain comprises formula:

N′HL1-SD1-CP-SD2-MM C′

and the second polypeptide chain comprises formula:

N′HL2-non-cleavable L2-C C′

Linker combinations disclosed in exemplary AK molecules may be used with any cytokine moiety disclosed herein. Linker combinations disclosed in exemplary AK molecules may be used with any masking moiety disclosed herein. Linker combinations disclosed in exemplary AK molecules may be used with any half-life extension moieties. In other words, the linker disclosed in exemplary AK molecules may be used in combinations with any cytokine moiety disclosed herein, masking moiety disclosed herein and/or half-life extension moiety disclosed herein.

2. Cleavage Product

Provided herein is a cleavage product capable comprising an active therapeutic moiety, preparable by proteolytic cleavage of the proteolytically cleavable linker in the polypeptide drug constructs as described anywhere herein.

Provided herein is a cleavage product of a ‘heterodimeric’ masked cytokine described anywhere herein.

The masked cytokines described herein comprise a cleavable linker. Upon proteolytic cleavage of the cleavable linker at the cleavage site, a cleavage product comprising the cytokine moiety is formed. The cytokine moiety in the cleavage product is activated since it is no longer masked by the masking moiety. The cytokine moiety in the cleavage product is therefore capable of binding to the target protein.

The tumor cell environment is complex and can comprise multiple different proteases. As such, the precise site at which a given cleavable peptide within a masked cytokine will be cleaved in the tumor cell environment may vary between tumor types, between patients with the same tumor type and even between cleavage products formed in the same tumor. Moreover, even after cleavage, further modification of the initial cleavage product, e.g. by removal of one or two terminal amino acids, may occur by the further action of proteases in the tumor cell environment. A distribution of cleavage products can thus be expected to form in the tumor cell environment of a patient following administration of a masked cytokine as described herein.

It will be understood that a cleavage site as referred to herein refers to a site between two specific amino acid residues within the cleavable peptide that are a target for a protease known to be associated with a tumor cell environment. In this sense, there may be more than one cleavage site present in a cleavable peptide as described herein where different proteases cleave the cleavable peptide at different cleavage sites. It is also possible that more than one protease may act on the same cleavage site within a cleavable peptide. Discussion of protease cleavage sites can be found in the art.

Thus, the cleavable peptides disclosed herein may be cleaved by one or more proteases. Provided herein is a cleavage product comprising a cytokine moiety capable of binding to it cognate receptor, preparable by proteolytic cleavage of the proteolytically cleavable linker in a masked cytokine as described anywhere herein.

Also provided herein is a distribution of cleavage products obtained or obtainable from a single structure of a masked cytokine, where each cleavage product within the distribution of cleavage products (i) is capable of binding to the target protein and (ii) comprises a cytokine (e.g. IL-2. IL-15 or IL-12 cytokine) moiety as defined anywhere herein.

Also provided herein is a cleavage product of a masked cytokine, where the cleavage product is capable of binding to the target protein, the cleavage product comprising a polypeptide comprising formula:

PCP-SD-C

wherein PCP is a portion of a proteolytically cleavable peptide; SD is a spacer domain; and C is a cytokine moiety.

Further provided herein is a cleavage product of a masked cytokine, where the cleavage product is capable of binding to the target protein, the cleavage product comprising a protein heterodimer comprising:

-   -   a) a first polypeptide chain comprising a first half-life         extension moiety; and     -   b) a second polypeptide chain comprising a polypeptide         comprising formula:

HL2-L2-C

wherein HL2 is a second half-life extension moiety; L2 is a non-cleavable linker; and C is a cytokine moiety; and wherein the first half-life extension moiety is associated with the second half-life extension moiety. Also provided herein is a distribution of cleavage products obtained or obtainable from a single structure of a masked cytokine, where each cleavage product within the distribution of cleavage products (i) is capable of binding to the target protein and (ii) comprises a protein heterodimer comprising:

-   -   a) a first polypeptide chain comprising a first half-life         extension moiety; and     -   b) a second polypeptide chain comprising a polypeptide         comprising formula:

HL2-L2-C

wherein HL2 is a second half-life extension moiety: L2 is a non-cleavable linker, and C is a cytokine moiety; and wherein the first half-life extension moiety is associated with the second half-life extension moiety.

Further provided herein is a cleavage product of a masked cytokine, where the cleavage product is capable of binding to the target protein, the cleavage product comprising a protein heterodimer comprising:

-   -   a) a first polypeptide chain comprising a polypeptide comprising         formula:

HL1-SD-PCP

wherein HL1 is a first half-life extension moiety; SD is a spacer domain; and PCP is a portion of a proteolytically cleavable peptide; and

-   -   b) a second polypeptide chain comprising a polypeptide         comprising formula:

HL2-L2-C

wherein HL2 is a second half-life extension moiety; L2 is a non-cleavable linker; and C a cytokine moiety; and wherein the first half-life extension moiety is associated with the second half-life extension moiety.

Within the cleavage product, the masking moiety, half-life extension moieties, cytokine moiety, linkers, space domains may be any one of those described herein, and any combination of those described herein.

The location of the cleavable peptide determines the structure of the resulting cleavage product comprising the cytokine moiety.

A “portion of a proteolytically cleavable peptide”, refers to a part of the original proteolytically cleavable peptide sequence after cleavage at the cleavage site has occurred. After cleavage, further modification of the initial cleavage product, e.g. by removal of one or two terminal amino acids, may also occur by the further action of proteases in the tumor cell environment. As such, cleavage products within the distribution of cleavage products that might be formed in the tumor cell environment of a patient following administration of a masked cytokine might not contain any portion of the proteolytically cleavable peptide.

In some embodiments, a “portion” refers to 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids or 6 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a “portion” refers to 2 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a “portion” refers to 3 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a “portion” refers to 4 amino acids of the original proteolytically cleavable peptide sequence.

In some embodiments, the ‘portion’ of the proteolytically cleavable peptide is from 3 to 6 amino acids in length. In some embodiments, the ‘portion’ of the proteolytically cleavable peptide is 3 or 4 amino acids in length.

Exemplary cleavage sites for cleavable linkers disclosed herein are disclosed below (* indicates a known or observed protease cleavage site within the cleavable peptide):

DLLA*VVAAS   ISSGLL*SG*RS

Accordingly, herein disclosed is the cleavage product of any one of the polypeptide drug constructs or masked cytokines disclosed herein.

3. Binding Assays

The strength, or affinity of immunological binding interactions, such as between a cytokine or functional fragment thereof and a binding partner (e.g., a target protein, such as a cytokine receptor) for which the cytokine or functional fragment thereof is specific, can be expressed in terms of the dissociation constant (Kd) of the interaction, wherein a smaller Kd represents a greater affinity. The binding of the cytokine to the cytokine receptor can be expressed in terms of the Kd. In some embodiments, the immunological binding interactions are between a masked cytokine (in the presence or absence of a protease) and a target protein, such as a cytokine receptor. In the context of IL-2 cytokine binding, the target protein could be IL-2R (comprising the IL-2Rα, IL-2Rβ, and IL-2Rγ chains), the IL-2Rα chain, the IL-2Rβ chain, or the IL-2Rα/β dimeric complex. Immunological binding properties of proteins can be quantified using methods well known in the art. For example, one method comprises measuring the rates of cytokine receptor (e.g., IL-2R)/cytokine (e.g., IL-2) complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Both the “on rate constant” (Kon) and the “off rate constant” (Koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of Koff/Kon enables the cancelation of all parameters not related to affinity, and is equal to the dissociation constant Kd. See Davies et al., Annual Rev Biochem. 59:439-473, (1990).

In some aspects, a masked cytokine described herein binds to a target protein with about the same or higher affinity upon cleavage with a protease as compared to the parental cytokine that comprises a masking moiety but does not comprise a cleavable peptide. The target protein can be any cytokine receptor. In some embodiments, the target protein is IL-2R (comprising the IL-2Rα, IL-2Rβ, and IL-2Rγ chains). In some embodiments, the target protein is IL-2Rα. In some embodiments, the target protein is IL-2Rβ. In some embodiments, the target protein is the IL-2Rα/β dimeric complex.

In some embodiments, a masked cytokine provided herein that does not comprise a cleavable peptide in the linker has a dissociation constant (Kd) of ≤1M, ≤150 nM, ≤100 nM, ≤50 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10-8 M or less, e.g. from 10-8M to 10-13 M, e.g., from 10-9 M to 10-13 M) with the target protein. In some embodiments, a masked cytokine provided herein that comprises a cleavable peptide in the linker has a dissociation constant (Kd) of ≤1M, ≤150 nM, ≤100 nM, ≤50 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or 0.001 nM (e.g. 10-8 M or less, e.g. from 10-8 M to 10-13 M, e.g., from 10-9 M to 10-13 M) with the target protein prior to cleavable with a protease. In some embodiments, a masked cytokine provided herein that comprises a cleavable peptide in the linker has a dissociation constant (Kd) of ≤1M, ≤150 nM, ≤100 nM, ≤50 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10-8 M or leas, e.g. from 10-8 M to 10-13 M, e.g., from 10-9M to 10-13 M) with the target protein upon cleavage with a protease. In some embodiments, the cytokine or functional fragment thereof of a masked cytokine provided herein has a dissociation constant (Kd) of ≥500M, ≥250M, ≥200M, ≥150M, ≥100M, ≥50, ≥10M, ≥1M, ≥500 nM, ≥250 nM, ≥150 nM, ≥100 nM, ≥50 nM, ≥1 nM, ≥1 nM, ≥0.1 nM, ≥0.01 nM, or ≥0.001 nM with the masking moiety of the masked cytokine. In some embodiments, the cytokine or functional fragment thereof of a masked cytokine provided herein has a dissociation constant (Kd) that is between about 200M and about 50 nM, such as about or at least about 175M, about or at least about ISM, about or at least about 125M, about or at least about 100M, about or at least about 75M, about or at least about 50M, about or at least about 25M, about or at least about 5M, about or at least about 1M, about or at least about 750 nM, about or at least about 500 nM, about or at least about 250 nM, about or at least about 150 nM, about or at least about 100 nM, about or at least about 75 nM, or about or at least about 50 nM. Assays for assessing binding affinity are well known in the art.

In some aspects, masked cytokines that exhibit a desired occlusion ratio are provided. The term “occlusion ratio” as used herein refers a ratio of (a) a maximum detected level of a parameter under a first set of conditions to (b) a minimum detected value of that parameter under a second set of conditions. In the context of a masked IL-2 polypeptide, for example, the occlusion ratio refers to the ratio of (a) a maximum detected level of target protein (e.g., IL-2R protein) binding to the masked IL-2 polypeptide in the presence of at least one protease capable of cleaving the cleavable peptide of the masked IL-2 polypeptide to (b) a minimum detected level of target protein (e.g., IL-2R protein) binding to the masked IL-2 polypeptide in the absence of the protease. Thus, the occlusion ratio for a masked cytokine can be calculated by dividing the EC50 of the masked cytokine pre-cleavage by the EC50 of the masked cytokine post-cleavage. The occlusion ratio of a masked cytokine can also be calculated as the ratio of the dissociation constant of the masked cytokine before cleavage with a protease to the dissociation constant of the masked cytokine after cleavage with a protease. In some embodiments, a greater occlusion ratio for the masked cytokine indicates that target protein bound by the masked cytokine occurs to a greater extent (e.g., predominantly occurs) in the presence of a protease capable of cleaving the cleavable peptide of the masked cytokine than in the absence of a protease.

In some embodiments, masked cytokines with an optimal occlusion ratio are provided herein. In some embodiments, an optimal occlusion ratio of a masked cytokine indicates the masked cytokine has desirable properties useful for the methods or compositions contemplated herein. In some embodiments, a masked cytokine provided herein exhibits an optimal occlusion ratio of about 2 to about 10.000, e.g., about 80 to about 100. In a further embodiment of any of the masked cytokine provided herein, the occlusion ratio is about 2 to about 7,500, about 2 to about 5,000, about 2 to about 2,500, about 2 to about 2.000, about 2 to about 1,000, about 2 to about 900, about 2 to about 800, about 2 to about 700, about 2 to about 600, about 2 to about 500, about 2 to about 400, about 2 to about 300, about 2 to about 200, about 2 to about 100, about 2 to about 50, about 2 to about 25, about 2 to about 15, about 2 to about 10, about 5 to about 10, about 5 to about 15, about 5 to about 20, about 10 to about 100, about 20 to about 100, about 30 to about 100, about 40 to about 100, about 50 to about 100, about 60 to about 100, about 70 to about 100, about 80 to about 100, or about 100 to about 1,000. In some embodiments, a masked cytokine provided herein exhibits an optimal occlusion ratio of about 2 to about 1,000. Binding of a masked cytokine to a target protein before cleavage and/or after cleavage with a protease can be determined using techniques well known in the art such as by ELISA.

In some embodiments, a masking moiety described herein binds to a cytokine or functional fragment thereof as described herein with lower affinity than the affinity between the cytokine or functional fragment thereof and a target protein (e.g., cytokine receptor). In certain embodiments, a masking moiety provided herein binds to a cytokine or functional fragment thereof as described herein with a dissociation constant (Kd) of ≥500M, ≥250M, ≥200M, ≥150M, ≥100M, ≥50M, ≥10M, ≥1M, ≥500 nM, ≥250 nM, ≥150 nM, ≥100 nM, ≥50 nM, ≥10 nM, ≥1 nM, ≥0.1 nM, ≥0.01 nM, or ≥0.001 nM.

4. Masked Cytokine Production

The masked cytokines described herein are prepared using techniques available in the art, exemplary methods of which are described.

4.1 Antibody Production

Some embodiments of the masked cytokine comprise an antibody or fragment thereof. The following sections provide further detail on the production of antibodies and antibody fragments, variants, and derivatives thereof, that may be used in some embodiments of the masked cytokine provided herein. In some embodiments, the masked cytokine is in the form of a dimer produced by two copies of a masked cytokine that are associated through disulfide bonds.

1. Antibody Fragments

The present invention encompasses. In some embodiments, antibody fragments. The antibody fragments can be any antibody fragments, such as an Fc domain, a portion of the heavy chain, a portion of the light chain, an Fab, an Fv, or an scFv, among other fragments. Antibody fragments may be generated by traditional means, such as enzymatic digestion, or by recombinant techniques. In certain circumstances, there are advantages of linking antibody fragments, rather than whole antibodies, to the masked cytokines described herein. For a review of certain antibody fragments, see Hudson et al. (2003) Nat. Med. 9:129-134.

Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from E. coli and other cell types, such as HEK293 and CHO cells, thus allowing the facile production of large amounts of these fragments. Alternatively, Fab-SH fragments can be directly recovered from culture media and chemically coupled to form F(ab)2 fragments (Carter et al.. Bio/Technology 10: 163-167 (19)2)). According to another approach. F(ab)2 fragments can be isolated directly from recombinant host cell culture. Fab and F(ab)2 fragments with increased in vivo half-life comprising FcRN/salvage receptor binding epitope residues are described in U.S. Pat. No. 5,869,046. Other techniques for the production of antibody fragments for use in the masked cytokines will be apparent to the skilled practitioner. In certain embodiments, a masked cytokine comprises a single chain Fv fragment (scFv). See WO 93/16185; U.S. Pat. Nos. 5,571,894, and 5,587,458. scFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an scFv. See Antibody Engineering, ed. Borrebaeck, supra. Also, in some embodiments, bi-scFv comprising two scFvs linked via a polypeptide linker can be used with the masked cytokines.

The present invention includes, in some embodiments, a linear antibody (e.g., as described in U.S. Pat. No. 5,641,870) or a single chain immunoglobulin comprising heavy and light chain sequences of the antibody linked via an appropriate linker. Such linear antibodies or immunoglobulins may be monospecific or bispecific. Such a single chain immunoglobulin can be dimerized to thereby maintain a structure and activities similar to those of the antibody, which is originally a tetramer. Also, in some embodiments, the antibody or fragment thereof may be an antibody that has a single heavy chain variable region and has no light chain sequence. Such an antibody is called a single domain antibody (sdAb) or a nanobody. These antibodies are also encompassed in the meaning of the functional fragment of the antibody according to the present invention. Antibody fragments can be linked to the masked cytokines described herein according to the guidance provided herein.

2. Humanized Antibodies

The invention encompasses, in some embodiments, humanized antibodies or antibody fragments thereof. In some embodiments, the humanized antibodies can be any antibodies, including any antibody fragment. Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody can have one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain. Humanization can be essentially performed following the method of Winter (Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536), by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such “humanized” antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies can be linked to the masked cytokines described herein according to the guidance provided herein.

3. Human Antibodies

Human antibodies of some embodiments of the invention can be constructed by combining Fv clone variable domain sequence(s) selected from human-derived phage display libraries with known human constant domain sequences(s). Alternatively, human monoclonal antibodies of some embodiments of the invention can be made by the hybridoma method, e.g., by using mouse, rat, bovine (e.g., cow), or rabbit cells, for example, to produce the human monoclonal antibodies. In some embodiments, the human antibodies and human monoclonal antibodies can be antibodies that bind to any antigen. In some embodiments, human monoclonal antibodies of the invention can be made by immunizing a non-human animal that comprises human immunoglobulin loci with the target antigen, and isolating the antibody from the immunized animal or from cells derived from the immunized animal. Examples of suitable non-human animals include a transgenic or transchromosomic animal, such as HuMAb Mouse® (Medarex, Inc.), KM Mouse®, “TC mice,” and Xenomouse™. See, e.g., Lonberg, et al. (1994) Nature 368: 856-859; Fishwild, D. et al. (1996) Nature Biotechnology 14: 845-851; WO2002143478; U.S. Pat. Nos. 5,939,598; 6,075,181; 6,114,598; 6,150,584; 6,162,963; and Tomizuka et al. (200) Proc. Natl. Acad. Sci. USA 97:722-727.

Human myeloma and murine-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications. pp. 51-63 (Marcel Dekker. Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991). Human antibodies can be linked to the masked cytokines described herein according to the guidance provided herein.

4. Bispecific Antibodies

Bispecific antibodies are monoclonal antibodies that have binding specificities for at least two different antigens. In certain embodiments, bispecific antibodies are human or humanized antibodies. In some embodiments, one of the binding specificities is for a first antigen and the other binding specificity is for a second antigen, which may be either two different epitopes on the same target protein, or two different epitopes on two different target proteins. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express the first antigen and/or the second antigen. Bispecific antibodies may also be used to recruit cells, such as T cells or natural killer cells, to kill certain cells, e.g., cancer cells. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g. F(ab′)2 bispecific antibodies). Bispecific antibodies can be linked to the masked cytokines described herein according to the guidance provided herein.

Methods for making bispecific antibodies are known in the art. See Milstein and Cuello. Nature, 305: 537 (1983), WO 93/08829 published May 13, 1993, Traunecker et al., EMBO J., 10: 3655 (1991); Kontermann and Brinkmann, Drug Discovery Today, 20(7):838-847. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986). Bispecific antibodies include cross-linked or “heteroconjugate” antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Heteroconjugate antibodies may be made using any convenient cross-linking method. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

5. Single-Domain Antibodies

In some embodiments, a single-domain antibody is linked to the masked cytokine in accordance with the guidance provided herein. The single-domain antibody can be any antibody. A single-domain antibody is a single polypeptide chain comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 B1). In some embodiments, a single-domain antibody consists of all or a portion of the heavy chain variable domain of an antibody. In some embodiment, the single domain antibody is a camelid-derived antibody obtained by immunization of a camelid with the target antigen. In some embodiments, the single domain antibody is a shark-derived antibody obtained by immunization of a shark with the target antigen. In some embodiments, the single domain antibody is a Nanobody (see, e.g., WO 2004041 X65A2 and US20070269422A1).

6. Antibody Variant

In some embodiments, amino acid sequence modification(s) of the antibodies or fragments thereof described herein are contemplated. For example, it may be desirable to improve the FcRn-binding affinity and/or pH-dependent FcRn-binding affinity of the antibody. It may also be desirable to promote heterodimerization of antibody heavy chains by introducing certain amino acid modifications. Methods for promoting heterodimerization of antibody chains, including certain modifications that can be made to facilitate heterodimerization, is described by Klein et al. (2012), MAbs, 4(6): 653-663.

Amino acid sequence variants of the antibody may be prepared by introducing appropriate changes into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid alterations may be introduced in the subject antibody amino acid sequence at the time that sequence is made.

A useful method for identification of certain residues or regions of the antibody that are preferred locations for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085. Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to affect the interaction of the amino acids with antigen. Those amino acid locations demonshating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed immunoglobulins are screened for the desired activity.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme or a polypeptide which increases the serum half-life of the antibody.

In some embodiments, the masked cytokine is modified to eliminate, reduce, or otherwise hinder protease cleavage near the hinge region. The “hinge region” of an IgG is generally defined as including E216 and terminating at P230 of human IgG1 according to the EU index as in Kabat, but, functionally, the flexible portion of the chain may be considered to include additional residues termed the upper and lower hinge regions, such as from E216 to G237 (Roux et al., 1998 J Immunol 161:4083) and the lower hinge has been referred to as residues 233 to 239 of the Fc region where FcγR binding was generally attributed. Modifications to any of the masked cytokines described herein, can be performed, for example, according to the methods described in US 20150139984A1, which is incorporated herein by reference, as well as by incorporating any of the modifications described therein.

In some embodiments, FcRn mutations that improve pharmacokinetics include, but are not limited to, M428L, T250Q/M428L, M252Y/S254T/T256E, P257I/N434H, D376V/N434H, P257I/Q311I, N434A, N434W, M428L/N434S, V259I/V308F, M252Y/S254T/T256E, V259I/V308F/M428L, T307Q/N434A, T307Q/N434S, T307Q/E380A/N434A, V308P/N434A, N434H, V308P. In some embodiments, such mutations enhance antibody binding to FcRn at low pH but do not change the antibody affinity at neutral pH.

In certain embodiments, an antibody or fragment thereof is altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition or deletion of glycosylation sites to the masked cytokine is conveniently accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences (for N-linked glycosylation sites) is created or removed. The alteration may also be made by the addition, deletion, or substitution of one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

Where the antibody or fragment thereof comprises an Fc region, the carbohydrate attached thereto may be altered. For example, antibodies with a mature carbohydrate structure that lacks fucose attached to an Fc region of the antibody are described in US Pat Appl No US 2003/0157108 (Presta, L.). See also US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Antibodies with a bisecting N-acetylglucosamine (GlcNAc) in the carbohydrate attached to an Fc region of the antibody are referenced in WO 2003/011878, Jean-Mairet et al, and U.S. Pat. No. 6,602,684, Umana et al. Antibodies with at least one galactose residue in the oligosaccharide attached to an Fc region of the antibody are reported in WO 1997/30087, Patel et al. See, also, WO 1998/58964 (Raju, S.) and WO 1999/22764 (Raju, S.) concerning antibodies with altered carbohydrate attached to the Fc region thereof. See also US 2005/0123546 (Umana et al.) on antigen-binding molecules with modified glycosylation.

In certain embodiments, a glycosylation variant comprises an Fc region, wherein a carbohydrate structure attached to the Fc region lacks fucose or has reduced fucose. Such variants have improved ADCC function. Optionally, the Fc region further comprises one or more amino acid substations therein which further improve ADCC, for example, substitutions at positions 298, 333, and/or 334 of the Fc region (Eu numbering of residues). Examples of publications related to “defucosylated” or “fucose-deficient” antibodies include: US 2003/0157108; WO 2000/61739: WO 2001/29246; US 2003/0115614; US 200210164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865: WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 20054035778: WO2005/053742; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004). Examples of cell lines producing defucosylated antibodies include Lee 13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545(1986); US Pat App No US 2003/0157108 A1. Presta, L; and WO 2004/056312 A1. Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614(2004)), and cells overexpressing (31,4-N-acetylglycosaminyltransferases III (GnT-III) and Golgi p-mannosidase II (ManII).

In any of the embodiments herein, the masked cytokine can be engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some embodiments, the masked cytokine may be produced in a cell line having a alpha1,6-fucosyltransferase (Fut8) knockout. In some embodiments, the host cells have been modified to have reduced intrinsic alpha1,6-fucosylation activity. Examples of methods for modifying the fucosylation pathways in mammalian host cells can be found in, e.g., Yamane-Ohnuki and Satoh, MAbs, 1(3): 230-236 (2009), the contents of which are incorporated herein by reference. Examples of methods and compositions for partially or completely inactivating the expression of the FUT8 gene can be found in, e.g., US Pub. No. 20160194665A1; WO2006133148A2, the contents of which are incorporated herein by reference. In some embodiments, the masked cytokine is produced in the Lec13 variant of CHO cells (see, e.g., Shields et al., J. Biol. Chem., 277(30):26733-40 (2002)) or the YB2/0 cell line having reduced FUT8 activity (see, e.g., Shinkawa et al., J. Biol. Chem., 278(5): 3466-73 (2003)). In some embodiments, small interfering RNA (siRNA) against genes relevant to alpha1,6-fucosylation can be introduced (see, e.g., Mori et al., Biotechnol. Bioeng. 88(7): 901-908 (2004); Imai-Nishiya et al., BMC Biotechnol. 7: 84 (2007); Omasa et al., J. Biosci. Bioeng., 106(2): 168,173 (2008)). In some further embodiments, the masked cytokine may be produced in a cell line overexpressing 31,4-N-acetylglucosaminyltransferase III (GnT-III). In further embodiments, the cell line additionally overexpresses Golgi p-mannosidase II (ManII). In some of the embodiments herein, the masked cytokine may comprise at least one amino acid substitution in the Fc region that improves ADCC activity.

In some embodiments, the masked cytokine is altered to improve its serum half-life. To increase the serum half-life of the cytokine, one may incorporate a FcRN/salvage receptor binding epitope into a linked antibody (especially an antibody fragment) as described in U.S. Pat. No. 5,739,277, for example. As used herein, the term “salvage receptor binding epitope” refers to an epitope of the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule (US 2003/0190311, U.S. Pat. Nos. 6,921,505; 6,165,745; 5,624,821; 5,648,260; 6,165,745; 5,834,597).

Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced by a different residue. Sites of interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 2 under the heading of “preferred substitutions.” If such substitutions result in a desirable change in biological activity, then more substantial changes, denominated “exemplary substitutions” in Table 2, or as further described below in reference to amino acid classes, may be introduced and the products screened.

TABLE 2 Original Preferred Residue Exemplary Substitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln; Asn Lys Asn (N) Gln; His; Asp; Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser Trt (W) Tyr; The Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or c) the bulk of the side chain. Amino acids may be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75. Worth Publishers, New York (1975)):

(1) non-polar, Ala (A), Val (V), Leu (L), lie (I), Pro (P), Phe (F), Trp (W), Met (M) (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q) (3) acidic: Asp (D), Glu (E) (4) basic: Lys (K), Arg (R), His (H)

Alternatively, naturally occurring residues may be divided into groups based on common side-chain properties:

(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, he; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientahon: Gly, Pro; (6) aromatic: Trp, Tyr, Phe,

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, into the remaining (non-conserved) sites.

Another type of substitutional variant involves the substitution of a naturally occurring amino acid residue for a non-naturally occurring amino acid residue. Non-naturally occurring amino acid residues can be incorporated, e.g., through tRNA recoding, or through any of the methods as described, e.g., in WO 2016154675A1, which is incorporated herein by reference.

One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have modified (e.g., improved) biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display, yeast display, or mammalian display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino acid substitutions at each site. The antibodies thus generated are displayed from filamentous phage particles as fusions to at least part of a phage coat protein (e.g., the gene II product of M13) packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity). In order to identify candidate hypervariable region sites for modification, scanning mutagenesis (e.g., alanine scanning) can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighbouring residues are candidates for substitution according to techniques known in the art, including those elaborated herein. Once such variants are generated, the panel of variants is subjected to screening using techniques known in the an, including those described herein, and antibodies with superior properties in one or more relevant assays may be selected for further development.

Nucleic acid molecules encoding amino acid sequence variants of the masked cytokines are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis. PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the antibody, for example.

It may be desirable to introduce one or more amino acid modifications in an Fc region of antibodies of the invention, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fe region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions including that of a hinge cysteine.

In some embodiments, a masked cytokine provided herein includes an antibody or fragment thereof having an IgG1, IgG2, IgG3, or IgG4 isotype with enhanced effector function. In some embodiments, a masked cytokine provided herein includes an antibody or fragment thereof having an IgG1 isotype with enhanced effector function. In some embodiments, a masked cytokine provided herein has an IgG1 isotype with enhanced effector function. In some embodiments, the masked cytokine is afucosylated. In some embodiments, the masked cytokine has increased levels of mannose moieties. In some embodiments, the masked cytokine has increased levels of bisecting glycan moieties. In some embodiments, the IgG1 comprises amino acid mutations.

In some embodiments, a masked cytokine provided herein includes an antibody having an IgG1 isotype (e.g., a human IgG1 isotype). In some embodiments, the IgG1 comprises one or more amino acid substitutions that enhance effector function. In one embodiment, the IgG1 comprises the amino acid substitutions S298A, E333A, and K334A wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions S239D and I332E wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions S239D, A330L, and I332E wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions P247I and A339D or A339Q wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions D280H, K290S with or without S298D or S298V wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions F243L, R292P, and Y300L, wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions F243L, R292P, Y300L, and P396L wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions F243L, R292P. Y300L, V305I, and P396L wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions G236A, S239D, and I332E wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K326A and E333A wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K326W and E333S wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K290E, S2980, T299A, with or without K326E wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K290N, S298G, T299A, with or without K326E wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitution K334V wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions L235S, S239D, and K334V wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V and Q331M, S239D, F243V, E294L, or S298T wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions E233L, Q311M. and K334V wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions L234I, Q311M, and K334V wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V and S298T, A330M, or A330F wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V, Q31 1M, and either A330M or A330F wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V, S298T, and either A330M or A330F wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V, S239D, and either A330M or S298T wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions L234Y. Y296W, and K290Y, F243V, or E294L wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions Y296W and either L234Y or K290Y wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions S239D, A330S, and I332E wherein the amino acid residues are numbered according to the EU index as in Kabat.

In some embodiments, the IgG1 comprises one or more amino acid substitutions that decrease or inhibit effector function. In one embodiment, the IgG1 comprises the amino acid substitution N297A, N297G, or N297Q wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitution L234A or L235A wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions C220S, C226S. C229S, and P238S wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions C226S, C229S, E233P, L234V, and L235A wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions L234F, L235E, and P331S wherein the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions S267E and L328F wherein the amino acid residues are numbered according to the EU index as in Kabat.

In accordance with this description and the teachings of the art, it is contemplated that in some embodiments, an antibody or fragment thereof of the masked cytokine may comprise one or more alterations as compared to the wild type counterpart antibody, e.g. in the Fc region. For example, it is thought that certain alterations can be made in the Fc region that would result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in WO99/51642. See also Duncan & Winter Nature 322:738-40 (1988); U.S. Pat. Nos. 5,648,260; 5,624,821; and WO94/29351 concerning other examples of Fc region variants. WO00/42072 (Presta) and WO 2004/056312 (Lowman) describe antibody variants with improved or diminished binding to FcRs. The content of these patent publications are specifically incorporated herein by reference. See also Shields et al. J. Biol. Chem. 9(2): 6591-6604 (2001). Antibodies with increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). These antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding capability are described in U.S. Pat. No. 6,194,551B1, WO99/51642. The contents of those patent publications are specifically incorporated herein by reference. See, also, Idusogie et al. J. Immunol. 164: 41784184 (2000).

4.2 Masked Cytokine-Drug Conjugates

The invention also provides masked cytokine-drug conjugates (MCDCs) comprising a masked cytokine provided herein, which can be any masked cytokine disclosed herein, conjugated to one or more agents. In some embodiments, the one or more agents is a cytotoxic agent, such as a chemotherapeutic agent or drug, growth inhibitory agent, toxin (e.g., protein toxin, enzymatically active

toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes. In some embodiments, the one or more agents is an immune stimulant.

In some embodiments, the one or more drugs conjugated to the masked cytokine includes, but is not limited to, a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 423 235 B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,56, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et ak. Cancer Res. 53:3336-3342 (1993); and Lode et ak, Cancer Res. 58:2925-2928 (1998)); an anthracycline such as daunomycin or doxorubicin (see Kratz et ak, Current Med. Chem. 13:477-523(2006); Jeffrey et ak, Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et ak, Bioconj. Chem. 16:717-721 (2005); Nagy et ak, Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et ak. Bioorg. & Med. Chem. Letters 12:1529-1532(2002); King et ak, J. Med. Chem. 45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a trichothecene; and CC1065.

In another embodiment, the one or more drugs conjugated to the masked cytokine includes, but is not limited to, an inhibitor of tubulin polymerization (e.g., maytansinoids and auristatins), DNA damaging agents (e.g., pyrrolobenzodiazepine (PBD) dimers, calicheamicins, duocarmycins and indo-linobenzodiazepine dimers), and DNA synthesis inhibitors (e.g., exatecan derivative Dxd).

In another embodiment, a masked cytokine-drug conjugate comprises a masked cytokine as described herein conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins. Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.

In another embodiment, a masked cytokine-drug conjugate comprises a masked cytokine as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugates. Examples include At211,1131,1125, Y90, Re186, Re188, Sm153, B1212, P32, Pb212 and radioactive isotopes of Lu. When the radioconjugated is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example tc99m or 1123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

In some embodiments, a masked cytokine-drug conjugate comprises a masked cytokine as described herein conjugated to one or more immune stimulants. In some embodiments, the immune stimulant is a stimulator of interferon genes (STING) agonist or a toll-like receptor (TER) agonist.

The STING agonist can be any agonist of STING. In some embodiments, the STING agonist is a cyclic dinucleotide (CDN). The CDN can be any CDN or derivative or variant thereof. In some embodiments, the STING agonist is a CDN selected from the group consisting of cGAMP, c-di-AMP, c-di-GMP, cAIMP, and c-di-IMP. In some embodiments, the STING agonist is a derivative or variant of a CDN selected from the group consisting of cGAMP, c-di-AMP, c-di-GMP, cAIMP, and c-di-IMP. In some embodiments, the STING agonist is 4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide, or a derivative or variant thereof. See, e.g., Sali et al. (2015) PloS Pathog., 11(12): e005324.

The TLR agonist can be an agonist of any TLR, such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, or TLR10. In some embodiments, the TLR agonist is an agonist of a TLR expressed on the cell surface, such as TLR1, TLR2, TLR4, or TLR5. In some embodiments, the TLR agonist is an agonist of a TLR expressed intracellularly, such as TLR3, TLR7, TLR8, TLR9, or TLR10.

Conjugates of a masked cytokine and a cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et ah, Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to an antibody. &e WO94/11026. The linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et ah, Cancer Res. 52:127-131 (1992), U.S. Pat. No. 5,208,020) may be used.

The MCDCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfonejbenzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A).

4.3 Vectors, Host Cells, and Recombinant Methods

For recombinant production of a masked cytokine of the invention, the one or more nucleic acids encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. DNA encoding the masked cytokine, including components thereof, is readily isolated and sequenced using conventional procedures. Many vectors are available. The choice of vector depends in part on the host cell to be used. Generally, host cells are of either prokaryotic or eukaryotic (generally mammalian) origin. It will be appreciated that constant regions of any isotype of antibody or fragment thereof, when applicable, can be used for this purpose, including IgG, IgM, IgA, IgD, and IgE constant regions, and that such constant regions can be obtained from any human or animal species. In some embodiments, one vector is used to encode the masked cytokine. In some embodiments, more than one vector is used to encode the masked cytokine.

1. Generating Masked Cytokines Using Prokaryotic Host Cells

a. Vector Construction

Polynucleotide sequences encoding polypeptide components of the masked cytokines of the invention can be obtained using standard recombinant techniques. Desired polynucleotide sequences of an antibody or antibody fragment thereof may be isolated and sequenced from antibody producing cells such as hybridoma cells. Alternatively, polynucleotides can be synthesized using nucleotide synthesizer or PGR techniques, or obtained from other sources. Once obtained, sequences encoding the components of the masked cytokine are inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in prokaryotic hosts. Many vectors that are available and known in the art can be used for the purpose of the present invention. Selection of an appropriate vector will depend mainly on the size of the nucleic acids to be inserted into the vector and the particular host cell to be transformed with the vector. Each vector contains various components, depending on its function (amplification or expression of heterologous polynucleotide, or both) and its compatibility with the particular host cell in which it resides. The vector components generally include, but are not limited to: an origin of replication, a selection marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, the heterologous nucleic acid insert and a transcription terminator sequence.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322, a plasmid derived from an E. coli species. pBR322 contains genes-encoding ampicillin (Amp) and tetracycline (Tet) resistance and thus provides easy means for identifying transformed cells. pBR322, its derivatives, or other microbial plasmids or bacteriophage may also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of endogenous proteins. Examples of pBR322 derivatives used for expression of particular antibodies are described in detail in Carter et ah, U.S. Pat. No. 5,648,237.

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, bacteriophage such as 7GEM™-11 may be utilized in making a recombinant vector which can be used to transform susceptible host cells such as E. coli LE392.

The expression vector of the invention may comprise two or more promoter-cistron pairs, encoding each of the polypeptide components. A promoter is an untranslated regulatory sequence located upstream (5′) to a cistron that modulates its expression. Prokaryotic promoters typically fall into two classes, inducible and constitutive. Inducible promoter is a promoter that initiates increased levels of transcription of the cistron under its control in response to changes in the culture condition, e.g. the presence or absence of a nutrient or a change in temperature.

A large number of promoters recognized by a variety of potential host cells are well known. The selected promoter can be operably linked to cistron DNA encoding either chain of the masked cytokine by removing the promoter from the source DNA via restriction enzyme digestion and inserting the isolated promoter sequence into the vector of the invention. Both the native promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the target genes.

In some embodiments, heterologous promoters are utilized, as they generally permit greater transcription and higher yields of expressed target gene as compared to the native target polypeptide promoter.

Promoters suitable for use with prokaryotic hosts include the PhoA promoter, the [3-galactamase and lactose promoter systems, a tryptophan (trp) promoter system and hybrid promoters such as the tac or the trc promoter. However, other promoters that are functional in bacteria (such as other known bacterial or phage promoters) are suitable as well. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to cistrons encoding, for example, the target light and heavy chains for masked cytokines comprising a light and heavy chain (Siebenlist et al. (1980) Cell 20: 269) using linkers or adaptors to supply any required restriction sites.

In one aspect of the invention, each cistron within the recombinant vector comprises a secretion signal sequence component that directs translocation of the expressed polypeptides across a membrane. In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. The signal sequence selected for the purpose of this invention should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the signal sequences native to the heterologous polypeptides, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group consisting of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II (STII) leaders, LamB, PhoE, PelB, OmpA and MBP. In one embodiment of the invention, the signal sequences used in both cistrons of the expression system are STII signal sequences or variants thereof.

In another aspect, the production of the polypeptide components according to the invention can occur in the cytoplasm of the host cell, and therefore does not require the presence of secretion signal sequences within each cistron. In that regard, for embodiments comprising immunoglobulin light and heavy chains, for example, the light and heavy chains are expressed with or without the sequences for the masking moiety, linker sequence, etc., folded and assembled to form functional immunoglobulins within the cytoplasm. Certain host strains (e.g., the E. coli trxB-strains) provide cytoplasm conditions that are favorable for disulfide bond formation, thereby permitting proper folding and assembly of expressed protein subunits. Proba and Pluckthun Gene, 159:203 (1995).

Masked cytokines of the invention can also be produced by using an expression system in which the quantitative ratio of expressed polypeptide components can be modulated in order to maximize the yield of secreted and properly assembled antibodies of the invention. Such modulation is accomplished at least in part by simultaneously modulating translational strengths for the polypeptide components.

Prokaryotic host cells suitable for expressing masked cytokines of the invention include Archaebacteria and Eubacteria, such as Gram-negative or Gram-positive organisms. Examples of useful bacteria include Escherichia (e.g., E. coli), Bacilli (e.g., B. subtilis). Enterobacteria, Pseudomonas species (e.g., P. aeruginosa), Salmonella typhimurium, Serratia marcescans, Klebsiella, Proteus, Shigella, Rhizobia, Vitreoscilla, or Paracoccus. In one embodiment, gram-negative cells are used. In one embodiment, E. coli cells are used as hosts for the invention. Examples of E. coli strains include strain W3110 (Bachmann. Cellular and Molecular Biology, vol. 2 (Washington, D.C.; American Society for Microbiology, 1987). pp. 1190-1219; ATCC Deposit No. 27.325) and derivatives thereof, including strain 33D3 having genotype W3110 AfhuA (AtonA) ptr3 lac 1q lacL8 AompTA (nmpc-fepE) degP41 kanR (U.S. Pat. No. 5,639,635). Other strains and derivatives thereof, such as E. coli 294 (ATCC 31,446). E. coli B, E, colik 1776 (ATCC 31,537) and E. coli RV308 (ATCC 31.608) are also suitable. These examples are illustrative rather than limiting. Methods for constructing derivatives of any of the above-mentioned bacteria having defined genotypes are known in the art and described in, for example, Bass et ah, Proteins, 8:309-314 (1990). It is generally necessary to select the appropriate bacteria taking into consideration replicability of the replicon in the cells of a bacterium. For example, E. coli, Serratia, or Salmonella species can be suitably used as the host when well-known plasmids such as pBR322, pBR325, pACYC177, or pKN410 are used to supply the replicon. Typically, the host cell should secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors may desirably be incorporated in the cell culture.

b. Masked Cytokine Production

Host cells are transformed with the above-described expression vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Transformation means introducing DNA into the prokaryotic host so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride is generally used for bacterial cells that contain substantial cell-wall barriers. Another method for transformation employs polyethylene glycol/DMSO. Yet another technique used is electroporation.

Prokaryotic cells used to produce the masked cytokines of the invention are grown in media known in the art and suitable for culture of the selected host cells. Examples of suitable media include luria broth (LB) plus necessary nutrient supplements. In some embodiments, the media also contains a selection agent, chosen based on the construction of the expression vector, to selectively permit growth of prokaryotic cells containing the expression vector. For example, ampicillin is added to media for growth of cells expressing ampicillin resistant gene.

Any necessary supplements besides carbon, nitrogen, and inorganic phosphate sources may also be included at appropriate concentrations introduced alone or as a mixture with another supplement or medium such as a complex nitrogen source. Optionally, the culture medium may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycollate, dithioerythritol and dithiothreitol.

The prokaryotic host cells are cultured at suitable temperatures. In certain embodiments, for E. coli growth, growth temperatures range from about 20° C. to about 39° C., from about 25° C. to about 37° C.; or about 30° C. The pH of the medium may be any pH ranging from about 5 to about 9, depending mainly on the host organism. In certain embodiments, for E. coli, the pH is from about 6.8 to about 7.4, or about 7.0.

If an inducible promoter is used in the expression vector of the invention, protein expression is induced under conditions suitable for the activation of the promoter. In one aspect of the invention, PhoA promoters are used for controlling transcription of the polypeptides. Accordingly, the transformed host cells are cultured in a phosphate-limiting medium for induction. In certain embodiments, the phosphate-limiting medium is the C.R.A.P. medium (see, e.g., Simmons et ah, J. Immunol. Methods (2002), 263:133-147). A variety of other inducers may be used, according to the vector construct employed, as is known in the art.

In one embodiment, the expressed masked cytokines of the present invention are secreted into and recovered from the periplasm of the host cells. Protein recovery typically involves disrupting the microorganism, generally by such means as osmotic shock, sonication or lysis. Once cells are disrupted, cell debris or whole cells may be removed by centrifugation or filtration. The proteins may be further purified, for example, by affinity resin chromatography. Alternatively, proteins can be transported into the culture media and isolated therein. Cells may be removed horn the culture and the culture supernatant being filtered and concentrated for further purification of the proteins produced. The expressed polypeptides can be further isolated and identified using commonly known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot assay.

In one aspect of the invention, masked cytokine production is conducted in large quantity by a fermentation process. Various large-scale fed-batch fermentation procedures are available for production of recombinant proteins. Large-scale fermentations have at least 1000 liters of capacity, and in certain embodiments, about 1,000 to 100,000 liters of capacity. These fermenters use agitator impellers to distribute oxygen and nutrients, especially glucose. Small scale fermentation refers generally to fermentation in a fermentor that is no more than approximately 100 liters in volumetric capacity, and can range horn about 1 liter to about 100 liters.

In a fermentation process, induction of protein expression is typically initiated after the cells have been grown under suitable conditions to a desired density, e.g., an OD550 of about 180-220, at which stage the cells are in the early stationary phase. A variety of inducers may be used, according to the vector construct employed, as is known in the art and described above. Cells may be grown for shorter periods prior to induction. Cells are usually induced for about 12-50 hours, although longer or shorter induction time may be used.

To improve the production yield and quality of the polypeptides of the invention, various fermentation conditions can be modified. For example, to improve the proper assembly and folding of, for example, secreted antibody polypeptides, additional vectors overexpressing chaperone proteins, such as Dsb proteins (DsbA, DsbB, DsbC, DsbD and or DsbG) or FkpA (a peptidylprolyl cis,trans-isomerase with chaperone activity) can be used to co-transform the host prokaryotic cells. The chaperone proteins have been demonstrated to facilitate the proper folding and solubility of heterologous proteins produced in bacterial host cells. Chen et al. (1999) J. Biol. Chem. 274:19601-19605; Georgiou et ak, U.S. Pat. No. 6,083,715; Georgiou et ak, U.S. Pat. No. 6,027,888; Bothmann and Pluckthun (2000) J. Biol. Chem. 275:17100-17105; Ramm and Pluckthun (2000) J. Biol. Chem. 275:17106-17113; Arie et ak (2001) Mol. Microbiol. 39:199-210.

To minimize proteolysis of expressed heterologous proteins (especially those that are proteolytically sensitive), certain host strains deficient for proteolytic enzymes can be used for the present invention. For example, host cell strains may be modified to effect genetic mutation(s) in the genes encoding known bacterial proteases such as Protease III, OmpT, DegP, Tsp, Protease I, Protease Mi. Protease V, Protease VI and combinations thereof. Some E. coli protease-deficient strains are available and described in, for example. Joly et ak (1998), supra; Georgiou et ak, U.S. Pat. No. 5,264,365; Georgiou et ak, U.S. Pat. No. 5,508,192; Kars et ak, Microbial Drug Resistance. 2:63-72 (1996).

In some embodiments, E. coli strains deficient for proteolytic enzymes and transformed with plasmids overexpressing one or more chaperone proteins are used as host cells in the expression system of the invention.

c. Masked Cytokine Purification

In some embodiments, the masked cytokine produced herein is further purified to obtain preparations that are substantially homogeneous for further assays and uses. Standard protein purification methods known in the art can be employed. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns, ethanol precipitation, reverse phase HPLC, chromatography on silica or on a cation-exchange resin such as DEAE, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, and gel filtration using, for example, Sephadex G-75.

In some embodiments, Protein A immobilized on a solid phase is used for immunoaffinity purification of the masked cytokines of the invention. Protein A is a 41 kD cell wall protein from Staphylococcus aureas which binds with a high affinity to the Fc region of antibodies. Lindmark et al (1983) J. Immunol. Meth. 62:1-13. The solid phase to which Protein A is immobilized can be a column comprising a glass or silica surface, or a controlled pore glass column or a silicic acid column. In some applications, the column is coated with a reagent, such as glycerol, to possibly prevent nonspecific adherence of contaminants.

As the first step of purification, a preparation derived from the cell culture as described above can be applied onto a Protein A immobilized solid phase to allow specific binding of the masked cytokine of interest to Protein A. The solid phase would then be washed to remove contaminants non-specifically bound to the solid phase. Finally, the masked cytokine of interest is recovered from the solid phase by elution.

Other methods of purification that provide for high affinity binding to a component of the masked cytokine can be employed in accordance with standard protein purification methods known in the art.

2. Generating Masked Cytokines Using Eukaryotic Host Cells

A vector for use in a eukaryotic host cell generally includes one or more of the following non-limiting components: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

a. Signal Sequence Component

A vector for use in a eukaryotic host cell may also contain a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide of interest. The heterologous signal sequence selected may be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available.

The DNA for such a precursor region is ligated in reading frame to DNA encoding the masked cytokine.

b. Origin of Replication

Generally, an origin of replication component is not needed for mammalian expression vectors. For example, the SV40 origin may typically be used only because it contains the early promoter.

c. Selection Gene Component

Expression and cloning vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, where relevant, or (c) supply critical nutrients not available from complex media.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the masked cytokine encoding nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.

For example, in some embodiments, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. In some embodiments, an appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity (e.g., ATCC CRL-9096).

Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding a masked cytokine, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3′-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Pat. No. 4,965,199. Host cells may include NS0, including cell lines deficient in glutamine synthetase (GS). Methods for the use of GS as a selectable marker for mammalian cells are described in U.S. Pat. Nos. 5,122,464 and 5,891,693.

d. Promoter Component

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to nucleic acid encoding a masked cytokine of interest, which can be any masked cytokine described herein. Promoter sequences are known for eukaryotes. For example, virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3′ end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3′ end of the coding sequence. In certain embodiments, any or all of these sequences may be suitably inserted into eukaryotic expression vectors.

Transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepahtis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restrichon fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Pat. No. 4,419,446. A modification of this system is described in U.S. Pat. No. 4,601,978. See also Reyes et ah, Nature 297:598-601 (1982), describing expression of human [3-interferon cDNA in murine cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the Rous Sarcoma Virus long terminal repeat can be used as the promoter.

e. Enhancer Element Component

Transcription of DNA encoding a masked cytokine of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the human cytomegalovirus early promoter enhancer, the murine cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. e also Yaniv, Nature 297:17-18 (1982) (describing enhancer elements for activation of eukaryotic promoters). The enhancer may be spliced into the vector at a position 5′ or 3′ to the masked cytokine-encoding sequence, but is generally located at a site 5′ from the promoter.

f. Transcription Termination Component

Expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding a masked cytokine. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94/11026 and the expression vector disclosed therein.

g. Selection and Transformation of Host Cells

Suitable host cells for cloning or expressing the DNA in the vectors herein include higher eukaryote cells described herein, including vertebrate host cells. Propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7. ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et ah, J. Gen Virol. 36:59(1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et ah, Proc. Natl. Acad. Sci. USA 77:4216 (1980)); murine sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BEL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); murine mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et ah, Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described-expression or cloning vectors for masked cytokine production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

h. Culturing Host Cells

The host cells used to produce masked cytokines of this invention may be cultured in a variety of media.

Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM). Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et ah. Meth. Enz. 58:44 (1979), Barnes et ah, Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; A; 921,162, 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature. pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

i. Purification of Masked Cytokines

When using recombinant techniques, the masked cytokines can be produced intracellularly, or directly secreted into the medium. If the masked cytokine is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, may be removed, for example, by centrifugation or ultrafiltration. Where the masked cytokine is secreted into the medium, supernatants from such expression systems may be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of adventitious contaminants.

The masked cytokine composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a convenient technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Pc domain, if any, that is present in the masked cytokine. Protein A can be used to purify antibodies that are based on human IgG1. IgG2, or IgG4 heavy chains (Lindmark et ak, J. Immunol. Methods 62:1-13 (1983)). Protein G is recommended for all murine isotypes and for human y3 (Guss et ak, EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached may be agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the masked cytokine comprises a CH3 domain, the Bakerbond ABX™ resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification.

Other techniques for protein purification such as fractionahon on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the masked cytokine to be recovered.

Following any preliminary purification step(s), the mixture comprising the masked cytokine of interest and contaminants may be subjected to further purification, for example, by low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, performed at low salt concentrations (e.g., from about 0-0.25M salt).

in general, various methodologies for preparing masked cytokines for use in research, testing, and clinical use are well-established in the art, consistent with the above-described methodologies and/or as deemed appropriate by one skilled in the art for a particular masked cytokine of interest.

5. Compositions

In some aspects, also provided herein are compositions comprising any of the masked cytokines described herein. In some embodiments, the composition comprises any of the exemplary embodiments of masked cytokine described herein. In some embodiments, the composition comprises a dimer of any of the masked cytokines described herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a masked cytokine and further comprises one or more of the components as described in detail below. For example, in some embodiments, the composition comprises one or more pharmaceutically acceptable carriers, excipients, stabilizers, buffers, preservatives, tonicity agents, non-ionic surfactants or detergents, or other therapeutic agents or active compounds, or combinations thereof. The various embodiments of the composition are sometimes referred to herein as formulations.

Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington: The Science and Practice of Pharmacy, 20th Ed., Lippincott Williams & Wilkins, Pub., Gennaro Ed., Philadelphia, Pa. 2000). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers, antioxidants including ascorbic acid, methionine. Vitamin E, sodium metabisulfite; preservatives, isotonicifiers, stabilizers, metal complexes (e.g. Zn-protein complexes); chelating agents such as EDTA and/or non-ionic surfactants.

Buffers can be used to control the pH in a range which optimizes the therapeutic effectiveness, especially if stability is pH dependent. Buffers can be present at concentrations ranging from about 50 mM to about 250 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof. For example, citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate. Additionally, buffers may be comprised of histidine and trimethylamine salts such as Tris.

Preservatives can be added to prevent microbial growth, and are typically present in a range from about 0.2%-1.0% (w/v). Examples of suitable preservatives commonly used with therapeutics include octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium halides (e.g., chloride, bromide, iodide), benzethonium chloride; thimerosal, phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol, 3-pentanol, m-cresol, o-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, ethanol, chlorobutanol, thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, and chlorphenesine (3p-chlorphenoxypropane-1,2-diol).

Tonicity agents, sometimes known as “stabilizers” can be present to adjust or maintain the tonicity of liquid in a composition. When used with large, charged biomolecules such as proteins and antibodies, they are often termed “stabilizers” because they can interact with the charged groups of the amino acid side chains, thereby lessening the potential for inter and intra-molecular interactions.

Tonicity agents can be present in any amount between about 0.1% to about 25% by weight or between about 1 to about 5% by weight, taking into account the relative amounts of the other ingredients. In some embodiments, tonicity agents include polyhydric sugar alcohols, trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.

Additional excipients include agents which can serve as one or more of the following: (1) bulking agents, (2) solubility enhancers. (3) stabilizers and (4) and agents preventing denaturation or adherence to the container wall. Such excipients include: polyhydric sugar alcohols (enumerated above); amino acids such as alanine, glycine, glutamine, asparagine, histidine, arginine, lysine, ornithine, leucine, 2-phenylalanine, glutamic acid, threonine, etc.; organic sugars or sugar alcohols such as sucrose, lactose, lactitol, trehalose, stachyose, mannose, sorbose, xylose, ribose, ribitol, myoinisitose, myoinisitol, galactose, galactitol, glycerol, cyclitols (e.g., inositol), polyethylene glycol; sulfur containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, a-monothioglycerol and sodium thio sulfate; low molecular weight proteins such as human serum albumin. bovine serum albumin, gelatin or other immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides (e.g., xylose, mannose, fructose, glucose; disaccharides (e.g., lactose, maltose, sucrose); trisaccharides such as raffinose; and polysaccharides such as dextrin or dextran.

Non-ionic surfactants or detergents (also known as “wetting agents”) can be present to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody. Non-ionic surfactants are present in a range of about 0.05 mg/mi to about 1.0 mg/ml or about 0.07 mg/ml to about 0.2 mg/ml. In some embodiments, non-ionic surfactants are present in a range of about 0.001% to about 0.1% w/v or about 0.01% to about 0.1% w/v or about 0.01% to about 0.025% w/v.

Suitable non-ionic surfactants include polysorbates (20, 40, 60, 65, 80, etc.), polyoxamers (184, 188, etc.), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, sucrose fatty acid ester, methyl celluose and carboxymethyl cellulose. Anionic detergents that can be used include sodium lauryl sulfate, dioctyle sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.

In order for the formulations to be used for in vivo administration, they must be sterile. The formulation may be rendered sterile by filtration through sterile filtration membranes. The therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accordance with known and accepted methods, such as by single or multiple bolus or infusion over a long period of time in a suitable manner, e.g., injection or infusion by subcutaneous, intravenous, intraperitoneal, intramuscular, intraarterial, intralesional or intraarticular routes, topical administration, inhalation or by sustained release or extended-release means.

Any of the masked cytokines described herein can be used alone or in combination with other therapeutic agents such is in the methods described herein. The term “in combination with” encompasses two or more therapeutic agents (e.g., a masked cytokine and a therapeutic agent) that are included in the same or separate formulations. In some embodiments, “in combination with” refers to “simultaneous” administration, in which case administration of the masked cytokine of the invention occurs simultaneously to the administration of the one or more additional therapeutic agents (e.g., at the same time or within one hour between administration (s) of the masked cytokine and administration of the one or more additional therapeutic agents). In some embodiments, “in combination with” refers to sequential administration, in which case administration of the masked cytokine of the invention occurs prior to and/or following, administration of the one or more additional therapeutic agents (e.g., greater than one hour between administration (s) of the masked cytokine and administration of the one or more additional therapeutic agents). Agents contemplated herein include, but are not limited to, a cytotoxic agent, a cytokine, an agent targeting an immune checkpoint molecule, an agent targeting an immune stimulatory molecule, a growth inhibitory agent, an immune stimulatory agent, an anti-inflammatory agent, or an anti-cancer agent.

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise a cytotoxic agent, cytokine, agent targeting an immune checkpoint molecule or stimulatory molecule, growth inhibitory agent, an immune stimulatory agent, an anti-inflammatory agent, or an anti-cancer agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The formulation may be presented in any suitable state, such as a liquid formulation, a solid state (lyophilized) formulation, or a frozen formulation. Approaches for preparing each of these types of formulations for therapeutic use are well known in the art.

6. Methods of Treatment

Provided herein are methods for treating or preventing a disease in a subject comprising administering to the subject an effective amount of any masked cytokine described herein or compositions thereof. In some embodiments, methods are provided for treating or preventing a disease in a subject comprising administering to the subject any composition described herein. In some embodiments, the subject (e.g., a human patient) has been diagnosed with cancer or is at risk of developing such a disorder. In some embodiments, methods are provided for treating or preventing disease in a subject comprising administering to the subject an effective amount of any masked cytokine described herein or compositions thereof, wherein the masked cytokine is activated upon cleavage by an enzyme. In some embodiments, the masked cytokine is activated at a tumor microenvironment. The masked cytokine is therapeutically active after it has cleaved. Thus, in some embodiments, the active agent is the cleavage product.

For the prevention or treatment of disease, the appropriate dosage of an active agent will depend on the type of disease to be treated, as defined herein, the severity and course of the disease, whether the agent is administered for preventive or therapeutic purposes, previous therapy, the subject's clinical history and response to the agent, and the discretion of the attending physician. The agent is suitably administered to the subject at one time or over a series of treatments.

In some embodiments, the protease acting to cleave the proteolytically cleavable peptide is an MMP.

In some embodiments of the methods described herein, an interval between administrations of a masked cytokine described herein is about one week or longer. In some embodiments of the methods described herein, an interval between administrations of a masked cytokine described herein is about two days or longer, about three days or longer, about four days or longer, about five days or longer, or about six days or longer. In some embodiments of the methods described herein, an interval between administrations of a masked cytokine described herein is about one week or longer, about two weeks or longer, about three weeks or longer, or about four weeks or longer. In some embodiments of the methods described herein, an interval between administrations of a masked cytokine described herein is about one month or longer, about two months or longer, or about three months or longer. As used herein, an interval between administrations refers to the time period between one administration of the masked cytokine and the next administration of the masked cytokine. As used herein, an interval of about one month includes four weeks. In some embodiments, the treatment includes multiple administrations of the masked cytokine, wherein the interval between administrations may vary. For example, in some embodiments, the interval between the first administration and the second administration is about one week, and the intervals between the subsequent administrations are about two weeks. In some embodiments, the interval between the first administration and the second administration is about two days, three days, four days, or five days, or six days, and the intervals between the subsequent administrations are about one week.

In some embodiments, the masked cytokine is administered on multiple occasions over a period of time. The dosage that is administered to the subject on multiple occasions can. In some embodiments, be the same dosage for each administration, or, in some embodiments, the masked cytokine can be administered to the subject at two or more different dosages. For example, in some embodiments, a masked cytokine is initially administered at one dosage on one or more occasions and is later administered at a second dosage on one or more occasions beginning at a later time point.

In some embodiments, a masked polypeptide described herein is administered at a flat dose. In some embodiments, a masked polypeptide described herein is administered to a subject at a dosage from about 25 mg to about 500 mg per dose. In some embodiments, the masked polypeptide is administered to a subject at a dosage of about 25 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 200 mg to about 225 mg, about 225 mg to about 250 mg, about 250 mg to about 275 mg, about 275 mg to about 300 mg, about 300 mg to about 325 mg, about 325 mg to about 350 mg, about 350 mg to about 375 mg, about 375 mg to about 400 mg, about 400 mg to about 425 mg, about 425 mg to about 450 mg, about 450 mg, to about 475 mg, or about 475 mg to about 500 mg per dose.

In some embodiments, a masked polypeptide described herein is administered to a subject at a dosage based on the subject's weight or body surface area (BSA). Depending on the type and severity of the disease, about 1 sg/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of masked polypeptide can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the masked polypeptide would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. In some embodiments, a masked polypeptide described herein is administered to a subject at a dosage from about 0.1 mg/kg to about 10 mg/kg or about 1.0 mg/kg to about 10 mg/kg. In some embodiments, a masked polypeptide described herein is administered to a subject at a dosage of about any of 0.1 mg/kg, 0.5 mg/kg, 1.0 mg kg, 1.5 mg/kg, 2.0 mg/kg, 2.5 mg/kg, 3.0 mg/kg, 3.5 mg/kg, 4.0 mg/kg, 4.5 mg/kg, 5.0 mg/kg, 5.5 mg/kg, 6.0 mg/kg, 6.5 mg/kg, 7.0 mg/kg, 7.5 mg/kg, 8.0 mg/kg, 8.5 mg/kg, 9.0 mg/kg, 9.5 mg/kg, or 10.0 mg/kg. In some embodiments, a masked polypeptide described herein is administered to a subject at a dosage of about or at least about 0.1 mg/kg, about or at least about 0.5 mg/kg, about or at least about 1.0 mg/kg, about or at least about 1.5 mg/kg, about or at least about 2.0 mg/kg, about or at least about 2.5 mg/kg, about or at least about 3.0 mg/kg, about or at least about 3.5 mg/kg, about or at least about 4.0 mg/kg, about or at least about 4.5 mg/kg, about or at least about 5.0 mg/kg, about or at least about 5.5 mg/kg, about or at least about 6.0 mg/kg, about or at least about 6.5 mg/kg, about or at least about 7.0 mg/kg, about or at least about 7.5 mg/kg, about or at least about 8.0 mg/kg, about or at least about 8.5 mg/kg, about or at least about 9.0 mg/kg, about or at least about 9.5 mg/kg, about or at least about 10.0 mg/kg, about or at least about 15.0 mg/kg, about or at least about 20 mg/kg, about or at least about 30 mg/kg, about or at least about 40 mg/kg, about or at least about 50 mg/kg, about or at least about 60 mg/kg, about or at least about 70 mg/kg, about or at least about 80 mg/kg, about or at least about 90 mg/kg, or about or at least about 100 mg/kg. Any of the dosing frequencies described above may be used.

A method of treatment contemplated herein is the treatment of a disorder or disease such as cancer with any of the masked cytokines or compositions described herein. Disorders or diseases that are treatable with the formulations of this present invention include leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma, lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma) or testicular cancer.

In some embodiments, provided herein is a method of treatment or prevention of a cancer by administration of any masked cytokines or compositions described herein. In some embodiments, provided herein is a method of treatment or prevention of a cancer by administration of any masked cytokine or composition described herein in combination with an anticancer agent. The anti-cancer agent can be any agent capable of reducing cancer growth, interfering with cancer cell replication, directly or indirectly killing cancer cells, reducing metastasis, reducing tumor blood supply, or reducing cell survival. In some embodiments, the anti-cancer agent is selected from the group consisting of a PD-1 inhibitor, an EGFR inhibitor, a HER2 inhibitor, a VEGFR inhibitor, a CTLA-4 inhibitor, a BTLA inhibitor, a B7H4 inhibitor, a B7H3 inhibitor, a CSFIR inhibitor, an HVEM inhibitor, a CD27 inhibitor, a KIR inhibitor, an NKG2A inhibitor, an NKG2D agonist, a TWEAK inhibitor, an ALK inhibitor, a CD52 targeting antibody, a CCR4 targeting antibody, a PD-L1 inhibitor, a KIT inhibitor, a PDGFR inhibitor, a BAFF inhibitor, an HD AC inhibitor, a VEGF ligand inhibitor, a CD19 targeting molecule, a FOFR1 targeting molecule, a DFF3 targeting molecule, a DKK1 targeting molecule, a MUC1 targeting molecule, a MUG 16 targeting molecule, a PSMA targeting molecule, an MSFN targeting molecule, an NY-ES0-1 targeting molecule, a B7H3 targeting molecule, a B7H4 targeting molecule, a BCMA targeting molecule, a CD29 targeting molecule, a CD151 targeting molecule, a CD123 targeting molecule, a CD33 targeting molecule, a CD37 targeting molecule, a CDH19 targeting molecule, a CEA targeting molecule, a Claudin 18.2 targeting molecule, a CFEC12A targeting molecule, an EGFRVIII targeting molecule, an EPCAM targeting molecule, an EPHA2 targeting molecule, an FCRH5 targeting molecule, an FLT3 targeting molecule, a GD2 targeting molecule, a glypican 3 targeting molecule, a gpA33 targeting molecule, a GPRC5D targeting molecule, an IL-23R targeting molecule, an IL-1RAP targeting molecule, a MCSP targeting molecule, a RON targeting molecule, a ROR1 targeting molecule, a STEAP2 targeting molecule, a TfR targeting molecule, a CD166 targeting molecule, a TPBG targeting molecule, a TROP2 targeting molecule, a proteasome inhibitor, an ABE inhibitor, a CD30 inhibitor, a FLT3 inhibitor, a MET inhibitor, a RET inhibitor, an IL-1(3 inhibitor, a MEK inhibitor, a ROS1 inhibitor, a BRAE inhibitor, a CD38 inhibitor, a RANKE inhibitor, a B4GALNT1 inhibitor, a SLAMF7 inhibitor, an IDH2 inhibitor, an mTOR inhibitor, a CD20 targeting antibody, a BTK inhibitor, a PI3K inhibitor, a FLT3 inhibitor, a PARP inhibitor, a CDK4 inhibitor, a CDK6 inhibitor, an EGFR inhibitor, a RAF inhibitor, a JAK1 inhibitor, a JAK2 inhibitor, a JAK3 inhibitor, an IL-6 inhibitor, a IL-17 inhibitor, a Smoothened inhibitor, an IL-6R inhibitor, a BCL2 inhibitor, a PTCH inhibitor, a PIGF inhibitor, a TGFB inhibitor, a CD28 agonist, a CD3 agonist, CD40 agonist, a GITR agonist, a 0X40 agonist, a VISTA agonist, a CD137 agonist, a LAG3 inhibitor, a TIM3 inhibitor, a TIGIT inhibitor, and an IL-2R inhibitor.

In some embodiments, provided herein is a method of treatment or prevention of a cancer by administration of any masked cytokine described herein in combination with an anti-inflammatory agent. The anti-inflammatory agent can be any agent capable of preventing, counteracting, inhibiting, or otherwise reducing inflammation.

In some embodiments, the anti-inflammatory agent is a cyclooxygenase (COX) inhibitor. The COX inhibitor can be any agent that inhibits the activity of COX-1 and/or COX-2. In some embodiments, the COX inhibitor selectively inhibits COX-1 (i.e., the COX inhibitor inhibits the activity of COX-1 more than it inhibits the activity of COX-2). In some embodiments, the COX inhibitor selectively inhibits COX-2 (i.e., the COX inhibitor inhibits the activity of COX-2 more than it inhibits the activity of COX-1). In some embodiments, the COX inhibitor inhibits both COX-1 and COX-2.

In some embodiments, the COX inhibitor is a selective COX-1 inhibitor and is selected from the group consisting of SC-560, FR122047, P6, mofezolac, TFAP, flurbiprofen, and ketoprofen. In some embodiments, the COX inhibitor is a selective COX-2 inhibitor and is selected from the group consisting of celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl) methane sulfonamide, parecoxib, lumiracoxib, RS 57067, T-614. BMS-347070, JTE-522, S-2474. SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, diclofenac, mefenamic acid, and SD-8381. In some embodiments, the COX inhibitor is selected from the group consisting of ibuprofen, naproxen, ketorolac, indomethacin, aspirin, naproxen, tolmetin, piroxicam, and meclofenamate. In some embodiments, the COX inhibitor is selected from the group consisting of SC-560, FR122047, P6, mofezolac, TFAP, flurbiprofen, ketoprofen, celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, a chromene derivative, a chroman derivative, N-(2-cyclohexyloxynitrophenyl) methane sulfonamide, parecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, diclofenac, mefenamic acid, SD-8381, ibuprofen, naproxen, ketorolac, indomethacin, aspirin, naproxen, tolmetin, piroxicam, and meclofenamate.

In some embodiments, the anti-inflammatory agent is an NF-κB inhibitor. The NF-κB inhibitor can be any agent that inhibits the activity of the NF-κB pathway. In some embodiments, the NF-κB inhibitor is selected from the group consisting of an IKK complex inhibitor, an IκB degradation inhibitor, an NF-κB nuclear translocation inhibitor, a p65 acetylation inhibitor, an NF-κB DNA binding inhibitor, an NF-κB transactivation inhibitor, and a p53 induction inhibitor.

In some embodiments, the IKK complex inhibitor is selected from the group consisting of TPCA-1. NF-κB Activation Inhibitor VI (BOT-64), BMS-345541, amlexanox, SC-514 (GK-01140), IMD-0354, and IKK-16. In some embodiments, the IκB degradation inhibitor is selected from the group consisting of BAY-IL-7082. MG-115. MG-132, lactacystin, epoxomicin, parthenolide, carfilzomib, and MLN-4924 (pevonedistat). In some embodiments, the NF-κB nuclear translocation inhibitor is selected from the group consisting of JSH-23 and rolipram. In some embodiments, the p65 acetylation inhibitor is selected from the group consisting of gallic acid and anacardic acid. In some embodiments, the NF-κB DNA binding inhibitor is selected from the group consisting of GYY-4137, p-XSC, CV-3988, and prostaglandin E2 (PGE2). In some embodiments, the NF-κB transactivation inhibitor is selected from the group consisting of LY-294002, wortmannin, and mesalamine. In some embodiments, the p53 induction inhibitor is selected from the group consisting of quinacrine and flavopiridol. In some embodiments, the NF-κB inhibitor is selected from the group consisting of TPCA-1, NF-κB Activation Inhibitor VI (BOT-64), BMS-345541, amlexanox, SC-514 (GK-01140), IMD-0354, IKK-16, BAY-11-7082, MG-115, MG-132, lactacystin, epoxomicin, parthenolide, carfilzomib, MLN-4924 (pevonedistat), JSH-23 rolipram, gallic acid, anacardic acid, GYY-4137, p-XSC, CV-3988, prostaglandin E2 (PGE2), LY-294002, wortmannin, mesalamine, quinacrine, and flavopiridol.

In some embodiments, provided herein is a method of treatment or prevention of a cancer by administration of any masked cytokine or composition described herein in combination with an anticancer therapeutic protein. The anti-cancer therapeutic protein can be any therapeutic protein capable of reducing cancer growth, interfering with cancer cell replication, directly or indirectly killing cancer cells, reducing metastasis, reducing tumor blood supply, or reducing cell survival. Exemplary anti-cancer therapeutic proteins may come in the form of an antibody or fragment thereof, an antibody derivative, a bispecific antibody, a chimeric antigen receptor (CAR) T cell, a fusion protein, or a bispecific T-cell engager (BiTE).

In some embodiments, provided herein is a method of treatment or prevention of a cancer by administration of any masked cytokine or composition described herein in combination with CAR-NK (Natural Killer) cells.

7. Articles of Manufacture or Kits

In another aspect, an article of manufacture or kit is provided which comprises any masked cytokine described herein. The article of manufacture or kit may further comprise instructions for use of the cytokines in the methods of the invention. Thus, in certain embodiments, the article of manufacture or kit comprises instructions for the use of a masked cytokine in methods for treating or preventing a disorder (e.g., a cancer) in an individual comprising administering to the individual an effective amount of a masked cytokine. For example, in certain embodiments, the article of manufacture or kit comprises instructions for the use of a masked polypeptide in methods for treating or preventing a disorder (e.g., a cancer) in an individual comprising administering to the individual an effective amount of a masked polypeptide. In certain embodiments, the individual is a human. In some embodiments, the individual has a disease selected from the group consisting of include leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma, lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer or testicular cancer.

The article of manufacture or kit may further comprise a container. Suitable containers include, for example, bottles, vials (e.g., dual chamber vials), syringes (such as single or dual chamber syringes), test tubes, and intravenous (IV) bags. The container may be formed from a variety of materials such as glass or plastic. The container holds the formulation. In some embodiments, the formulation is a lyophilized formulation. In some embodiments, the formulation is a frozen formulation. In some embodiments, the formulation is a liquid formulation.

The article of manufacture or kit may further comprise a label or a package insert, which is on or associated with the container, may indicate directions for reconstitution and/or use of the formulation. The label or package insert may further indicate that the formulation is useful or intended for subcutaneous, intravenous, or other modes of administration for treating or preventing a disorder (e.g., a cancer) in an individual. The container holding the formulation may be a single-use vial or a multi-use vial, which allows for repeat administrations of the reconstituted formulation. The article of manufacture or kit may further comprise a second container comprising a suitable diluent. The article of manufacture or kit may further include other materials desirable from a commercial, therapeutic, and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

In a specific embodiment, the present invention provides kits for a single dose-administration unit. Such kits comprise a container of an aqueous formulation of therapeutic cytokine, including both single or multi-chambered pre-filled syringes. Exemplary pre-filled syringes are available from Vetter GmbH, Ravensburg, Germany.

The article of manufacture or kit herein optionally further comprises a container comprising a second medicament, wherein the masked cytokine is a first medicament, and which article or kit further comprises instructions on the label or package insert for treating the subject with the second medicament, in an effective amount.

In another embodiment, provided herein is an article of manufacture or kit comprising the formulations described herein for administration in an auto-injector device. An auto-injector can be described as an injection device that upon activation, will deliver its contents without additional necessary action from the patient or administrator. They are particularly suited for self-medication of therapeutic formulations when the delivery rate must be constant and the time of delivery is greater than a few moments.

8. Definitions

Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

It is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a.” “an.” and “the” include plural referents unless the content clearly dictates otherwise.

The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.

It is understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

As used herein, the term “and/or” refers to any one of the items, any combination of the items, or all of the items with which the term is associated. For instance, the phrase “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A and B or C; B and A or C; C and A or B; A (alone); B (alone); and C (alone).

The term “antibody” includes polyclonal antibodies, monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab′)2, and Fv). The term “immunoglobulin” (Ig) is used interchangeably with “antibody” herein.

The term “diabodies” refers to small antibody fragments with two antigen-binding sites, which comprise a heavy chain variable (VH) domain connected to a light chain variable (VL) domain in the same polypeptide chain (VH-VL).

The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. An IgM antibody consists of 5 of the basic heterotetramer units along with an additional polypeptide called a J chain, and contains 10 antigen binding sites, while IgA antibodies comprise from 2-5 of the basic 4-chain units which can polymerize to form polyvalent assemblages in combination with the J chain. In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the a and y chains and four CH domains for p and s isotypes. Each L chain has at the N-terminus, a variable domain (VL) followed by a constant domain at its other end. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CHI). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a VH and VL together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see e.g., Basic and Clinical Immunology, 8th Edition, Daniel P. Sties, Abba 1. Terr and Tristram G. Parsolw (eds). Appleton & Lange, Norwalk, Conn., 1994, page 71 and Chapter 6.

The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains (CH), immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, having heavy chains designated a, 8, e, y and p, respectively. The y and a classes are further divided into subclasses on the basis of relatively minor differences in the CH sequence and function, e.g., humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. IgG1 antibodies can exist in multiple polymorphic variants termed allotypes (reviewed in Jefferis and Lefranc 2009. mAbs Vol 1 issue 4 1-7) any of which are suitable for use in the invention. Common allotypic variants in human populations are those designated by the letters a,f,n,z.

An “isolated” antibody is one that has been identified, separated and/or recovered from a component of its production environment (e.g., naturally or recombinantly). In some embodiments, the isolated polypeptide is free of association with all other components from its production environment. Contaminant components of its production environment, such as that resulting from recombinant transfected cells, are materials that would typically interfere with research, diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the polypeptide is purified: (1) to greater than 95% by weight of antibody as determined by, for example, the Lowry method, and In some embodiments, to greater than 99% by weight; (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, an isolated polypeptide or antibody is prepared by at least one purification step.

The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translation modifications (e.g., isomerizations, amidations) that may be present in minor amounts. In some embodiments, monoclonal antibodies have a C-terminal cleavage at the heavy chain and/or light chain. For example, 1, 2, 3, 4, or 5 amino acid residues are cleaved at the C-terminus of heavy chain and/or light chain. In some embodiments, the C-terminal cleavage removes a C-terminal lysine from the heavy chain. In some embodiments, monoclonal antibodies have an N-terminal cleavage at the heavy chain and/or light chain. For example, 1, 2, 3, 4, or 5 amino acid residues are cleaved at the N-terminus of heavy chain and/or light chain. In some embodiments truncated forms of monoclonal antibodies can be made by recombinant techniques. In some embodiments, monoclonal antibodies are highly specific, being directed against a single antigenic site. In some embodiments, monoclonal antibodies are highly specific, being directed against multiple antigenic sites (such as a bispecific antibody or a multispecific antibody). The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, for example, the hybridoma method, recombinant DNA methods, phage-display technologies, and technologies for producing human or human-like antibodies in animals that have parts or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences.

The terms “full-length antibody,” “intact antibody” or “whole antibody” are used interchangeably to refer to an antibody in its substantially intact form, as opposed to an antibody fragment. Specifically, whole antibodies include those with heavy and light chains including an Fc region. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. In some cases, the intact antibody may have one or more effector functions.

An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding region and/or the variable region of the intact antibody, and/or the constant region of the intact antibody. Examples of an antibody fragment include the Fc region of the antibody, a portion of the Fc region, or a portion of the antibody comprising the Fc region. Examples of antigen-binding antibody fragments include domain antibodies (dAbs), Fab, Fab′, F(ab′)2 and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata et ah, Protein Eng. 8(10): 1057-1062 (19951); single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. Single heavy chain antibodies or single light chain antibodies can be engineered, or in the case of the heavy chain, can be isolated from camelids, shark, libraries or mice engineered to produce single heavy chain molecules.

Papain digestion of antibodies produced two identical antigen-binding fragments, called “Fab” fragments, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain (CHI). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab′)2 fragment which roughly corresponds to two disulfide linked Fab fragments having different antigen-binding activity and is still capable of cross-linking antigen. Fab′ fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of the CHI domain including one or more cysteines from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences and glycan in the Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of cells.

“Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative subshtuyions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST. BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

Antibody “effector functions” refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptors); and B cell activation.

“Binding affinity” as used herein refers to the strength of the non-covalent interactions between a single binding site of a molecule (e.g., a cytokine) and its binding partner (e.g., a cytokine receptor). In some embodiments, the affinity of a binding protein (e.g., a cytokine) can generally be represented by a dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein.

An “isolated” nucleic acid molecule encoding the cytokine polypeptides described herein is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the environment in which it was produced. In some embodiments, the isolated nucleic acid is free of association with all components associated with the production environment. The isolated nucleic acid molecules encoding the polypeptides and cytokine polypeptides herein is in a form other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from nucleic acid encoding the polypeptides and cytokine polypeptides herein existing naturally in cells.

The term “pharmaceutical formulation” refers to a preparation that is in such form as to permit the biological activity of the active ingredient to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.

Such formulations are sterile.

“Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

As used herein, the term “treatment” refers to clinical intervention designed to alter the natural course of the individual or cell being treated during the course of clinical pathology. Desirable effects of treatment include decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis. An individual is successfully “treated”, for example, if one or more symptoms associated with a disorder (e.g., a neoplastic disease) are mitigated or eliminated. For example, an individual is successfully “treated” if treatment results in increasing the quality of life of those suffering from a disease, decreasing the dose of other medications required for treating the disease, reducing the frequency of recurrence of the disease, lessening severity of the disease, delaying the development or progression of the disease, and/or prolonging survival of individuals.

As used herein, “in conjunction with” or “in combination with” refers to administration of one treatment modality in addition to another treatment modality. As such, “in conjunction with” or “in combination with” refers to administration of one treatment modality before, during or after administration of the other treatment modality to the individual.

As used herein, the term “prevention” includes providing prophylaxis with respect to occurrence or recurrence of a disease in an individual. An individual may be predisposed to, susceptible to a disorder, or at risk of developing a disorder, but has not yet been diagnosed with the disorder. In some embodiments, masked cytokines described herein are used to delay development of a disorder.

As used herein, an individual “at risk” of developing a disorder may or may not have detectable disease or symptoms of disease, and may or may not have displayed detectable disease or symptoms of disease prior to the treatment methods described herein. “At risk” denotes that an individual has one or more risk factors, which are measurable parameters that correlate with development of the disease, as known in the art. An individual having one or more of these risk factors has a higher probability of developing the disorder than an individual without one or more of these risk factors.

An “effective amount” refers to at least an amount effective, at dosages and for periods of time necessary, to achieve the desired or indicated effect, including a therapeutic or prophylactic result.

An effective amount can be provided in one or more administrations. A “therapeutically effective amount” is at least the minimum concentration required to effect a measurable improvement of a particular disorder.

A therapeutically effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in the individual. A therapeutically effective amount may also be one in which any toxic or detrimental affects of the masked cytokine are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at the dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at the earlier stage of disease, the prophylactically effective amount can be less than the therapeutically effective amount.

“Chronic” administration refers to administration of the medicament(s) in a continuous as opposed to acute mode, so as to main the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

As used herein, an “individual” or a “subject” is a mammal. A “mammal” for purposes of treatment includes humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual or subject is human.

9. Examples

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Although some examples describe the engineering, production, and/or testing of “masked” versions of an polypeptide construct, some examples also employ parental “non-masked” versions of the polypeptide construct, such as for comparison, or other constructs that include one or more of the components described herein that are tested as controls for comparison. Accordingly, the description of, for instance, testing done on masked polypeptide constructs does not necessarily mean that non-masked versions of the construct were not also tested.

Example 1: Engineering of Masked IL-2 Polypeptides

Masked IL-2 polypeptide constructs are generated in accordance with the teachings herein. In the S subsequent examples, some experiments involve use of the masked IL-2 polypeptide constructs in monomer form, and some experiments involve use of the masked IL-2 constructs in dimer form, such as a dimer formed through disulfide bonds linking two copies of the same masked polypeptide construct (homodimer), or a heterodimer formed by two different polypeptides (see, e.g., Table 5).

Masked IL-2 polypeptide constructs are generated that include an IL-2 polypeptide or functional fragment thereof, a masking moiety, and a half-life extension moiety, such as an antibody or fragment thereof (e.g., an Fc region, heavy chain, and/or light chain). Some IL-2 polypeptide constructs are also generated that include an IL-2 polypeptide or functional fragment thereof linked to a half-life extension moiety without also including a masking moiety. Some of the constructs also include a linker that comprises a cleavable peptide and links the masking moiety to the IL-2 polypeptide or functional fragment thereof, thereby resulting in an activatable masked IL-2 polypeptide construct. Some of the constructs also include a linker that links the IL-2 polypeptide or functional fragment thereof to the half-life extension domain. Some of the constructs also include a linker that links the IL-2 polypeptide or functional fragment thereof to the masking moiety. The masked IL-2 polypeptide constructs that do not include a cleavable peptide in the linker that links the IL-2 polypeptide or functional fragment thereof to the masking moiety are also referred to as non-activatable masked IL-2 polypeptide constructs or non-activatable IL-2 polypeptide constructs because they do not include a cleavable peptide. The structure and composition of exemplary IL-2 polypeptide constructs are provided in Table 3.

TABLE 3 Cytokine or Half-life Structure Construct functional fragment Masking moiety extension (N- to C-terminal Amino Acid # thereof (C) Linker (L1) (MM) Linker (L2) domain (H) direction) Sequence AK032 SEQ ID NO: 62 — — — SEQ ID NO: 65 H-C SEQ ID NO: 67 AK035 SEQ ID NO: 3 — — — SEQ ID NO: 65 H-C SEQ ID NO: 68

Also generated are masked IL-2 polypeptide constructs that include an IL-2 polypeptide or functional fragment thereof, a first masking moiety, a second masking moiety, and a half-life extension moiety, such as albumin, an antibody or fragment thereof (e.g, an Fc region, heavy chain, and/or light chain), an albumin-binding peptide, an IgG-binding peptide, or a polyamino acid sequence. Some of the constructs also include a linker that links the first masking moiety to the IL-2 polypeptide or functional fragment thereof. Some of the constructs also include a linker that links the second masking moiety to the IL-2 polypeptide or functional fragment thereof. Some of the constructs include a cleavable peptide in the linker linking the first masking moiety to the IL-2 polypeptide or functional fragment thereof and/or the linker linking the second masking moiety to the IL-2 polypeptide or functional fragment thereof, thereby resulting in an activatable masked IL-2 polypeptide construct. Some of the constructs also include a linker linking the second masking moiety to the half-life extension moiety. The masked IL-2 polypeptide constructs that do not include a cleavable peptide in either of the linkers that link the IL-2 polypeptide or functional fragment thereof to the first masking moiety or the second masking moiety are also referred to as non-activatable masked IL-2 polypeptide constructs or non-activatable IL-2 polypeptide constructs 13 because they do not include a cleavable peptide. The structure and composition of exemplary IL-2 polypeptide constructs are provided in Table 4.

Cytokine or Masking functional Masking Half-life Construct moiety Linker fragment Linker moiety extension Structure Amino Acid # (MM1) (L1) thereof (C) (L2) (MM2) Linker (L3) moiety (H) (N- to C- terminal direction) Sequence AK041 SEQ ID SEQ ID SEQ ID NO: SEQ ID SEQ ID SEQ ID SEQ ID NO: H-LI-MM1-L2-C-L3-MM2 SEQ ID NO: NO: 60 NO: 61 62 NO: 63 NO: 64 NO: 17 65 66

Also generated are masked IL-2 polypeptide constructs that include an IL-2 polypeptide or functional fragment thereof, a masking moiety, a first half-life extension moiety, and a second half-life extension moiety, an antibody or fragment thereof (e.g., an Fc region, heavy chain, and/or light chain). The masking moiety is linked to the first half-life extension moiety, the IL-2 polypeptide or functional fragment thereof is linked to the second half-life extension moiety, and the first half-life extension moiety and the second half-life extension moiety contain modifications promoting the association of the first and the second half-life extension moiety. In one exemplary embodiment, the masking moiety is linked to the first half-life extension moiety and includes the amino acid sequence of SEQ ID NO: 38, and the IL-2 polypeptide or functional fragment thereof is linked to the second half-life extension moiety and includes the amino acid sequence of SEQ ID NO: 4M, and the first half-life extension moiety and the second half-life extension moiety contain modifications promoting the association of the first and the second half-life extension moiety. In one exemplary embodiment of a non-masked IL-2 polypeptide construct, the embodiment comprises an IL-2 polypeptide or functional fragment thereof linked to a first half-life extension moiety, and comprises a second half-life extension moiety, where the IL-2 polypeptide or functional fragment thereof is linked to the first half-life extension moiety and includes the amino acid sequence of SEQ ID NO: 48, and the second half-life extension moiety includes the amino acid sequence of SEQ ID NO: 79. Some of the constructs also include a linker that links the masking moiety to the first half-life extension moiety, and/or a linker that links the IL-2 polypeptide or functional fragment thereof to the second hair-life extension moiety. The first and second half-life extension moiety of some of the constructs are also linked. In some constructs, the first and second half-life extension moiety of some of the constructs are linked by a linker. Some of the constructs include a cleavable peptide in the linker linking the masking moiety to the first half-life extension moiety and/or the linker linking the IL-2 polypeptide or functional fragment thereof to the second half-life extension moiety, thereby resulting in an activatable masked IL-2 polypeptide construct. The masked IL-2 polypeptide constructs that do not include a cleavable peptide in either the linker that links the IL-2 polypeptide or functional fragment thereof to the second half-life extension moiety or the linker that links the masking moiety to the first half-life extension moiety are also referred to as non-activatable masked IL-2 polypeptide constructs or non-activatable IL-2 polypeptide constructs because they do not include a cleavable peptide. The structure and composition of exemplary IL-2 polypeptide constructs are provided in Table 5.

Cytokine or functional Structure Construct fragment thereof Masking moiety Half-life extension (N - to C-terminal Amino Acid # (C) Linker (L1) (MM) Linker (L2) moiety (H) direction) Sequence AK081 SEQ ID NO; 62 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 85 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK109 — SEQ ID NO: 17 SEQ ID NO: 4 — SEQ ID NO: 80 H-LI-MM SEQ ID NO: 86 SEQ ID NO: 62 — — — SEQ ID NO: 81 H-C SEQ ID NO; 87 AK110 — SEQ ID NO: 17 SEQ ID NO: 4 — SEQ ID NO: 82 H-LI-MM SEQ ID NO: 88 SEQ ID NO: 62 — — — SEQ ID NO: 83 H-C SEQ ID NO: 89 AK111 SEQ ID NO: 62 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 85 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK165 SEQ ID NO: 62 SEQ ID NO: 18 — — SEQ ID NO: 83 H-L1-C SEQ ID NO: 90 — — — — SEQ ID NO: 84 H SEQ ID NO: 91 AK166 SEQ ID NO: 62 SEQ ID NO: 18 — — SEQ ID NO: 83 H-L1-C SEQ ID NO: 90 — SEQ ID NO: 75 SEQ ID NO: 4 — SEQ IDNO:82 H-L1-MM SEQ ID NO: 92 AK167 SEQ ID NO: 3 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 45 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK168 SEQ ID NO: 3 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 45 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO; 9 H-L1-MM SEQ ID NO: 38 AK189 SEQ ID NO: 62 SEQ ID NO: 76 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 93 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK190 SEQ ID NO: 62 SEQ ID NO: 77 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 94 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK191 SEQ ID NO: 3 SEQ ID NO: 20 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 46 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK192 SEQ ID NO: 3 SEQ ID NO: 76 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 95 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO; 9 H-L1-MM SEQ ID NO: 38 AK193 SEQ ID NO: 3 SEQ ID NO: 77 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 96 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO; 38 AK197 SEQ ID NO: 3 SEQ ID NO: 21 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 47 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO; 38 AK203 SEQ ID NO: 3 SEQ ID NO: 22 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 48 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO:9 H-L1-MM SEQ ID NO: 38 AK209 SEQ ID NO: 3 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 49 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO; 9 H-L1-MM SEQ ID NO: 38 AK210 SEQ ID NO: 62 SEQ ID NO: 20 — — SEQ ID NO; 12 H-L1-C SEQ ID NO: 97 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK211 SEQ ID NO: 3 SI Q ID NO: 23 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 98 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK215 SEQ ID NO: 69 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 99 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK216 SEQ ID NO: 70 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 100 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK218 SEQ ID NO: 71 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 101 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK219 SEQ ID NO: 72 SEQ ID NO: 18 - — SEQ ID NO: 12 H-L1-C SEQ ID NO: 102 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK220 SEQ ID NO: 873 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 103 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK223 SEQ ID NO: 74 SEQ ID NO: 18 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 104 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK235 SEQ ID NO: 3 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 49 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK253 SEQ ID NO: 3 SEQ ID NO: 23 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 98 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK304 SEQ ID NO: 69 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 105 — — — — SEQ ID NO: 9 H SEQ ID NO: 70 AK305 SEQ ID NO: 69 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 105 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK306 SEQ ID NO: 70 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 106 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK307 SEQ ID NO: 70 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 106 — SEQ ID NO: 14 SEQ ID NO:4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK308 SEQ ID NO: 71 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 107 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK309 SEQ ID NO: 71 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 107 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK 310 SEQ ID NO: 72 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 108 — — — — SEQ ID NO: 79 H SEQ ID NO: 79 AK 311 SEQ ID NO: 72 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 108 — SEQ ID NO: 14 SEQ ID NO:4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK 312 SEQ ID NO: 73 SEQ ID NO: 78 — — — H-L1-C SEQ ID NO: 109 — — — — — H SEQ ID NO: 79 AK 313 SEQ ID NO: 73 SEQ ID NO: 78 — — SEQ ID NO: 13 H-L1-C SEQ ID NO: 109 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK 314 SEQ ID NO: 74 SEQ ID NO: 78 — — SEQ ID NG: 12 H-L1-C SEQ ID NO: 110 — — — — SEQ ID NO: 9 H SEQ ID NO: 79 AK 315 SEQ ID NO: 74 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 110 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38 AK 316 SEQ ID NO: 62 SEQ ID NO: 78 — — SEQ ID NO: 12 H-L1-C SEQ ID NO: 112 — SEQ ID NO: 14 SEQ ID NO: 4 — SEQ ID NO: 9 H-L1-MM SEQ ID NO: 38

Example 2: In Vitro Characterization of Masked IL-2 Polypeptides

The masked IL-2 polypeptide constructs generated in Example 1 are characterized using several cellular and functional assays in vitro.

Production

Plasmids encoding the constructs (e.g., masked IL-2 polypeptide constructs) were transfected into either Expi293 cells (Life Technologies A14527) or HEK293-6E cells (National Research Council; NRC). Transfections were performed using 1 mg of total DNA using PEIpro (Polyplus Transfection, 115-1(10) in a 1:1 ratio with the total DNA. The DNA and PEI were each added to 50 mL of OptiMem (Life Technologies 31985088) medium and sterile filtered. The DNA and PEI were combined for 10 minutes and added to the Expi293 cells with a cell density of 1.8-2.8×10V cells/mL or 0.85-1.20×I0V cells/m, for expi293 cells or HEK293 cells, respectively, and a viability of at least 95%. The HEK293-6E transfection was performed with a cell density of and a viability of at least 95%, following the same protocol used for the Expi293 transfections. After 5-7 days, the cells were pelleted by centrifugation at 3000×g and the supernatant was filtered through a 0.2 μm membrane. Protein A resin (CaptivA, Repligen CA-PRI-0005) was added to the filtered supernatant and incubated for at least 2 hours at 4° C. with shaking. The resin was packed into a column, washed with 15 column volumes of 20 mM citrate, pH 6.5, and then washed with 15 column volumes of 20 mM citrate, 500 mM sodium chloride, pH 6.5. The bound protein was eluted from the column with 20 mM citrate, 100 mM NaCl, pH 2.9.

The titer (mg/L) of exemplary constructs produced, including parental (e.g., non-masked) and masked constructs, is provided in Table 6, below.

TABLE 6 Construct Titer ID (mg/L) AK032 5.8 AK035 16.7 AK081 23.5 AK111 12.7 AK165 13.5 AK166 17.1 AK167 56.4 AK168 36.1 AK203 83.2 AK209 27.3 AK211 43.8 AK235 35.9 AK253 41.4 AK304 19.9 AK305 53.2 AK306 29.3 AK307 62.9 AK314 60 AK315 59.8 AK316 69.2 AK308 74.5 AK309 90.8 AK310 44 AK311 64.9 AK312 154 AK313 81.2

SDS-PAGE Analysis

For SDS-PAGE analysis, protein samples were made with 4× Laemmli sample buffer (BioRad Catalog Number 1610747). For the reduced samples, 0.1 M Bond Breaker TCEP Solution (Thermo Scientific 77720) was added and the samples were heated for 5 minutes at 65° C. The proteins were loaded into a 12-well NuPage 4-12% Bis-Tris Protein Gel (Invitrogen NP0322BOX), with 4 μg of protein loaded per well. The gel was stained using SimplyBlue SafeStain (Invitrogen LC6065).

As depicted in FIG. 4 , SDS-PAGE analysis was performed on the flow-through (FT) samples (i.e., proteins that did not bind to the Protein A column) and the eluted (E) samples (i.e., proteins that bound to the Protein A column and were eluted from it) following production and purification of exemplary constructs (AK304, AK305, AK307, AK308, AK309, AK310, AK311, AK312, AK313, AK314, and AK315). This exemplary data demonstrates that constructs as described herein can be successfully produced and purified.

Reporter Bioassays

Reporter bioassays are performed on masked IL-2 polypeptide constructs, along with non-masked parental constructs or other controls, to monitor activation of a downstream pathway, such as the JAK-STAT pathway.

In some studies, HEK-Blue IL-2 reporter cells (Invivogen) were used to test activation of the JAK-STAT pathway in accordance with the following method. HEK-Blue IL-2 cells passage 6 (p6) (97% live) were washed 2× with assay medium (DMEM+10% heat-inactivated FBS), plated in 3 plated at 5e4 cells/well in 150 uL of assay medium, and rested in assay medium for about 2 hours to allow adherence to plate. Each construct tested was diluted to 300 pM in assay medium, then diluted 1:2 down the plate, 50 uL, of each dilution was added, for a final starting concentration of 75 pM. HEK-Blue IL-2 cell supernatant was harvested after 24 hours, an incubated with Quantiblue (180 uL-20 uL supernatant), plus 3 wells/plate of assay medium, at 37 deg C. for 1 hour. The absorbance was read using a Biotek Neo2 at 625 nm.

In some studies, CTLL2 cells were used to test activation of the JAK-STAT pathway in accordance with the following method. CT112 cells were plated at 40,000 cell per well in RPMI with 10% FBS. Dilutions of the constructs of interest were added and incubated at 37 degrees. After 6 hours, the Bio-Glo reagent was added and luminescence measured with a BioTek Synergy Neo2 plate reader.

Receptor Binding

The binding of the masked IL-2 polypeptide constructs generated in Example 1 is assessed. ELISA plates are coated with a receptor subunit, such as IL-2Rα (also referred to as CD25), IL-2Rβ (also referred to as CD122), or IL-2Rγ (also referred to as CD132), or combinations thereof. Dilutions of masked IL-2 polypeptide constructs are allowed to bind to the receptor subunit(s) and are detected using an anti-huFc-HRP detection antibody. The binding of the masked IL-2 polypeptide constructs is determined in conditions with and without protease cleavage.

On-Cell Receptor Binding

The on-cell receptor binding of the masked IL-2 polypeptide constructs generated in Example 1 is assessed. Dilutions of masked IL-2 polypeptide constructs are allowed to bind to peripheral blood lymphocytes or tissue culture cells, such as CTLL2 cells and are detected by fluorescence activated cell sorting (FACS) using an anti-huFc-FITC or anti-albumin-FITC detection antibody. The binding of the masked IL-2 polypeptide constructs is determined in conditions with and without protease cleavage.

Receptor Binding Affinity

The binding affinity of the masked IL-2 polypeptide constructs generated in Example 1 is assessed. The binding affinity of the masked IL-2 polypeptide constructs is determined in conditions with and without protease cleavage.

For SPR studies testing binding of masked and non-masked IL-2 polypeptide constructs, Reichert Carboxymethyl Dextran Hydrogel Surface Sensor Chips were coated and immobilized with the construct of interest (e.g., a masked IL-2 polypeptide construct or non-masked IL-2 polypeptide construct) at 30 ug/ml in 10 mM Sodium Acetate, pH 5.0 via amine coupling with EDC and NHS. Dilutions of CD25-Fc or Fc-CD122 in PBST (CD25: 16 nM, 8 nM, 4 nM, 2 nM, 1 nM and CD122: 500 nM, 250 nM, 12.5 nM, 62.5 nM, 31.25 nM) were prepared. Using a Reichert 4 Channel SPR, dilutions of CD25 or CD122 were flowed over the clips with the immobilized construct to determine the on rate at 25 degrees C. At equilibrium (approximately 3 minutes), the flow buffer was changed to PBST, to determine the off rates over 6 minutes. Between each run the chip was regenerated with 10 mM glycine, pH 2.0.

FIGS. 5A-5D depicts the efficacy of mutations on IL-2 which prevent binding to its alpha-receptor, using SPR analysis that tested the binding of an exemplary masked IL-2 polypeptide construct (AK168) to CD25− Fc. FIG. 5A depicts the interaction between AK168 and CD25-Fc, FIG. 5B depicts the interaction between AK168 activated with MMP and CD25-Fc, and FIG. 5C depicts the interaction between a recombinant human IL-2 (rhIL-2) control and CD25-Fc. FIG. 5D provides a table summarizing the data obtained for the association constant (ka), dissociation constant (kd), equilibrium dissociation constant (KD), as well as the Chi² value and U-value for each interaction. These results demonstrate that this exemplary masked IL-2 polypeptide construct (AK168) did not demonstrate detectable binding to CD25-Fc, while the wild-type rhIL-2 control did demonstrate detectable binding.

FIGS. 6A-6D depicts the masking of IL-2 towards its beta-receptor as well as restoration of binding post activation with protease, using SPR analysis that tested the binding of an exemplary masked IL-2 polypeptide construct (AK111) to CD122-Fc. FIG. 6A depicts the interaction between AK111 and CD122-Fe, FIG. 6B depicts the interaction between AK111 activated with MMP and CD122-Fc, and FIG. 6C depicts the interaction between a recombinant human IL-2 (rhIL-2) control and CD122-Fc. FIG. 6D provides a table summarizing the data obtained for the association constant (ka), dissociation constant (kd), equilibrium dissociation constant (KD), as well as the Chi value and U-value for each interaction. These results demonstrate that this exemplary masked IL-2 polypeptide construct (AK111) did not demonstrate detectable binding to CD122-Fc unless it has been activated with protease, while the rhIL-2 control did demonstrate detectable binding. Additional exemplary SPR data is provided below in Table 7 for various constructs tested, including masked and non-masked constructs. For some structures, when applicable, the KD was determined for the construct with or without having been previously cleaved by a protease.

TABLE 7 KD for CD25 KD for CD122 KD for CD122 Construct (without protease cleavage) (without protease cleavage) (after protease cleavage) rhlL2 0.878 nM 124 nM N/A AK032  1.76 nM 260 nM N/A AK035 No binding detected 110 nM N/A AK081 0.875 nM 347 nM N/A AK109   167 nM No binding detected 118 nM AK110 0.911 nM No binding detected 195 nM AK111  0.4 nM No binding detected 235 nM AK168 No binding detected Not determined 175 nM AK215 No binding detected AK216 No binding detected AK218 Weak binding AK219 Weak binding AK220 Weak or no binding detected AK223 No binding detected

Cleavage

The cleavage rate of the masked IL-2 polypeptide constructs is assessed by conducting receptor-binding assays, as described above, after incubation of the masked IL-2 peptide constructs in the presence or absence of a protease, and with the protease, if any, inactivated at various time points, such as by the addition of EDTA. The cleavage rate is also assessed using reducing and non-reducing polyacrylamide gel electrophoresis (PAGE) and by mass spectrometry whole mass and peptide map analyses. The cleavage rate is also assessed using an ex vivo assay in which the masked IL-2 polypeptide constructs are exposed to human, mouse, or cynomolgus monkey peripheral blood lymphocytes, or normal human tissue or human tumor tissue.

For some protease activation studies, MMP10 was diluted to 50 ng/uL in MMP cleavage buffer and activated with 1 mM APMA for 2 h at 37° C. 5 μL of protease (250 ng total) of the activated protease was incubated with 1 uM of masked cytokine constructs and incubated at 37 degrees for 2 hours. Cleavage was assessed by SDS-PAGE using AnykD™ Criterion™ TGX Stain-Free™ Protein Gels. A similar approach is taken to test cleavage by other proteases.

FIG. 7A depicts an exemplary structure of a masked IL-2 polypeptide prior to (left) and after (right) cleavage by a protease, such as a protease associated with the tumor environment. FIG. 7B depicts SDS-PAGE analysis of an exemplary masked IL-2 polypeptide construct that was incubated in the absence (left lane) or presence (right lane) of the MMP10 protease.

Proliferation

Proliferation of IL-2 responsive tissue culture cell lines, such as CTLL2, YT, TF1B, LGL, HH, and CT6, following treatment with the masked IL-2 polypeptide constructs generated in Example 1 is assessed. For experiments involving the masked IL-2 polypeptide constructs, cells are plated in 96 well tissue culture plates in media lacking IL-2 for 2-4 hours and then treated with the masked IL-2 polypeptide constructs at various concentrations. After incubation at 37 degrees for 24-48 hours, the cell number is determined by the addition of MTS, alamar blue, luciferase, or a similar metabolic detection reagent, and the colorimetric, fluorescent or luciferase readout detected by a plate spectrophotometer reader.

The proliferation of immune cells following treatment with the masked IL-2 polypeptide constructs generated in Example 1 is also assessed. Human, mouse, or cynomolgus peripheral blood mononuclear cells (PBMCs) are treated with the constructs at various concentrations, and the proliferation of cell types, such as Natural Killer (NK) cells, CD8+ T cells, CD4+ T cells, and/or Treg cells, is determined by staining for the particular cell type and analysis via fluorescence activated cell sorting (FACS). In some experiments, some PBMCs are treated with controls for comparison. In some experiments, some PBMCs are treated with aldesleukin as a control for the masked IL-2 polypeptide treatment. In some experiments, the NK cells are stained as CD45+CD3− CD56+, the CD8+ T cells are stained as CD45+CD3+CD8+, the CD4+ T cells are stained as CD45+CD3+CD4+CD25-, and the Treg cells are stained as CD45+CD3+CD4+CD25+ FOXP3+. In some experiments, the PBMCs are treated for a period of five days. In some experiments, the PBMCs are also stained with K67, a marker of cell proliferation. In some experiments, the PBMCs are labeled with CFSE (Sigma-Aldrich) prior to treatment and proliferation is measured by determining the extent of CFSE dilution. In some experiments, each construct, as well as aldesleukin and/or other controls, is administered at one or more concentrations, such as one or more concentrations ranging from 0.0001 nM to 500 nM.

STAT5 Activation

The activation of Signal Transducer and Activator of Transcription 5 (STAT5) following treatment with the masked IL-2 polypeptide constructs generated in Example 1 is also assessed. PBMCs are treated with the constructs for a specified period of time and are then immediately fixed to preserve the phosphorylation status of proteins, such as STAT5. In some experiments, some PBMCs are treated with controls for comparison. In some experiments, some PBMCs are treated with aldesleukin as a control for the masked IL-2 polypeptide treatment. In some experiments, the masked IL-2 polypeptide constructs are tested in conditions with and without protease cleavage (e.g., activation). In some experiments, the PBMCs are treated for 10 minutes, 15 minutes, 20 minutes, or 25 minutes. In some experiments, each construct, as well as aldesleukin and/or other controls, is administered at one or more concentrations, such as one or more concentrations ranging from 0.0001 nM to 500 nM. In some experiments, the fixed and permeabilized PBMCs are then stained with an antibody specific for phosphorylated STAT5 (phospho-STAT5) and are analyzed by flow cytometry. In some experiments, total and phosphorylated levels of STAT5 are measured. The phospho-STAT5 status of certain cell types, such as NK cells, CD8+ T cells, CD4+ T cells, and/or Treg cells, is determined by staining for the particular cell type. In some experiments, the NK cells are stained as CD45+CD3− CD56+, the CD8+ T cells are stained as CD454 CD3+C1D8+, the CD4+ T cells are stained as CD45+CD3+CD4+CD25−, and the Treg cells are stained as CD45+CD3+CD4+CD25+ FOXP3+.

The activation of STAT5 in the mouse cell lines, such as CTLL-2 cells, following treatment with the masked IL-2 polypeptide constructs generated in Example 1 is also assessed. In some experiments, some CTLL-2 cells are treated with controls for comparison. In some experiments, some CTLL-2 cells are treated with aldesleukin as a control for the masked IL-2 polypeptide treatment. In some experiments, the masked IL-2 polypeptide constructs are tested in conditions with and without protease cleavage (e.g., activation). In some experiments, the CTLL-2 cells are treated for 10 minutes, 15 minutes, 20 minutes, or 25 minutes, and are then fixed to preserve the phosphorylation status of proteins, such as STAT5. In some experiments, each construct, as well as aldesleukin and/or other controls, is administered at one or more concentrations. In some experiments, total and phosphorylated levels of STAT5 are measured.

In some studies, the levels of intracellular STAT5 activation (pSTAT5 signal) induced by IL-2 was determined by the following method. Frozen human PBMCs were thawed in water bath and added to 39 mL pre-warmed media (RPMI1640 medium plus 10% FBS, 1% PIS, 1% NEA), spun and reconstitute in media at 10E6 cells/mL. Cells were plated at 5E5 per well cells in a 96 well plate. IL-2 (e.g., rhIL-2 or an exemplary IL-2-containing polypeptide construct) diluted in medium was added to each well, and incubated at 37° C. for 20 min. Cells were then fix with 200 ul/well Fixation buffer (eBiosciences) at 4° C. overnight. After centrifugation, the fixed cells were resuspended in 200 ul cold BD Phosflow buffer and incubated at 4° C. for 30 min. After washing the cells twice, they were treated with Biolegend Human TruStain FcX (2.5 uL in 50 uL total per sample in Staining buffer) for 5 min on ice. Staining antibodies were added; 5 ul pSTAT5-APC (pY694, BD), 10 ul CD56-BV421 (5.1H11, Biolegend), 10 ul CD4-PerCP/Cy5.5 (A161A1. Biolegend), and 10 ul CD3-FITC (UCHT1, Biolegend) and incubated for 30 min. on ice, protected from light. Cells were washed 2 times and resuspended, and analyzed by flow cytometry.

FIGS. 8A-8D depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK032, AK035, AK041, or rhIL-2 as a control. The levels of STAT5 activation (%) are shown for NK cells. CD8+ T cells, effector T cells (Teff), and regulatory T cells (Treg). The AK032 and AK035 constructs include an IL-2 polypeptide linked to an Fc domain, and the AK041 construct includes an IL-2 polypeptide linked to a CD25 domain and a CD122 domain. As shown, engineered IL-2 polypeptide constructs can, in some embodiments, reduce activation of Treg cells while retaining or enhancing activation of CD8+ T cells and NK cells.

FIGS. 9A-9C depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK081 and AK032. The AK081 construct with and without prior exposure to MMP10 was tested. An isotype control as well as a no IL-2 negative control was also tested. The levels of STAT5 activation (%) are shown for NK cells, CD8+ T cells, and CD4+ T cells. The AK032 and AK081 constructs include an IL-2 polypeptide linked to an Fc domain, and the AK081 construct includes a cleavable peptide in the linker connecting the IL-2 polypeptide to the Fc domain. As shown, the non-masked monomeric AK08I IL-2 polypeptide construct stimulates STAT5 activation of PBMCs with or without protease activation similarly to the non-masked dimeric AK032 IL-2 polypeptide construct.

FIGS. 10A-10D depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK081 and AK111, as well as controls that included an rhIL-2 and anti-RSV antibody. A no-treatment control was also tested. The AK111 construct is an exemplary masked IL-2 polypeptide construct that includes a wildtype form of an IL-2 polypeptide (except for a C125A mutation). As shown in FIGS. 10A-10D, the masked IL-2 polypeptide construct AK111 demonstrated reduced STAT5 activation as compared to the non-masked IL-2 polypeptide construet AK081. FIG. 10D provides EC50 (pM) and fold-change data for the AK081, AK1111 constructs, as well as the rhIL-2 control.

FIGS. 11A-11D depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK167 and AK168, as well as controls that included an rhIL-2 and anti-RSV antibody. A no-treatment control was also tested. The AK168 construct is an exemplary masked IL-2 polypeptide construct that includes a mutant form of an IL-2 polypeptide that eliminates or reduces CD25 binding. The AK167 construct is a parental, non-masked form of the AK168 construct that includes the same mutant IL-2 polypeptide. As shown in FIGS. 11A-11C, the non-masked AK167 construct demonstrated reduced STAT5 activation as compared to the rhIL-2 control, and the masked IL-2 polypeptide construct AK168 did not induce detectable STAT5 activation. FIG. 11D provides EC50 (pM) and fold-change data for the AK167. AK168 constructs, as well as the rhIL-2 control. The EC50 of the AK168 construct was non-detectable (n.d.).

FIGS. 12A-12D depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK165 and AK166, as well as an isotype control and an IL-2-Fc control, that were (+MMP10) or were not previously exposed to the MMP10 protease. The AK166 construct is an exemplary masked IL-2 polypeptide construct that includes a wildtype form of an IL-2 polypeptide (except for a C125A mutation). The AK165 construct is a parental, non-masked form of the AK166 construct that includes the same IL-2 polypeptide. The key as shown in FIG. 12A also applies to FIG. 12B, and the key as shown in FIG. 12C also applies to FIG. 12D. As shown in FIGS. 12A-12D STAT5 activation was greatly diminished for the masked AK166 construct (without protease cleavage), but was restored to levels resembling the 1L2-Fc control following exposure to the activating protease MMP10.

FIGS. 13A-13C depict the results from STAT5 activation studies, as described above, using the exemplary constructs AK109 and AK110, as well as an isotype control and an IL-2-Fc control, that were (+MMP10) or were not previously exposed to the MMP10 protease. The AK109 and AK110 construct are exemplary masked IL-2 polypeptide constructs that include half-life extension moieties having different heterodimerization mutations. The key as shown in FIG. 13B also applies to FIG. 13A. As shown in FIGS. 13A-13C. STAT5 activation was greatly diminished for the masked AK09 and AK110 construct (without protease cleavage), but was greatly increased to levels approaching the 1L2-Fc control following exposure to the activating protease MMP10.

FIGS. 14A-14D depict the results from STAT5 activation studies, as described above, using the constructs AK211, AK235, AK253, AK306, AK310, AK314, and AK316, as well as an an rhIL-2 control. This includes constructs that are parental, non-masked constructs (AK235, AK253, AK306, AK310, AK314) that include various mutations that modulate CD25 binding. FIG. 14D provides EC50 data for each of the tested constructs as well as the rhIL-2 control.

FIGS. 15A-15D depict the results from STAT5 activation studies, as described above, using the constructs AK081, AK167, AK216, AK218, AK219, AK220, and AK223 that have been activated by protease, as well as an an rhIL-2 control. A no-treatment control was also tested. This includes masked IL-2 polypeptide constructs (AK216, AK218, AK219, AK220, and AK223) that include various mutations that modulate CD25 binding. The constructs were previously exposed to an activating protease prior to testing their ability to activate STAT5. FIG. 15D provides EC50 data for each of the tested constructs as well as the rtIL-2 control.

FIGS. 16A-16C depict the results from STAT5 activation studies, as described above, using the constructs AK081, AK189, AK190, and AK210, as well as an an anti-RSV control. This includes masked IL-2 polypeptide constructs (AK189, AK190, AK2101 that include an IL-2 polypeptide having a C125A mutation and include the same cleavable peptide sequence (RAAAVKSP; SEQ ID NO: 27) but having different linker sequences due to differences in the amino acid residues on the N-terminus of the protease cleavage sequence. The key as shown in FIG. 16A also applies to FIGS. 16B and 16C.

FIGS. 17A-17C depict the results from STAT5 activation studies, as described above, using the constructs AK167, AK191, AK192, and AK193, as well as an an anti-RSV control. This includes masked IL-2 polypeptide constructs (AK189, AK190, AK210) that include an IL-2 polypeptide having R38A, F42A, Y45A, E62A, and C125A mutations and include the same cleavable peptide sequence (RAAAVKSP; SEQ ID NO: 27) but having different linker sequences due to differences in the amino acid residues on the N-terminus of the protease cleavage sequence. The key as shown in FIG. 17A also applies to FIGS. 17B and 17C.

Example 3 In Vivo Characterization of Masked IL-2 Pharmacokinetics

The pharmacokinetics of the masked IL-2 polypeptide constructs generated in Example 1 is assessed in vivo using mouse models.

Mice are treated intravenously, intraperitoneally or subcutaneously with the constructs and the concentration of the construct in the plasma is measured over time. In some experiments, some mice are treated with controls for comparison. In some experiments, some mice are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. In some experiments, the mice that are treated have tumors. In some experiments, the mice that are treated are tumor-free. In some experiments, mice are treated with the constructs and blood is drawn at various times over the course of treatment, which may include drawing blood prior to the initiation of treatment and processing it to obtain plasma. In some experiments, blood is drawn at various time points over the course of two weeks, three weeks, or four weeks or more of treatment. In some experiments, the mean plasma concentration of the administered constructs, as well as aldesleukin and/or other controls, is measured. Masked IL-2 polypeptide constructs are detected in the plasma samples after dilution into PBS Tween with IL-2- and human Fc-specific ELISAs and are quantified using a standard curve generated for each construct. The percentage of full length and cleaved constructs is determined by western blot with anti-huFc-HRP and anti-huIL-2-HRP and by whole mass and peptide mass spectrometry. The pharmacokinetics of the masked IL-2 polypeptide constructs in tumors is also assessed in vivo using mouse models. Mice having tumors are treated intravenously or subcutaneously with the constructs and the concentration of the construct in tumors of the mice is assessed. In some experiments, some mice are treated with controls for comparison. In some experiments, some mice are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. Tumors are analyzed for the presence of the constructs as well as the presence of particular proteases. In some experiments, the tumors are analyzed for the presence and percentage of full length and cleaved constructs.

Some pharmacokinetic studies were carried out according to the following method. C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×10⁵ cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm³ sized tumors (day 0), the mice received a single 2 mg/kg intravenous dose of the construct of interest (e.g., a non-masked parental IL-2 polypeptide construct, a masked IL-2 polypeptide construct, or a non-cleavable masked IL-2 polypeptide construct) in PBS. Constructs tested include, for instance. AK032, AK081, AK111, AK167, AK168 AK191, AK197, AK203, AK209, and AK211. Plasma were collected at 5 min, days 1, 2 and 5 after dosing. Drug levels were determined using ELISAs utilizing anti-human IgG (clone M1310G05, Biolegend) as the capture antibody and various detection antibodies. HRP or biotin conjugated detection antibodies against human IgG (ab97225, Abcam) or CD122 (clone 9A2, Ancell) and IL-2 (Poly5176, Biolegend) were utilized to detect total and non-cleaved drug levels, respectively.

FIGS. 18A-18D describe results from pharmacokinetic studies carried out, as described above, in tumor-bearing mice using the constructs AK032, AK081, AK111, AK167, and AK168, as well as an anti-RSV control. FIG. 18A provides a simplistic depiction of the structure of each of the constructs tested. As indicated. AK111 and AK168 are exemplary masked IL-2 polypeptide constructs. The AK167 and AK168 constructs include mutations (R38A, F42A, Y45A, and E62A) that eliminate or reduce binding to CD25. FIG. 18A shows Fc levels in plasma (μg/mL) by detecting human IgG, FIG. 18C shows Fc-CD122 levels in plasma (μg/mL) by detecting human CD122, and FIG. 18D shows Fc-1L2 levels in plasma (μg/mL) by detecting human IL-2.

FIGS. 19A-19D describe results from pharmacokinetic studies carried out, as described above, in tumor-bearing mice using the constructs AK167, AK191 AK197, AK203, AK209, and AK211, as well as an anti-RSV control. FIG. 19A provides a simplistic depiction of the structure of each of the constructs tested. As indicated, AK168, AK191, AK197, AK203, and AK209 are exemplary masked IL-2 polypeptide constructs that each include a different cleavable peptide sequence in the linker connecting the IL-2 polypeptide to the half-life extension moiety. FIG. 19B shows Fc levels in plasma (μg/mL) by detecting human IgG, FIG. 19C shows Fc-IL2 levels in plasma (μg/mL) by detecting human IL-2, and FIG. 19D shows Fc-CD122 levels in plasma (μg/mL) by detecting human CD122. As shown in FIGS. 19B, 19C and 19D, the Fe levels, Fc-1L2 levels, and Fc-CD122 levels in the plasma are similar among the masked IL-2 polypeptide constructs tested.

Bioactivity in Mice

The in vivo bioactivity of the masked IL-2 polypeptide constructs generated in Example 1 is assessed in vivo using mouse models, such as C57BL/6 mice. Mice are treated with the constructs and in vivo bioactivity is assessed. In some experiments, some mice are treated with controls for comparison. In some experiments, some mice are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. In some experiments, the mice that are treated have tumors. In some experiments, the mice that are treated are tumor-free. In some experiments, the dose-dependent expansion of immune cells is assessed in the mice. In some experiments, the mice are treated with various doses of a construct, aldesleukin, or other control. In some experiments, the mice are treated over the course of two weeks. Blood is collected from the mice at various time points and is then stained using antibodies to immune cell markers of interest. In some experiments, the longitudinal kinetics of the proliferation and expansion of certain circulating cell types, such as CD8+ T cells, NK cells, and Treg cells, is also determined, as well as the ratio of CD8+ T cells and NK cells to CD4+CD25+FoxP3+ Treg cells. In some experiments, the mice are assessed for vascular leakage, such as by assessing for edema and lymphocyte infiltration in certain organs like the lung and liver as determined by organ wet weight and histology.

In some studies, vascular leakage was assessed in order to assess potential toxicity-related effects mediated by IL-2 based therapies by performing the following method. Repeated dose toxicity studies were conducted using C57BL %6 female mice that were purchased from Charles River Laboratories and were 8-10 weeks old weighing 18-22 grams at the start of study. Groups of 5 mice received daily intraperitoneal injections of masked and non-masked IL-2 constructs in PBS daily for 4 or 5 days. The constructs tested included AK081, AK111, AK167, and AK168. A control antibody was also administered as a control. Two hours after the last dose, all mice received an intravenous injection of 0.1 ml of 1% Evans blue (Sigma, cat #E2129) in PBS. Two hours after Evans blue administration, mice were anesthetized and perfused with 10 U/mi heparin in PBS. Spleen, lung and liver were harvested and fixed in 3 ml of 4% PFA 2 days at 4° C. prior to measuring the absorbance of the supernatant at 650 nm with NanoDrop OneC (Thermo Fisher Scientific, Waltham, Mass.) as an indicator of vascular leak of Evans blue. Fixed organs were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histopathological studies and quantification were carried out by NovoVita Histopath Laboratory. LLC. (Allston, Mass.) according to standard procedures. FIGS. 25A-50D depict results from an in vivo study as described above for assessing vascular leakage using the exemplary masked IL-2 polypeptide constructs AK111 and AK168, as well as the non-masked IL-2 polypeptide constructs AK081 and AK167, and an anti-RSV control. FIG. 25A shows the percentage (%) of body weight loss, and FIGS. 25B, 25C and 25D shows the weight in grams of the liver, lung, and spleen, respectively, for each.

Vascular leakage as indicated by measuring the extent of dye leakage into tissues was also assessed for the AK081, AK111, AK167, and AK168 constructs, along with an anti-RSV control, with results shown in FIGS. 26A and 26B for the liver and lung, respectively. The extent of dye leakage was measured based on absorbance at 650 nm.

Vascular leakage as indicated by measuring the extent of mononuclear cell perivascular invasion into the liver and lung was also assessed for the AK081, AK111, AK167, and AK168 constructs, along with an anti-RSV control, with results shown in FIGS. 27A and 27B for the liver and lung, respectively. The average number of mononuclear cells in the liver (FIG. 27A) and the average number of mononuclear cells in the lung (FIG. 27B) depicted for each. As shown in FIG. 27B, for instance, the masked IL-2 polypeptide constructs AK111 and AK168 did not result in a detectable number of mononuclear cells in the lung, unlike the non-masked constructs AK081 and AK167.

Infiltrating Immune Cell Phenotype

The phenotype of immune cells infiltrating tumors in vivo in mouse models treated with the masked IL-2 polypeptide constructs generated in Example 1 is assessed. Mice are treated with the constructs and the phenotype of tumor-infiltrating immune cells is assessed. In some experiments, some mice are treated with controls for comparison. In some experiments, some mice are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. Mice bearing tumors are treated with a construct, aldesleukin, or another control, and tumors, tissues such as liver, lung, and spleen, and blood, are collected at various time points following the initial dose, such as five days, seven days, or ten days after the initial dose. In some experiments, immune cells are isolated from the tumors, tissues, and blood, and are subject to phenotypic assessment using flow cytometry. In some experiments, the isolated immune cells are assessed using markers of interest, such as those for CD8+ T cells, Memory CD8+ T cells, activated NK cells. CD4+ T cells, and CD4+ Treg cells.

In some studies, the phenotype of immune cells infiltrating tumors in vivo was assessed using the following method. C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×10′ cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm³ sized tumors (day 0), the mice received a single 2 mg/kg intravenous dose of the construct of interest (e.g., a non-masked parental IL-2 polypeptide construct, a masked IL-2 polypeptide construct, or a non-cleavable masked IL-2 polypeptide construct) in PBS. On day 5, mice were euthanized by C02 asphyxiation and tumors, livers, spleens and blood were harvested. Cell suspensions were prepared from spleens by mechanical disruption and and passing through a 40 μm cell strainer. The tumor tissues were enzymatically digested using Miltenyi Tumor Dissociation Kit reagents (Miltenyi cat #130-096-730) and the gentleMACS Dissociator (Miltenyi) was used for the mechanical dissociation steps. Red blood cells in the spleen and tumor cell suspensions and blood were lysed using ACK buffer (Gibco cat #A10492). The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience), CD3 (clone 2C11, Biolegend), CD8 (clone 53-6.7, BD Biosciences), CD4 (clone RM-45, BD Biosciences), FOXP3 (MF-14, Biolegend), CD25 (3C7, Biolegend), CD44 (clone IM7, eBioscience), and NKp46 (29A1.4, eBioscience). Data acquisition was carried out on the MACSQuant Analyzer low cytometer (Milenyi) and data were analyzed using the FlowJo.

Results from studies testing the in vivo responses of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumor, as carried out as described above, using the AK032, AK081, AK111, AK167, and AK168 constructs, as well as an anti-RSV IgG control, are shown in FIGS. 20A-20L. AK111 and AK168 are exemplary masked IL-2 polypeptide constructs.

Results from studies testing the in vivo responses of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumor, as carried out as described above, using the AK167, AK168, AK191, AK197, AK203, AK209, and AK211 constructs, as well as an anti-RSV IgG control, are shown in FIGS. 21A-21L. AK168, AK191, AK197, AK203, and AK209 are exemplary masked IL-2 polypeptide constructs that each include a different cleavable peptide sequence in the linker connecting the IL-2 polypeptide to the half-life extension moiety. Statistical analysis was performed using One-way ANOVA as compared to the non-cleavable AK211 construct.

Results from studies testing the in vivo responses of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumor, as carried out as described above, using the AK235, AK191, AK192, AK193, AK210, AK189, AK19X, and AK211 constructs are shown in FIGS. 22A-22L. AK191, AK192, AK193, AK210, AK189, and AK190 are exemplary masked IL-2 polypeptide constructs that each include a cleavable peptide sequence in the linker connecting the IL-2 polypeptide to the half-life extension moiety. The linker sequence also differs among these constructs, depending on the linker sequence utilized. AK189, AK190, and AK210 include an IL-2 polypeptide having a C125A mutation, and AK191, AK192, and AK193 include an IL-2 polypeptide having C125A. R38A, F42A, Y45A, and E62A mutations. The AK235 construct is a non-masked construct and the AK211 construct includes a non-cleavable linker sequence. Statistical analysis was performed using One-way ANOVA as compared to the non-cleavable AK211 construct.

Results from studies testing the in vivo T cell activation in spleen, blood, and tumor, as carried out as described above, using the AK235, AK191, AK192, AK193, AK210, AK189, AK190, and AK211 constructs, as described above, are shown in FIGS. 23A-23I. T cell activation was measured as the mean fluorescence intensity (MFI) of CD25 in CD8+ T cells, CD4+ T cells, or Foxp3-+ cells in the spleen, blood, and tumor. Statistical analysis was performed using One-way ANOVA as compared to the non-cleavable AK211 construct.

In Vivo Cleavage

The in vivo cleavage of masked LL-2 cytokine constructs is assessed. In some studies, a control antibody is administered for comparison. In some studies, in vivo cleavage is assessed by administering the construct of interest in a mouse and, after a certain period of time, capturing human IgG and then measuring the levels of, e.g., human IgG, CD122, and IL-2.

In some studies testing the in vivo cleavage of masked IL-2 polypeptide constructs, drug levels (i.e., levels of the administered construct, including cleavage byproducts) were determined using ELISAs utilizing anti-human IgG (clone M1310G05, Biolegend) as the capture antibody and various detection antibodies. HRP or biotin conjugated detection antibodies against human IgG (ab97225, Abcam) or CD122 (clone 9A2, Ancell) and IL-2 (Poly5176, Biolegend) were utilized to detect total and non-cleaved drug levels, respectively. The concentrations of cleaved and released IL-2 is calculated by subtracting non-cleaved (i.e., intact) from total drug concentrations. FIGS. 24A-24D depict the results from studies testing the in vivo cleavage of the exemplary masked IL-2 polypeptide constructs AK168 (cleavable peptide sequence: MPYDLYHP; SEQ ID NO: 24) and AK209 (cleavable peptide sequence: VPLSLY; SEQ ID NO: 28). The AK167 construct is a cleavable non-masked IL-2 polypeptide construct that includes the same IL-2 polypeptide as the masked AK168 construct. As shown in FIGS. 24A-24D, both the masked (AK168 and AK209) and non-masked (AK167) constructs were effectively cleaved, and both cleavable peptide sequences were cleaved. FIG. 24E depicts results from a pharmacokinetic study of total plasma IgG concentration (μg/mL) for total levels of the AK167, AK168, and AK209 constructs, and for levels of non-cleaved forms of each construct.

Tumor Eradication and Inhibition of Metastasis

The ability of the masked IL-2 polypeptide constructs generated in Example 1 to promote tumor eradication and to inhibit metastasis is assessed in vivo using mouse models, such as syngeneic MC38. CT26, and B16F10 tumor models.

Mice are implanted with tumor cells subcutaneously, and tumors are allowed to grow to a palpable size. Tumor-bearing mice are treated with the masked IL-2 constructs or the masked IL-15 polypeptide constructs and tumor volume is measured over the course of treatment. In some experiments, some mice are treated with controls for comparison. In some experiments, some mice are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. Tumor volume is measured periodically over the course of treatment. In some experiments, body weight is also measured periodically over the course of treatment. In some experiments, plasma samples are produced over the course of the treatment and analyzed for pharmacokinetics, pharmacodynamics, cleavage, and blood markers, such as those for CD8+ T cells, Memory (D8+ T cells, activated NK cells, CD4+ T cells, and CD4+ Treg cells.

The capability of the masked IL-2 polypeptide constructs to inhibit metastasis is also assessed in vivo using mouse models suitable for metastasis studies, such as syngeneie CT26 tumor models for assessing lung metastasis. Mice are implanted with tumor cells subcutaneously. In some experiments, tumors are allowed to grow to a palpable size prior to treatment. In some experiments, treatment begins before tumors grow to palpable size. Tumor-bearing mice are treated with the masked IL-2 constructs are assessed for tumor cell metastasis into tissues such as lungs, liver, and lymph nodes.

In some studies, a syngeneic tumor model was used to assess the ability of masked IL-2 polypeptide constructs to reduce tumor volume in accordance with the following method. C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜125 mm3 sized tumors (day 0), the mice were randomized to receive 2 mg/kg doses of AK081, AK111, AK167, or AK168, or an anti-RSV antibody as a control, in PBS. Mice were dosed intraperitoneally, three times a week for 6 doses. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)/2) using dial calipers and body weights were recorded twice weekly. FIGS. 28A and 28B show results from a syngeneic tumor model study that assessed tumor volume and body weight over the course of treatment. As shown in FIG. 28A, treatment using exemplary IL-2 polypeptide constructs, including the masked constructs AK111 and AK168, resulted in tumor growth inhibition over time as compared to the anti-RSV control. As shown in FIG. 28B, there was a general lack of body weight reduction observed when the mice were treated with the masked constructs AK111 and AK168.

Bioactivity in Cynomolgus Monkeys

The in vivo bioactivity of the masked IL-2 polypeptide constructs generated in Example 1 is assessed in vivo in cynomolgus monkeys. Cynomolgus monkeys are treated with the constructs and in vivo bioactivity, pharmacokinetics, and cleavage is assessed. In some experiments, some monkeys are treated with controls for comparison. In some experiments, some monkeys are treated with aldesleukin as a control for masked IL-2 polypeptide treatment. In some experiments, the monkeys are treated with various doses of the construct, aldesleukin, or other control. Blood is collected from the monkeys at various time points and is then evaluated for certain cell types, such as CD8+ T cells, Memory CD8+ T cells, activated NK cells, CD4+ T cells, and CD4+ Treg cells, and/or markers of interest, such as for the dose-response of total lymphocytes, Ki67+, and of soluble CD25. In some experiments, the longitudinal kinetics of the proliferation and expansion of certain circulating T and NK cell types is assessed. In some experiments, pharmacokinetics and cleavage of the masked IL-2 polypeptide constructs are determined by ELISA, PAGE, and mass spectrometry.

To test the safety profile of exemplary masked IL-2 polypeptide constructs in non-human primates, a dose ranging study is performed in accordance with the following method. Groups of 3 healthy male cynomolgus monkeys (Macaca fascicularis) are randomly assigned to receive a single intravenous bolus dose of 2 mL/kg of activatable (i.e., cleavable) masked IL-2 polypeptide proteins or non-cleavable masked IL-2 polypeptide proteins at 10, 30 and 100 nmol/kg in 100 mM sodium citrate buffer (pH 5.5). A third group receives the parental non-masked, cleavable protein at 3, 10 and 30 nmol/kg as a positive control. This third group is dosed at a lower range to account for higher potency of the parental non-masked molecules. Doses are calculated in moles to account for differences in molecular weight. Blood samples are collected before dosing and 1, 24, 48, 72, 96, 168, 264 and 336 hours post-dosing. An automated hematology analyzer is used to monitor changes in lymphocyte subsets and serum chemistry. Total and intact (i.e., non-cleaved) drug levels are measured from plasma using custom ELISA as described above. Soluble CD25 levels are measured with an ELISA (R&D systems, cat #DR2A00) to monitor immune stimulation. Plasma levels of inflammatory cytokines are quantified using custom multiplexed electrochemiluminescence assay (Meso Scale Discovery). Blood pressure is monitored as an indicator of vascular leak syndrome. PK is analyzed using an ELISA that captures IL-2 and detects human Fc and by an ELISA that captures human Fc and detects human Fc.

Example 4

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×10⁵ cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm sized tumors (day 0), the mice received a single high dose intraperitoneal dose of various Fc-IL-2 constructs in PBS. Plasma were collected at 5 min, days 3, 5 and 7 after dosing.

-   -   The constructs used are shown in FIG. 68 :

Immunophenotyping was performed using a FACS-based method. On day 5, mice were euthanized by CO2 asphyxiation and tumors, livers, spleens and blood were harvested. Cell suspensions were prepared from spleens by mechanical disruption and and passing through a 40 μm cell strainer. The tumor tissues were enzymatically digested using Miltenyi Tumor Dissociation Kit reagents (Miltenyi cat #130-096-730) and the gentleMACS Dissociator (Miltenyi) was used for the mechanical dissociation steps. Red blood cells in the spleen and tumor cell suspensions and blood were lysed using ACK buffer (Gibco cat #A10492).

The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience), CD3 (clone 2C11, Biolegend), CD8 (clone 53-6.7, BD Biosciences), CD4 (clone RM-45, BD Biosciences). Data acquisition was carried out on the MACSQuant Analyzer flow cytometer (Milenyi) and data were analyzed using the FlowJo.

Drug levels were determined using ELISAs utilizing anti-human IgG (clone M1310G05, Biolegend) as the capture antibody and various detection antibodies. HRP or biotin conjugated detection antibodies against human IgG (ab97225, Abcam) or CD122 (clone 9A2, Ancell) and IL-2 (Poly5176, Biolegend) were utilized to detect total and non-cleaved drug levels, respectively.

AK471 with I253A FcRn mutation induced robust CD8 T cells expansion in the TME while remaining inactive in the periphery as shown in FIGS. 29A and 29B.

AK471 has slightly shorter half-life compared to aglyco-hIgG1 as shown in FIGS. 30 A, B and C.

There is no evidence of cleavage or decapitation with AK471 in the plasma (FIGS. 31 A, B and C).

Example 5 Summary of Cys to Ser Mutations on CD122

The two free cysteines on the CD122 masking domain were mutated to serines to increase protein stability and mitigate developability risks including, without being limited as to theory, aggregation, oxidation, and immunogenicity. The mutant was evaluated in an accelerated stability study, where the control and the Cys to Ser mutant was incubated for a prolonged time (3 weeks), with elevated temperature (40° C.), and in multiple pHs. Various analyses were performed to assess the impact of the cysteine mutations. The results demonstrate that the Cys to Ser mutant clearly enhanced the protein stability as evidenced by significantly reduced aggregation under stress. After 3 weeks incubation at pH8.0, the constructs with the cysteines mutated exhibit low levels of aggregation as compared to the control constructs, which do not contain the cysteine mutations, that have greater than fifty (50) percent aggregation as measured by SEC-HPLC. CE-SDS demonstrated that the construct with the mutated cysteines remains unaggregated (>99%) for pH6.0 and pH8.0 incubation, where the control constructs contained levels of aggregation up to fifteen (15) percent 1.

In addition, constructs with the mutated cysteines in the CD122 masking protein interact with the IL-2 protein in a similar manner as the control constructs, which contain a wild-type CD122 masking protein (i.e. without mutation of the cysteine residues). In addition, the constructs with the mutated cysteines in the CD122 masking protein are similar in both functional assays and pharmacodynamics studies as the control constructs, which contain a CD122 masking protein without the cysteine mutations.

Experimental Protocols Stability Study

Samples were incubated in a Galaxy 170 S air incubator set to 40° C. Three buffer systems were tested: 20 mM Citrate pH 5.0, 20 mM histidine pH 6.0, and 20 mM tris pH 8.0. The pH of each was calibrated at room temperature (approximately 27C) and buffers were adjusted to within 0.05 pH units with HCl/NaOH. Buffers were filtered by 0.22 um bottle top filters. Samples were buffer exchanged approximately 3000-fold into starting buffer via spin concentration. Sample aliquots were removed under sterile conditions at day 0, 1, 3, 7, 14, and 21, and stored at −80° C. before being evaluated in the below analytical tests.

SEC-HPLC

An HPLC system was used to assess the aggregation level in the incubated samples: the system was calibrated with along with molecular weight standards. Levels of high molecular weight species (“HMWS”) were measured in each sample. Increases in HMWS indicated increasing levels of aggregation.

The results of these studies is shown in FIGS. 32A and 32B. The key represents ‘AK’ molecule numbers, where AK341 is a Cys to Ser mutant and AK209 is a control.

CE-SDS

CE-SDS was run on a labchip machine. In general, a reducing agent was used for experiments under reducing conditions. Samples were subjected to high heat before samples were loaded into 96-well PCR plate. Recombinant human IL-2 was used as a low molecular weight protein control. Levels of HMWS were measured in each sample. Increases in HMWS indicated increasing levels of aggregation.

The results of these studies is shown in FIGS. 33A-33D. The key represents ‘AK’ molecule numbers, where AK341 is a Cys to Ser mutant and AK209 is a control.

Example 6

The constructs used are as follows:

Protease Protease Half-life AK# substrate site on extension AK209 VPLSLY IL-2 Agly-hIgG1 AK341* VPLSLY IL-2 Agly-hIgG1 AK438 VPLSLY CD 122 Agly-hIgG1 AK471 VPLSLY IL-2 FcRn-I253A AK50S VPLSLY CD 122 FeRn-I253A AKS04 VPLSLY IL-2 FcRn-hIgG4 AK511 VPLSLY CD 122 FcRn-hIgG4 AK203 DSGGFMLT IL-2 Agly-hIgG1 AK442 DSGGPVTT CD 122 Agly-hIgG1 AK168 MPYDLYHP IL-2 Agly-hIgG1 AK252 MPYDLYHP CD 122 Agly-hIgG1 AK509 MPYDLYHP IL-2 FcRn-I253A AK510 MPYDLYHP CD122 FcRn-I253A AK191 RAAAVKSP IL-2 Agly-hIgG1 AK503  RAAAVKSP CD122 Agly-hIgG1 AK211 - Non-cleavable AK253 - parental (no mask); no cleavage site; always active AK341* contains two cys -> ser mutations on CD122.

i. Anti-Tumor Activity—AK438 and AK442

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive Fc-IL-2 constructs in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)/2) using dial calipers and body weights were recorded twice weekly. Mice were sacrificed upon reaching humane end points of tumor burden (2000 mm3) or body weight loss due to toxicity (20%).

Results are shown in FIGS. 34A and B.

AK341* Contains two cys→ser mutations on CD122

ii. Peripheral (Spleen) Vs Tumor CD8 T Cell Expansion—AK438 and AK442

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×10 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm³ sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6.

Immunophenotyping on day 7 was performed using a FACS-based method from peripheral blood. Red blood cells were lysed using ACK buffer (Gibco cat #A10492). The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience), CD3 (clone 2C11, Biolegend), CDR (clone 53-6.7. BD Biosciences), CD4 (clone RM-45, BD Biosciences) and Ki-67 (clone SOLA15, eBioscience). Data acquisition was carried out on the MACSQuant Analyzer flow cytometer (Milenyi) and data were analyzed using the FlowJo. A one-way ANOVA with Bonferonni's post-test was performed to determine the statistical significance of treatment vs. control AK211)(*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

Results are shown in FIGS. 35A and B.

iii. Anti-tumor activity—AK252, AK438, AK209 and AK471

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)/2) using dial calipers and body weights were recorded twice weekly. Mice were sacrificed upon reaching humane end points of tumor burden (2000 mm3) or body weight loss due to toxicity (20%).

Results are shown in FIGS. 36A and 368 .

iv. Peripheral (Spleen) Vs Tumor CD8 T Cell Expansion—AK252, AK438, AK209, AK471

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6.

Immunophenotyping on day 7 was performed using a FACS-based method from peripheral blood. Red blood cells were lysed using ACK buffer (Gibco cat #A10492). The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience). CD3 (clone 2C11, Biolegend), CD8 (clone 53-6.7, BD Biosciences), CD4 (clone RM-45, BD Biosciences) and Ki-67 (clone SOLA15, eBioscience). Data acquisition was carried out on the MACSQuant Analyzer flow cytometer (Milenyi) and data were analyzed using the FlowJo. A one-way ANOVA with Bonferonni's post-test was performed to determine the statistical significance of treatment vs. control AK211) (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

Results are shown in FIGS. 37A and 37B.

v. Anti-Tumor Activity—AK252, AK442, AK203, AK508 and AK510

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)2) using dial calipers and body weights were recorded twice weekly. Mice were sacrificed upon reaching humane end points of tumor burden (2000 mm3) or body weight loss due to toxicity (20%).

Results are shown in FIGS. 38A and 388 .

vi. Peripheral (Spleen) Vs Tumor CD8 T Cell Expansion—AK252, AK442, AK203, AK5W and AK510

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6.

Immunophenotyping on day 7 was performed using a FACS-based method from peripheral blood. Red blood cells were lysed using ACK buffer (Gibco cat #A10492). The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience), CD3 (clone 2C11, Biolegend). CD8 (clone 53-6.7, BD Biosciences), CD4 (clone RM-45, BD Biosciences) and Ki-67 (clone SOLA) 5, eBioscience). Data acquisition was carried out on the MACSQuant Analyzer flow cytometer (Milenyi) and data were analyzed using the FlowJo. A one-way ANOVA with Bonferonni's post-test was performed to determine the statistical significance of treatment vs. control AK211) (*P<0.05; **P<0.01: ***P<0.001: ****P<0.0001).

Results are shown in FIGS. 39A and 39B.

vii. Anti-tumor activity—AK252, AK508, AK509, AK510, AK511

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)/2) using dial calipers and body weights were recorded twice weekly. Mice were sacrificed upon reaching humane end points of tumor burden (2000 mm3) or body weight loss due to toxicity (20%).

Results are shown in FIGS. 40A-40D.

viii. Peripheral (Spleen) Vs Tumor CD8 T Cell Expansion—AK252, AK508, AK509, AK510, AK511

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive 40 AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6.

Immunophenotyping on day 7 was performed using a FACS-based method from peripheral blood. Red blood cells were lysed using ACK buffer (Gibco cat #A10492). The cell suspensions were stained with the following antibodies: CD45 (clone 30-F11, eBioscience), CD3 (clone 2C11, Biolegend), CD8 (clone 53-6.7. BD Biosciences), CD4 (clone RM-45, BD Biosciences) and Ki-67 (clone SOLA15, eBioscience). Data acquisition was carried out on the MACSQuant Analyzer flow cytometer (Milenyi) and data were analyzed using the FlowJo. A one-way ANOVA with Bonferonni's post-test was performed to determine the statistical significance of treatment vs. control AK211)(*P<0.05; **P<0.01; ***P<1.001; ****P<0.0001). AK252++ produced in-house lot #AK252-06B, AK252 produced by ATUM lot #AK252-A-01A.

Results shown in FIGS. 41A and 41B.

ix. Anti-Tumor Activity—AK252, AK43& AK442, AK209, AK341

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tumor volume was calculated (Length*(Width{circumflex over ( )}2)/2) using dial calipers and body weights were recorded twice weekly. Mice were sacrificed upon reaching humane end points of tumor burden (2000 mm3) or body weight loss due to toxicity (20%).

Results are shown in FIGS. 42A and 42B.

x. Splenomegaly and Lung Edema—AK252, AK438, AK442, AK209, AK341

C57BL/6 female mice were purchased from Charles River Laboratories and were 8-10 weeks old at the start of study. MC38 tumor cells (5×105 cells per mouse) were injected subcutaneously into the right flank of each mouse. Upon reaching ˜100 mm3 sized tumors (day 0), the mice were randomized to receive AK253 at very low dose level and all other Fc-IL-2 constructs at high dose level in PBS. Mice were dosed intravenously on days 0, 3 and 6. Tissues were harvested and weighed on day 6.

Results are shown in FIGS. 43A and 43B.

Example 7

i. Cleavage of Peptides by NAT Vs. RCC Culture Supernatant

Sequences comprising cleavage peptides (shown in bold below) were incubated in either ‘NAT’ (Normal Adjacent Tissue) or ‘RCC’ (Renal Cell Carcinoma) culture supernatants, to test the specificity of each peptide's cleavage.

To this end, peptide sequencing by mass spectrometry was used to identify cleaved fragments produced for the synthetic peptides shown in the table below, using a published technique called multiplexed substrate profiling by mass spectrometry (MSP-MS) (O'Donoghue A. J. et al. Nat Methods. 2012 November; 9(11):1095-100.) Cleavages were monitored in these reactions over time, and the peptides found to be cleaved in the earliest time points were deemed to be most sensitive to proteolytic activity in the conditioned media samples.

Synthetic Peptide Sequence (bolded sequences show Earliest the cleavable cleaved Earliest peptide; time cleaved Sub- *indicates point- time point- strate cleavage site) NAT RCC NAT RCC AK-15 RSGVPLS*LYSGSG 0 3/5 15 min GGK AK-18 RSGMP*YDLY*HPS 5/5 5/5 15 min 15 min GK AK-21 RGPDSGGF*ML*TS 3/5 5/5 15 min 15 min GK AK-28 RGSGHEQLTVSGGS 0 0 K AK-49 RSGR*AAAVKSPSG 0 3/5 15-60-240 min K AK-02 RGSGISSGLLSGRS 5/5 5/5 15-60 min 15-60 min *D*N*HSGK AK-50 RGDLLAVVA*ASGG 0 5/5 15-60 min K AK-88 RGGISSGLL*SG*R 0 5/5 15-60 min SGK

Cleavage peptides DLLAVVA*AS and ISSGLL*SG*RS were found to be the most specific. Sequences comprising these peptides did not cleave in the NAT culture, but cleaved in every run in the RCC culture.

Example 8

The following constructs used in this example are shown in FIG. 69 .

Details on the domain features and sequences of each AK molecule is as follows:

AK904 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA158 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(Hole) TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS AK904 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)-IL15 TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK V1 Non- VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD cleavable ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N79Q) YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSG GGSGPSGSPGNWVNVISDLKKIEDLIQSMHIDAT LYTESDVHPSCKVTAMKCFLLELQVISLESGDAS IHDTVENLIILAQNSLSSNGQVTESGCKECEELE EKNIKEFLQSFVHIVQMFINTS AK910 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA440 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(Hole) TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK CD122(C122S, VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD C168S) ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSQ FTCFYNSRANISCVWSQDGALQDTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQKLTTV DIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAP ISLQVVHIVETHRSNISWEISQASHYFERHLEFE ARTLSPGHTWEEAPLLTLKQKQEWISLETLTPDT QYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAAL GKD 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA904 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)-IL15 TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK V1 Non- VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD cleavable ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N79Q) YKTTPPVLDSDGSFFLYSKITVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGSSPPGGOSSG GGSGPSGSPGNWVNVISDLKKIEDLIQSMHIDAT LYTESDVHPSCKVTAMKCFLLELQVISLESGDAS LHDTVENLIILAQNSLSSNGQVTESGCKECEELE EKNIKEFLQSFVHIVQMFINTS AK932 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA440 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(Hole) TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK CD122(C122S, VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD C168S) ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSQ FTCFYNSRANISCVWSQDGALQDTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQKLTTV DIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAP ISLQVVHVETHRSNISWEISQASHYFERHLEFEA RTLSPGHTWEEAPLLTLKQKQEWISLETLTPDTQ YEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALG KD 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA924 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)- TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK [DLLAVVAA]- VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD IL15 ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N79Q) YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS *cleavable CSVMHEALHNHYTQKSLSLSPGSGSDLLAVVAAS peptide bolded SGPGSGNWVNVISDLKKIEDLIQSMHIDATLYTE SDVHPSCKVTAMKCFLLELQVISLESGDASIHDT VENLIILAQNSLSSNGQVTESGCKECEELEEKNI KEFLQSFVHIVQMFINTS AK938 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA822 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(hole)- TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK [DLLAVVAA]- VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD CD122 ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN *cleavable YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS peptide bolded CSVMHEALHNHYTQKSLSLSPGSGSPSGDLLAVV AASSGPGSOSPAVNGTSQFTCFYNSRANISCVWS QDGALQDTSCQVHAWPDRRRWNQTCELLPVSQAS WACNLILGAPDSQKLTTVDIVTLRVLCREGVRWR VMAIQDFKPFENLRLMAPISLQVVHVETHRSNIS WEISQASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWISLETLTPDTQYEFQVRVKPLQGEFTT WSPWSQPLAFRTKPAALGKD 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA904 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)-IL15 TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK V1 Non- VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD cleavable ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N79Q) YKTTPPVLDSDOSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSG GGSGPSGSPGNWVNVISDLKKIEDLIQSMHIDAT LYTESDVHPSCKVTAMKCFLLELQVISLESGDAS IHDTVENLIILAQNSLSSNGQVTESGCKECEELE EKNIKEFLQSFVHIVQMFINTS AK930 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA440 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(hole) TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK CD122(C122S, VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD C168S) ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSQ FTCFYNSRANISCVWSQDGALQDTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQKLTTV DIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAP ISLQVVHIVETHRSNISWEISQASHYFERHLEFE ARTLSPGHTWEEAPLLTLKQKQEWISLETLTPDT QYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAAL GKD 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA922 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)- TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK (ISSGLLSGR) VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD IL15 ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N799) YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS *cleavable CSVMHEALHNHYTQKSLSLSPGGGSSGGSPISSG peptide bolded LLSGRSSGPGSGSNWVNVISDLKKIEDLIQSMHI DATLYTESDVHPSCKVTAMKCFLLELQVISLESG DASIHDTVENLIILAQNSLSSNGQVTESGCKECE ELEEKNIKEFLQSFVHIVQMFINTS AK936 1^(st) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA823 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(hole)- TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK (ISSGLLSGR) VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD CD122 ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGPPSGSSPISSG LLSGRSSGGGAVNGTSQFTCFYNSRANISCVWSQ DGALQDTSCQVHAWPDRRRWNQTCELLPVSQASW ACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRV MAIQDFKPFENLRLMAPISLQVVHVETHRSNISW EISQASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWISLETLTPDTQYEFQVRVKPLQGEFTTW SPWSQPLAFRTKPAALGKD 2^(nd) polypeptide DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS DNA904 chain: RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK Fc(knob)-IL15 TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK V1 Non- VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD cleavable ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN (N71Q, N79Q) YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSG GGSGPSGSPGNWVNVISDLKKIEDLIQSMHIDAT LYTESDVHPSCKVTAMKCFLLELQVISLESGDAS IHDTVENLIILAQNSLSSNGQVTESGCKECEELE EKNIKEFLQSFVHIVQMFINTS

Importantly. AK932 and AK930, and their ‘flipped’ counterparts AK938 and AK936 include a peptide substrate (the sequence of which is depicted in the box above each molecule and bolded in the sequence table table). AK904 is a non-cleavable unmasked construct, and AK910 is a non-cleavable masked construct, both acting as negative controls.

The above AK molecules include an IL-15 domain, however it will be appreciated that however the results and conclusions of this data are equally relevant for IL-2 constructs.

Cleavage was Achieved for Masked Constructs Including a Peptide Substrate.

Constructs were incubated with MMP7, 9 and 10. Cleavage for each construct was analysed by SDS-PAGE and confirmed by HEK-Blue IL-2 bioassay.

The HEK-Blue assay was carried out as follows:

Conditions: Cell plate: 96 well plate. Cell density: 50K cls/well. Time point for HEK Blue detection were tested: 1 h. Construct number: Total 14 constructs that were tested.

Assay Flowchart is shown in FIG. 70 .

The results are shown in the table below, where a ‘X’ indicates not fully cleaved and a indicates Cleavage:

ID MMP Cleavage AK904  7 X  9 X 10 X AK910  7 X  9 X 10 X AK932  7 √  9 — 10 — AK938  7 √  9 — 10 — AK930 7 (36 hr) √  9 — 10 — AK936  7 √  9 — 10 —

The specific EC₅₀ readout results from the HEK-Blue IL-2 bioassay are shown in the table below.

ID MMP EC50 (pM) Max AK904 (1:1:2) — 14.78 1.44  7 17.08 1.37  9 16.00 1.43 10 22.93 1.45 AK910 (1:1:2) — 1219.34  1.31  7 284.17  1.42  9 519.09  1.40 10 490.52  1.40 AK932 (1:1:2) — 2403.11  1.22  7  9.30 1.43  9 — — 10 — — AK938 (1:1:2) — 885.13  1.31  7 18.03 1.38  9 — — 10 — — AK930 (1:1:2) — 1858.76  1.22  7  8.00 1.41  9 — — 10 — — AK936 (1:1:2) — 785.85  1.37  7 16.11 1.40  9 — — 10 — —

The SDS-PAGE gel results are shown in FIGS. 44A-D. The HEK-Blue IL-2 bioassay results are shown in FIGS. 45A-F.

Example 9

This example demonstrates the masking and cleavage of exemplary IL-12 constructs.

The following used in this example are shown in FIG. 71 .

AK671 is an unmasked molecule, AK663 does not comprise a cytokine, and AK664 is non-cleavable. These three molecules serve as controls.

The cleavage peptide for each construct is show at the top of each column.

AK066, AK667, AK918, AK920 and AK069 are ‘version 1’ constructs. AK605, AK668, AK919, AK921, AK670 are ‘version 2’ constructs. AK924, AK922, AK925 and AK923 are ‘version 3’ constructs.

The cleavable linker (protease site linker). i.e. between the HL2 and the IL-12 domain, and the non-cleavable linker (b2 receptor linker) between HL11 and the masking moiety for each version is shown below:

v1 Protease site linker b2 receptor linker V1 GGSGGSXXXXXXSGP V1 PGGSGP V2 GGSGGSGGSXXXXXXSGP V2 GGSPG V3 GGSGGGSG

Where applicable, all of these constructs comprise a KDNTEGRV mutation to the GAG binding domain of the IL-12p40 subunit, a C252S mutation of the IL-12p40 subunit, and a C242S mutation of the IL-12RB2 domain. Sequences for each construct are shown in the table below:

AK671 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPARIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQOOGNVFSCSVMHEALHNHYTQKSLSLSPGK 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSGGSGGSSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLD QSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSA ERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIK PDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVAT PDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACL PLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNA KLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLH AFRIRAVTIDRVMSYLNAS AK663 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVELEPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSW SDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLRGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWOQGNVFSCSVMBEALHNHYTQKSLSLSPGK AK664 1^(st) polypeptide chain DKTHTCPPCPAFELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSFSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKHLYKGSWS DWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSGGSGGSSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLD QSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSA ERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIK PDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVAT PDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACL PLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNA KLLMDPRRQIPLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLH AFRIRAVTIDRVNSYLNAS AK665 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSW SDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSVPLSLYSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLD QSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSA ERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIK PDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVAT PDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACL PLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLEMYQVEFKTMNA KLLMDPERQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLH AFRIRAVTIDRVMSYLNAS AK666 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPG GSGPKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRR INFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWR DEGLVLLNRLRYRPSNSRLNNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGS WSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSVPLSLYSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSS EVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEP KNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDP PKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKTSA TVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDP GMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLE LTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLL MDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFR IRAVTIDRVMSYLNAS AK667 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPG GSGPKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRR INFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWR DEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGS WSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSMPYDLYHPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQ SSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQK EPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAE RVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKP DPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKT SATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATP DPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLP LELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAK LLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS AK668 1^(st) polypeptide cnain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSW SDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSMPYDLYHPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWT LDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILK DQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDI IKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFT DKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPV ATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEA CLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTM NAKLLMDPKRQIPLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCIL LHAFRIRAVTIDRVMSYLNAS AK918 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPG GSGPKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRR INFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWR DEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGS WSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCFPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGS GGSDSGGFMLTSGPIWELKKDVYVVELDWYPDAPGEWVLTCDTPEEDGITWTLDQSS EVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEP KNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDP PKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKTSA TVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDP GMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLE LTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLL MDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFR IRAVTIDRVMSYLNAS AK919 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGS PGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRIN FHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQK GEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESP ESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRDE GLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSWS DWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSDSGGFMLTSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWT LDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILK DQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDI IKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFT DKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPV ATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEA CLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTM NAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCIL LHAFRIRAVTIDRVMSYLNAS AK920 1^(st) polypeptide chain DETHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPG GSGPKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRR INFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSLGSSSSLPSTETFLDIVRPLPPWDIRIKFQKASVSRSTLYWR DEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGS WSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSRAAAVKSPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQ SSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQK EPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAE RVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKP DPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKT SATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATP DPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLP LELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAK LLMDPKRQIELDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS AK921 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSW SDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSRAAAVKSPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWT LDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILK DQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDI IKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFT DKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPV ATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEA CLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTM NAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCIL LHAFRIRAVTIDRVMSYLNAS AK922 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVELEPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTEPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGGSGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFD RRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLT PESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLY WRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYK GSWSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTEPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSISSGLLSGRSSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTL DQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKD QKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLS AERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDII KPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTD KTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVA TPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEAC LPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMN AKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILL HAFRIRAVTIDRVMSYLNAS AK923 1^(st) polypeptide chain DKTHTCPPCFAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGGSGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFD RRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLT PESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLY WRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYK GSWSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVPLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSISSGLLSGRSSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGIT WTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDI LKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAA TLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIR DIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRV FTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNL PVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTV EACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFK TMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLC ILLHAFRIRAVTIDRVMSYLNAS AK924 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGGSGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFD RRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPRNLTWQKQCKDIYCDYLDFGINLT PESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLY WRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYK GSWSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSRAAAVKSPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQ SSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQK EPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAE RVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKP DPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTDKT SATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATP DPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLP LELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAK LLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS AK925 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGGSGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFD RRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLS CIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLT PESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLY WRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYK GSWSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSRAAAVKSPSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWT LDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILK DQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDI IKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFT DKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPV ATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEA CLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTM NAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCIL LHAFRIRAVTIDRVMSYLNAS AK669 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAETKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKARGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPG GSGPKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRR INFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCI QKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPE SPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWR DEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGS WSDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSISSGLLSGRSSGPIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTL DQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKD QKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLS AERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDII KPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVFTD KTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVA TPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEAC LPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMN AKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILL HAFRIRAVTIDRVMSYLNAS AK670 1^(st) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SPGKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRI NFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQ KGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPES PESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRSTLYWRD EGLVLLNRLRYRPSNSRLWNMVNVTKAKCRHDLLDLKPFTEYEFQISSKLHLYKGSW SDWSESLRAQTPEE 2^(nd) polypeptide chain DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDKAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGG SGGSGGSISSGLLSGRSSGPIWELKKDVYVVELDWYPDAPGEMWLTCDTPEEDGITW TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDIL KDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAAT LSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRD IIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFSVQVQGKDNTEGRVF TDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLP VATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVE ACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKT MNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCI LLHAFRIRAVTIDRVMSYLNAS

i) Ex Vivo Cleavage Assay (WB/IL-12 Signaling)

1 uM of IL-12 construct were incubated with W0 ul of conditioned media overnight or 90 ul of plasma, for the following times (d1-d2-d4-d7-d9-d11) at 37° C. The cleavage rate is calculated as a ratio or, cleaved construct/(cleaved construct+ intact construct), using a western blot anti-human IL-12 and anti-human IL-12Rb. The activation of these constructs by human tissue conditioned media is assessed using a post-IL-12 receptor signalling assay where 0.05×106 HEK-Blue cells are incubated with 37.5 nM of constructs, for 24h.

The flowchart used in this Example is shown in FIG. 72 .

Results are shown in FIG. 40 and in the tables below.

Molecules with the following cleavage sites exhibited readily detectable cleavage in the tumor supernatants:

  RAAAVKSP ISSGLLSGRS MPYDLYHP

The cleavage sites sensitivity was observed in the following order:

RAAAVKSP>ISSGLLSGRS>MPYDLYHP

Therefore, the IL-12 constructs that harbor these cleavage sites represent good candidates for tumor selective activation in RCC and other types of cancers.

Cutoff 1%, n = 30 % Cleavage % Activity (signalinh assay) ISSGLLSGRS ISSGLLSGRS AK669 AK670 AK922 AK923 AK669 AK670 AK922 AK923 % of samples with >1% Cleavage, activity 2 5 2 2 3 9 1 8 Frequency of cleavage, activation (%) 6.7 16.7 6.7 6.7 10.0 30.0 3.3 26.7 % Activation (Median) 5.5 1.8 5.8 8.2 1.7 2.2 5.8 1.2 RAAAVKSP RAAAVKSP AK920 AK921 AK924 AK925 AK920 AK921 AK924 AK925 % of samples with >1% Cleavage, activity 7 4 3 3 7 5 6 7 Frequency of cleavage, activation (%) 23.3 13.3 10.0 10.0 23.3 16.7 20.0 23.3 % Activation (Median) 1.8 2.0 13.6 2.6 1.9 2.5 1.8 1.7 MPYDLYHP MPYDLYHP AK667 AK668 AK667 AK668 % of samples with >1% Cleavage, activity 2 2 5 8 Frequency of cleavage, activation (%) 6.7 6.7 16.7 26.7 % Activation (Median) 2.3 2.7 1.5 1.7 VPLSLYSG VPLSLYSG AK665 AK666 AK665 AK666 % of samples with >1% Cleavage, activity 7 1 7 4 Frequency of cleavage, activation (%) 23 3 23 13 % Activation (Median) 2.5 1 2.1 1.6 DSGGFMLT DSGGFMLT AK918 AK919 AK918 AK919 % of samples with >1% Cleavage, activity 5 4 3 5 Frequency of cleavage, activation (%) 17 13 10 17 % Activation (Median) 1.8 2.1 1.7 1.3

ii) In Vitro Cleavage Analysis: HEK Blue IL-12 and SDS-PAGE Analysis

Testing IL-12 molecules with HEK-Blue IL-12 cells:

HEK-Blue IL-2 reporter cells developed by Invivogen have been specifically designed to monitor the activation of the JAK-STAT pathway. These cells were generated by stable transfection of HEK293 cells with the human IL-12Rβ1 and IL-12Rβ2 genes, along with the human TyK2, JAK2, and STAT4 genes to obtain a fully functional IL-12 signaling pathway. In addition, a STAT4-inducible SEAP reporter gene was also introduced. Upon stimulation. HEK-Blue™ IL-12 cells trigger the activation of STAT4 and the subsequent secretion of SEAP. The levels of STAT4-induced SEAP can be readily monitored using QUANTI-Blue™. HEK-Blue IL-12 cells can be used to validate the functionality, toxicity, and variable dosage effects of human or murine IL-12. HEK Blue IL-12 cells were grown in passage media until ˜80% confluent. Washed single-cell suspension in assay media was plated and serial dilutions of IL-12 molecules in assay media were added to cells. Plate was incubated at 37° C. for 24 h. After 24 h. Quanti-Blue solution (Invivogen) was prepared and cell supernatant was added to the Quanti-Blue solution and incubated for 1-2 h at 37° C. Absorbance at 625 nm measured. Data analysis was performed in Graphpad Prism, version 8.3. Background was subtracted from raw data and the data were fit nonlinearly: [Agonist] vs. response-Variable slope (four parameters). EC50 value of each IL-12 construct was reported.

Masking:

Results are shown in the tables below and in FIGS. 47, 48A and B.

Run 1, Run 2, Average Construct EC₅₀ Aklusion EC₅₀ Aklusion Aklusion AK671 24.7 N/A 15.2 N/A N/A rhlL-12 9.6 N/A 8.2 N/A N/A AK386 null 477.9 19.4 367.5 14.9 17.1 AK664 null 1854.0 75.2 1677.0 68.0 71.6 AK665 null 1303.0 52.9 1491.0 60.5 56.7 AK666-01A null 1775.0 72.0 2009.0 81.5 76.8 AK666-02A null 1725.0 70.0 1537.0 62.4 66.2 AK667 null 3104.0 125.9 2035.0 82.6 104.2 AK668 null 1383.0 56.1 1370.0 55.6 55.8 AK669 null 895.6 36.3 1193.0 48.4 42.4 AK670 null 740.9 30.1 862.1 35.0 32.5 AK922 null 1183.0 48.0 1101.0 44.7 46.3 AK923 null 1562.0 63.4 1188.0 48.2 55.8 AK918 null 2886.0 117.1 3116.0 126.4 121.7 AK919 null 1230.0 49.9 1475.0 59.8 54.9 AK920 null 1116.0 45.3 1116.0 45.3 45.3 AK921 null 1638.0 68.9 1352.0 54.8 61.9 AK924 null 1030.0 41.8 766.4 31.1 36.4 AK925 null 995.1 40.4 914.8 37.1 38.7

Parental AK671 is less potent than rhIL-12 (but not significantly, i.e. 3 Mold). All masked constructs are more akluded than AK386, AK067 and AK918 are both >100-fold akluded.

As compared to AK386, the new molecules that have the GAG-binding domain mutation, the cysteines to serines mutations, new optimized linkers, as well as different cleavage sites, all exhibit improved masking.

Cleavage:

Cleavage of the constructs was testing using exemplary proteases MMP7, 9 and 10.

Batch 1

300 ng Total construct AK ID Protein Lot # MMP cleaved, ug AK663 AK663-01A  7 8.8 AK664 AK664-01A  7 14.8  AK665 AK665-01A  7 14.8  AK666 AK666-01A  7 14.8  AK667 AK667-01A 10 14.9  AK668 AK668-01A 10 14.9  AK669 AK669-01A  2 14.9  AK670 AK670-01A  2 14.9  AK671 AK671-01A  7 11.3  AK386 AK386-03A  7 14.9  AK674 AK674-01A  7 15.1 

Results are shown in FIGS. 49A-H and 50A-K

Batch 2

300 ng Total construct AK ID Protein Lot # MMP cleaved, ug AK667 AK667-01A 7, 9, 10 14.86 AK671 AK671-01A 7, 9, 10 11.31 AK918 AK918-01A 7 14.84 AK919 AK919-01A 7 14.85 AK920 AK920-01A 8 14.83 AK921 AK921-01A 9 14.84 AK386 AK386-03A 7 14.90

Re-suits are shown in FIGS. 51A-B and 52A-G

300 ng Total construct AK ID Protein Lot # MMP cleaved, ug AK386 AK386-04A 7, 10 14.9 AK922 AK922-01A  7 14.9 AK923 AK923-01A  7 14.9 AK924 AK924-01A 10 14.8 AK925 AK925-01A 10 14.9 AK671 AK671-02A N/A N/A

Results are shown in FIGS. 53 and 54A-E

Overall, the new molecules with different cleavage sites are all susceptible to MMP cleavage in vitro. For all the molecules, there is a restoration or activity post cleavage. These compounds represent good candidates for tumor selective activable IL-12 molecules.

Example 10

The following constructs were used in this example:

Control Molecules (as Shown in FIG. 73)

-   -   Positive control: unmasked AK904     -   Cleavage control: masked, non-cleavable AK910

Masked Cleavable Molecules: (as Shown in FIG. 74)

-   -   Cytokine-substrate construct: AK930     -   Mask-substrate construct: AK936

Details on the domain features and sequences of each AK molecule is set out in Example 8.

CT26 Murine Tumor Model—In Vivo Evaluation of the PD of Test Articles in the Treatment of CT26 Tumor Bearing Mice

Balb/c mice were injected with CT26 cells s.c, and monitored for tumor growth. Once tumor sizes reached 175-223 mm3, animals were randomized (n=4 per group). A single i.v. injection of test article was administered at dose levels according to the table. Body weights were measured on day 0 and day 5. On day 5, animals were sacrificed, and tissues were collected for immunophenotyping.

Dosing Dosing Test Molecule (nMoles/kg) (mg/kg) 1 Vehicle * * 2 AK904 (parental) 6.7 0.43 3 AK904 (parental) 22.2 1.45 4 AK910 (NC) 222 20 5 AK930 66.6 6 6 AK930 222 20 7 AK936 66.6 6 8 AK936 22.2 2 * Vehicle volume is the same volume of the highest-dosed group.

The Results are as follows,

i) Tissue Weight, Tumor Weight and Body Weight Change (%) on Day 5

FIG. 55A: Mice treated with high dose AK904 and AK931 and low and high doses of AK936 demonstrated a significant loss in body weight.

FIG. 55B: No significant difference in tumor volume was observed across all treated mice.

FIG. 55C: Mice treated with high dose AK904 and AK936 demonstrated a significant increase in lung weight.

FIG. 55D: A significant increase in spleen weight was demonstrated in all mice treated with test article, either with low dose, high dose, or both dosing regimens.

ii) NK Cell Frequency

FIGS. 56A and B: Mice demonstrated a dose-dependent increase in % NK cells in the blood and spleen.

FIG. 56C: Mice in all treatment groups demonstrated increase % NK in the tumor.

iii) NK Ki67 MFI

FIGS. 57A, B, and C: Mice demonstrated a dose-dependent increase in proliferation marker K167 in NK cells in the blood, spleen, and tumor.

iv) CD8+ T Cell Frequency

FIG. 58A: Mice treated with unmasked AK904 demonstrated a dose-dependent increase in % CD8 T cells in the blood.

FIG. 58B: Mice demonstrated a dose-dependent increase in % CDR T cells in the spleen.

FIG. 58C: Mice in all treatment groups did not demonstrate an increase % CD8 T cells in the tumor (inconclusive evidence).

v) CD8+ T Ki67 MF1

FIGS. 59A and B: Mice demonstrated a dose-dependent increase in proliferation marker Ki67 in CD8 T cells in the blood and spleen.

FIG. 59C: Mice in all treatment groups did not demonstrate an increase in Ki67 in CD8 T cells in the tumor.

vi) CD8+T:Treg Ratio

FIGS. 60A and B: Mice treated with AK904 and AK936 demonstrated a dose-dependent increased CD8/Treg ratio in the blood and spleen.

FIG. 60C: Mice treated with AK904, AK930 and AK936 demonstrated a dose-dependent increased CD8/Treg ratio in the tumor,

B16F10 Murine Tumor Model—IL-15 PKPD Stub, in B16-F10 Model

C57BL/6) mice were injected with MC38 cells s.c. and monitored for tumor growth. Once tumor sizes reached 175-225 mm3, animals were randomized (n=4 per group, except for AK904 and vehicle groups, which contained n8 per group), A single i.v. injection of test article was administered at dose levels according to the table. Plasma was collected at 5 mini, 2 h, 6 h, and on day 5 for PK analysis, Body weights were measured on day 0 and day 5. On day 5, animals were sacrificed, and tissues were collected for immunophenotyping.

Dosing Dosing Test Molecule (nMoles/kg) (mg/kg) 1 Vehicle * * 2 AK904 (parental) 6.7 0.43 3 AK904 (parental) 22.2 1.45 4 AK910 (NC) 66.6 6 5 AK910 (NC) 222 20 6 AK930 66.6 6 7 AK930 222 20 8 AK936 66.6 6 9 AK936 222 20 * Vehicle volume is the same volume of the highest-dosed group.

The Results are as follows.

i) Tissue Weight, Tumor Weight and Body Weight Change (%) on Day 5

FIG. 61A: Mice treated with high dose AK904 and AK936 demonstrated a significant loss in body weight.

FIG. 61B: No significant difference in tumor volume was observed across all treated mice.

FIG. 61C: Mice treated with low and high dose AK904 and AK936 demonstrated a significant increase in lung weight.

FIG. 61D: No significant increase in spleen weight was demonstrated in any mice treated with test article.

ii) Masked IL-15 Showed Longer Half-Life than Unmasked Control

FIG. 62A: A similar PK profile is observed between molecules AK910, AK930 and AK936.

FIG. 62B: AK910, AK930 and AK936 have 2-3 fold longer half-life, compared to AK904.

FIGS. 62C and D: AK910, AK930 and AK936 have similar and dose-dependent C_(max) and AUC_((O-last),) as expected.

iii) NK

FIGS. 63A-C: Mice demonstrated a dose-dependent increase in % NK cells in the blood, spleen, and tumor.

iv) CD8+ T Cell

FIGS. 64A and B: Mice treated with AK904 and AK936 demonstrated an increase in % CD8 T cells in the blood and spleen.

FIG. 64C: Mice in all treatment groups demonstrated an increase % CD8 T cells in the tumor.

v) CD8+T:Treg Ratio

FIGS. 65A and B: Mice treated with AK90 and AK936 demonstrated an increased CD8/Treg ratio in the blood and spleen.

FIG. 65C: Mice treated with AK904, AK930 and AK936 demonstrated a dose-dependent increased CD8/Treg ratio in the tumor.

Example 11

The following construct was used in this Example (FIG. 75 ):

AK923 (ISSGLGLRS) IL-12: Ex Vivo Cleavage by Human Tumor

The process of ex vivo human tumor cleavage assay is shown in FIG. 76A. Human primary tumor tissues were gently dissociated and culture for 1, 2 or 3 days (500 mg in 30 ml RPMI). Conditioned media (90 μl), containing proteases secreted by the tumor and its microenvironment, was collected for incubation with the AK923 molecules (1 μM) for 24 hours, at 37 C. The percentage of cleaved molecule was quantified using the fluorescent triplex western blot. The frequency of cleavage represents the % of tumor samples which were able to cleave the drug. Results are shown in FIG. 66 .

FIG. 76B shows flow-chart for evaluation of AK923 cleavage by various tumor cells. AK923 drug (1 μM) was incubated in 90 μL of plasma from Healthy human Control Donors (10 donors), Melanoma 3 patients (8 donors) and Head and Neck patients (10 donors), for 1, 2, 4, 7, 9, and 11 days at 37° C. The percentage of cleaved molecule was quantified using the fluorescent triplex western blot. Data points represent the median of 8 or 10 donors. Results are shown in FIG. 67 .

The present invention is not intended to be limited in scope to the particular disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such variations may be practiced without departing from the true scope and spirit of the disclosure and are intended to fall within the scope of the present disclosure.

10. Sequences

NEW SEQ Exemplary DESCRIPTION ID NO. AK number AMINO ACID SEQUENCE IL-2 1 MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGIN precursor NYKNPKLTRMLTFKfYHPKKATELKHLQCLEEELKPLEBVLNLAQSKNF HLRPRDLISNIVIVLELKGSETTYMCEYADETATIVEFLNRWITFCQSI ISTLT IL-2 mature 2 APTSSSTKETQLQLEHLLLDLQMILNGINNYKSPKLTRMLTFKFYMPKK ATELKHLQCLEEETKFLEEVLNLAQSKNFHLRPRDLISNINVIVLELKG SETTFMCEYADETATIVEFLNRWIFCQSIISTLT IL-2 (R38A, 3 AK168 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKK F42A, Y45A, AK191 ATELRHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKG E62, C125A) AK197 SETTFMCEYADETATIVEFLNRWITFAQSIISTLT AK203 AK471 AK442 AK438 AK34l AK530 AK539 AK540 AK541 AK523 AK524 AK525 MM 4 AK168 AVSGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRNNQTCE AK209 LLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDF AK191 KPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLS AK197 PGHTWEEAPLLTLKQRQEWICLETLTFDTQYEFQVRVKPLQCEFTTWSP AK203 WSQPLAFRTKPAALGKD AK471 AK442 AK438 AK539 AK540 AK541 AK523 AK524 AK525 MM (C122S, 5 AK341 AVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCE C168S) AK530 LLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDF KPFENLRLMAPISLQVVHVETHRSNISWEISQASHYFERHLEFEARTLS PGHTWEEAPLLTLKQKQEWISLETLTPDTQYEFQVRVKPLQGEFTTWSP WSQPLAFRTKEAALGKD Parent 6 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG IgG1_human VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV heavy chain EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV constant DSHEDPEVRFNWYVDGVEVHNAKTKPREEQYYNSTYRVVSVLTVLEQDN gamma 1 LNGKEYKCKVSNKALPAPIERTISKARCQPRERQVYTLPPSRDELTKNQ VSLTCLKGFYPSDIAVENESNGQPENNYKTTPPVLDSDGSFFLYSKLST VDRSRNQQGNVFSCSVMHEALHNHYTOKSLSLSPGE Parent 7 DKTATCPPCPAFELLGGPSVFLFPPKEKDTLMISRTPEVTCVWVDVSHE IgG1_human DPEVKFNWYVDGVEVMNAETKEREEQYNSTYRVVSVLTVLHQDWLNGKE heavy chain YKCKVSNKALPAPTERTISKAEGQEREPQVYTLPPSRDELTKNQVSLTC constant LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR gamma 1 - Fc WQQGNVFSCSMNNHEALHNHYTORSLSLSPG domain HL1 (Y349C, 8 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE T366S, L38A, DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE Y407V) YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVSGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG HL1 (Y349C, 9 AK168 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE T366S, L38A, AK209 DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE Y407V, AK191 YSCKYSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC N2972A) AK197 AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR AK203 WQQGNVFSCSVMHEALHNHYTQRSLSLSPG AK442 AK430 AK34l AK530 AK539 AK540 AK541 AK523 AK524 AK525 HL1 (Y349C, 10 AK471 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHE T366S, L38A, DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE Y407V, YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC N297A, AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR I253A) WQQGNVFSCSVMHEALHNHYTQKSLSLSPG HL2 (S354C, 11 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE T366W) DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDESR NQQGNVFSCSVMHEALHNRYTQKSLSLSPG HL2 (S354C, 12 AK168 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE T366W, AK209 DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE N297A) AKl91 YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC AK197 LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR AK203 WQQGNVFSCSVMHEALHNHYTQKSLSLSPG AK442 AK438 AK341 AK530 AK539 AK540 AK541 HL2 (S354C, 13 AK471 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHE T366W, DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE N297A, YKCKVSNKALPAPIEKTLSKAKGQPREPQVYTLPPCRDELTKNQVSLWC I253A) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDRSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPG 1^(st) linker 14 AK168 PSGS (non- AK209 (cleavable) AK191 AK197 AK203 AK471 AK341 AK539 AK540 AK541 1^(st) linker 15 AK442 GGPSGSSPGDSGGFMLTSGGG L1 (cleavable) 1^(st) linker 16 AK438 GPPSGSSPGVPLSLYGSGGG L1 (cleavable) 1^(st) linker 17 AK530 GPPSGSSPMPYDLYHPSGG L1 (cleavable) 1^(st) linker 242 AK523 GSPDLLAVVAASSGP L1 (cleavable) 1^(st) linker 243 AK524 GSPGDLLAVVAASSGP L1 (cleavable) 1^(st) linker 244 AK525 GSGSPSDLLAVVAASSGP L1 (cleavable) 2^(nd) linker 18 AK168 GGSSPPMPYDLYHPSGP L2 (cleavable) 2^(nd) linker 19 AK209 GSPGVPLSLYSGP L2 AK471 (cleavable) AK341 2^(nd) linker 20 AK191 GGSGRAAAVKSPSGP L2 (cleavable) 2^(nd) linker 21 AK197 GGSGHEQLTVSGP L2 (cleavable) 2^(nd) linker 22 AK203 GSGPDSGGFMLTSGP L2 (cleavable) 2^(nd) linker 23 AK442 GGSSPPGGGSSGGGSGP L2 (non- AK438 (cleavable) AK530 AK523 AK524 AK525 2^(nd) linker 245 AE539 GGPSDLLAVVAASSGP L2 (cleavable) 2^(nd) linker 246 AK540 GSGPSDLLAVVAASSGP L2 (cleavable) 2^(nd) linker 247 AK541 GSSGGPDLLAVVAASSGP L2 (cleavable) Cleavable 24 AK16B MPYD*LYHP peptide AK530 *indicates cleavage site Cleavable 25 AK203 DSCG*FMLT peptide AK442 *indicates cleavage site Cleavable 26 AK197 HEQ*LTV peptide *indicates cleavage site Cleavable 27 AK191 RAAA*VKSP peptide *indiCates cleavage site Cleavable 28 AK209 VPLS*LY peptide AK471 *indicates cleavage site AK341 AK438 Cleavable 248 AK50 DLLA*VVAAS peptide AK539 *indicates cleavage site AK540 AK541 AK523 AK524 AK525 Cleavable 249 AK88 I*SSG*LLSGRS peptide *indicates cleavage site C terminal 29 AK168 SGP spacer AK209 domain AK191 AK197 AK203 AK471 AK348 AK539 AK540 AK541 AK523 AK524 AK525 C terminal 30 AK442 SGGG spacer AK530 domain C terminal 31 AK438 GSGGG spacer domain N terminal 32 AK168 GGSSPP spacer domain N terminal 33 AK203 GSGP spacer domain N terminal 34 AK209 GSPG spacer AK341 domain AK471 AK524 N terminal 35 AK191 GGSG spacer AK197 domain N terminal 36 AK442 GPPSGSSPG spacer AK348 domain N terminal 37 AK530 GPPSGSSP spacer domain N terminal 250 AK539 GGPS spacer domain N terminal 251 AK540 GSGPS spacer domain N terminal 252 AK541 GSSGGP spacer domain N terminal 253 AK523 GSP spacer domain N terminal 254 AK525 GSGSPS spacer domain 1^(st) 38 AK168 DKTRTCPPCPAPELLGGESVFLFPPKPKDELMLSRTPEVTCVVVDVSHE polypeptide AK192 DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRWVSVLTVLHQDWLNGKE chain - A AK197 YKCKVSNKALPAPLERTLSKAKGZPREPQVCTLPPSRDELTKNQVSLSC (HL1-L1-MM) AK203 AVKGFYPSDIAVENESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR AK209 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSQFTCEYNS AK539 EANISCVWSQDGALQDPSCQVHAWPDRRRNNQTCELLPVSQASWACNLI AK540 LGAPDSQKLTTVDIVTLRVLGREGVRWRVMAIQDFSPFENLRLMAPISL AK541 QVVHVETERCNISWEISQASHYFERHLEFEARTLSPGHTKEEAPLLTLR QKQEWICLETLPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTRPAALG KD 1^(st) 39 AK341 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTEPREEQYASTYRVVSVLTVLHQDWLSGKE chain - B YKCRVSNSALPAPIEKTISKAKGQPREPQVCTLPPSRDELTENQVSLSC (HL1-L1-MM) AVKGFYPSDIAVEWESNGQPENNYKTTPRVLDSDSSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSCFTCFYNS RANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASWACNLI LGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISL QVVHVETHRSNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLR QKQEWISLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAAL GKD 1^(st) 40 AK530 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFSWYVDGVEVBNAKTKFRSSQVASTYRWSVLTVLTHQDWLEGKE chain - C YKCKVSNKALPAPIEKTISKAKGQFEEPQVCTLPFSRDSLYKNQVSLSC (HL1-L1-MM) AVKSFYPSDIAVREWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPMPYDLYHPSG GGAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQT CELLPVSQASWANLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQD FKPFENLRLMAPISLQVVHVETHRSNISWEISQASHYFERHLEFEARTL SPGHTKEEAPLLTLKQKQEWISLETLTPDTQYEFQVRVKPLGGEFTTWS FWSQPLAFRTKPAALGKD 1^(st) 41 AK442 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKNWTVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLHGKEY chain - D KCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCA (HL1-L1-MM) VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSKW QQGNVFSCSVMHEALHNHYTQKGLSLSPGGPPSGSSFGDSGGFHLTSGG GAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHANPDRRRWNQTC ELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQD FKPTENLRLMAPISLQVVHVETNRCNISWEISQASHYFERHLEFEARTL SPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWS PWSQPLAFRTKPAALGKD 1^(st) 42 AK438 DKTATCPPCPAPELLGGPSVELEPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKENWYVDGVEVANAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - E YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC (MLI-L1-MM) AVKGEYPSDIAVEWESNGGPENNYKTTPPVLDSDGSFELVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPGVPLSLYGSGG GAVNGTSQFTCYYNSRANISCVWSQDGALQDTSCQVHAWPDERRRWNQT CELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQ DFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEART LSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTW SPWSQPLAFRTKPAALGKD 1^(st) 43 AK471 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - G YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC (HL-L2-C) AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGPGSGSAVNGTSQFTCFYNSR ANISCVNSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASWACNLIL GAPDSQKLTTVDIVTLRVLCREGVRNRVMAIQDFKPFENLRLMGAPISL QVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLK QKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAAL GKD 1^(st) 44 AK252 DKTRTCPPCPAPELLGGPSVELEPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - H YKCKVSNNALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC (HL-L2-C) AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPMPYDLYHPSGG GAVNGTSQFTCFYSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCE LLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDF KPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLS PGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSP NSQPLAFRTKPAALGKD 1^(st) 255 AK523 DKTHTCPPCPAPELLGGPSVELFPPKPKDTLMISRTPEVTCVVVDVSRE polypeptide DPEVKFNWYVDGVEVANAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - I YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTENQVSLSC (HL-L1-2M) AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSEFLVSKLTVDESR WQCGNVFSCSVMNEALANHYTQKSLSLSPGGSPDLLAVVAASSGPAVNI GTSQFTCFYHSRANISCVWSQDGALCDTSCQVHAWPDRRRWNQTCELLP VSQASWACNLILGAPDSQELTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGH TWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQ PLAFRTKPAALGKD 1^(st) 256 AK524 DKTHTCPPCPAPELLGGPSVFLFPPKPSDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - J YKCKVSNKALPAPIEKTISKARCQPREPQVCTLPPSRDELTKNQVSLSC (HL-11-2M) AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGDLLAVVAASSGPAVN GTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLP VSGASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGH TWEEAPLLTLKQKEWICLETLTPDTQYEFQVRVKPLQGEFTTQSPWSQP LAFRTKPAALGKD 1^(st) 257 AK525 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYEVYSVLTVLHQDWLNGKE chain - K YKCRVSNEALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC (HL-L1-MM) AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGSGSPSDLLAVVAASSGPAV NGTSQFTCFYNSRANISCVNSQDGALQDTSCQVHAWPDRRRWNQTCELL PVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFRP FENLRLMAPISLQVVHTEHRCNISWEISQASHYFERHLEFEARTLSPGH TWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQ PLAFRTKPAALGKD 2^(nd) 45 AK168 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - A YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDLYHPSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 46 AK191 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDYSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - B YKCKVSNKALPAPIEKTISRAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNNYTQKSLSLSPGGGSGRAAAVKSPSGPAPTS SSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATEL KHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETT FMCEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 47 AK197 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - C YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSGHEQLTVSGPAPTSSS TKKTQLQLEHLLLDLQMLINGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFM CEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 48 AK203 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - D YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSGPDSGGFMLTSGPAPTS SSTKKTQLQLEMLLLDLGMILNGINNYKNPKLTAMLTAKFAMPKKATEL KHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETT FMCEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 49 AK209 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide AK341 DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - E YKCKVSNKALPAPIERTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSGPAPTSSS TRKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFM CEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 50 AK471 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - F YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGSFFLYSKLTVDRSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSGPAPTSSS TKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELRGSETTFM CEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 51 AK442 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide AK438 DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - G AK530 YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKSQVSLWC (HL-L2-C) AK252 LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR AK523 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSGGGSGPAP AK524 TSSSTKKTQLQLEHLLLDLQMILNGINNYKNTKLTAMLTAKFAMPKKAT AK525 ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT 2^(nd) 258 AK539 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVCCDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - H YCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCL (HL-L2-C) VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDRSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGGGPSDLLAVVAASSGPAPTS SSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATEL KHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETT FMCEYADETATIVEFLNRWITFAQSIISTL 2^(nd) 259 AK540 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE chain - H YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-L2-C) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSGPSDLLAVVAASSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPRLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITPAQSIISTLT 2^(nd) 260 AK541 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE polypeptide DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRWVSVLTVLHQDWLNGKE chain - H YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC (HL-12-c) LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSSGGFDLLAVVAASSGPA PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKA TELKHLGCLEEALKPLEEVLSLAQSKNTHLRPRDLISNINVIVLELKGS ETTFMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 52 AK168 LYHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTA product KFAMPKKATELKHLQCLEEALKPLEEVLNLAQSKNFHLRPADLISNINV CP IVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 53 AK191 VKSPSGPAPTSSSTKKTQLQLEHLLLDLQMILSGINNYKNPKLTAMLTA product KFAMPKKATELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINV CP IVLELKGSETTTMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 54 AK197 LYVSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAK produCt FAMPKKATELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVI CP VLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 55 AK203 FMLTSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTA produCt KFAMPKKATELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINV CP IVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 56 AK209 LYSGPAPTSSSTKKTQLOLEHLLLDLQMILNSGINNYKNPKLTAMLTAK product AK341 FAMPKKATELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVI CP AK471 VLELKGSETTFMCEYADETATIVEFLARWITFAQSIISTLT Cleavage 57 AK442 DKTHTCPPCPAPELLGGPSVELFPPKPEDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDSLSGKE CP YKCKVSNSALPAPIEKTLSKAKCQPREPQVYTLPPCRDELTKNGVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALRNRYTOKSLSLSPGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTARFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFALRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT; (2^(nd) polypeptide chain - SEQ ID NO: 265) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTTSKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMNEALHNHYTQKSLSLSPGGPPSGSSPGDSGG (1^(st) polypeptide chain - SEQ ID NO: 266) Cleavage 58 AK438 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE CP YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCEDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNFKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNTHLRPRDLISNINVIVLELKGSE TTEMCEYADETATIVEFLNRWITFAQSIISTLT; (2^(nd) polypeptide chain - SEQ ID NO: 267) DKTHTCPPCPAPELLGGRSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGSPPSGSSPGVPLS (1^(st) polypeptide chain - SEQ ID NO: 268) Cleavage 59 AK530 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE CP YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSFGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLGMILNGINNYKNPKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLKRWITFAQSIISTLT; (2^(nd) polypeptide chain - SEQ ID NO: 269) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPMPYD (1^(st) polypeptide chain - SEQ ID NO: 270) Cleavage 261 AK539 VVAASSGPAPTSSSTKKTQLQLEHLLLDLQMILKGINNYKNPKLTAMLT product AK540 AKFAMPKKATELKHLQCLEEALKPLEEVLNLAQSKHFHLRPRDLISNIN CP AK541 VIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Cleavage 262 AK523 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE CP YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLMC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT (2^(nd) polypeptide chain - SEQ ID NO: 271) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSDLLA (1^(st) polypeptide chain- - SEQ ID NO: 272) Cleavage 263 AK524 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE CP YKCKVSNKALPAPIEKTISEAEGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESEGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSFGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT (2^(nd) polypeptide chain - SEQ ID NO: 273) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGGPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVPSCSVMHEALHNHYTQKSLSLSPGGSPGDLLA(1^(st) polypeptide chain - SEQ ID NO: 274) Cleavage 264 AK525 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE product DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE CP YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSSGGGSGPAP TSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKAT ELKHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE TTFMCEYADETATIVEFLNRWITFAQSIISTLT (2^(nd) polypeptide chain - SEQ ID NO: 275) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DFEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSGSPSDLLA (1^(st) polypeptide chain - SEQ ID NO: 276}

10.1 Other Sequences:

SEQ ID DESCRIPTION NO SEQUENCE MM1 60 ELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWDNQC QCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIY HFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQPQLICT Linker L1 61 PA IL-2 62 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLE domain EELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT Linker L2 63 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG MM2 64 AVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASW ACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISLQVVHVE THRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYE FQVRVKPLQ HL 65 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Polypeptide  66 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPAELCDDDPPEIP HATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWDNQCQCTSSATRNTT KQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYY QCVQGYRALHRGPAESVCKMTHGKTRWTQPQLICTGGGGGGGGGGGGGGGGGGGGGGGG GGGGGGGGGGGAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPK AKTELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCE YADETATIVEFLNRWITFAQSIISTLTGPPSGSSPMPYDLYHPSGGGAVNGTSQFTCFYN ASRNISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLT TVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISLQWHVETHRCNISWEISQASH YFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQ Polypeptide 67 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAPTSSSTKKTQLQ LEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLA QSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Polypeptide 68 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAPTSSSTKKTQLQ LEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEALKPLEEVLNL AQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT IL-2 69 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLE domain ERLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT IL-2 70 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTEKFYMPKKATELKHLQCLE domain EELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT IL-2 71 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLE domain FSLKPLFFVLNLAQSKNFHLRPRDLISNINVIVLFLKGSETTFMCFYADFTATIVFFLNRWI TFAQSIISTLT IL-2 72 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTAKFYMPKKATELKHLQCLE domain EELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT IL-2 73 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFRMPKKATELKHLQCLE domain EELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT IL-2 74 APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTSKFYMPKKATELKHLQCLE domain ESLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT Linker L1 75 PGSG Linker L1 76 GGSSPPRAAAVKSPSGP Linker L1 77 GGPGGPRAAAVKSPSGP Linker L1 78 GSPGVPLSLYSGP HL 79 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HL 80 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL KSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG HL 81 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYDTTPPVLD SDGSFFLVSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG HL 82 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKKLTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DS DGS FFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG HL 83 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVEGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQESLSLSPG HL 84 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKKLTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Polypeptide 85 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELK HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 86 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL KSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPMPY DLYHPSGGGAVNGTSQFTCFYNSRANISCVVVSQDGALQDTSCQVHAWPDRRRWNQTCE LLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAP ISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLE TLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKD Polypeptide 87 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYDTTPPVLD SDGSFFLVSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAPTSSSTKKTQLQ LEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLA QSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Polypeptide 88 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKKLTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGPPSGSSPMPY DLYHPSGGGAVNGTSQFTCFYNSRANISCVVVSQDGALQDTSCQVHAWPDRRRWNQTCE LLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAP ISLQWHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLE TLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKD Polypeptide 89 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVEGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQESLSLSPGAPTSSSTKKTQLQ LEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLA QSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT Polypeptide 90 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVCTLPPSRDELTKNQVSLSCAVEGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQESLSLSPGGGSSPPMPYDLY HPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKH LQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT Polypeptide 91 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKKLTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Polypeptide 92 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRKKLTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGPGSGAVNGTSQ FTCFYNSRANISCVWSQDGALQDTSCQVHAWPDKRRWNQTCELLPVSQASWACNLILG APDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISLQWHVETHRCNIS WEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVK PLQGEFTTWSPWSQPLAFRTKPAALGKD Polypeptide 93 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELK HLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 94 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGPGGPRAAAV KSPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELK HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 95 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPRAAAV KSPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELK HLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 96 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGPGGPRAAAV KSPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATELK HLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 97 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSGRAAAVKS PSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHL QCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 98 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPGGGSS GGGSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTAKFAMPKKATEL KHLQCLEEALKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 99 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELK HLQCLEERLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 100 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTEKFYMPKKATELK HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 101 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELK HLQCLEESLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 102 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTAKFYMPKKATELK HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATI VEFLNRWITFAQSIISTLT Polypeptide 103 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFRMPKKATELK HLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 104 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSSPPMPYDL YHPSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTSKFYMPKKATELK HLQCLFFSLKPLFEVLNLAQSKNFHLRPRDLISNINVIVLELKGSFTTFMCEYADETATIVE FLNRWITFAQSIISTLT Polypeptide 105 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL EERLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSIISTLT Polypeptide 106 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTEKFYMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRW ITFAQSIISTLT Polypeptide 107 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL EESLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRW ITFAQSIISTLT Polypeptide 108 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTAKFYMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSIISTLT Polypeptide 109 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFRMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSIISTLT Polypeptide 110 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTSKFYMPKKATELKHLQGL EESLKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATFVEFLN RWITFAQSIISTLT Polypeptide 111 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD chain GVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGKVFSCSVMHEALHNHYTQKSLSLSPGGSPGVPLSLYSG PAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRW ITFAQSIISTLT

10.2 List of Constructs

The table below shows the full sequences for molecules labelled by ‘AK’ reference number. The component parts of the sequence are also shown as well as the order in which they are assembled in the chains of the molecules. Individual chains are labelled by a ‘DNA’ reference number:

Component1 Component2 Component3 Molecule name newnames Sequence Sequence Sequence AK368 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP NVFSCSVMHEALHNHYTQKSLSLSP LAFRTK PAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 9) AK368 DNA476 Knob: DKTHTCPPCPAPELLGGPSVFLFPP G NPMGSDPVNFKLLRWNG hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID [NPMGSC PEVKFNWYVDGVEVKNAKTKPREEQ NO: 325) PVNFKLLR YASTYRVVSVLTVLHQDWLNGKEYK WNG]- CKVSNKALPAPIEKTISKAKGQPRE hIL2(F42S, PQVYTLFPCRDELTKNQVSLWCLVK E82S, C12SA) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNEYTQKSLSLSP G (SEQ ID NO: 12) AK375 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFP GGSS APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD PPGGG NGINNYKNPKLTAMLTAKFAMPKKA (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE SSGG TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, DYNSTLRVVSALPIQHQDWMSGKEF GSGP KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, KCKVNNKDLGAPIERTISKPKGSVR (SEQ ID TTFMCEYADETATIVEFLNRWITFA E62A, C125A) APQVYVLPPCEEEMTKKQVTLWCMV NO: 23) QSIISTLT TDFMPEDIYVEWTNNGKTELNYKNT (SEQ ID EPVLDSDGSYFMVSKLRVEKKNWVE NO: 3) RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK376 DNA479 hole: TIKPCPPCKCPAPNAAGGPSVFIFP mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (LALAPG) DPDVQISWFVNNVEVHTAQTQTHRE DYNSTLRVVSALPIQHQDWMSGKEF KCKVNNKDLGAPIERTISKPKGSVR APQVCVLPPPEEEMTKKQVTLSCAV TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 281) AK376 DNA478 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GSFG VPLSLY mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD (SEQ ID (SEQ ID (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 34) NO: 28) [VPLSLY]- DYNSTLRVVSALPIQHQDWMSGKEF hIL2(R38A, KCKVNNKDLGAPIERTISKPKGSVR F42A, Y45A, APQVYVLPPCEEEMTKKQVTLWCMV E62A, C125A) TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK376 DNA479 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (LALAPG) DPDVQISWFVNNVEVHTAQTQTHRE DYNSTLRVVSALPIQHQDWMSGKEF KCKVNNKDLGAPIERTISKPKGSVR APQVCVLPPPEEEMTKKQVTLSCAV TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 281) AK377 DNA477 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GGSSP APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD PGGGS NGINNYKNPKLTAMLTAKFAMPKKA (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE SGG TELKHLQCLEEALKPLEEVLNLAQS [VPLSLY]- DYNSTLRVVSALPIQHQDWMSGKEF GSGP KNFHLRPRDLISNINVIVLELKGSE hIL2(R38A, KCKVNNKDLGAPIERTISKPKGSVR (SEQ ID TTFMCEYADETATIVEFLNRWITFA F42A, Y45A, APQVYVLPPCEEEMTKKQVTLWCMV NO: 23) QSIISTLT E62A, C125A) TDFMPEDIYVEWTNNGKTELNYKNT (SEQ ID EPVLDSDGSYFMVSKLRVEKKNWVE NO: 3) RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK377 DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQD mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122 DYNSTLRVVSALPIQHQDWMSGKEF DIVTLRVLCREGVRWRVMAIQDFKP KCKVNNKDLGAPIERTISKPKGSVR FENLRLMAPISLQVVHVETHRCNIS APQVCVLPPPEEEMTKKQVTLSCAV WEISQASHYFERHLEFEARTLSPGH TDFMPEDIYVEWTNNGKTELNYKNT TWEEAPLLTLKQKQEWICLETLTPD EPVLDSDGSYFMVSKLRVEKKNWVE TQYEFQVRVKPLQGEFTTWSPWSQP RNSYSCSVVHEGLHNHHTTKSFSRT LAFRTKPAALGKD PG (SEQ ID NO: 4) (SEQ ID NO: 281) AK378 DNA470 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE [VPLSLY]- DYNSTLRVVSALPIQHQDWMSGKEF hIL2(R38A, KCKVNNKDLGAPIERTISKPKGSVR F42A, Y45A, APQVYVLPPCEEEMTKKQVTLWCMV E62A, C125A) TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK378 DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQD mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122 DYNSTLRVVSALPIQHQDWMSGKEF DIVTLRVLCREGVRWRVMAIQDFKP KCKVNNKDLGAPIERTISKPKGSVR FENLRLMAPISLQVVHVETHRCNIS APQVCVLPPPEEEMTKKQVTLSCAV WEISQASHYFERHLEFEARTLSPGH TDFMPEDIYVEWTNNGKTELNYKNT TWEEAPLLTLKQKQEWICLETLTPD EPVLDSDGSYFMVSKLRVEKKNWVE TQYEFQVRVKPLQGEFTTWSPWSQP RNSYSCSVVHEGLHNHHTTKSFSRT LAFRTKPAALGKD PG (SEQ ID NO: 4) (SEQ ID NO: 281) AK397 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK397 DNA258 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GSGP DSGGFMLT hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID NO: 25) PEVKFNWYVDGVEVHNAKTKPREEQ NO: 33) YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK429 DNA477 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GGSSP APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD PGGG NGINNYKNPKLTAMLTAKFAMPKKA (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE SSGG TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, DYNSTLRVVSALPIQHQDWMSGKEF GSGP KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, KCKVNNKDLGAPIERTISKPKGSVR (SEQ ID TTFMCEYADETATIVEFLNRWITFA E62A, C125A) APQVYVLPPCEEEMTKKQVTLWCMV NO: 23) QSIISTLT TDFMPEDIYVEWTNNGKTELNYKNT (SEQ ID EPVLDSDGSYFMVSKLRVEKKNWVE NO: 3) RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK429 DNA520 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP HHHH mFcIgG2a (LALAPG)- PKIKDVLMISLSPIVTCVVVDVSED HHHH NoAnnotation DPDVQISWFVNNVEVHTAQTQTHRE (SEQ ID Found DYNSTLRVVSALPIQHQDWMSGKEF NO: 308) KCKVNNKDLGAPIERTISKPKGSVR APQVCVLPPPEEEMTKKQVTLSCAV TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 281) AK430 DNA477 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GGSSP APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD PGGGS NGINNYKNPKLTAMLTAKFAMPKKA (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE SGG TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, DYNSTLRVVSALPIQHQDWMSGKEF GSGP KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, KCKVNNKDLGAPIERTISKPKGSVR (SEQ ID TTFMCEYADETATIVEFLNRWITFA E62A, C125A) APQVYVLPPCEEEMTKKQVTLWCMV NO: 23) QSIISTLT TDFMPEDIYVEWTNNGKTELNYKNT (SEQ ID EPVLDSDGSYFMVSKLRVEKKNWVE NO: 3) RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK430 DNA521 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQD mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122- DYNSTLRVVSALPIQHQDWMSGKEF DIVTLRVLCREGVRWRVMAIQDFKP NoAnnotation KCKVNNKDLGAPIERTISKPKGSVR FENLRLMAPISLQVVHVETHRCNIS Found APQVCVLPPPEEEMTKKQVTLSCAV WEISQASHYFERHLEFEARTLSPGH TDFMPEDIYVEWTNNGKTELNYKNT TWEEAPLLTLKQKQEWICLETLTPD EPVLDSDGSYFMVSKLRVEKKNWVE TQYEFQVRVKPLQGEFTTWSPWSQP RNSYSCSVVHEGLHNHHTTKSFSRT LAFRTKPAALGKD PG (SEQ ID NO: 4) (SEQ ID NO: 281) AK431 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GGSSPP APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD GGGSS NGINNYKNPKLTAMLTAKFAMPKKA (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE GG TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, DYNSTLRVVSALPIQHQDWMSGKEF GSGP KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, KCKVNNKDLGAPIERTISKPKGSVR (SEQ ID TTFMCEYADETATIVEFLNRWITFA E62A, C125A) APQVYVLPPCEEEMTKKQVTLWCMV NO: 23) QSIISTLT TDFMPEDIYVEWTNNGKTELNYKNT (SEQ ID EPVLDSDGSYFMVSKLRVEKKNWVE NO: 3) RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK431 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVKNCSHLECFYNSRANVSCMWSHE mFcIgG2a (LALAPG)- PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID EALNVTTCHVHAKSNLRHWNKTCEL mCD122- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) TLVRQASWACNLILGSFPESQSLTS NoAnnotationFound DYNSTLRVVSALPIQHQDWMSGKEF VDLLDINVVCWEEKGWRRVKTCDFH KCKVNNKDLGAPIERTISKPKGSVR PFDNLRLVAPHSLQVLHIDTQRCNI APQVCVLPPPEEEMTKKQVTLSCAV SWKVSQVSHYIEPYLEFEARRRLLG TDFMPEDIYVEWTNNGKTELNYKNT HSWEDASVLSLKQRQQWLFLEMLIP EPVLDSDGSYFMVSKLRVEKKNWVE STSYEVQVRVKAQRN RNSYSCSVVHEGLHNHHTTKSFSRT NTGTWSPWSQPLTFRTRPADPMKE PG (SEQ ID (SEQ NO: 326) ID NO: 281) AK432 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GSPG VPLSLY mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD (SEQ ID (SEQ ID (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 34) NO: 28) [VPLSLY]- DYNSTLRVVSALPIQHQDWMSGKEF hIL2(R38A, KCKVNNKDLGAPIERTISKPKGSVR F42A, Y45A, APQVYVLPPCEEEMTKKQVTLWCMV E62A, C125A) TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK432 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQD mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122- DYNSTLRVVSALPIQHQDWMSGKEF DIVTLRVLCREGVRWRVMAIQDFKP NoAnnotation KCKVNNKDLGAPIERTISKPKGSVR FENLRLMAPISLQVVHVETHRCNIS Found APQVCVLPPPEEEMTKKQVTLSCAV WEISQASHYFERHLEFEARTLSPGH TDFMPEDIYVEWTNNGKTELNYKNT TWEEAPLLTLKQKQEWICLETLTPD EPVLDSDGSYFMVSKLRVEKKNWVE TQYEFQVRVKPLQGEFTTWSPWSQP RNSYSCSVVHEGLHNHHTTKSFSRT LAFRTKPAALGKD PG (SEQ ID NO: 4) (SEQ ID NO: 281) AK433 Knob: TIKFCPPCKCPAPNAAGGPSVFIFP GSPG VPLSLY mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSSD (SEQ ID (SEQ ID (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 34) NO: 28) [VPLSLY]- DYNSTLRVVSALPIQHQDWMSGKEF hIL2(R38A, KCKVNNKDLGAPIERTISKPKGSVR F42A, Y45A, APQVYVLPPCEEEMTKKQVTLWCMV E62A, C125A) TDFMPEDIYVEWTNNGKTELNYKNT EPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCSVVHEGLHNHHTTKSFSRT PG (SEQ ID NO: 280) AK433 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVKNCSHLECFYNSRANVSCMWSHE mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID EALNVTTCHVHAKSNLRHWNKTCEL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 14) TLVRQASWACNLILGSFPESQSLTS hCD122- DYNSTLRVVSALPIQHQDWMSGKEF VDLLDINVVCWEEKGWRRVKTCDFH NoAnnotation KCKVNNKDLGAPIERTISKPKGSVR PFDNLRLVAPHSLQVLHIDTQRCNI Found APQVCVLPPPEEEMTKKQVTLSCAV SWKVSQVSHYIEPYLEFEARRRLLG TDFMPEDIYVEWTNNGKTELNYKNT HSWEDASVLSLKQRQQWLFLEMLIP EPVLDSDGSYFMVSKLRVEKKNWVE STSYEVQVRVKAQRNNTGTWSPWSQ RNSYSCSVVHEGLHN PLTFRTRPADPMKE (SEQ ID HHTTKSFSRTPG NO: 326) (SEQ ID NO: 281) AK435 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK435 F8ScFvVersion1- EVQLLESGGGLVQPGGSLRLSCAASG GGS DKTHTCPPCPAPELLGGPSVFLFPP Hole: FTFSLFTMSWVRQAPGKGLEVVVSA KPKDTLMISRTPEVTCVVVDVSHED hFc(N297A)- ISGSGGSTYYADSVKGRFTISRDNS PEVKFNWYVDGVEVHNAKTKPREEQ hCD122- KNTLYLQMNSLRAEDTAVYYCAKST YASTYRVVSVLTVLHQDWLNGKEYK NoAnnotation HLYLFDYWGQGTLVTVSSGGGGSGG CKVSNKALPAPIEKTISKAKGQPRE Found GGSGGGGSEIVLTQSPGTLSLSPGE PQVCTLPPSRDELTKNQVSLSCAVK RATLSCRASQSVSMPFLAWYQQKPG GFYPSDIAVEWESNGQPENNYKTTP QAPRLLIYGASSRATGIPDRFSGSG PVLDSDGSFFLVSKLTVDKSRWQQG SGTDFTLTISRLEPEDFAVYYCQQM NVFSCSVMHEALHNH RGRPPTFGQGTKVEIK YTQKSLSLSPG (SEQ (SEQ ID ID NO: 9) NO: 282) AK436 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHA hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) WPDRRRWNQTCELLFVSQASWACNL YASTYRVVSVLTVLHQDWLNGKEYK ILGAPDSQKLTT CKVSNKALPAPIEKTISKAKGQPRE VDIVTLRVLCREGVRWRVMAIQDFK PQVCTLPPSRDELTKNQVSLSCAVK PFENLRLMAPIS GFYPSDIAVEWESNGQPENNYKTTP LQVVHVETHRCNISWEISQASHYFE PVLDSDGSFFLVSKLTVDKSRWQQG RHLEFEARTLSP MVFSCSVMHEALHNHYTQKSLSLSP GHTWEEAPLLTLKQKQEWICLETLT G PDTQYEFQVRVK (SEQ PLQGEFTTWSPWSQPLAFRTKPAAL ID GKD NO: 9) (SEQ ID NO: 4) AK436 DNA542 Knob: DKTHTCPPCPAPELLGGPSVFLFPP APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED NGINNYKNPKLTAMLTAKFAMPKKA [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK437 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 9) AK437 DNA545 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GISSGLL APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED SGRSSGP NGINNYKNPKLTAMLTAKFAMPKKA [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK NO: 311) KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK438 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSS APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED PPGG NGINNYKNPKLTAMLTAKFAMPKKA hIL2(R38A, PEVKFNWYVDGVEVHNAKTKPREEQ GSSGG TELKHLQCLEEALKPLEEVLNLAQS F42A, Y45A, YASTYRVVSVLTVLHQDWLNGKEYK GSGP KNFHLRPRDLISNINVIVLELKGSE E62A, C125A) CKVSNKALPAPIEKTISKAKGQPRE (SEQ ID TTFMCEYADETATIVEFLNRWITFA PQVYTLPPCRDELTKNQVSLWCLVK NO: 23) QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12)  AK438 DNA543 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 36) NO: 28) YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK439 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK439 DNA544 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (R38A, F42A, CKVSNKALPAPIEKTISKAKGQPRE Y45A, E62A, PQVYTLPPCRDELTKNQVSLWCLVK L80F, RS3D, GFYPSDIAVEWESNGQPENNYKTTP L85V, 186V, PVLDSDGSFFLYSKLTVDKSRWQQG I92F, C125A) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK440 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 9) AK440 DNA544 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (R38A, F42A, CKVSNKALPAPIEKTISKAKGQPRE Y45A, E62A, PQVYTLPPCRDELTKNQVSLWCLVK L80F, RS3D, GFYPSDIAVEWESNGQPENNYKTTP L85V, 186V, PVLDSDGSFFLYSKLTVDKSRWQQG I92F, C125A) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK441 DNA543 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED SSPG (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 28) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK441 DNA546 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSP APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED PGGG NGINNYKNPKLTAMLTAKFAMPKKA hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ SSGG TELKHLQCLEEALKPLEEVLNLAQS (R38A, F42A, YASTYRVVSVLTVLHQDWLNGKEYK GSGP KNFHFDPRDWSNINVFVLELKGSET Y45A, E62A, CKVSNKALPAPIEKTISKAKGQPRE (SEQ ID TFMCEYADETATIVEFLNRWITFAQ L80F, RS3D, PQVYTLPPCRDELTKNQVSLWCLVK NO: 23) SIISTLT L85V, 186V, GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID I92F, C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NO: 328) NVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 12) AK442 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPP APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED GGGSS NGINNYKNPKLTAMLTAKFAMPKKA hIL2(R38A, PEVKFNWYVDGVEVHNAKTKPREEQ GG TELKHLQCLEEALKPLEEVLNLAQS F42A, Y45A, YASTYRVVSVLTVLHQDWLNGKEYK GSGP KNFHLRPRDLISNINVIVLELKGSE E62A, C125A) CKVSNKALPAPIEKTISKAKGQPRE (SEQ ID TTFMCEYADETATIVEFLNRWITFA PQVYTLPPCRDELTKNQVSLWCLVK NO: 23) QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK442 DNA553 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPS DSGGFMLT hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED GSSPG (SEQ ID [DSGGFMLT]- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 25) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK443 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 9) AK443 DNA554 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK444 DNA281 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSGP DSGGFMLT hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 33) NO: 25) hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK444 DNA440 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LPVSQASWACNLILGAPDSQKLTTV (C122S, C168S) YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQPFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRSNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWISLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 5) ID NO: 9) AK449 DNA547 Hole: EPKSSDKTHTCPPCPAPELLGGPSV PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A + EPKSS)- VSHEDPEVKFNWYVDGVEVHNAKTK NO: 14) LFVSQASWACNLILGAPDSQKLTTV Hole: PREEQYASTYRVVSVLTVLHQDWLN DIVTLRVLCREGVRWRVMAIQDFKP hFc(N297A)- GKEYKCKVSNKALPAPIEKTISKAK FENLRLMAPISLQVVHVETHRCNIS hCD122 GQPREPQVCTLPPSRDELTKNQVSL WEISQASHYFERHLEFEARTLSPGH SCAVKGFYPSDIAVEWESNGQPENN TWEEAPLLTLKQKQEWICLETLTPD YKTTPPVLDSDGSFFLVSKLTVDKS TQYEFQVRVKPLQGEFTTWSPWSQP RWQQGNVFSCSVMHEALHNHYTQKS LAFRTKPAALGKD LSLSPG (SEQ ID NO: 4) (SEQ ID NO: 285) AK449 DNA550 Knob: EPKSSDKTHTCPPCPAPELLGGPSV GSPG VPLSLY hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD (SEQ ID (SEQ ID (N297A + EPKSS)- VSHEDPEVKFNWYVDGVEVHNAKTK NO: 34) NO: 28) hIL2(R38A, PREEQYASTYRVVSVLTVLHQDWLN F42A, Y45A, GKEYKCKVSNKALPAPIEKTISKAK E62A, C125A) GQPREPQVYTLPPCRDELTKNQVSL WCLVKGFYPSDIAVEWESNGQPENN NYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG (SEQ ID NO: 288) AK450 DNA548 Hole: AKTDKTHTCPPCPAPELLGGPSVFL PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A + AKT)- HEDPEVKFNWYVDGVEVHNAKTKPR NO: 14) LFVSQASWACNLILGAPDSQKLTTV Hole: EEQYASTYRVVSVLTVLHQPWLNGK DIVTLRVLCREGVRWRVMAIQDFKP hFc(N297A)- EYKCKVSNKALPAPIEKTISKAKGQ FENLRLMAPISLQVVHVETHRCNIS hCD122 PREPQVCTLPPSRDELTKP WEISQASHYFERHLEFEARTLSPGH NQVSLSCAVKGFYPSDIAVEWESNG TWEEAPLLTLKQKQEWICLETLTPD QPENNYKTTPPVLDSDGSFFLYSKL TQYEFQVRVKPLQGEFTTWSPWSQP TVDKSRWQQGNVFSCSVMHEALHNH LAFRTKPAALGKD YTQKSLSLSPG (SEQ ID (SEQ NO: 4) ID NO: 286) AK450 DNA551 Knob: AKTDKTHTCPPCPAPELLGGPSVFL GSPG VPLSLY hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS (SEQ ID (SEQ ID (N297A + AKT)- HEDPEVKFNWYVDGVEVHNAKTKPR NO: 34) NO: 28) [VPLSLY]- EEQYASTYRVVSVLTVLHQDWLNGK hIL2(R38A, EYKCKVSNKALPAPIEKTISKAKGQ F42A, Y45A, PREPQVYTLPPCRDELTKNQVSLWC E62A, C125A) LVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLS LSPG (SEQ ID NO: 289) AK451 DNA549 Hole: AKTEPKSSDKTHTCPPCPAPELLGG PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 PSVFLFPPKPKDVLMISRTPEVTCV (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A VVDVSHEDPEVKFNWYVDGVEVHNA NO: 14) LFVSQASWACNLILGAPDSQKLTTV AKTEPKSS)- CTKPREEQYASTYRVVSVLTVLHQD DIVTLRVLCREGVRWRVMAIQDFKP hCD122 WLNGKEYKCKVSNKALPAPIEICTI FENLRLMAPISLQVVHVETHRCNIS SKAKGQPREPQVCTLPPSRDELTKN WEISQASHYFERHLEFEARTLSPGH QVSLSCAVKGFYPSDIAVEWESNGQ TWEEAPLLTLKQKQEWICLETLTPD PENNYKTTPPVLDSDG TQYEFQVRVKPLQGEFTTWSPWSQP SFFLVSKLTVDKSRWQQGNVFSCSV LAFRTKPAALGKD MHEALHNHYTQKSLSLSPG (SEQ ID NO: 4) (SEQ ID NO: 287) AK451 DNA552 Knob: AKTFPKSSDKTFITCPPCPAPELLG GSPG VPLSLY hFcIgG1 GPSVFLFPPKPKDTLMISRTPEVTC (SEQ ID (SEQ ID (N297A VVVDVSHEDPEVKFNWYVDGVEVHN NO: 34) NO: 28) AKTAKTEPKSS)- AKTKPREEQYASTYRWSVLTVLHQD [VPLSLY]- WLNGKEYKCKVSNKALPAPIEKTI hIL2(R38A, SKAKGQPREPQVYTLPPCRDELTKN F42A, Y45A, QVSLWCLVKGFYPSDIAVEWESNGQ E62A, C125A) PENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 290) AK452 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK452 DNA563 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK453 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK453 DNA565 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 28) hIL2(E15L, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG (SEQ ID NVFSCSVMHEALHNHYTQKSLSLSP NO: 34) G (SEQ ID NO: 12) AK454 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK454 DNA566 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK455 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK455 DNA567 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK456 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK456 DNA568 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15F, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK462 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GGSSPPG APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A) VYTIPPPKEQMAKDKVSLTCMITDF QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK462 DNA532 Hole: VRSGCKPCICTVPEVSSVFIFPPKP mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (DAPG) VQFSWFVDDVEVHTAQTQPREEQFN STFRSVSELPIMHQDWLKGKEFKCR VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKKQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPI MKTDGSYFVYSKLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) AK463 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A) VYTIPPPKEQMAKDKVSLTCMITDF QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK463 DNA533 Hole: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (DAPG)- KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) LFVSQASWACNLILGAPDSQKLTTV STFRSVSELPIMHQDWLKGKEFKCR DIVTLRVLCREGVRWRVMAIQDFKP VNSAAFGAPIEKTISKTKGRPKAPQ FENLRLMAPISLQVVHVETHRCNIS VYTIPPPKKQMAKDKVSLTCMITDF WEISQASHYFERHLEFEARTLSPGH FPEDITVEWQWNGQPAENYKNTQPI TWEEAPLLTLKQKQEWICLETLTPD MKTDGSYFVYSKLNVQKSNWEAGNT TQYEFQVRVKPLQGEFTTWSPWSQP FTCSVLHEGLHNHHTEKSLSHSPG LAFRTKPAALGKD (SEQ (SEQ ID NO: 4) ID NO: 284) AK464 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A) VYTIPPPKEQMAKDKVSLTCMITDF QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK464 DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVKNCSHLECFYNSRANVSCMWSHE mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID EALNVTTCHVHAKSNLRHWNKTCEL (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) TLVRQASWACNLILGSFPESQSLTS hCD122 STFRSVSELPIMHQDWLKGKEFKCR VDLLDINVVCWEEKGWRRVKTCDFH VNSAAFGAPIEKTISKTKGRPKAPQ PFDNLRLVAPHSLQVLHIDTQRCNI VYTIPPPKKQMAKDKVSLTCMITDF SWKVSQVSHYIEPYLEFEARRRLLG FPEDITVEWQWNGQPAENYKNTQPI HSWEDASVLSLKQRQQWLFLEMLIP MKTDGSYFVYSKLNVQKSNWEAGNT STSYEVQVRVKAORNN FTCSVLHEGLHNHHTEKSLSHSPG TGTWSPWSQPLTFRTRPADPVIKF (SEQ (SEQ ID ID NO: 326) NO: 284) AK465 DNA531 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSPG VPLSY mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID (SEQ ID (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NO: 34) NO: 28) [VPLSLY] STFRSVSELPIMHQDWLKGKEFKCR hIL2(R38A, VNSAAFGAPIEKTISKTKGRPKAPQ F42A, Y45A, VYTIPPPKEQMAKDKVSLTCMITDF E62A) FPEDITVEWQWNGQPAENYDNTQPI MDTDGSYFVYSDLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK466 DNA5332 Hole: VRSGCKPCICTVPEVSSVFIFPPKP GSPG mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID (DAPG) VQFSWFVDDVEVHTAQTQPREEQFN NO: 34) Knob: STFRSVSELPIMHQDWLKGKEFKCR mFcIgG1 VNSAAFGAPIEKTISKTKGRPKAPQ (DAPG)- VYTIPPPKKQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPI MKTDGSYFVYSKLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) AK466 DNA531 [VPLSLY]- VRSGCKPCICTVPEVSSVFIFPPKP VPLSY hIL2(R38A, F42A, KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID Y45A, VQFSWFVDDVEVHTAQTQPREEQFN NO: 28) E52A, STFRSVSELPIMHQDWLKGKEFKCR C125A) VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKEQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYDNTQPI MDTDGSYFVYSDLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK466 DNA533 Hole: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP PGSG AVNGTSQFTCFYNSRANISCVWSQD (DAPG)-hCD122 KDVLTITLTPKVTCVVVAISKDDPE S (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) LFVSQASWACNLILGAPDSQKLTTV STFRSVSELPIMHQDWLKGKEFKCR DIVTLRVLCREGVRWRVMAIQDFKP VNSAAFGAPIEKTISKTKGRPKAPQ FENLRLMAPISLQVVHVETHRCNIS VYTIPPPKKQMAKDKVSLTCMITDF WEISQASHYFERHLEFEARTLSPGH FPEDITVEWQWNGQPAENYKNTQPI TWEEAPLLTLKQKQEWICLETLTPD MKTDGSYFVYSKLNVQKSNWEAGNT TQYEFQVRVKPLQGEFTTWSPWSQP FTCSVLHEGLHNHHTEKSLSHSPG LAFRTKPAALGKD (SEQ (SEQ ID NO: 4) ID NO: 284) AK467 DNA531 Knob: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP GSPG VPLSY (DAPG)-[VPLSLY]- KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID (SEQ ID hIL2(R38A, F42A, VQFSWFVDDVEVHTAQTQPREEQFN NO: 34) NO: 28) Y45A, ES2A, STFRSVSELPIMHQDWLKGKEFKCR C325A) VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKEQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYDNTQPI MDTDGSYFVYSDLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK467 DNA534 Hole: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVKNCSHLECFYNSRANVSCMWSHE (DAPG)-hCD122 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID EALNVTTCHVHAKSNLRHWNKTCEL VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) TLVRQASWACNLILGSFPESQSLTS STFRSVSELPIMHQDWLKGKEFKCR VDLLDINVVCWEEKGWRRVKTCDFH VNSAAFGAPIEKTISKTKGRPKAPQ PFDNLRLVAPHSLQVLHIDTQRCNI VYTIPPPKKQMAKDKVSLTCMITDF SWKVSQVSHYIEPYLEFEARRRLLG FPEDITVEWQWNGQPAENYKNTQPI HSWEDASVLSLKQRQQWLFLEMLIP MKTDGSYFVYSKLNVQKSNWEAGNT STSYEVQVRVKAORNN FTCSVLHEGLHNHHTEKSLSHSPG TGTWSPWSQPLTFRTRPADPVIKF (SEQ (SEQ ID ID NO: 326) NO: 284) AKA68 DNA576 Hole: hFc(N237A, DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD M2S2Y, S254T, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL T256E)-hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDG TQYEFQVRVKPLQGEFTTWSPWSQP SPFLVSKLTVDKSRWQGQMVFSCSV LAFRTKPAALGKD MHEALHNHYTQKSLSLSPG (SEQ ID (SEQ NO: 4) ID NO: 292) AK468 DNA580 Knob: hFc(M297A, DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSY M252Y, S254T, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID (SEQ ID T2S6E)-[VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2, R38A, F42A, YASTYRVVSVLTVLHQDWLNGKEYK Y45A, E52A, CKVSNKALPAPIEKTISKAKGQPRE C125A) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVPSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 294) AK469 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS (SEQ ID AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED NO: 14) GALQDTSCQVHAWPDRRRWNQTCEL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ LFVSQASWACNLILGAPDSQKLTTV hCD122 YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP NVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 10) AK469 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297, KPKDTLMASRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE (R38A, F42A, CKVSNKALPAPIEKTISKAKGQFRE NO: 23) TTFMCEYADETATIVEFLNRWITFA Y45A, E52A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT C125A) GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) AK470 DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL M252Y, PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV S254T, YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP T256E)- CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS hCD122 PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDG TQYEFQVRVKPLQGEFTTWSPWSQP SPFLVSKLTVDKSRWQGQMVFSCSV LAFRTKPAALGKD MHEALHNHYTQKSLSLSPG (SEQ ID (SEQ NO: 4) ID NO: 292) AK470 DNA578 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLYITREPEVTCVVVDVSHED GSGP NGINNYKNPKLTAMLTAKFAMPKKA M252Y, PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS 52547, YASTYRVVSVLTVLHQDWLNGKEYK NO: 23) KNFHLRPRDLISNINVIVLELKGSE T256E)- CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA hIL2(R38A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT F42A, GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID Y45A, E62A, PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) C125A) NVPSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 294) AK471 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV HCD122 YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP NVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 10) AK471 DNA579 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(M297, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) [VPLSLY]- YASTYRVVSVLTVLHQDWLNGKEYK hIL2(R38A, CKVSNKALPAPIEKTISKAKGQFRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, GFYPSDIAVEWESNGQPENNYKTTP C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) AK439 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK439 DNA544 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (R38A, F42A, CKVSNKALPAPIEKTISKAKGQPRE Y45A, E62A, PQVYTLPPCRDELTKNQVSLWCLVK L80F, RS3D, GFYPSDIAVEWESNGQPENNYKTTP L85V, 186V, PVLDSDGSFFLYSKLTVDKSRWQQG I92F, C125A) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK440 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK440 DNA544 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (R38A, F42A, CKVSNKALPAPIEKTISKAKGQPRE Y45A, E62A, PQVYTLPPCRDELTKNQVSLWCLVK L80F, RS3D, GFYPSDIAVEWESNGQPENNYKTTP L85V, 186V, PVLDSDGSFFLYSKLTVDKSRWQQG I92F, C125A) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK441 DNA543 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 36) NO: 28) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK441 DNA546 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED GSGP (SEQ ID NGINNYKNPKLTAMLTAKFAMPKKA hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 23) TELKHLQCLEEALKPLEEVLNLAQS (R38A, F42A, YASTYRVVSVLTVLHQDWLNGKEYK KNFHFDPRDWSNINVFVLELKGSET Y45A, E62A, CKVSNKALPAPIEKTISKAKGQPRE TFMCEYADETATI L80F, RS3D, PQVYTLPPCRDELTKNQVSLWCLVK VEFLNRWITFAQSIISTLT L85V, 186V, GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID I92F, C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NO: 328) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK442 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED GSGP (SEQ ID NGINNYKNPKLTAMLTAKFAMPKKA hIL2(R38A, PEVKFNWYVDGVEVHNAKTKPREEQ NO: 23) TELKHLQCLEEALKPLEEVLNLAQS F42A, Y45A, YASTYRVVSVLTVLHQDWLNGKEYK KNFHLRPRDLISNINVIVLELKGSE E62A, C125A) CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK442 DNA553 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSPG DSGGFMLT hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [DSGGFMLT]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 36) NO: 25) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK443 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK443 DNA554 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK444 DNA281 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSGP DSGGFMLT hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 33) NO: 25) hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK444 DNA440 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS (SEQ ID AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED NO: 14) GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ LPVSQASWACNLILGAPDSQKLTTV (C122S, C168S) YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQPFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRSNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWISLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 5) ID NO: 9) AK449 DNA547 Hole: EPKSSDKTHTCPPCPAPELLGGPSV PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A + EPKSS)- VSHEDPEVKFNWYVDGVEVHNAKTK NO: 14) LFVSQASWACNLILGAPDSQKLTTV Hole: PREEQYASTYRVVSVLTVLHQDWLN DIVTLRVLCREGVRWRVMAIQDFKP hFc(N297A)- GKEYKCKVSNKALPAPIEKTISKAK FENLRLMAPISLQVVHVETHRCNIS hCD122 GQPREPQVCTLPPSRDELTKNQVSL WEISQASHYFERHLEFEARTLSPGH SCAVKGFYPSDIAVEWESNGQPENN TWEEAPLLTLKQKQEWICLETLTPD YKTTPPVLDSDGSFFLVSKLTVDKS TQYEFQVRVKPLQGEFTTWSPWSQP RWQQGNVFSCSVMHEALHNHYTQKS LAFRTKPAALGKD LSLSPG (SEQ ID NO: 4) (SEQ ID NO: 285) AK449 DNA550 Knob: EPKSSDKTHTCPPCPAPELLGGPSV GSPG VPLSLY hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD (SEQ ID (SEQ ID (N297A + EPKSS)- VSHEDPEVKFNWYVDGVEVHNAKTK NO: 34) NO: 28) hIL2(R38A, PREEQYASTYRVVSVLTVLHQDWLN F42A, Y45A, GKEYKCKVSNKALPAPIEKTISKAK E62A, C125A) GQPREPQVYTLPPCRDELTKNQVSL WCLVKGFYPSDIAVEWESNGQPENN NYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQK SLSLSPG (SEQ ID NO: 288) AK450 DNA548 Hole: AKTDKTHTCPPCPAPELLGGPSVFL PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A + AKT)- HEDPEVKFNWYVDGVEVHNAKTKPR NO: 14) LFVSQASWACNLILGAPDSQKLTTV Hole: EEQYASTYRVVSVLTVLHQPWLNGK DIVTLRVLCREGVRWRVMAIQDFKP hFc(N297A)- EYKCKVSNKALPAPIEKTISKAKGQ FENLRLMAPISLQVVHVETHRCNIS hCD122 PREPQVCTLPPSRDELTKP WEISQASHYFERHLEFEARTLSPGH NQVSLSCAVKGFYPSDIAVEWESNG TWEEAPLLTLKQKQEWICLETLTPD QPENNYKTTPPVLDSDGSFFLYSKL TQYEFQVRVKPLQGEFTTWSPWSQP TVDKSRWQQGNVFSCSVMHEALHNH LAFRTKPAALGKD YTQKSLSLSPG (SEQ ID NO: 4) (SEQ ID NO: 286) AK450 DNA551 Knob: AKTDKTHTCPPCPAPELLGGPSVFL GSPG VPLSLY hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS (SEQ ID (SEQ ID (N297A + AKT)- HEDPEVKFNWYVDGVEVHNAKTKPR NO: 34) NO: 28) [VPLSLY]- EEQYASTYRVVSVLTVLHQDWLNGK hIL2(R38A, EYKCKVSNKALPAPIEKTISKAKGQ F42A, Y45A, PREPQVYTLPPCRDELTKNQVSLWC E62A, C125A) LVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLS LSPG (SEQ ID NO: 289) AK451 DNA549 Hole: AKTEPKSSDKTHTCPPCPAPELLGG PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG1 PSVFLFPPKPKDVLMISRTPEVTCV (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (N297A VVDVSHEDPEVKFNWYVDGVEVHNA NO: 14) LFVSQASWACNLILGAPDSQKLTTV AKTEPKSS)- CTKPREEQYASTYRVVSVLTVLHQD DIVTLRVLCREGVRWRVMAIQDFKP hCD122 WLNGKEYKCKVSNKALPAPIEICTI FENLRLMAPISLQVVHVETHRCNIS SKAKGQPREPQVCTLPPSRDELTKN WEISQASHYFERHLEFEARTLSPGH QVSLSCAVKGFYPSDIAVEWESNGQ TWEEAPLLTLKQKQEWICLETLTPD PENNYKTTPPVLDSDG TQYEFQVRVKPLQGEFTTWSPWSQP SFFLVSKLTVDKSRWQQGNVFSCSV LAFRTKPAALGKD MHEALHNHYTQKSLSLSPG (SEQ ID NO: 4) (SEQ ID NO: 287) AK451 DNA552 Knob: AKTFPKSSDKTFITCPPCPAPELLG GSPG VPLSLY hFcIgG1 GPSVFLFPPKPKDTLMISRTPEVTC (SEQ ID NO: 34) (SEQ ID (N297A VVVDVSHEDPEVKFNWYVDGVEVHN NO: 28) AKTAKTE AKTKPREEQYASTYRVVSVLTVLHQ PKSS)- DWLNGKEYKCKVSNKALPAPiEKTI [VPLSLY]- SKAKGQPREPQVYTLPPCRDELTKN hIL2(R38A, QVSLWCLVKGFYPSDIAVEWESNGQ F42A, Y45A, PENNYKTTPPVLDSDGSFFLYSKLT E62A, C125A) VDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 290) AK452 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS (SEQ ID AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED NO: 14) GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK452 DNA563 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID -[VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK453 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 9) AK453 DNA565 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15L, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK454 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK454 DNA566 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15R, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK455 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK455 DNA567 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(L18C, YASTYRVVSVLTVLHQDWLNGKEYK D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK456 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK456 DNA568 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(E15F, YASTYRVVSVLTVLHQDWLNGKEYK L18C, D20R, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 12) AK462 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GGSSPP APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGGSS NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN GG TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR GSGP KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ (SEQ ID TTFMCEYADETATIVEFLNRWITFA VYTIPPPKEQMAKDKVSLTCMITDF NO: 23) QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID E62A) NO: 283) AK462 DNA532 Hole: VRSGCKPCICTVPEVSSVFIFPPKP mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (DAPG) VQFSWFVDDVEVHTAQTQPREEQFN STFRSVSELPIMHQDWLKGKEFKCR VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKKQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPI MKTDGSYFVYSKLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) AK463 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A) VYTIPPPKEQMAKDKVSLTCMITDF QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK463 DNA533 Hole: VRSGCKPCICTVPEVSSVFIFPPKP PGSGS (SEQ ID AVNGTSQFTCFYNSRANISCVWSQD mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE NO: 14) GALQDTSCQVHAWPDRRRWNQTCEL (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN LFVSQASWACNLILGAPDSQKLTTV hCD122 STFRSVSELPIMHQDWLKGKEFKCR DIVTLRVLCREGVRWRVMAIQDFKP VNSAAFGAPIEKTISKTKGRPKAPQ FENLRLMAPISLQVVHVETHRCNIS VYTIPPPKKQMAKDKVSLTCMITDF WEISQASHYFERHLEFEARTLSPGH FPEDITVEWQWNGQPAENYKNTQPI TWEEAPLLTLKQKQEWICLETLTPD MKTDGSYFVYSKLNVQKSNWEAGNT TQYEFQVRVKPLQGEFTTWSPWSQP FTCSVLHEGLHNHHTEKSLSHSPG LAFRTKPAALGKD (SEQ (SEQ ID NO: 4) ID NO: 284) AK464 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GSGP NGINNYKNPKLTAMLTAKFAMPKKA (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, STFRSVSELPIMHQDWLKGKEFKCR NO: 23) KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, VNSAAFGAPIEKTISKTKGRPKAPQ TTFMCEYADETATIVEFLNRWITFA E62A) VYTIPPPKEQMAKDKVSLTCMITDF QSIISTLT FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID MDTDGSYFVYSDLNVQKSNWEAGNT NO: 3) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK464 DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKP PGSGS (SEQ ID AVKNCSHLECFYNSRANVSCMWSHE mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE NO: 14) EALNVTTCHVHAKSNLRHWNKTCEL (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN TLVRQASWACNLILGSFPESQSLTS hCD122 STFRSVSELPIMHQDWLKGKEFKCR VDLLDINVVCWEEKGWRRVKTCDFH VNSAAFGAPIEKTISKTKGRPKAPQ PFDNLRLVAPHSLQVLHIDTQRCNI VYTIPPPKKQMAKDKVSLTCMITDF SWKVSQVSHYIEPYLEFEARRRLLG FPEDITVEWQWNGQPAENYKNTQPI HSWEDASVLSLKQRQQWLFLEMLIP MKTDGSYFVYSKLNVQKSNWEAGNT STSYEVQVRVKAORNN FTCSVLHEGLHNHHTEKSLSHSPG TGTWSPWSQPLTFRTRPADPVIKF (SEQ (SEQ ID ID NO: 326) NO: 284) AK465 DNA531 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSPG (SEQ ID VPLSY mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE NO: 34) (SEQ ID (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NO: 28) [VPLSLY] STFRSVSELPIMHQDWLKGKEFKCR hIL2(R38A, VNSAAFGAPIEKTISKTKGRPKAPQ F42A, Y45A, VYTIPPPKEQMAKDKVSLTCMITDF E62A) FPEDITVEWQWNGQPAENYDNTQPI MDTDGSYFVYSDLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK466 DNA5332 Hole: VRSGCKPCICTVPEVSSVFIFPPKP mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (DAPG) VQFSWFVDDVEVHTAQTQPREEQFN STFRSVSELPIMHQDWLKGKEFKCR VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKKQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPI MKTDGSYFVYSKLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) AK466 DNA531 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSPG VPLSY mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID (SEQ ID (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NO: 34) NO: 28) [VPL51Y]- STFRSVSELPIMHQDWLKGKEFKCR hIL2(R38A, VNSAAFGAPIEKTISKTKGRPKAPQ F42A, VYTIPPPKEQMAKDKVSLTCMITDF Y45A, E52 FPEDITVEWQWNGQPAENYDNTQPI A, MDTDGSYFVYSDLNVQKSNWEAGNT C125A) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK466 DNA533 Hole: VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVNGTSQFTCFYNSRANISCVWSQD mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122 STFRSVSELPIMHQDWLKGKEFKCR DIVTLRVLCREGVRWRVMAIQDFKP VNSAAFGAPIEKTISKTKGRPKAPQ FENLRLMAPISLQVVHVETHRCNIS VYTIPPPKKQMAKDKVSLTCMITDF WEISQASHYFERHLEFEARTLSPGH FPEDITVEWQWNGQPAENYKNTQPI TWEEAPLLTLKQKQEWICLETLTPD MKTDGSYFVYSKLNVQKSNWEAGNT TQYEFQVRVKPLQGEFTTWSPWSQP FTCSVLHEGLHNHHTEKSLSHSPG LAFRTKPAALGKD (SEQ (SEQ ID NO: 4) ID NO: 284) AK467 DNA531 Knob: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP GSPG VPLSY (DAPG)-[VPLSLY]- KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID (SEQ ID hIL2(R38A, F42A, VQFSWFVDDVEVHTAQTQPREEQFN NO: 34) NO: 28) Y45A, ES2A, STFRSVSELPIMHQDWLKGKEFKCR C325A) VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKEQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYDNTQPI MDTDGSYFVYSDLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 283) AK467 DNA534 Hole: mFcIgG1 VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVKNCSHLECFYNSRANVSCMWSHE (DAPG)-hCD122 KDVLTITLTPKVTCVVVAISKDDPE (SEQ ID EALNVTTCHVHAKSNLRHWNKTCEL VQFSWFVDDVEVHTAQTQPREEQFN NO: 14) TLVRQASWACNLILGSFPESQSLTS STFRSVSELPIMHQDWLKGKEFKCR VDLLDINVVCWEEKGWRRVKTCDFH VNSAAFGAPIEKTISKTKGRPKAPQ PFDNLRLVAPHSLQVLHIDTQRCNI VYTIPPPKKQMAKDKVSLTCMITDF SWKVSQVSHYIEPYLEFEARRRLLG FPEDITVEWQWNGQPAENYKNTQPI HSWEDASVLSLKQRQQWLFLEMLIP MKTDGSYFVYSKLNVQKSNWEAGNT STSYEVQVRVKAORNN FTCSVLHEGLHNHHTEKSLSHSPG TGTWSPWSQPLTFRTRPADPVIKF (SEQ (SEQ ID ID NO: 326) NO: 284) AKA68 DNA576 Hole: hFc(N237A, DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD M2S2Y, S254T, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL T256E)-hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDG TQYEFQVRVKPLQGEFTTWSPWSQP SPFLVSKLTVDKSRWQGQMVFSCSV LAFRTKPAALGKD MHEALHNHYTQKSLSLSPG (SEQ ID (SEQ NO: 4) ID NO: 292) AK468 DNA580 Knob: hFc(N297A, DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSY M252Y, S254T, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID (SEQ ID T2S6E)-[VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2(R38A, F42A, YASTYRVVSVLTVLHQDWLNGKEYK Y45A, E52A, CKVSNKALPAPIEKTISKAKGQPRE C125A) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVPSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 294) AK469 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122 YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDfAVEWESNIGQPENNYKTT TWEEAPLLTLKQKQEWICLETLTPD PPVLDSDGSFFLVSK TQYEFQVRVKPLQGEFTTWSPWSQP LTVDKSRWQQGNVFSCSVMHEALHN LAFRTKPAALGKD HYTQKSLSLSPG (SEQ ID NO: 4) (SEQ ID NO: 10) AK469 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297, KPKDTLMASRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE (R38A, F42A, CKVSNKALPAPIEKTISKAKGQFRE NO: 23) TTFMCEYADETATIVEFLNRWITFA Y45A, E52A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT C125A) GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) AK470 DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL M252Y, PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV S254T, YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP T256E)- CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS hCD122 PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSPFLVSKLTVDKSRWQGQ TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 292) AK470 DNA578 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPP APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLYITREPEVTCVVVDVSHED GGGSS NGINNYKNPKLTAMLTAKFAMPKKA M252Y, PEVKFNWYVDGVEVHNAKTKPREEQ GG TELKHLQCLEEA 52547, YASTYRVVSVLTVLHQDWLNGKEYK GSGP LKPLEEVLNLAQSKNFHLRPRDLIS T256E)- CKVSNKALPAPIEKTISKAKGQPRE (SEQ ID NINVIVLELKGSETTFMCEYADETA hIL2(R38A, PQVYTLPPCRDELTKNQVSLWCLVK NO: 23) TIVEFLNRWITFAQSIISTLT F42A, GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID Y45A, E62A, PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) C125A) NVPSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 294) AK471 DNA57S Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV HCD122 YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDfAVEWESNIGQPENNYKTT TWEEAPLLTLKQKQEWICLETLTPD PPVLDSDGSFFLVSK TQYEFQVRVKPLQGEFTTWSPWSQP LTVDKSRWQQGNVFSCSVMHEALHN LAFRTKPAALGKD HYTQKSLSLSPG (SEQ ID NO: 4) (SEQ ID NO: 10) AK471 DNA579 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(M297, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) [VPLSLY]- YASTYRVVSVLTVLHQDWLNGKEYK hIL2(R38A, CKVSNKALPAPIEKTISKAKGQFRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, GFYPSDIAVEWESNGQPENNYKTTP C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) AK475 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPG hFc(N297A) KPKDTLMISRTPEVTCVVVDVSHED GGSSGG hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ GSGP (R38A, YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) PQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP APTSSSTKKTQLQLEHLLLDLQMIL G NGINNYKNPKLTAMLTAKFAMPKKA (SEQ TELKHLQCLEEALKPLEEVLNLAQS ID KNFHLRPRDLISNINVIVLELKGSE NO: 12) TTFMCEYADETATIVEFLNRWITFA QSIISTLT (SEQ ID E62A, C123A) NO: 3) AK475 DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LPVSQASWACNLILGAPDSQLTTVD (C1688S) YASTYRVVSVLTVLHQDWLNGKEYK IVTLRVLCREGVRWRVMAIQDFKPF CKVSNKALPAPIEKTISKAKGQPRE ENLRLMAPISLQVVHVETHRCNISW PQVCTLPPSRDELTKNQVSLSCAVK EISQASHYFERHLEFEARTLSPGHT GFYPSDIAVEWESNGQPENNYKTTP WEEAPLLTLKQKQEWISLETLTPDT PVLDSDGSFFLVSKLTVDKSRWQQG QYEFQVRVKPLQGEFTTWSPWSQPL MVFSCSVMHEALHNHYTQKSLSLSP AFRTKPAALGKD G (SEQ ID (SEQ NO: 327) ID NO: 9) AK476 DNA263 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, C123A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 12) AK476 DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LPVSQASWACNLILGAPDSQLTTVD (C1688S) YASTYRVVSVLTVLHQDWLNGKEYK IVTLRVLCREGVRWRVMAIQDFKPF CKVSNKALPAPIEKTISKAKGQPRE ENLRLMAPISLQVVHVETHRCNISW PQVCTLPPSRDELTKNQVSLSCAVK EISQASHYFERHLEFEARTLSPGHT GFYPSDIAVEWESNGQPENNYKTTP WEEAPLLTLKQKQEWISLETLTPDT PVLDSDGSFFLVSKLTVDKSRWQQG QYEFQVRVKPLQGEFTTWSPWSQPL MVFSCSVMHEALHNHYTQKSLSLSP AFRTKPAALGKD G (SEQ ID (SEQ NO: 327) ID NO: 9) AK477 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK477 DNA554 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (E15R, L18C, CKVSNKALPAPIEKTISKAKGQPRE D20R, R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 12) AK484 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK484 DNA581 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (L18C, R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK485 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK485 DNA582 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, C125A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK486 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK486 DNA583 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16E, R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, C125A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK487 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK487 DNA584 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (D20L, R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, C125A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK488 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK488 DNA585 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, L18C, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK489 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK489 DNA586 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16E, L18C, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) Ak490 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) Ak490 DNA587 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (L18C, d20L, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) Ak491 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) Ak491 DNA588 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, L18C, CKVSNKALPAPIEKTISKAKGQPRE D20L, R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) Ak492 DNA158 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP (N297A) KPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) Ak492 DNA589 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16E, L18C, CKVSNKALPAPIEKTISKAKGQPRE D20L, R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK493 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) Ak493 DNA581 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (L18C, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK494 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK494 DNA582 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A, C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK495 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK495 DNA583 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16E, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A, C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK496 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK496 DNA584 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (D20L, R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK E62A, C125A) GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK497 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK497 DNA585 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, L18C, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK498 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK498 DNA586 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16E, L18C, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK499 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK499 DNA587 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (L18C, d20L, CKVSNKALPAPIEKTISKAKGQPRE R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK500 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 9) AK500 DNA588 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H16Y, L18C, CKVSNKALPAPIEKTISKAKGQPRE D20L, R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK501 DNA187 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD (N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHA hCD122 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) WPDRRRWNQTCELLFVSQASWACNL YASTYRVVSVLTVLHQDWLNGKEYK ILGAPDSQKLTT CKVSNKALPAPIEKTISKAKGQPRE VDIVTLRVLCREGVRWRVMAIQDFK PQVCTLPPSRDELTKNQVSLSCAVK PFENLRLMAPIS GFYPSDIAVEWESNGQPENNYKTTP LQVVHVETHRCNISWEISQASHYFE PVLDSDGSFFLVSKLTVDKSRWQQG RHLEFEARTLSP MVFSCSVMHEALHNHYTQKSLSLSP GHTWEEAPLLTLKQKQEWICLETLT G PDTQYEFQVRVK (SEQ PLQGEFTTWSPWSQPLAFRTKPAAL ID GKD NO: 9) (SEQ ID NO: 4) AK501 DNA589 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (H163, L18C, CKVSNKALPAPIEKTISKAKGQPRE D20L, R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPENNYKTTP E62A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK502 DNA543 Hole: hFc DKTHTCPPCPAPELLGGPSVFLFPP GPPSG VPLSLY (N297A)- KPKDTLMISRTPEVTCVVVDVSHED SSPG (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 28) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK502 DNA577 Knob: DKTHTCPPCPAPQLLGGPSVFLFPP GSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED GSGP NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK NO: 23) KNFHLRPRDLISNINVIVLELKGSE (R38A, CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT E62A, C125A) GFYPSDIAVEWESNGQPEN (SEQ ID NIYKTTPPVLDSDGSFFIYSKLTVD NO: 3) KSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG (SEQ ID NO: 13) AK503 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED GSGP NGINNYKNPKLTAMLTAKFAMPKKA hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS (R38A, YASTYRVVSVLTVLHQDWLNGKEYK NO: 23) KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE TTFMCEYADETATIVEFLNRWITFA E62A, C125A) PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK503 DNA606 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSP RAAAVKSP hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID NO: 27) [RAAAVKSP]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 37) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG MVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK504 DNA603 Hole: ESKYGPPCPPCPAPEFLGGPSVFLF PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG4- PPKPKDTLMISRTPEVTCVVVDVSQ (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 EDPEVQFNWYVDGVEVHNAKTKPRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV EQFNSTYRVVSVLTVLHQDWLNGKE DIVTLRVLCREGVRWRVMAIQDFKP YKCKVSNKGLPSSIEKTISKAKGQP FENLRLMAPISLQVVHVETHRCNIS REPQVCTLPPSQEEMTKNQVSLSCA WEISQASHYFERHLEFEARTLSPGH VKGFYPSDIAVEWESNGQPENNYKT TWEEAPLLTLKQKQEWICLETLTPD TPPVLDSDGSFFLYSRLTVDKSRWQ TQYEFQVRVKPLQGEFTTWSPWSQP EGNVFSCSVMHEALHNHYTQKSLSL LAFRTKPAALGKD SLG (SEQ ID NO: 4) (SEQ ID NO: 295) AK504 DNA605 Knob: ESKYGPPCPPCPAPEFLGGPSVFLF GSPG VPLSLY hFc(N297A)- PPKPKDTLMISRTPEVTCVVVDVSQ (SEQ ID (SEQ ID [VPLSLY]- EDPEVQFNWYVDGVEVHNAKTKPRE NO: 34) NO: 28) hIL2 EQFNSTYRVVSVLTVLHQDWLNGKE (R38A, YKCKVSNKGLPSSIEKTISKAKGQP F42A, Y45A, REPQVYTLPPSQEEMTKNQVSLSWC E62A, LVKGFYPSDIAVEWESNGQPENNYK C125A) TTPPVLDSDGSFFLYSRLTVDKSRW QEGNVFSCSVMHEALHNHYTQKSLS LSLG (SEQ ID NO: 296) AK505 DNA603 Hole: ESKYGPPCPPCPAPEFLGGPSVFLF PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFcIgG4- PPKPKDTLMISRTPEVTCVVVDVSQ (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL hCD122 EDPEVQFNWYVDGVEVHNAKTKPRE NO: 14) LFVSQASWACNLILGAPDSQKLTTV EQFNSTYRVVSVLTVLHQDWLNGKE DIVTLRVLCREGVRWRVMAIQDFKP YKCKVSNKGLPSSIEKTISKAKGQP FENLRLMAPISLQVVHVETHRCNIS REPQVCTLPPSQEEMTKNQVSLSCA WEISQASHYFERHLEFEARTLSPGH VKGFYPSDIAVEWESNGQPENNYKT TWEEAPLLTLKQKQEWICLETLTPD TPPVLDSDGSFFLYSRLTVDKSRWQ TQYEFQVRVKPLQGEFTTWSPWSQP EGNVFSCSVMHEALHNHYTQKSLSL LAFRTKPAALGKD SLG (SEQ ID (SEQ NO: 4) ID NO: 295) AK505 DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLF GSSPPGGGSSGG APTSSSTKKTQLQLEHLLLDLQMIL IgG4 PPKPKDTLMISRTPEVTCVVVDVSQ GSGP NGINNYKNPKLTAMLTAKFAMPKKA hFc- EDPEVQFNWYVDGVEVHNAKTKPRE (SEQ ID TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, EQFNSTYRVVSVLTVLHQDWLNGKE NO: 23) KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, YKCKVSNKGLPSSIEKTISKAKGQP TTFMCEYADETATIVEFLNRWITFA E62A, C125A) REPQVYTLPPSQEEMTKNQVSLSWC QSIISTLT LVKGFYPSDIAVEWESNGQPENNYK (SEQ ID TTPPVLDSDGSFFLYSRLTVDKSRW NO: 3) QEGNVFSCSVMHEALHNHYTQKSLS LSLG (SEQ ID NO: 296) AK508 DNA577 Knob: DKTHTCPPCPAPQLLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE (R38A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT E62A, C125A) GFYPSDIAVEWESNGQPEN (SEQ ID NIYKTTPPVLDSDGSFFIYSKLTVD NO: 3) KSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG (SEQ ID NO: 13) AK508 DNA609 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSG VPLSLY hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED SSPG (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 28) I253A)- YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) hCD122 CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) AK509 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVWSQD hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LFVSQASWACNLILGAPDSQKLTTV hCD122 YASTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GFYPSDIAVEWESNGQPENNYKTTP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP NVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID NO: 4) (SEQ ID NO: 10) AK509 DNA623 Knob: DKTHTCPPCPAPQLLGGPSVFLFPP GGSSPP MPYDLYHP hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 32) NO: 24) [MPYDLYHP]- YASTYRVVSVLTVLHQDWLNGKEYK hIL2 CKVSNKALPAPIEKTISKAKGQPRE (R38A, PQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, GFYPSDIAVEWESNGQPEN E62A, NIYKTTPPVLDSDGSFFIYSKLTVD C125A) KSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG (SEQ ID NO: 13) AK510 DNA577 Knob: DKTHTCPPCPAPQLLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE (R38A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT E62A, C125A) GFYPSDIAVEWESNGQPEN (SEQ ID NIYKTTPPVLDSDGSFFIYSKLTVD NO: 3) KSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG (SEQ ID NO: 13) AK510 DNA608 Hole: hFc(N297A, DKTHTCPPCPAPELLGGPSVFLFPP MPYDLYHP I253A)- KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID [MPYDLYHP]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 24) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) AK511 DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLF GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL IgG4 PPKPKDTLMISRTPEVTCVVVDVSQ GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA hFc- EDPEVQFNWYVDGVEVHNAKTKPRE GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, EQFNSTYRVVSVLTVLHQDWLNGKE (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, YKCKVSNKGLPSSIEKTISKAKGQP NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A, C125A) REPQVYTLPPSQEEMTKNQVSLSWC QSIISTLT LVKGFYPSDIAVEWESNGQPENNYK (SEQ ID TTPPVLDSDGSFFLYSRLTVDKSRW NO: 3) QEGNVFSCSVMHEALHNHYTQKSLS LSLG (SEQ ID NO: 296) AK511 DNA621 Hole: ESKYGPPCPPCPAPEFLGQPSVFLF PSGSSPG VPLSLY hFcIgG4 PPKPKDTLMISRTPEVTCVVVDVSQ (SEQ ID (SEQ ID [VPLSLY]- EDPEVQFNWYVDGVEVHNAKTKPRE NO: 313) NO: 28) hCD122 EQFNSTYRVVSVLTVLHQDVVLNGK EYKCKVSNKGLPSSIEKTISKAKGQ PREPQVCTLPPSQEEMTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRW QEGNVFSCSVMHEALHNHYTQKSLS ISLGGP (SEQ ID NO: 297) AK512 DNA577 Knob: DKTHTCPPCPAPQLLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2 YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE (R38A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA F42A, Y45A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT E62A, C125A) GFYPSDIAVEWESNGQPEN (SEQ ID NIYKTTPPVLDSDGSFFIYSKLTVD NO: 3) KSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG (SEQ ID NO: 13) AK512 DNA625 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED I253A) PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) AK513 DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLF GSSPPGG APTSSSTKKTQLQLEHLLLDLQMIL IgG4 PPKPKDTLMISRTPEVTCVVVDVSQ GSSGG NGINNYKNPKLTAMLTAKFAMPKKA hFc- EDPEVQFNWYVDGVEVHNAKTKPRE GSGP TELKHLQCLEEALKPLEEVLNLAQS hIL2(R38A, EQFNSTYRVVSVLTVLHQDWLNGKE (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, YKCKVSNKGLPSSIEKTISKAKGQP NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A, C125A) REPQVYTLPPSQEEMTKNQVSLSWC QSIISTLT LVKGFYPSDIAVEWESNGQPENNYK (SEQ ID TTPPVLDSDGSFFLYSRLTVDKSRW NO: 3) QEGNVFSCSVMHEALHNHYTQKSLS LSLG (SEQ ID NO: 296) AK513 DNA626 Hole: ESKYGPPCPPCPAPEFLGGPSVFLF hFcIgG4 PPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTYRVVSVLTVLHQDVWLNGK EYKCKVSNKGLPSSIEKTISKAKGQ PREPQVCTLPPSQEEMTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRW QEGMVFSCSVMHEALHNHYTQKSLS LSLGPG (SEQ ID NO: 298) AK526 DNA670 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPG APTSSSTKKTQLQLEHLLLDLQMIL hFc-hIL2 KPKDTLMISRTPEVTCVVVDVSHED GGSSGG NGINNYKNPKLTAMLTAKFAMPKKA (R38A, PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS F42A, Y45A, YNSTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE E62A, C125A) CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 11) AK526 DNA672 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSPG VPLSLY hFc- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 36) NO: 28) hCD122 YNSTYRVVSVLWLHQDWLNGKEYKC KVSNKALPAPIEHISKAKGQPREPQ VCTLPPSRDELTKNQVSLSCAVKGF YPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 8) AK530 DNA25 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPPGG APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A, KPKDTLMISRTPEVTCVVVDVSHED GSSGG NGINNYKNPKLTAMLTAKFAMPKKA hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ GSGP TELKHLQCLEEALKPLEEVLNLAQS (R38A, YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE F42A, Y45A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA E62A, PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT C125A) GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK530 DNA612 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSP MPYDLYHP hFc(N297A, KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 9) NO: 24) [MPYDLYHP]- YASTYRVVSVLTVLHQDWLNGKEYK hCD122 CKVSNKALPAPIEKTISKAKGQPRE (C122S, PQVCTLPPSRDELTKNQVSLSCAVK C168S) GFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSF FLVSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSPG (SEQ ID NO: 3) AK531 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSSPP APTSSSTKKTQLQLEHLLLDLQMIL hFc(N297A)* KPKDTLMISRTPEVTCVVVDVSHED GGGS MGINNYKNPKLTAMLTAKFAMPKKA hIL2(R38A, PEVKFNWYVDGVEVHNAKTKPREEQ SGGGSGP TELKHLQCLEEALKPLEEVLNLAQS Y45A, YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID KNFHLRPRDLISNINVIVLELKGSE C125A) CKVSNKALPAPIEKTISKAKGQPRE NO: 23) TTFMCEYADETATIVEFLNRWITFA PQVYTLPPCRDELTKNQVSLWCLVK QSIISTLT GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID PVLDSDGSFFLYSKLTVDKSRWQQG NO: 3) NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 12) AK531 DNA614 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSG DSGGFMLT hFc(N297A)- KPKDTLMISRTPEVTCVVVDVSHED SSPG (SEQ ID [DSGGFMLT]- PEVKENWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 25) hCD122 YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) (C122S, CKVSNKALPAPIEKTISKAKGQPRE C16SS) PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPFNNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 9) AK532 DNA669 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVMGTSQFTCFYNSRANISCVWSQD hFc-hCD122 KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID GALQDTSCQVHAWPDRRRWNQTCEL PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) LPVSQASWACNLILGAPDSQKLTTV YNSTYRVVSVLTVLHQDWLNGKEYK DIVTLRVLCREGVRWRVMAIQDFKP CKVSNKALPAPIEKTISKAKGQPRE FENLRLMAPISLQVVHVETHRCNIS PQVCTLPPSRDELTKNQVSLSCAVK WEISQASHYFERHLEFEARTLSPGH GEYPSDIAVEWESNGQPENNYKTCP TWEEAPLLTLKQKQEWICLETLTPD PVLDSDGSFFLVSKLTVDKSRWQQG TQYEFQVRVKPLQGEFTTWSPWSQP MVFSCSVMHEALHNHYTQKSLSLSP LAFRTKPAALGKD G (SEQ ID (SEQ NO: 4) ID NO: 8) AK532 DNA671 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG hFc- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID [VPLSLY]- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) hIL2 YNSTYRVVSVLTVLHQDWLNGKEYK (R38A, F42A, CKVSNKALPAPIEKTISKAKGQPRE Y45A, PQVYTLPPCRDTLTKNQVSLWCLVK E62A; GFYPSDIAVEWE C125A) SNGQPENNYKTTPPVLDSDGSFFLY VPLSLY SKLTVDKSRWQQGNVFSCSVMHEAL (SEQ ID HNHYTQKSLSLSPG NO: 28) (SEQ ID NO: 11) Component4 Component5 Molecule name newnames Sequence Sequence FullSSequence AK368 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT hFc(N297A)- CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTY hCD122 RVVSVLTVLHQDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVIDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK368 DNA476 Knob: GP APTSSSTKKTQLQLEHLLLDLQMI DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT hFc(N297A)- LNGINNYKNPKLTRMLTSKFYMPK CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTY [NPMGSDP KATELKHLQCLEESLKPLEEVLNL RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK VNFKLLRW AQSKNFHLRPRDLISNINVIVLEL GQPREPQVYT1PPCRDELTKNQVSLWCLVKGFYPSDIAVE NG]-hIL2 KGSETTFMCEYADETATIVEFLNR WESNGQPENNYKTTPPVIDSDGSFFLYSKLTVDKSRWQQG (F42S, WITFAQSIISTLT (SEQ ID NVFSCSVMHEALHNHYTQKSLSLSPG E62S, C1213A) NO: 74) (SEQ ID NO: 360) AK375 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWEFNNVEVHTAQTQTHREDYNST (LALAPG)- LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP hIL2(R38A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTDFMPEDIYV F42A, EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVE Y45A, E62A, RNSYSCSVVHEGLHNHHTTKSFSRTPGGGSSPPGGGSSGG C125A) GSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKL TAMLTAKEAMPKKATELKHLQCLEEALKPLEEVLNLAQSK NFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT (SEQ ID NO: 361) AK375 DNA479 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNST (LALAPG) LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP KGSVRAPQVCVLPPPEEEMTKKQVTLSCAVTDFMPEDIYV EWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCVVHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) AK376 DNA478 Knob: SGP APTSSSTKKTQL TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSP mFcIgG2a (SEQ ID QLEHLLLDLQMI IVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED (LALAPG)- NO: 29) LNGiNNYKNPKL YNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIE [VPLSLY]- TAMLTAKFAMP RTISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTD hIL2 KKATELKHLQCL FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK (R38A, EEALKPLEEVLN LRVEKKNWVERNSYSCSLLHEGLHNHHTTKSFSRTPGG F42A, LAQSKNFHLRPR SPGVPLSLYSGPAPTSSSTKKTQLQLEHLLLDLQMIL Y45A, DLISNINVIVLEL NGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEA E62A, KGSETTFMCEY LKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS C125A) ADETATIVEFLN ETTFMCEYADETATIVEFLNRWITFAQSIISTLT RWITFAQSIISTL (SRQ ID NO: 362) T (SEQ ID NO: 3) AK376 DNA479 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNST (LALAPG) LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP KGSVRAPQVCVLPPPEEEMTKKQVTLSCAVTDFMPEDIYV EWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCVVHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) AK377 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWEFNNVEVHTAQTQTHREDYNST (LALAPG)- LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP hIL2(R38A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTDFMPEDIYV F42A, EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVE Y45A, RNSYSCSVVHEGLHNHHTTKSFSRTPGGGSSPPGGGSSGG E62A, GSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKL C125A) TAMLTAKEAMPKKATELKHLQCLEEALKPLEEVLNLAQSK NFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT (SEQ ID NO: 361) AK377 DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAPG)- NVEVHTAQTQTHREDYNSTLRVVSALPIQH hCD122 QDWMSGKEFKCKVNNKDLGAPIERTISKPK GSVRAPQVCVLPPPEEEMTKKQVTLSCAVT DFMPEDIYVEWTNNGCTELNYKNTEPVLDS DGSYFMVSKLRVEKKNWVERNSYSCSWHEG LKNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVVVSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 363) AK378 DNA478 Knob: SGP APTSSSTKKTQL TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSP mFcIgG2a (SEQ ID QLEHLLLDLQMI IVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED (LALAPG)- NO: 29) LNGiNNYKNPKL YNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIE [VPLSLY]- TAMLTAKFAMP RTISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTD hIL2 KKATELKHLQCL FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK (R38A, EEALKPLEEVLN LRVEKKNWVERNSYSCSLLHEGLHNHHTTKSFSRTPGG F42A, LAQSKNFHLRPR SPGVPLSLYSGPAPTSSSTKKTQLQLEHLLLDLQMIL Y45A, DLISNINVIVLEL NGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEA E62A, KGSETTFMCEY LKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS C125A) ADETATIVEFLN ETTFMCEYADETATIVEFLNRWITFAQSIISTLT RWITFAQSIISTL (SEQ ID NO: 362) T (SEQ ID NO: 3) AK378 DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAPG)- NVEVHTAQTQTHREDYNSTLRVVSALPIQH hCD122 QDWMSGKEFKCKVNNKDLGAPIERTISKPK GSVRAPQVCVLPPPEEEMTKKQVTLSCAVT DFMPEDIYVEWTNNGCTELNYKNTEPVLDS DGSYFMVSKLRVEKKNWVERNSYSCSWHEG LKNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVVVSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 363) AK397 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (N297A) EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK397 DNA278 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELIGGPSVFLFPPKPKDTLMIS hFc(N297A)- (SEQ ID QLEHLLLDLQMI RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK [DSGGFMLT] NO: 29) LNGINNYKNPKL TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK hIL2 TRMLTFKFYMP VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD (C125A) KKATEIKHIQCL ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN EEELKPLEEVLN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS LAQSKNFHLRPR CSVMHEALHNHYTQKSLSLSPGGSGPDSGGFMLT DLISNINVTVLEL SGPAPTSSSTKKTQLQLEHLLIDLQMILNGINNY KGSETTFMCEY KNPKLTRMLTFKFYMPKKATELKHLQCLEEELKP ADETATIVEFLN LEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS RWITFAQSIISTL ETTFMCEYADETATlVEFlNRWITFAQSIISTL T (SEQ ID T (SEQ ID NO: 357) NO: 62) AK429 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKD mFcIgG2a VLMISLSPIVTCVVVDVSEDDPDVQISWFV (LALAPG)- NNVEVHTAQTQTHREDYNSTLRVVSALPIQ hIL2(R38A, HQDWMSGKEFKCKVNNKDLGAPIERTISKP F42A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMV Y45A, TDFMPEDIYVEWTNNGKTELYKNTEPVLDS E62A, DGSYFMYSKLRVEKKNWVERNSYSCSVVHE C125A) GLHNHHTTKSFSRTPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 361) AK429 DNA520 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a LMLSLSPTVTCVVVDVSEDDPDVQISWFVN (LALAPG)- NVEVHTAQTQTHREDYNSTLRVVSALPIQH No QDVVMSGKEFKCKVNNKDLGAPIERTISKP Annotation KGSVRAPQVCVLPPPEEEMTKKQVTLSCAV Found TDFMPEDIYVEWTNNGKTELNYKMTEPVLD SDGSYFMVSKLRVEKKNWVERNSYSCSVVH EGLHNHHTTKSFSRTPGHHHHHHHH (SEQ ID NO: 365) AK430 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKD mFcIgG2a VLMISLSPIVTCVVVDVSEDDPDVQISWFV (LALAPG)- NNVEVHTAQTQTHREDYNSTLRVVSALPIQ hIL2(R38A, HQDWMSGKEFKCKVNNKDLGAPIERTISKP F42A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMV Y45A, TDFMPEDIYVEWTNNGKTELYKNTEPVLDS E62A, DGSYFMYSKLRVEKKNWVERNSYSCSVVHE C125A) GLHNHHTTKSFSRTPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 361) AK430 DNA521 Hole: GHHH TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a HHHHH LMISISPIVTCVVVDVSEDQPDVQISWFVN (LALAPG)- (SEQ ID NVEVHTAQTQTHREDYNSTLRWSALPIQHQ hCD122 NO: 334) PWMSGKEFKCKVNNKDLGAPIERTISKPKG No SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD Annotation FMPEDIYVEWTNNGKTELNYKNTEPVLDSD Found GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASVVACNLILGAPDS QKITTVDIVTLRVICREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP ILTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKDGHH HHHHHH (SEQ ID NO: 366) AK431 DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKD mFcIgG2a VLMISLSPIVTCVVVDVSEDDPDVQISWFV (LALAPG)- NNVEVHTAQTQTHREDYNSTLRVVSALPIQ hIL2(R38A, HQDWMSGKEFKCKVNNKDLGAPIERTISKP F42A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMV Y45A, TDFMPEDIYVEWTNNGKTELYKNTEPVLDS E62A, DGSYFMYSKLRVEKKNWVERNSYSCSVVHE C125A) GLHNHHTTKSFSRTPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 361) AK431 DNA522 Knob: GHHH TIKPCPPCKCPAPNAAGGP5VFIFPPKIKDV mFcIgG2a HHHHH LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAPG)- (SEQ ID NVEVHTAQTQTHREDYNSTLRWSALPIQHQ hCD122 NO: 334) DWMSGKEFKCKVNNKDLGAPIERTISKPKG No SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD Annotation FMPEDIYVEWTNNGKTELNYKNTEPVLDSD Found GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVKNCSHLEC FYNSRANVSCMWSHEEALNVTTCHVHAKSN LRHWNKTCELTLVRQASWACMLILGSFPES QSLTSVDLLDINVVCWEEKGWRRVKTCDFH PFDNLRLVAPHSLQVLHIDTQRCNISWKVS QVSHYIEPYLEFEARRRLLGHSWEDASVLS LKQRQQWLFLEMLIPSTSYEVQVRVKAQRN NTGTWSPWSQPLTFRTRPADPMKEGHHHHH HHH (SEQ ID NO: 367) AK432 DNA478 Knob: SGP APTSSSTKKTQL TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSP mFcIgG2a (SEQ ID QLEHLLLDLQMI IVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED (LALAPG)- NO: 29) LNGINNYKNPKL YNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIE [VPLSLY] TAMLTAKFAMP RTISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTD hIL2(R38A, KKATELKHLQCL FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK F42A, EEALKPLEEVLN LRVEKKNWVERNSYSCSLLHEGLHNHHTTKSFSRTPGG Y45A, LAQSKNFHLRPR SPGVPLSLYSGPAPTSSSTKKTQLQLEHLLLDLQMIL E62A, DLISNINVIVL NGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEA C125A) ELKGSETTFMC LKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS EYADETATIVEF ETTFMCEYADETATIVEFLNRWITFAQSIISTLT LNRWITFAQSII (SEQ ID NO: 362) STLT (SEQ ID NO: 3) AK432 DNA521 Hole: GHHH TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a HHHHH LMISISPIVTCVVVDVSEDQPDVQISWFVN (LALAPG)- (SEQ ID NVEVHTAQTQTHREDYNSTLRWSALPIQHQ hCD122 NO: 334) PWMSGKEFKCKVNNKDLGAPIERTISKPKG No SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD Annotation FMPEDIYVEWTNNGKTELNYKNTEPVLDSD Found GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASVVACNLILGAPDS QKITTVDIVTLRVICREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP ILTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKDGHH HHHHHH (SEQ ID NO: 366) AK433 DNA478 Knob: SGP APTSSSTKKTQL TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSP mFcIgG2a (SEQ ID QLEHLLLDLQMI IVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED (LALAPG)- NO: 29) LNGINNYKNPKL YNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIE [VPLSLY] TAMLTAKFAMP RTISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTD hIL2(R38A, KKATELKHLQCL FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK F42A, EEALKPLEEVLN LRVEKKNWVERNSYSCSLLHEGLHNHHTTKSFSRTPGG Y45A, LAQSKNFHLRPR SPGVPLSLYSGPAPTSSSTKKTQLQLEHLLLDLQMIL E62A, DLISNINVIVL NGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEA C125A) ELKGSETTFMC LKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS EYADETATIVEF ETTFMCEYADETATIVEFLNRWITFAQSIISTLT LNRWITFAQSII (SEQ ID NO: 362) STLT (SEQ ID NO: 3) AK433 DNA522 Knob: GHHH TIKPCPPCKCPAPNAAGGP5VFIFPPKIKDV mFcIgG2a HHHHH LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAPG)- (SEQ ID NVEVHTAQTQTHREDYNSTLRWSALPIQHQ hCD122 NO: 334) DWMSGKEFKCKVNNKDLGAPIERTISKPKG No SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD Annotation FMPEDIYVEWTNNGKTELNYKNTEPVLDSD Found GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVKNCSHLEC FYNSRANVSCMWSHEEALNVTTCHVHAKSN LRHWNKTCELTLVRQASWACMLILGSFPES QSLTSVDLLDINVVCWEEKGWRRVKTCDFH PFDNLRLVAPHSLQVLHIDTQRCNISWKVS QVSHYIEPYLEFEARRRLLGHSWEDASVLS LKQRQQWLFLEMLIPSTSYEVQVRVKAQRN NTGTWSPWSQPLTFRTRPADPMKEGHHHHH HHH (SEQ ID NO: 367) AK435 DNA263 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc (SEQ ID QLEHLLLDLQMI MISRTPEVTCVVVDVSHEDPEVKFNWYVDG (N297A)- NO: 29) LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [VPLSLY] TAMLTAKFAMP DWLNGKEYKCKVSNKALPAPIEKTISKAKG hIL2(R38A, KKATELKHLQCL QPREPQVYTLPPCRDELTKNQVSLWCLVKG F42A, EEALKPLEEVLN FYPSDIAVEWESMGQPENNYICRRPPVLDS Y45A, LAQSKNFHLRPR QGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, DLISNINVIVL ALHNHYTQKSLSISPGGSPGVPLSLYSGPA C125A) ELKGSETTFMC PTSSSTKKTQLQIPHLIIQLQMILNGINNY EYADETATIVEF KNPKLTAMLTAKFAMPKKATELKHLQCLEE LNRWITFAQSII ALKPLEEVLNLAQSKNFHLRPRDLISNINV STLT IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID ITFAQSIISTLT (SEQ ID NO: 49) NO: 3) AK435 DNA516 F8ScFv PGSGS AVNGTSQFT EVQLLESGGGLVQPGGSLRLSCAASGFTFSL Version1- (SEQ ID CFYNSRANI FTMSVWRQAPGKGLEWVSAISGSGGSTYYA Hole: NO: 14) SCVWSQDGA DSVKGRFTISRDNSKNTLYLQMNSLRAEOT hFc LQDTSCQVH AVYYCAKSTHLYLFDYWGQGTLVTVSSGGG (N297A)- AWPDRRRWN GSGGGGSGGGGSEIVLTQSPGTLSLSPGER hCD122 QTCELLPVS ATLSCRASQSVSMPFLAWYQQKPGQAPRLL QASWACNL IYGASSRATGIPDRFSGSGSGTDFTLTISR ILGAPDSQK LEPEDFAVYYCQQMRGRPPTFGQGTKVEIK LTTVDIVTL GGSDKTHTCPPCPAPELLGGPSVFLFPPKP RVLCREGV KDTLMISRTPEVTCVVVDVSHEDPEVKFNW RWRVM YVDGVEVHNAKTKPREEQYASTYRWSVLTV AIQDFKPFE LHQDWLNGKEYKCKVSNKALPAPIEKTISK NLRLMAPIS AKGQPREPQVCTLPPSRDELTKNQVSLSCA LQVVHVETH VKGFYPSDIAVEWESNGQPENNYKTTPPVL RCNI DSDG5FFLVSKLTVDKSRWQQGNVFSCSVM SWEISQASH HEALHNHYTQKSLSLSPGPGSGSAVNGTSQ YFERHLEFE FTCFYNSRANISCVWSQDGALQDTSCQVHA ARTLSPGHT WPDRRRWNNQTCELLPVSQASWACNLILGA WEEA PDSQKLTYVDIVTLRVLCREGVRWRVMAIQ PLLTLKQKQ DFKPFENLRLMAPISLQVVHVETHRCNISW EWICLETLT EISQASHYFERHLEFEARTLSPGHTWEEAP PDTQYEFQV LLTLKQKQEWICLETLTPDTQYEFQVRVKP RVKP LQGEFTTWSPWSQPLAFRTKPAALGKD LQGEFTTWS (SEQ ID NO: 364) PWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK436 DNA187 Hole: DKTHTCPPCPAPELLGGPSVTLFPPKPKDTL hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDG hCD122 VEVHNAKTKPREEQYASTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSQIAVEWESNGQPENNYKTTPPVLQSD GSFFLVSKLTVQKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWP0 RRRWNQTCEILPVSQASWACNLILGAPQSQ KLTTVDIVTLRVLCREGVRWRVMAIQDFKP FENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQFWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD(SEQ ID NO: 38) AK436 DNA542 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc MISRTPEVTCVVVDVSHEDPEVKFNWYVDG (N297A)- VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2 DWLNGKEYKCKVSNKALPAPIEKTISKAKG (R38A, QPREPQVYTLPPCRDELTKNQVSLWCLVKG F42A, FYPSDIAVEWESNGQPENNYKTTPPVLDSO Y45A, GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA E62A, LHNHYTQKSLSLSPGGISSGLLSGRSOQPS C125A) GPAPTSSSTKKTQLQLEHLLLQLQMILNGI NNYKNPKLTAMLTAKFAMPKKATELKHLQC LEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYAQETATIVEFI NRWTFAQSIISTLT (SEQ ID NO: 373) AK437 DNA187 Hole: DKTHTCPPCPAPELLGGPSVTLFPPKPKDTL hFc MISRTPEVTCVVVDVSHEDPEVKFNWYVDG (N297A)- VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hCD122 DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSQIAVEWESNGQPENNYKTTPPVLQSD GSFFLVSKLTVQKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWP0 RRRWNQTCEILPVSQASWACNLILGAPQSQ KLTTVDIVTLRVLCREGVRWRVMAIQDFKP FENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQFWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD(SEQ ID NO: 38) AK437 DNA545 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc MISRTPEVTCVVVDVSHEDPEVKFNWYVDG (N297A)- VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2 PWLNGKEYKCKVSNKALPAPIEKHSKAKGQ (R38A, PRGPQVYTIPPCRDELTKNQVSLWCIVKGF F42A, YPSDIAVEWESNGQPENNYKTTPPVLDSDG Y45A, SFFLYSKLTVDKSRWQQGNVFSCSVMHEAL E62A, HNHYTQKSLSLSPGGISSGLLSGRSSGPAP C125A) TSSSTKKTQLQLEHLLLDLQMILNGINNYK NPKLTAMLTAKFAMPKKATELKHLQCLEEA LKPLEEVLNLAQSKNFHLRPRDLISNINVI VLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT(SEQ ID NO: 376) AK438 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LMISRTPEVTCVVVDVSHEDPEVKFNWYVD (N297A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKALPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESMGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 51) AK438 DNA543 Hole: GSGGG AVNGTSQFT DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID CFYNSRANI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY] NO: 31) SCVWSQDGA GVEVHNAKTKPREEQYASTYRWSVLTVLHQ HCD122 LQDTSCQVH DWINGKEYKCKVSNKALPAPIEKTISKAKG AWPDRRRWN QPREPQVCTLPPSRDELTKNQ QTCELLPVS VSLSCAVKGFYPSDIAVEWESNGQPENNYK QASWACNL TTPPVLDSDGSFFLVSKLTVDKSRWQQGNV ILGAPDSQK FSCSVMHEALHNHYTQKSLSLSPGGPPSGS LTTVDIVTL SPGVPLSLYGSGGGAVNGTSQFTCFYNSRA RVLCREGV NISCVWSQDGALQDTSCQVHAWPDRRRWNQ RWRVM TCELLPVSQASWACNLILGAPDSQKLTTVD AIQDFKPFE IVTLRVLCREGVRWRVMAIQDFKPFENLRL NLRLMAPIS MAPISLQVVHVETHRCNISWEISQASHYFER LQVVHVETH HLEFEARTLSPGHTWEEAPLLTLKQKQEWI RCNI CLETLTPDTQYEFQVRVKPLQGEFTTWSPW SWEISQASH SQPLAFRTKPAALGKD YFERHLEFE (SEQ ID NO: 42) ARTLSPGHT WEEA PLLTLKQKQ EWICLETLT PDTQYEFQV RVKP LQGEFTTWS PWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK439 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK439 DNA544 SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT Knob: (SEQ ID QLEHLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hFc(N297A)- NO: 29) LNGINNYKNPKL GVEVHNAHTKPREEQYASTYRVV5VLTVLH [VPLSLY]- TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK hIL2 KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK (R38A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS F42A, LAQSKNFHFDP DGSFFLYSKLTVOKSRWQQGNVFSCSVMHE Y45A, RDWSNIMVFVL ALHNHYTQKSLSISPGGSPGVPLSLYSGPA E62A, SIKGSETTFMCE PTSSSTKKTQLQLEHLLLDLQMIING1NNY L80F, YADETATIVEFL KNPKLTAMLTAKFAMPKKATELKHLQCLEE R81D, NRWITFAQSII ALKPLEEVLNLAQSKNFHFDPRDWSNINVF L85V, STIT VLELKGSETTFMCEYADETATIVEFLNRWI 185V, (SEQ ID TFAQSIISTLT I92F, NO: 328) (SEQ ID NO: 375) C125A) AK440 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGP6SGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK440 DNA544 SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT Knob: (SEQ ID NO: 29) QLEHLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hFc(N297A)- LNGINNYKNPKL GVEVHNAHTKPREEQYASTYRVV5VLTVLH [VPLSLY]- TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK hIL2 KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK (R38A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS F42A, LAQSKNFHFDP DGSFFLYSKLTVOKSRWQQGNVFSCSVMHE Y45A, RDWSNIMVFVL ALHNHYTQKSLSISPGGSPGVPLSLYSGPA E62A, SIKGSETTFMCE PTSSSTKKTQLQLEHLLLDLQMIING1NNY L80F, YADETATIVEFL KNPKLTAMLTAKFAMPKKATELKHLQCLEE R81D, NRWITFAQSII ALKPLEEVLNLAQSKNFHFDPRDWSNINVF L85V, STIT VLELKGSETTFMCEYADETATIVEFLNRWI 185V, (SEQ ID TFAQSIISTLT I92F, NO: 328) (SEQ ID NO: 375) C125A) AK441 DNA543 Hole: hFc(N297A)- GSGGG AVNGTSQFT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL [VPLSLY]- (SEQ ID CFYNSRANI MISRTPEVTCVVVDVSHEDPEVKFNWYVDG hCD122 No: 31) SCVWSQDGA VEVHNAKTKPREEQYASTYRVVSVLTVLHQ LQDTSCQVH DWLNGKEYKCKVSNKALPAPIEKTISKAKG AWPDRRRWN QPREPQVCTLPPSRDELTKNQVSLSCAVKG QTCELLPVS FYPSDIAVEWESNGQPENMYKTTPPVLDSD QASWACNL GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA ILGAPDSQK LHNHYTQKSLSLSPGGPPSGSSPGVPLSLY LTTVDIVTL GSGGGAVNGTSQFTCFYNSRANISCVWSQD RVLCREGV GALQDTSCQVHAWPDRRRWNQTCELLPVSQ RWRVM ASWACNLILGAPDSQKLTTVDIVTLRVLCR AIQDFKPFE EGVRWRVMAIQDFKPFENLRLMAPISLQVV NLRLMAPIS HVETHRCNISWEISQASHYFERHLEFEART LQVVHVETH LSPGHTWEEAPLLTLKQKQEWICLETLTPD RCNI TQYEFQVRVKPLQGEFTTWSPWSQPLAFRT SWEISQASH KPAALGKD (SEQ ID NO: 42) YFERHLEFE ARTLSPGHT WEEA PLLTLKQKQ EWICLETLT PDTQYEFQV RVKP LQGEFTTWS PWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK441 DNA546 Knob: hFc DKTHTCPPCPAPELLGGPSVFLFPPKPKDT (N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYV hIL2 DGVEVHNAKTKPREEQYASTYRWSVLTVLH (R3SA, QDWINGKEYKCKVSNKALPAPIEKTISKAK F42A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS E62A, DGSFFLYSKLTVQKSRWQQGNVFSCSVMHE L30F, ALHNHYTQKSLSLSPGGGSSPPGGGSSGG R81D, GSGPAPTSSSTKKTQLQLEHLLLDLQMILN I85V, GINNYKNPKLTAMLTAKFAMPKKATELKH I86V, LQCLEEALKPLEEVLNLAQSKNFHFDPRDV I32F, VSNINVFVLELKGSETTFMCEYADETATIV C125A) EFLNRWITFAQSHSTLT (SEQ ID NO: 377) AK442 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKBTL hFc(N297A)- MISRTPEVTCWVDVSHEQPEVKFNWYVDGV hIL2(R33A, EVHNAKTKPREEQYASTYRVVSVLTVLHQD F42A, WLNGKEYKCKVSNKALPAPIEKTISKAKGQ Y45A, PREPQVYTLPPCRDELTKNQVSLWCLVKGF E62A, YPSDIAVEWESNIGQPENNYKTTPPVLDSD C125A) GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGGGSSPPGGGSSGGGS GPAPTSSSTKKTQLQLEHLLLDLQMILNGI NNYKNPKLTAMLTAKFAMPKKATELKHLQC LEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT(SEQ ID NO: 51) AK442 DNA553 Hole: SGGG AVNGTSQFT DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ ID CFYNSRANI MISRTPEVTCVVVDVSHEDPEVKFNWYVDG [DSGGFMLT]- NO: 30) SCVWSQDGA VEVHNAKTKPRFEQYASTYRVVSVLTVLHQ hCD122 LQDTSCQVH DWLNGKEYKCKVSNKALPAPIEKTISKAKG AWPDRRRWN QPREPQVCTLPPSRDELTKNQVSLSCAVKG QTCELLPVS FYPSDIAVEWESNGQPENNYKTTRPVLDSD QASWACNL GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA ILGAPDSQK LHNHYTQKSLSLSPGGPPSGSSPGDSGGFM LTTVDIVTL LTSGGGAVNGTSQFTCFYNSRANISCVWSQ RVLCREGV DGALQDTSCQVHAWPDRRRWNQTCELLPVS RWRVM QASWACNLILGAPDSQKLTTVDIVTLRVLC AIQDFKPFE REGVRWRVMAIQDFKPFENLRLMAPISLQW NLRLMAPIS HVETHRCNISWEISQASHYFERHLEFEART LQVVHVETH LSPGHTWEEAPLLTLKQKQEWICLETLTPD RCNI TQYEFQVRVKPLQGEFTTWSPWSQPLAFRT SWEISQASH KPAALGKD (SEQ ID NO: 41) YFERHLEFE ARTLSPGHT WEEA PLLTLKQKQ EWICLETLT PDTQYEFQV RVKP LQGEFTTWS PWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK443 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGP6SGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK443 DNA554 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc (SEQ ID QLRHLCLRLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD (N297A)- NO: 29) LNGSNNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH [VPLSLY]- TAMLTAKFAMP QDWLNGKEYKCKVSNKALP hIL2 KKATELKHLQCL APIEKHSKAKGQPREPQVYTLPPCRDELTK (E15R, EEALKPLEEVLN NQVSLWCLVKGFYPSDIAVEWESNGQPENN L18C, LAQSKNFHLRPR YKTTPPVLDSDGSFFLYSKLTVDKSRW D20R, DLISNINVLEL QQGNVFSCSVMHEALHNHYTQQKSLSLSPG R38A, KGSETTFMCEY GSPGVPLSLYSGPAPTSSSTKKTQLQLRHL F42A, ADETATIVEFLN CLRLQMILNGINNYKNPKLTAMLTAKFAMP Y45A, RWITFCQSIIST KKATELKHLQCLEEALKPLEEVLNLAQSKN E62A) LT FHLRPRDLISNINVIVLELKGSETTFMCEY (SEQ ID ADETATIVERNRWITFCQSIISTLT NO: 339) (SEQ ID NO: 385) AK444 DNA281 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A), (SEQ ID QLEHLLLDLQMI IMISRTPEVTCVVVDVSHEDPEVKFNWYVD [DSGGFMLT]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKHSKAKG (R38A, KKATELKHLQCL QPREPQVYTLPPCRDELTKNQVSLWCLVKG F42A, EEALKPLEEVLN FYPSDIAVEWESNGQPENNYKTTPPVLDSD Y45A, LAQSKNFHLRPR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA E62A, DLISNINVIVL LHNHYTQKSLSLSPGGSGPDSGGFMLTSGP Cl25A) ELKGSETTFMC APTSSSTKKTQLQIEHLLLDLQMILNGINN EYADETATIVEF YKNPKLTAMLTAKFAMPKKATELKHLQCLE LNRWITFAQSII EALKPLEEVLNLAQSKNFHLRPRDLISNIN STLT VIVLELKGSETTFMCEYADETAnVEFLNRW (SEQ ID ITFAQSIISTLT (SEQ ID NO: 48) NO: 3) AK444 DNA440 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LMISRTPEVTCVVVDVSHEDPEVKFNWYVD (N297A)- GVEVHNAKTKPRGEQYASTYRVVSVLTVLH hCD122 QDWLNGKEYKCKV (C122S, SNKALPAPIEKTISKAKGQPREPQVCTLPP C168S) SRDELTKNQVSLSCAVKGFYPSDIAVEVVE SNGQPENNYKTTPPVLDSDGSFFLVSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGPGSGSAVNGTSQFTCFYNSRANISCV WSQDGALQDTSCQVHAWPORRRWNQTCELL PVSQASWACNLILGAPDSQKLTTVDIVTLR VLCREGVRWRVMAIQDFKPFENLRLMAPIS LQVVHVETHRSNISWEISQASHYFERHLEFE ARTLSPGHTWEEAPLLTLKQKQEWISLETL TPDTQYEFQVRVKPLQGEFTTVVSPWSQPL AFRTKPAALGKD (SEQ ID NO: 39) AK449 DNA547 Hole: EPKSSDKTHTCPPCPAPELLGGPSV hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD (N29 VSHEDPEVKFNWYVDGVEVHNAKTK 7A + EPKSS)- PREEQYASTYRVVSVLTVLHQDWLN Hole: GKEYKCKVSNKALPAPIEKTISKAK hFc GQPREPQVCLPPSRDELTKNQVSLS (N297A)- CAVKGFYPSDIAVEWESNGQPENNY hCD122 KTTPPVLDSDGSFFLVSKLTVCKSR WQQGNVFSCSVMHEALHNHYTQKSL SLSPGPGSGSAVNGTSQFTCFYMSR ANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILG APDSQKLTTVDIVTLRVLCREGVRW RVMAIQDFKPFENLRLMAPISLQVVH VETHRCNISWEISQASHYFERHLEF EARTLSPGHTWEEAPLLTLKQKQEW ICLETLTPDTQYEFQVRVKPLQGEF FTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 378) AK449 DNA550 Knob: SGP APTSSSTKKTQL EPKSSDKTHTCPPCPAPELLGGPVF hFcIgG1 (SEQ QLEHLLLDLQMI LFPPKPKDTLMISRTPEVTCVVVDV (N29 ID LNGINNYKNPKL SHEDPEVKFNWY 7A + EPKSS)- NO: 29) TAMLTAKFAMP VDGVEVHNAKTKPREEQYASTFYRV hIL2 KKATELKHLQCL VSVLTVLHQDWLNGKEYKCKVSNKA (R38A, EEALKPLEEVLN LPAPIEKTISKAKGQPREPQVYTLP F42A, LAQSKNFHLRPR PCRDELTKNQVSLWCLVKGFYPSDI Y45A, DLISNINVIVLEL AVEWESNGQPENNYKTTPPVLDSDG E62A, KGSETTFMCEY SFFLYSKLTVDKSRWQQGNVFSCSV C125A) ADETATIVEFLN MHEALHNHYTQKSLSLSPGGSPGVP RWITFAQSIISTL LSLYSGPAPTSSSTKKTQLQLEHLL T LDLQMILNGINNYKNPKLTAMLTAK (SEQ ID FAMPKKATELKHLQCLEEALKPLEE NO: 3) VLNLAQSKNFHLRPRDLISNINVIV LELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 381) AK449 DNA548 Hole: AKTDKTHTCPPCPAPELLGGPSVFL hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS (N29 HEDPEVKFNWYVDGVEVHNAKTKPR 7A + AKT)- EEQYASTYRVVSVLTVLHQDWLNGK Hole: EYKCKVSNKALPAPIEKTISKAKGQ hFc PREPQVCTLPPSRDELTKNQVSLSC (N297A)- AVKGFYPSDIAVEWESNGQPENNYK hCD122 TTPPVLDSDGSFFLVSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLS LSPGPGSGSAVNGTSQFTCFYNSRA NISCVWSQDGALQDTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGA PDSQKLTTVDIVTLRVLCREGVRWR VMAIQDFKPFENLRLMAPISLQVVH VETHRCNISWEISQASHYFERHLEF EARTLSPGHTWEEAPLLTLKQKQEW ICLETLTPDTQYEFQVRVKPLQGEF TTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 379) AK450 DNA551 Knob: SGP APTSSSTKKTQL AKTDKTHTCPPCPAPELLGGPSVFL hFcIgG1 (SEQ QLEHLLLDLQMI FPPKPKDTLMISRTPEVTCVVVDVS (N29 ID LNGINNYKNPKL HEDPEVKFNWYVDGVEVHNAKTRPR 7A + NO: 29) TAMLTAKFAMP EEQYASTYRVVSVLTVLHQDWLNGK AKT)- KKATELKHLQCL EVKCKVSNKALPAPIEKTISKAKGQ [VPLSLY]- EEALKPLEEVLN PREPQVYTLPPCRDELTKNQVSLWC hIL2 LAQSKNFHLRPR LVKGFYPSDIAVEWESNGQPENNYK (R38A, DLISNINVIVLEL TTPPVLDSDQSFFLYSKLTVDKSRW F42A, KGSETTFMCEY QQGIWFSCSVMHEALHNHYTQKSLS Y45A, ADETATIVEFLN LSPGGSPGVPLSLYSGPAPTSSSTK E62A, RWITFAQSIISTL KTQLQLEHLLLDLQMILNGINNYKN C125A) T PKLTAMLTAKFAMPKKATELKHLQC (SEQ ID LEEALKPLEEVLNLAQSKNFHLRPR NO: 3) DLISNINVIVLELKGSETTFMCEYA DETATIVEFLNRWITFAQSIISTLT (SEQ ID NO: 382) AK451 DNA549 Knob: AKTEPKSSDKTHTCPPCPAPELLGG hFcIgG1 PSVFLFPPKPKDTLMISRTPEVTCV (N29 VVDVSHEDPEVKFNWYVDGVEVHNA 7A + KTKPREEQYASTYRVVSVLTVLHQD AKTEPKSS)- WLNGKEYKCKVSNKALPAPIEKTIS hCD122 KAKGQPREPQVCTLPPSRDEITKNQ VSLSCAVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLVSKLTV DKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGPGSGSAVNGTSQFTCF YNSRANISCVWSQDGALQPTSCQVH AWPDRRRWNQTCELLPVSQASWACN LILGAPDSQKLTTVDIVTLRVLCRE GVRWRVMAIQDFKPFENLRLMAPIS LQVVHVETHRCNISWEISQASHYFER HLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPL QGEFTTWSPWSQPLAFRTKPAALGK D (SEQ ID NO: 380) AK451 DNA552 Knob: SGP APTSSSTKKTQL AICTEPKSSDKTHTCPPCPAPELLG hFcIgG1 (SEQ QLEHLLLDLQMI GPSVFLFPPKPKDTLMISRTPEVTC (N29 ID LNGINNYKNPKL VVVDVSHEDPEVKFNWYVDGVEVHN 7A + NO: 29) TAMLTAKFAMP AKTKPREEQYASTYRVVSVLTVLHQ AKTEPKSS)- KKATELKHLQCL DWLNGKEYKCKVSNKALPAPIEKLIS [VPLSLY]- EEALKPLEEVLN KAKGQPREPQVYTLPPCRDELTKNQ hIL2 LAQSKNFHLRPR VSLWCLVKGFYPSDIAVEWESNGQP (R38A, DLISNINVIVLEL ENNYKTTPPVLDSDGSFFLYSKLTV F42A, KGSETTFMCEY DKSRWQQSNVFSCSVMHEALHNHYT Y45A, ADETATIVEFLN QKSLSLSPGGSPGVPLSLYSGPAPT E62A, RWITFAQSIISTL SSSTKKTQLQLEHLLLDLQMILNGI C125A) T NNYKNPKLTAMLTAKFAMPKKATEL (SEQ ID KHLQCLEEALKPLEEVLNLAQSKNF NO: 3) HLRPRDLISNINVIVLELKGSETTF MCEYADETATIVEFLNRWITFAQSI STLT(SEQ ID NO: 383) AK452 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK452 DNA563 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPK hFc (SEQ QLRHLCLRLQMI PKDTLMISRTPEVTCVVVDVSHEDP (N297A) ID LNGINNYKNPKL EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY]- NO: 29) TAMLTAKFAMP ASTYRVVSVLWLHQDWLNGKEYKCK hIL2 KKATELKHLQCL VSNKALPAPIEKTISKAKGQPREPQ (R38A, EEALKPLEEVLN VYTLPPCRDELTKNQVSLWCLVKGF F42A, LAQSKNFHLRPR YPSDIAVEWESNGQPENNYKTTPPV Y45A, DLISLINVIVLE IDSDGSFFLYSKLWDKSRVYQQGNV E62A, LKGSETTFMCEY FSCSVMHEALHNHYTQKSLSLSPGG C125A) ADETATIVEFLN SPGVPLSLYSGPAPTSSSTKKTQLQ RWITFCQSIIST LRMLCLRLQMILNGINNYKNPKLTA LT MLTAKFAMPKKATELKHLQCLEEAL (SEQ ID KPLEEVLNLAQSKNFHLRPRDLISL NO: 340) INVIVLELKGSETTFMCEYAOETAT IVEFLNRWITFCQSIISTLT (SEQ ID NO: 386) AK453 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK453 DNA565 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPK hFc (SEQ QLLHLCLRLQMI PKDTLMISRTPEVTCVVVDVSHEDP (N297A) ID LNGINNYKNPKL EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY]- NO: 29) TAMLTAKFAMP ASTYRVVSVLWLHQDWLNGKEYKCK hIL2 KKATELKHLQCL VSNKALPAPIEKTISKAKGQPREPQ (E15R, EEALKPLEEVLN VCTLPPCRDELTKNQVSLWCLVKGF L18C, LAQSKNFHLRPR YPSDIAVEWESMGQPENNYKTTPPV D20R, DLISLINVIVLE LDSDGSFFLYSKLTVDKSRWQQGNV R38A, LKGSETTFMCEY FSCSVMHEALHNHYTQKSLSLSPGG F42A, ADETATIVEFLNR SPGVPLSLYSGPAPTSSSTKKTQLQ Y45A, WITFCQSIISTLT LLHLCLRLQMILNGINNYKNPKLTA E62A, (SEQ ID MLTAKFAMPKKATELKHLQCLEEAL N88L) NO: 341) KPLEEVLNLAQSKNFHLRPRDLISL INVIVLELKGSETTFMCEYADETAT IVEFLNRWITFCQSIISTLT (SEQ ID NO: 387) AK454 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGP6SGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK454 DNA566 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPK hFc (SEQ QLRHLCLDLQM PKDTLMISRTPEVTCVCCDVSHEDP (N297A)- ID ILNGINNYKNPK EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY] NO: 29) LTAMLTAKFAM ASTYRVVSVLTVLHQDWLNGKEYKC hIL2 PKKATELKHLQC KVSNKALPAPIEKTISKAKGQPREP (E15R, LEEALKPLEEVL QVYTLPPCRDELTKMQVSLWCLVKG L18C, NLAQSKNFHLR FYPSDIAVEWESNGQPENNYKTTPP R38A, PRDLISLINVIVL VLDSDGSFFLYSKLTVDKSRWQQGN F42A, ELKGSETTFMCE VFSCSVMHEALHNHYTQKSLSLSPG Y45A, YADETATIVEFL GSPGVPLSLYSGPAPTSSSTKKTQL E62A, NRWITFCQSIIS QLRHLCLDLQMILMGINNYKNPKLT N88L) TLT AMLTAKFAMPKKATELKHLQCLEEA (SEQ ID LKPLEEVLNWQSKNFHLRPRDLISL NO: 342) INVIVLELKGSETTFMCEYADETAT IVEFLNRVVITFCQSIISTLT (SEQ ID NO: 388) AK455 DNA187 Hole: SGP DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 ID GVEVHNAKTKPREEQYASTYRWSVLTVLHQ NO: 29) DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGP6SGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK455 DNA565 Knob: APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFP hFc QLEHLCLRLQMI PKPKDTLMISRTPE (N297A) LNGINNYKNPKL VTCVVVDVSHEOPEVKFNWYVDGVE [VPLSLY]- TAMLTAKFAMP VHNAKTKPREEQYASTYRVVSVLTV hIL2 KKATELKHLQCL LHQDWLNGKEYKCKVSNKALPAPIE (L18C, EEALKPLEEVLN KTISKAKGQPREPQVYTLPPCRDEL D20R, LAQSKNFHLRPR TKMQVSLWCLVKGFYPSDIAVEWES R38A, DLISLINVIVLEL NGQPENNYKTTPPVLDSDGSFFLYS F42A, KGSETTFMCEYA KLTVDKSRWQQGNVFSCSVMHEALH Y45A, DETATIVEFINR NHYTQKSLSLSPGGSPGVPLSLYSG E62A, WITFCQSIISTLT PAPTSSSTKICTQLQLEHLCLRLQM N88L) (SEQ ID ILNGINNYKNPKLTAMLTAKFAMPK NO: 343) KATELKHLQCLEEALKPLEEVLNLA QSKNFHLRPRDLISLINVIVLELKG SETTFMCEYADETATIVEFLNRWIT FCQSIISTLT (SEQ ID NO: 389) AK456 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGP6SGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 38) AK456 DNA568 Knob: SGP APTSSSTKKT HFc(N297A)- (SEQ QLQLFHLCLR DKTHTCPPCPAPELLGGPSVFLFPPKPKDT [VPLSLY]- ID LQMILNGINN LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hIL2(E15F, NO: 29) YKNPKLTAML GVEVHNAKTKPREEQYASTYRVVSVLTVLHQ L18C, D20R, TAKFAMPKKA DWLNGKEYKCKVSNKALPAPIEKTISKAKG R38A, F42A, TELKHLQCLE QPREPQVYTIPPCRDEITKNQVSLWCIVKG Y45A, E62A, EALKPLEEVLN FYPSDIAVEWESNGQPENNYKTTPPVLDSD N88L) LAQSKNFHLRPR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA DLISLINVIVLE LHNHYTQKSLSLSPGGSPGVPLSLYSGPAP LKGSETTFMCEY TSSSTKKTQLQLFHLCLRLQMILNGINNYK ADETATIVEFLN NPKLTAMLTAKFAMPKKATELKHLQCLEEA RWITFCQSIIST LKPLEEVLNLAQSKNFHIRPRDLISLINVI LT VLELKGSETTFMCEYADETATIVEFLNRWI (SEQ ID TFCQSIISTLT (SEQ ID NO: 390) NO: 344) AK462 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT MFcIgG1(DAP ITITPKVTCVVVAISKDDPEVQFSWFVDDV G)- EVHTAQTQPREEQFNSTFRSVSELPIMHQD hIL2(R38A, WLNGKEFKCRVNSAAFGAPIEKTISKTKGR F42A, PKAPQVYTIPPPKEQMAKDKVSLTCMITDF Y45A, FPEDITVEWQWNGQPAENYDNTQPIMDTDG E62A, SYFVYSDLNVQKSNWEAGNTFTCSVLHEGL C125A) HNHHTEKSLSHSPGGGSSPPGGGSSGGGSG PAPTSSSTKKTQLQLEHLLLDLQMILNGIN NYKNPKLTAMLTAKFAMPKKATELKHLQCL EEALKPLEEVLNLAQSKNFHLRPRDLISNI NVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSHSTLT (SEQ ID NO: 369) AK462 DNA532 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT MFcIgG1 ITLTPKVTCVVAISKDDPEVQFSWFVDDVE (DAPG) VHTAQTGPREEQFNSTFRSVSELPIMHQDW LNGKEFKCRVNSAAFGAPIEKTISKTKGRP KAPQVYTIPPPKKQMAKDKVSITCMITDFF PEDITVEWQWNGQPAENYKNTQ PIMKTDGSYFVYSKLNVQKSNWEAGNTFTC SVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) AK463 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT MFcIgG1 ITLTPKVTCVVVAISKDDPEVQFSWFVDDV (DAPG)- EVHTAQTQPREEQFNSTFRSVSELPIMHQD hIL2(R38A, WLNGKEFKCRVNSAAFGAPIEKTISKTKGR F42A, PKAPQVTIPPPKEQMAKDKVSLTCMITDFF Y45A, PEDITVEWQWNGQPAENYDNTQPIMDTDGS E62A, YFVYSDLNVQKSNWEAGNTFTCSVLHEGLH C125A) NHHTEKSLSHSPGGGSSPPGGGSSGGGSGP APTSSSTKKTQLQLEHLLLDIQMILNGINN YKNPKLTAMLTAKFAMPKKATELKHLQCLE EALKPLEEVLNLAQSKNFHLRPRDLISNIN VIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSHSTLT (SEQ ID NO: 369) AK463 DNA533 Hole: VRSGCKPGCTVPGVSSVFIFPPKPKDVLTI mFcIgG1 TLTPKVTCVVVAISKDDPEVQFSWFVDDVE (DAP VHTAQTQPREEQFNSTFRSVSELPIMHQDW G)- LNGKEFKCRVNSAAFGAPIEKTISKTKGRP hCD122 KAPQVYTIPPPKKQPMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPIMKTDG SYFVYSKLNVQKSNWEAGNTFTCSVLHEGL HNHHTEKSLSHSPGPGSGSAVNGTSQFTCF YNSRANISCVWSQPGALQPTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 371) AK464 DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 ITLTPKVTCVVVAISKDDPEVQFSWFVDDV (DAPG)- EVHTAQTQPREEQFNSTFRSVSELPIMHQD hIL2 WLNGKEFKCRVNSAAFGAPIEKTISKTKGR (R38A, PKAPQVTIPPPKEQMAKDKVSLTCMITDFF F42A, PEDITVEWQWNGQPAENYDNTQPIMDTDGS Y45A, YFVYSDLNVQKSNWEAGNTFTCSVLHEGLH E62A, C125A) NHHTEKSLSHSPGGGSSPPGGGSSGGGSGP APTSSSTKKTQLQLEHLLLDIQMILNGINN YKNPKLTAMLTAKFAMPKKATELKHLQCLE EALKPLEEVLNLAQSKNFHLRPRDLISNIN VIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSHSTLT (SEQ ID NO: 369) AK464 DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 ITLTPKVTCVWAISKDDPEVQFSWFV (DAP DDVEVHTAQTQPREEQFNSTFRSVSELPIM G)- HQDWLNGKEFKCRVNSAAFGAPIE mCD122 KTISKTKGRPKAPQVYTIPPPKKQMAKDKV SLTCMITDFFPEDITVEWQWNGQP AENYKNTQPIMKTDGSYFVYSKLNVQKSNW EAGNTFTCSVLHEGLHNHHTEKSL SHSPGPGSGSAVKNCSHLECFYNSRANVSC MWSHEEALNVTTCHVHAKSNLRH WNKTCELTLVRQASWACNLILGSFPESQSL TSVDLLOINWCWEEKGWRRVKTC DFHPFDNLRLVAPHSLQVLHIDTQRCNISW KVSQVSHYIEPYLEFEARRRLLGHS WEDASVLSLKQRQQVVLFLEMLIPSTSYEV QVRVKAQRNNTGTWSPWSQPLTFR TRPADPMKE (SEQ ID NO: 372) AK465 DNA531 Knob: SGP APTSSSTKKTQL VRSGCKPCICTVPEVSSVFIFPPKPKDVLH MFcIgG1(DAP (SEQ QLEHLLLDLQMI TLTPKVTCVWAISKDDPEVQFSWFV G)- ID LNGINNYKNPKL DDVEVHTAQTQPREEQFNSTFRSVSELPIM [VPLSLY]- NO: 29) TAMLTAKFAMP HQDWLNGKEFKCRVNSAAFGAPIE hIL2(R38A, KKATELKHLQCL KTISKTKGRPKAPQVYTIPPPKEQMAKDKV F42A, EEALKPLEEVLN SLTCMITDFFPEDITVEWQWNGQP Y45A, LAQSKNFHLRPR AENYDNTQPIMDTDGSYFVYSDLNVQKSNV E62A, DLISNINVIVLEL VEAGNTFTCSVLHEGLHNHHTEKS C125A) KGSETTFMCEY LSHSPGGSPGVPISLYSGPAPTSSSTKKTQ ADETATIVEFLN LQLEHLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLE (SEQ ID LKGSETTFMCEYADETATIVEFLMRWITFA NO: 3) QSIISTLT (SEQ ID NO: 370) AK465 DNA532 Hole: VRSGCKPGCTVPGVSSVFIFPPKPKDVLTI mFcIgG1 TLTPKVTCVVVAISKDDPEVQFSWFVDDVE (DAP VHTAQTQPREEQFNSTFRSVSELPIMHQDW G) LNGKEFKCRVNSAAFGAPIEKTISKTKGRP KAPQVYTIPPPKKQPMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPIMKTDG SYFVYSKLNVQKSNWEAGNTFTCSVLHEGL HNHHTEKSLSHSPGPGSGSAVNGTSQFTCF YNSRANISCVWSQPGALQPTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 371) AK466 DNA531 Knob: SGP APTSSSTKKTQL VRSGCKPCICTVPEVSSVFIFPPKPKDVLH MFcIgG1(DAP (SEQ QLEHLLLDLQMI TLTPKVTCVWAISKDDPEVQFSWFV G)- ID LNGINNYKNPKL DDVEVHTAQTQPREEQFNSTFRSVSELPIM [VPLSLY]- NO: 29) TAMLTAKFAMP HQDWLNGKEFKCRVNSAAFGAPIE hIL2(R38A, KKATELKHLQCL KTISKTKGRPKAPQVYTIPPPKEQMAKDKV F42A, EEALKPLEEVLN SLTCMITDFFPEDITVEWQWNGQP Y45A, LAQSKNFHLRPR AENYDNTQPIMDTDGSYFVYSDLNVQKSNV E62A, DLISNINVIVLEL VEAGNTFTCSVLHEGLHNHHTEKS C125A) KGSETTFMCEY LSHSPGGSPGVPISLYSGPAPTSSSTKKTQ ADETATIVEFLN LQLEHLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLE (SEQ ID LKGSETTFMCEYADETATIVEFLMRWITFA NO: 3) QSIISTLT (SEQ ID NO: 370) AK466 DNA533 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 ITLTPKVTCVWAISKDDPEVQFSWFV (DAP DDVEVHTAQTQPREEQFNSTFRSVSELPIM G)- HQDWLNGKEFKCRVNSAAFGAPIE mCD122 KTISKTKGRPKAPQVYTIPPPKKQMAKDKV SLTCMITDFFPEDITVEWQWNGQP AENYKNTQPIMKTDGSYFVYSKLNVQKSNW EAGNTFTCSVLHEGLHNHHTEKSL SHSPGPGSGSAVKNCSHLECFYNSRANVSC MWSHEEALNVTTCHVHAKSNLRH WNKTCELTLVRQASWACNLILGSFPESQSL TSVDLLOINWCWEEKGWRRVKTC DFHPFDNLRLVAPHSLQVLHIDTQRCNISW KVSQVSHYIEPYLEFEARRRLLGHS WEDASVLSLKQRQQVVLFLEMLIPSTSYEV QVRVKAQRNNTGTWSPWSQPLTFR TRPADPMKE (SEQ ID NO: 372) AK467 DNA531 Knob: SGP APTSSSTKKTQL VRSGCKPCICTVPEVSSVFIFPPKPKDVLH MFcIgG1(DAP (SEQ QLEHLLLDLQMI TLTPKVTCVWAISKDDPEVQFSWFV G)- ID LNGINNYKNPKL DDVEVHTAQTQPREEQFNSTFRSVSELPIM [VPLSLY]- NO: 29) TAMLTAKFAMP HQDWLNGKEFKCRVNSAAFGAPIE hIL2(R38A, KKATELKHLQCL KTISKTKGRPKAPQVYTIPPPKEQMAKDKV F42A, EEALKPLEEVLN SLTCMITDFFPEDITVEWQWNGQP Y45A, LAQSKNFHLRPR AENYDNTQPIMDTDGSYFVYSDLNVQKSNV E62A, DLISNINVIVLEL VEAGNTFTCSVLHEGLHNHHTEKS C125A) KGSETTFMCEY LSHSPGGSPGVPISLYSGPAPTSSSTKKTQ ADETATIVEFLN LQLEHLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLE (SEQ ID LKGSETTFMCEYADETATIVEFLMRWITFA NO: 3) QSIISTLT (SEQ ID NO: 370) AK467 DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 ITLTPKVTCVWAISKDDPEVQFSWFV (DAP DDVEVHTAQTQPREEQFNSTFRSVSELPIM G)- HQDWLNGKEFKCRVNSAAFGAPIE mCD122 KTISKTKGRPKAPQVYTIPPPKKQMAKDKV SLTCMITDFFPEDITVEWQWNGQP AENYKNTQPIMKTDGSYFVYSKLNVQKSNW EAGNTFTCSVLHEGLHNHHTEKSL SHSPGPGSGSAVKNCSHLECFYNSRANVSC MWSHEEALNVTTCHVHAKSNLRH WNKTCELTLVRQASWACNLILGSFPESQSL TSVDLLOINWCWEEKGWRRVKTC DFHPFDNLRLVAPHSLQVLHIDTQRCNISW KVSQVSHYIEPYLEFEARRRLLGHS WEDASVLSLKQRQQVVLFLEMLIPSTSYEV QVRVKAQRNNTGTWSPWSQPLTFR TRPADPMKE (SEQ ID NO: 372) AK468 DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LYITREPEVTCVVVDVSHEDPEVKFNWYVD M252Y, GVEVHNAKTKPREEQYASTYRVVSVLTVLH S254T, QDWLNGKEYKCKVSNKALPAPIEKTISKAK T256E)- GQPREPQVCTLPPSRDELTKNQVSLSCAVK hCD122 GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTISPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 392) AK468 DNA580 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, (SEQ QLEHLLLDLQMI LYITREPEVTCVVVDVSHEDPEVKFNWYVD M252Y, ID LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH S2547, NO: 29) TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK T256E)- KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK [VPLSLY]- EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTPPVLD hIL2(R38A, LAQSKNFHLRPR SDGSFFLYSKLTVDKSRWQQGNVF F42A, DLISNINVIVLEL SCSVMHEALHNHYTQKSLSLSPGGSPGVPL Y45A, KGSETTFMCEY SLYSGPAPTSSSTKKTQLQLEHLLLDLQMI E62A, ADETATIVEFLN LNGINNYKNPKITAMLTAKFAMPKKATELK C125A) RWITFAQSIISTL HLQCLEEALKPLEEVLNLAQSKNFHLRPRD T LISNINVIVLELKGSETTFMCEYADETATI (SEQ ID VEFLNRWITFAQSIISTLT NO: 3) (SEQ ID NO: 396) AK469 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAIDKPREEQYASTYRVVSVLTVLH HCD122 QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQPFK PFENLRIMAPISLQVVHVETHRCNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWICLETLTPDTQYEFQVRVKPLQG EFTTVVSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 43) AK469 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) AK470 DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LYITREPEVTCVVVDVSHEDPEVKFNWYVD (N297A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH M252Y, QDWLNGKEYKCKVSNKALPAPIEKTISKAK S254T, GQPREPQVCTLPPSRDELTKNQVSLSCAVK T256E)- GFYPSDIAVEWESNGQPENNYKTTPPVLDS hCD122 DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTISPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 392) AK470 DNA578 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LYITREPEVTCVVVDVSHEDPEVKFNWYVD (N297A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH M252Y, QDWLNGKEYKCKVSNKALPAPIEKTISKAK S254T, GQPREPQVCTLPPCRDELTKNQVSLWCLVK T256E)- GFYPSDIAVEWESNGQPENNYKTTPPVLDS hIL2 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE (R38A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG F42A, SGPAPTSSSTKKTQLQLEHLILDLQMILNG Y45A, INNYKNPKLTAMLTAKFAMPKKATELKHLQ E62A, CEEALKPLEEVLNLAQSKNFHLRPRDLISN C125A) INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 394) AK471 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAIDKPREEQYASTYRVVSVLTVLH hCD122 QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQPFK PFENLRIMAPISLQVVHVETHRCNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWICLETLTPDTQYEFQVRVKPLQG EFTTVVSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 43) AK471 DNA579 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, (SEQ QLEHLLLDLQMI LMASRTPEVTCVVDVSHEDPEVKFNWYVDG I253A)- ID LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [VPLSLY]- NO: 29) TAMLTAKFAMP DWLNGKEYKCKVSNKALPAPIEKTISKAKG hIL2(R38A, KKATELKHLQCL QPREPQVYTLPPCRDELTKNQVSLWCAVKG F42A, EEALKPLEEVLN FYPSDIAVEWESNGQPE Y45A, LAQSKNFHLRPR NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ E62A, DLISNINVIVLEL QGNVFSCSVMHEALHNHYTQKSLSLSPGGS C125A) KGSETTFMCEY PGVPLSLYSGPAPTSSSTKKTQLQIEHLLL ADETATIVEFLN DLQMILNGINNYKNPKLTAMLTAKFAMPKK RWITFAQSIISTL ATELKHLQCLEEALKPLEEVLNLAQSKNFH T LRPRDLISNINVIVLELKGSETTFMCEYAD (SEQ ID ETATIVEFLNRWITFAQSIISTLT NO: 3) (SEQ ID NO: 50) AK475 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVVTCVVVDVSHEDPEVKFNWYV hIL2(R38A, DGVEVHNAKTKPREEQYASTYRVVSVLTVL F42A, HQDWLNGKEYKCKVSNKALPAPIEKTISKA Y45A, KGQPREPQVYTLPPCRDELTKNQVSLWCLV E62A, KGFYPSDIAVEVVESNGQPENNYKTTPPVL C125A) DSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGGGSSPPGGGSSG GGSGPAPTSSSTKKTQLQLEHLLLDLQMIL NGINNYKNPKITAMLTAKFAMPKKATELKH IQCLEEALKPLEEVLNLAQSKNFHLRPRDL ISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT (SEQ ID NO: 51) AK475 DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122(C168 GVEVHNAKTKPREEQYASTYRWSVITVLHQ 8) DWINGKEYKCKVSNKAIPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLSCAVKG FYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGPGSGSAVNGTSQFTCFYNSRANIS CVWSQDGALQDTSCQVHAWPDRRRWNQTCE LLPVSQASWACNLILGAPDSQKLTTVDIVTL RVLCREGVRWRVMAIQDFKPFENLRLMAPI SLQVVHVETHRCNISWEISQASHYFERHLEF EARTISPGHTWEEAPLLTLKQKQEWISLET LTPDTQYEFQVRVKPLQGEFTTWSPWSQPL AFRTKPAALGKD (SEQ ID NO: 368) AK476 DNA263 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ QLEHLLLDLQMI MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV [VPLSLY]- ID LNGINNYKNPKL EVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(R38A, NO: 29) TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK F42A, KKATELKHLQCL GQPREPQVYTLPPCRDEITKNQVSLWCLVK Y45A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTPPVLDSD E62A, LAQSKNFHLRPR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA C125A) DLISNINVIVLEL LHNHYTQKSLSLSPGGSPGVPLSLYSGPAP KGSETTFMCEY TSSSTKKTQLQLEHLLLDLQMILNGINNYK ADETATIVEPLN NPKLTAMLTAKFAMPKKATELKHLQCLEEA RWITFAQSIISTL LKPL6EVLNLAQSKNFHLRPRDLISNINVI T VLELKGSETTFMCEYAQETATIVEFLNRWI (SEQ ID NO: 3) TFAQSIISTLT (SEQ ID NO: 49) AK476 DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRWSVITVLHQ (C168S) DWINGKEYKCKVSNKAIPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLSCAVKG FYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGPGSGSAVNGTSQFTCFYNSRANIS CVVVSQDGALQDTSCQVHAWPDRRRWNQTCE LLPVSQASWACNLILGAPDSQKLTTVDIVTL RVLCREGVRWRVMAIQDFKPFENLRLMAPI SLQVVHVETHRCNISWEISQASHYFERHLEF EARTISPGHTWEEAPLLTLKQKQEWISLET LTPDTQYEFQVRVKPLQGEFTTWSPWSQPL AFRTKPAALGKD (SEQ ID NO: 368) AK477 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK477 DNA554 Knob: APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- QLRHLCLRLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVITVLH hIL2(E15R, TAMLTAKFAMP QDWLNGKEYKCKV L18C, D2GR, KKATELKHLQCL SNKALPAPIEKTISKAKGQPREPQVYTLPP R38A, F42A, EEALKPLEEVIN CRDELTKNQVSLWCLVKGFYPSDIAVEWES Y45A, E62A) LAQSKNFHLRPR NGQPENNYKTTPPVLDSDGSFFLYSKLTVD DLISNINVIVLEL KSRWQQGNVFSCSVMHEALHNHYTQKSLSL KGSETTFMCEY SPGGSPGVPLSLYSGPAPTSSSTKKTQLQL ADETATIVEFLN RHLCLRLQMILNGINNYKNPKLTAMLTAKF RWITFCQSIISTL AMPKKATELKHLQCLEEALKPLEEVLNLAQ T SKNFHLRPRDLISNINVIVLELKGSETTFM (SEQ ID CEYADETATIVEFLNRWITFCQSIISTLT NO: 339) (SEQ ID NO: 385) AK484 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK484 DNA581 Knob: SGP APTSSSTKKTQL KTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- QLEHLCLDLQM LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- ILNGINNYKNPK GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(L18C, L7AMLTAKFAM QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, PKKATELKHLQC GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A) LEEALKPLEEVL GFYPSDIAVEWESNGQPENNYKTTPPVLDS NLAQSKNFHLR DGSFFLY PRDLISNINVIVL DSKLTVDKSRWQQGNVFSCSVMHEALKNHYT ELKGSETTFMCE QKSLSLSPGGSPGVPLSLYSGPAFTSSSTK YADETATIVEFL KTQLQLEHLCLDLQMILNGINNYKNPKLTA NRWITFCQSHST MLTAKFAMPKKATELKHIQCIEEALKPLEE LT VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID NO: 365) SETTFMCEYADETATIVEFLNRWITFCQSI ISTLT (SEQ ID NO: 397) AK485 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK485 DNA582 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT HFc(N297A)- (SEQ ID QLEYLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(H16Y, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS C125A) LAQSKNFHLRPR DGSFFLY DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSISLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQLEYLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID NO: 346) SETTFMCEYADETATIVEFLNRWITFAQSH STLT (SEQ ID NO: 398) AK486 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) Ak486 DNA583 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELLLDLQMI LMISRTPEVTCVVVDVS [VPLSLY]- NO: 29) LNGINNYKNPKL HEDPEVKFNWYVDGVEVHNAKTKPREEQYA hIL2(H16E, TAMLTAKFAMP STYRVVSVLTVLHQDWLNGKEYKCKVSNKA R38A, F42A, KKATELKHLQCL LPAPIEKTISKAKGQPREPQVYTLPPCRDE Y45A, E52A, EEALKPLEEVIN LTKNQVSLW Cl25A) LAQSKNFHLRPR CLVKGFYPSDIAVEWESNGQPENNYIOTPP DLISNINVIVLEL VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS KGSETTFMCEY VMHEALHNHYTQKSLSLSPGGSPGVPLSLY ADETATIVEFLN SGPAPTSSSTKKTQLQLEELLLDLQMILNG RWITFAQSIISTL INNYKNPKLTAMLTAKFAMPKKATELKHLQ T CLEEALKPLEEVLNLAQSKNFHLRPRDLISN (SEQ ID NO: 347) INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 399) AK487 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK487 DNA584 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLLLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2,(D20L, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R3SA, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS C125A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLLLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFAQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFAQSIISTLT (SEQ ID NO: 400) 348) AK488 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK488 DNA585 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGiNNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(H16Y, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E52A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS Cl25A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEYLCLDLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFCQSIISTLT (SEQ ID NO: 401) 349) AK489 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK489 DNA586 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLDLQMI LMISRTPEVTCVVVDVSHEOPEV [VPLSLY]- NO: 29) LNGINNYKNPKL KFNWYVDGVEVHNAKTKPREEQYASTYRVV hIL2(H16E, TAMLTAKFAMP SVLTVLHQDVVLNGKEYKCKVSNKALPAPI L18C, R38A, KKATELKHLQCL EKTISKAKGQPREPQVYTLPPCRDELTKNQ F42A, Y45A, EEALKPLEEVLN VSLWCLVKGFYPSDIAVEWESNGQPEN E62A) LAQSKNFHLRPR NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ DLISNINVIVLEL GNVFSCSVMHEALHNHYTQKSLSLSPGGSP KGSETTFMCEY GVPLSLYSGPAPTSSSTKKTQLQLEELCLD ADETATIVEFLN LQMILNGINNYKNPKLTAMLTAKFAMPKKA RWITFCQSIISTL TELKHLQCLEEALKPLEEVLNLAQSKNFHL (SEQ ID NO: RPRDLISNINVIVLELKGSETTFMCEYADE 350) TATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 402) AK490 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK490 DNA587 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(L18C, TAMLTAKFAMP QPWLNGKEYKCKVSNKALPAPIEKTISKAK D20L, R38A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKMQVSLWCLVK F42A, Y45A, EEALKPLEEVLN GFYPSDIAVEWESMGQPENNYKTTPPVLDS E62A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLCLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCBYADETATIVEFLNRW (SEQ ID NO: 351) ITFCQSIISTLT (SEQ ID NO: 403) AK491 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK491 DNA588 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAICTKPREEQYASTYRVVSVLTVL hIL2(H16Y, TAMLTAKFAMP HQDWLNGKEYKCKVSNKALPAPIEKTISKA L18C, KKATELKHLQCL KGQPREPQVYTLPPCRDELTKNQVSLWCLV D20L, R38A, EEALKPLEEVLN KGFYPSDIAVEWESNGQPENNYKTTPPVLD F42A, Y45A, LAQSKNFHLRPR SDGSFFLY E62A) DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSLSLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQIEYLCLLLQMILNGINNYKNPKLTA RWITFCQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID SETTFMCEYADETATIVEFLNRWITFCQSI NO: 352) ISTLT (SEQ ID NO: 404) AK492 DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) AK4921 DNA589 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWWDG [VPLSLY]- NO: 29) LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2(H16E, TAMLTAKFAMP DWLNGKEVKCKVSNKALPAPIFKTISKAKG L18C, KKATELKHLQCL QPRFPQVYTLPPCRDELTKNQVSIAVCLVK D20L, R38A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS F42A, Y45A, LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A) DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEELCLLLQMILNGINNY ADETATIVEFLN KNPKLT RWITFCQSIISTL AMLTAKFAMPKKATELKHLQCLEEALKPLE T (SEQ ID NO: EVLNLAQSKNFHLRPRDLISNINVIVLELK 353) GSETTFMCEYADETATIVEFLNRWITFCQS IISTLT (SEQ ID NO: 405) AK493 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK493 DNA581 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLCLDLQM LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) ILNGiNNYKNPK GVEVHNAKTKPREEQYASTYRVVSVLWLHQ hIL2(L18C, LTAMLTAKFAM DWLNGKEYKCKVSNKALPAPIEKTISKAKG R38A, PKKATELKHLQC QPREPQVYTLPPCRDELTKMQVSLWCLVKG F42A, Y45A, LEEALKPLEEVL FYPSDIAVEWESNGQPENNYKTTPPVLDSD E62A) NLAQSKNFHLR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA PRDLISNINVIVL LHNHYTQKSLSLSPGGSPGVPLSLYSGPAP ELKGSETTFMCE TSSSTKKTQLQLEHLCLDLQMILNGIMNYK YADETATIVEFL NPKLTAMLTAKFAMPKKATELKHLQCLEEA NRWITFCQSIIST LKPLEEVLNLAQSKNFHLRPRDLISNINVI LT VLELKGSETTFMCEYAOETATIVEFLNRWI (SEQ ID NO: 345) TFCQSIISTLT (SEQ ID NO: 397) AK494 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK485 DNA582 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(H16Y, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, Y45A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS E62A) LAQSKNFHLRPR DGSFFLY DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSISLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQLEYLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID NO: 346) SETTFMCEYADETATIVEFLNRWITFAQSH STLT (SEQ ID NO: 398) AK495 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK495 DNA583 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELLLDLQMI LMISRTPEVTCVVVDVS [VPLSLY]- NO: 29) LNGINNYKNPKL HEDPEVKFNWYVDGVEVHNAKTKPREEQYA hIL2(H16E, TAMLTAKFAMP STYRVVSVLTVLHQDWLNGKEYKCKVSNKA R38A, F42A, KKATELKHLQCL LPAPIEKTISKAKGQPREPQVYTLPPCRDE Y45A, E52A, EEALKPLEEVIN LTKNQVSLW Cl25A) LAQSKNFHLRPR CLVKGFYPSDIAVEWESNGQPENNYIOTPP DLISNINVIVLEL VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS KGSETTFMCEY VMHEALHNHYTQKSLSLSPGGSPGVPLSLY ADETATIVEFLN SGPAPTSSSTKKTQLQLEELLLDLQMILNG RWITFAQSIISTL INNYKNPKLTAMLTAKFAMPKKATELKHLQ T CLEEALKPLEEVLNLAQSKNFHLRPRDLISN (SEQ ID NO: 347) INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 399) AK496 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK496 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLLLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2,(D20L, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS C125A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLLLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFAQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFAQSIISTLT (SEQ ID NO: 400) 348) AK497 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK497 DNA585 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGiNNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(H16Y, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E52A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS Cl25A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEYLCLDLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFCQSIISTLT (SEQ ID NO: 401) 349) AK498 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK498 DNA586 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLDLQMI LMISRTPEVTCVVVDVSHEOPEV [VPLSLY]- NO: 29) LNGINNYKNPKL KFNWYVDGVEVHNAKTKPREEQYASTYRVV hIL2(H16E, TAMLTAKFAMP SVLTVLHQDVVLNGKEYKCKVSNKALPAPI L18C, R38A, KKATELKHLQCL EKTISKAKGQPREPQVYTLPPCRDELTKNQ F42A, Y45A, EEALKPLEEVLN VSLWCLVKGFYPSDIAVEWESNGQPEN E62A) LAQSKNFHLRPR NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ DLISNINVIVLEL GNVFSCSVMHEALHNHYTQKSLSLSPGGSP KGSETTFMCEY GVPLSLYSGPAPTSSSTKKTQLQLEELCLD ADETATIVEFLN LQMILNGINNYKNPKLTAMLTAKFAMPKKA RWITFCQSIISTL TELKHLQCLEEALKPLEEVLNLAQSKNFHL (SEQ ID NO: RPRDLISNINVIVLELKGSETTFMCEYADE 350) TATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 402) AK499 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK499 DNA587 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(L18C, TAMLTAKFAMP QPWLNGKEYKCKVSNKALPAPIEKTISKAK D20L, R38A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKMQVSLWCLVK F42A, Y45A, EEALKPLEEVLN GFYPSDIAVEWESMGQPENNYKTTPPVLDS E62A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLCLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCBYADETATIVEFLNRW (SEQ ID NO: 351) ITFCQSIISTLT (SEQ ID NO: 403) AK500 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK500 DNA588 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAICTKPREEQYASTYRVVSVLTVL hIL2(H16Y, TAMLTAKFAMP HQDWLNGKEYKCKVSNKALPAPIEKTISKA L18C, KKATELKHLQCL KGQPREPQVYTLPPCRDELTKNQVSLWCLV D20L, R38A, EEALKPLEEVLN KGFYPSDIAVEWESNGQPENNYKTTPPVLD F42A, Y45A, LAQSKNFHLRPR SDGSFFLY E62A) DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSLSLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQIEYLCLLLQMILNGINNYKNPKLTA RWITFCQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID SETTFMCEYADETATIVEFLNRWITFCQSI NO: 352) ISTLT (SEQ ID NO: 404) AK501 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK501 DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLKGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVIDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 38) AK501 DNA589 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWWDG [VPLSLY]- NO: 29) LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2(H16E, TAMLTAKFAMP DWLNGKEVKCKVSNKALPAPIFKTISKAKG L18C, KKATELKHLQCL QPRFPQVYTLPPCRDELTKNQVSIAVCLVK D20L, R38A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS F42A, Y45A, LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A) DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEELCLLLQMILNGINNY ADETATIVEFLN KNPKLT RWITFCQSIISTL AMLTAKFAMPKKATELKHLQCLEEALKPLE T (SEQ ID NO: EVLNLAQSKNFHLRPRDLISNINVIVLELK 353) GSETTFMCEYADETATIVEFLNRWITFCQS IISTLT (SEQ ID NO: 405) AK502 DNA543 Knob: AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWWDGV [VPLSLY]- SQDGALQDTSC EVHNAKTKPREEQYASTYRVVSVLWLHQDW hCD122 QVHAWPDRRR LNGKEYKCKVSNKALPAPIEKTISKAKGQP WNQTCELLPVS REPQVCTLPPSRDELTKNQVSLSCAVKGFY QASWACNLILG PSDIAVEWESNGQPENNYKTTPPVLDSDGS APDSQKLTTVDI FFLVSKLTVDKSRWQQGNVFSCSVMHEALH VTLRVLCREGVR NHYTQKSLSLSPGGPPSGSSPGVPLSLYGS WRVMAIQDFK QGGAVNGTSQFTCFYNSRANISCVWSQDGA PFENLRLMAPIS LQDTSCQVHAWPDRRRWNQTCELLPVSQAS LQVVHVETHRC WACNLILGAPDSQKLTTVDIVTLRVLCREG NISWEISQASHY VRWRVMAIQDFKPFENLRLMAPISLQVVHVE FERHLEFEARTL THRCNISWEISQASHYFERHLEFEARTISP SPGHTWEEAPL GHTWEEAPLLLIKQKQEWICLETITPDTQYE LTLKQKQEWICL FQVRVKPLQGEFTTWSPWSQPLAFRTKPAA ETLTPDTQYEFQ LGKD (SEQ ID NO: 42) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK502 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) AK503 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LMISRTPEVTCVVVDVSHEDPEVKFNWYVD (N297A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKALPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESMGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 51) AK503 DNA506 AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL YNSRANISCVW MISRTPEYTCVVVDVSHEDPEVKFNWYVDG SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESMGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPRAAAVKS WRVMAIQDFK PSGGGAVNGTSQFTCFYNSRANISCVLVSQ PFENLRLMAPIS OGALQDTSCQVHAWPDRRRWNQTCELLPVS LQVVHVETHRC QASWACNLILGAPDSQKLTTVDIVTLRVLC NISWEISQASHY REGVRWRVMAIQDFKPFENLRLMAPISLQV FERHLEFEARTL VHVETHRCNISWEISQASHYFERHLEFEAR SPGHTWEEAPL TLSPGHTWEEAPLLTLKQKQEWICLETLTP LTLKQKQEWICL DTQYEFQVRVKPLQGEFITWSPWSQPLAFR ETLTPDTQYEFQ TKPAALGKD (SEQ ID NO: 409) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK504 DNA603 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4- DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hCD122 VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSL GPGSGSAVNGTSQFTCFYNSRANISCVWSQ DGALQDTSCQVHAWPDRRRWNQTCELLPVS QASWACNLILGAPDSQKLTTVDIVTLRVLC REGVRWRVMAIQDFKPFENLRLMAPISLQW HVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP LLTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 406) AK504 DNA605 Knob: SGP APTSSSTKKTQL ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4-hIL2- (SEQ ID QLEHLLLDLQMI DTLMISRTPEVTCVVVDVSQEDPEVQFNWY [VPLSLY]- NO: 29) LNGINNYKNPKL VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hIL2(R38A, TAMLTAKFAMP LHQDWLMGKEYKCKVSNKGLPSSIEKTISK F42A, Y45A, KKATELKHLQCL AKGQPREPQVYTLPPCQEEMTKNQVSLWCL E62A, C125A) EEALKPLEEVLN VKGFYPSDIAVEWESMGQPENNYKTTPPVL LAQSKNFHLRPR DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM DLISNINVIVL HEALHNHYTQKSLSLSLGGSPGVPLSLYSG ELKGSETTFMC PAPTSSSTKKTQLQLEHLLLDLQMILNGIN EYADETATIVEF NYKNPKLTAMLTAKFAMPKKATELKHLQCL LNRWITFAQSII EEALKPLEEVLNLAQSKNFHLRPRDLISNI STLT NVIVLELKGSETTFMCEYAOETATIVEFLN (SEQ ID RWITFAQSIISTLT (SEQ ID NO: 408) NO: 3) AK504 DNA603 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4- DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hCD122 VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSL GPGSGSAVNGTSQFTCFYNSRANISCVWSQ DGALQDTSCQVHAWPDRRRWNQTCELLPVS QASWACNLILGAPDSQKLTTVDIVTLRVLC REGVRWRVMAIQDFKPFENLRLMAPISLQW HVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP LLTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 406) AK504 DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK IgG4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hFc- VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hIL2(R38A, LHQDWLNGKEYKCKVSNKGLPSSIEKTISK F42A, Y45A, AKGQPREPQVYTLPPCQEEMTKNQVSLWCL E62A, C125A) VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGGGSSPPGGGSSG GGSGPAPTSSSTKKTQLQLEHLLLDLQMIL NGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDL ISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT (SEQ ID NO: 407) AK508 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) AK508 DNA609 Hole: GSGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A, (SEQ YNSRANISCVW MASRTPEVTCVVVDVSHEDPEVKFNWWDGV I253A)- ID SQDGALQDTSC EVHNAKTKPREEQYASTYRVVSVLTVLHQD [VPLSLY]- NO: QVHAWPDRRR WLNGKEYKCKVSNKALPAPIEKTISKAKGQ hCD122 31) WNQTCELLPVS PREPQVCTLPPSRDELTKNQVSLSCAVKGF QASWACNLILG YPSDIAVEVVESNGQPENNYKTTPPVLDSD APDSQKLTTVDI 6SFFLVSKLTVDKSRWQQGNVFSCSVMHEAL VTLRVLCREGVR HNHYTQKSLSLSPGGPPSGSSPGVPLSLYG WRVMAIQDFK SGGGAVNGTSQFTCFYNSRANISCVWSQDG PFENLRLMAPIS ALQDTSCQVHAWPDRRRWNQTC LQVVHVETHRC ELLPVSQASWACNLILGAPDSQKLTTVDIV NISWEISQASHY TLRVLCREGVRWRVMAIQDFKPFENLRLMA FERHLEFEARTL PISLQVVHVETHRCNISWEISQASHYFERH SPGHTWEEAPL LEFEARTLSPGHTWEEAPLLTLKQKQEWIC LTLKQKQEWICL LETLTPDTQYEFQVRVKPLQGEFTTWSPWS ETLTPDTQYEFQ QPLAFRTKPAALGKD VRVKPLQGEFTT (SEQ ID NO: 411) WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK509 DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAIOKPREEQYASTYRVVSVLTVLH hCD122 QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQPFK PFENLRIMAPISLQVVHVETHRCNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWICLETLTPDTQYEFQVRVKPLQG EFTTVVSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 43) AK509 DNA623 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297, (SEQ QLEHLLLDLQMI MASRTPEVTCVVVDVSHEDPEVKFNWYVDG I253A)- ID LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [MPYDLYHP] NO: TAMLTAKFAMP PWLNGKEYKCKVSNKALPAPIEKTISKAKG hIL2 29) KKATELKHLQCL QPREEQVYTLPPCRDELTKNQVSLWCLVKG (R38A, EEALKPLEEVLN FYPSDIAVEWESNGQPENNYKTTPPVLDSD F42A, LAQSKNFHLRPR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA Y45A, DLISNINVIVL LHNHYTOKSLSLSPGGGSSPPMPYDLYHPS E62A, ELKGSETTFMC GPAPTSSSTKKTQLQLEHLLLDLQMILNGI C125A) EYADETATIVEF NNYKNPKLTAMLTAKFAMPKKATELKHLQC LNRWITFAQSII LEEALXPLEEVLNLAQSKNFHLRPRDLISN STLT INVIVLELKGSETTFMCEYADETATIVEFL (SEQ ID NRWITFAQSIISTLT NO: 3) (SEQ ID NO: 415) AK510 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) AK510 DNA608 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A, (SEQ YNSRANISCVW MASRTPEVTCVVVDVSHEDPEVKFNWYVDG I253A)- ID SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [MPYDLYHP]- NO: QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG hCD122 30) WNQTCELLPVS OPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPMPYDLYH WRVMAIQDFK PSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQVVHVETHRC ASWACNLILGAPDSQKLTTVDIVTLRVLCRE NISWEISQASHY GVRWRVMAIQDFKPFENLRLMAPISLQVVH FERHLEFEARTL VETHRCNISWEISQASHYFERHLEFEARTL SPGHTWEEAPL SPGHTWEEAPLLTLKQKQEWICLETLTPDT LTLKQKQEWICL QYEFQVRVKPLQGEFTTWSPWSQPLAFRTK ETLTPDTQYEFQ PAALGKD (SEQ ID NO: 410) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK511 DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK IgG4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hFc- VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hIL2(R38A, LHQDWLNGKEYKCKVSNKGLPSSIEKTISK F42A, Y45A, AKGQPREPQVYTLPPCQEEMTKNQVSLWCL E62A, C125A) VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGGGSSPPGGGSSG GGSGPAPTSSSTKKTQLQLEHLLLDLQMIL NGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDL ISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT (SEQ ID NO: 407) AK511 DNA621 Hole: GSGGG AVNGTSQFTCF ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4- (SEQ YNSRANISCVW DTLMISRTPEVTCVVVDVSQEDPEVQFNWY [VPLSLY]- ID SQD6ALQDTSC VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hCD122 NO: QVHAWPDRRR LHQDWLNGKEYKCKVSNKGLPSSIEKTISK 31) WNQTCELLPVS AKGQPREPQVCTLPPSQEEMTKNQVSLSCA QASWACNLILG VKGFYPSDIAVEWESNGQPENNYKTTPPVL APDSQKLTTVDI DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM VTLRVLCREGVR HEALHNHYTQKSLSLSLGGPPSGSSPGVPL WRVMAIQDFK SLYGSGGGAVNGTSQFTCFYNSRANISCVW PFENLRLMAPIS SQDGALQDTSCQVHAWPDRRRWNQTCELLP LQVVHVETHRC VSQASWACIMLILGAPDSQKLTTVDIVTLR NISWEISQASHY VLCREGVRVVRVMAIQDFKPFELMLRLMAP FERHLEFEARTL ISLQVVHVETHRCNISWEISQAS SPGHTWEEAPL HYFERHLEFEARTLSPGHTWEEAPLLTLKQ LTLKQKQEWICL KQEWICLETLTPDTQYEFQVRVKPLQGERT ETLTPDTQYEFQ WSPWSQPLAFRTKPAALGKD VRVKPLQGEFTT (SEQ ID NO: 414) WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK512 DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) AK512 DNA625 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A, MASRTPEVTCVVVDVSHEDPEVKFNWYVDG I253A) VEVHNAKTKPREEQYASTYRVVSVLTVLHQ PWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPG (SEQ ID NO: 10) AK513 DNA504 Knob: Ig64 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFc- DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hIL2(R38A, VDGVEVHNAKTKPREEQFNSTYRVVSVLTV F42A, Y45A, LHQDWLNGKEYKCKVSNKGLPSSIEKTISK E62A, C125A) AKGQPREPQVYTLPPCQEEMTKNQVSLWCL VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGGGSSPPGGGSSG GGSGPAPTSSSTKKTQLQLEHLLLDLQMIL NGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDL ISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT (SEQ ID NO: 407) AK513 DNA626 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK HFcIgG4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGPG (SEQ ID NO: 298) AK526 DNA670 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc- LMISRTPEVTCWVDVSHEDPEVKFNWYVDG hIL2(R38A, VEVHNAKTKPREEQYNSTYRWSVLTVLHQD F42A, Y45A, WLNGKEYKCKVSNKALPAPIEKTISKAKGQ E62A, C125A) PREPQWTLPPCRDELTKNQVSLWCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGGGSSPPGGGSSGGGSGP APTSSSTKKTQLQLEHLLLDLQMILNGINN YKNPKLTAMLTAKFAMPKKATELKHLQCLE EALKPLEEVLNLAQSKNFHLRPRDLISNIN VIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSIISTLT (SEQ ID NO: 423) AK526 DNA672 Hole: hFc- GSGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFIFPPKPKDTL [VPLSLY]- (SEQ YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWYVDG hCD122 ID SQD6ALQDTSC VEVHNAKTKPREEQYNSTYRVVSVLTVLHQ NO: QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG 31) WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPGVPLSLY WRVMAIQDFK GSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQVVHVETHRC ASWACNLILGAPDSQKLTTVDIVTIRVLCR NISWEISQASHY EGVRWRVMAIQDFKPFENLRLMAPISLQVV FERHLEFEARTL HVETHRCNISWEISQASHYFERHLEFEART SPGHTWEEAPL LSPGHTWEEAPLITIKQKQEWSCIETITPD LTLKQKQEWICL TQYEFQVRVKPLQGEFTTWSPWSQPLAFRT ETLTPDTQYEFQ KPAALGKD (SEQ ID NO: 425) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) AK530 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hIL2(R38A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH F42A, Y45A, QDWLNGKEYKCKVSNKALPAPIEKTISKAK E62A; C125A) GQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESMGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 51) AK530 DNA612 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ ID YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWYVDG [MPYDLYHP]- NO: 30) SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hCD122 QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG (C122S, WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG C168S) QASWACNLILG FYPSQIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPMPYDLYH WRVMAIQDRC PSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQWHVETHRS ASWACIMLILGAPDSQKLTTVDIVTLRVLC NISWEISQASHY REGVRWRVMAIQDFKPFENLRLMAPISLQV FERHLEFEARTL VHVETHRSNISWEISQASHYFERHLEFEAR SPGHTWEEAPL TISPGHTWEEAPLLTIKQKQEWISLETLTP LTLKQKQEWISL DTQYEFQVRVKPLQGEFTTWSPWSQPLAFR ETLTPDTQYEFQ TKPAALGKD (SEQ ID NO: 40) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 5) AK531 DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hIL2(R38A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH F42A, Y45A, QDWLNGKEYKCKVSNKALPAPIEKTISKAK E62A, C125A) GQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESMGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNLAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 51) AK531 ANA614 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID YNSRANISCVW LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [DSGGMLT]- NO: 30) SQDGALQDTSC GVEVHNAKTKPREEQYASTYRVVSVLTVLH hCD122 QVHAWPDRRR QDWLNGKEYKCKVSNKALPAPIEKTISKAK (C122S, WNQTCELLPVS GQPREPQVCTLPPSRDELTKNQVSLSCAVK C168S) QASWACNLILG GFYPSQIAVEWESNGQPENNYKTTPPVLDS APDSQKLTTVDI DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE VTLRVLCREGVR ALHNHYTQKSLSLSPGGPPSGSSPGDSGGF WRVMAIQDRC MLTSGGGAVNGTSGFTCFYNSRANISCVWS PFENLRLMAPIS QDGALQDTSCQVHAWPDRRRWNQTCELLPV LQWHVETHRS SQASWACNLILGAPDSQKLTTVDIVTLRVL NISWEISQASHY CREGVRWRVMAIQDFKPFENLRLMAPISLQ FERHLEFEARTL VVHVETHRSNISWEISQASHYFERHLEFEA SPGHTWEEAPL RTLSPGHTWEEAPLLTLKQKQEWISLETIT LTLKQKQEWISL PDTQYEFQVRVKPLQGEFTTWSPWSQPLAF ETLTPDTQYEFQ RTKPAALGKD (SEQ ID NO: 413) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 5) AK532 DNA669 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWINGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHMHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQWHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 422) AK532 DNA561 Knob: SGGG APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc (SEQ QLEHLLLDLQMI IMISRTPEVTCVVVDVSHEDPEVKFNWYV [VPLSLY]- ID LNGiNNYKNPKL DGVEVHNAKTKPREEQYNSTYRVVSV hIL2(R38A, NO: TAMLTAKFAMP LTVLHQDWLNGKEYKCKVSNKALPAPIEKT F42A, Y45A, 30) KKATELKHLQCL ISKAKGQPREPQVYTLPPCRDELTKNQVSL E62A, C125A) EEALKPLEEVLN WCLVKGFYPSDIAVEWESNGQPENNYKTTP LAQSKNFHLRPR PVLCSDGSFFLYSKLTVDKSRWQQGNVFSC DLISNINVIVLEL SVMHEALHNHYTQKSLSLSPGSSPGVPLSL KGSETTFMCEY YSGPAPTSSSTKKTQLQLEHLLLDLQMILN ADETATIVEFLN GINNYKNPKLTAMLTAKFAMPKKATELKHL RWITFAQSIISTL QCIEEALKPLEEVLNLAQSKNFHIRPRDLI T SNINVIVLELKGSETTFMCEYADETATIVE (SEQ ID FLNRWITFAQSRSTLT NO: 3) (SEQ ID NO: 424)  component1 Component2 Component3 name newnames Sequence Sequence Sequence DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ EVHNAKTKPREEQYASTYRVVSVLTVLHQDW ID LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS 14) DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL AVNGTSQFTCFYNSRANISCVWSQDGALQDT hFc(N297A) MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV SCQVHAWPDRRRWNQTCELLPVSQASWACN EVHNAKTKPREEQYASTYRVVSVLTVLHQDW LILGAPDSQKLTTVDIVTLRVLCREGVRWR LNGKEYKCKVSNKALPAPIEKTISKAKGQPR VMAIQDFKPFENLRLMAPISLQVVHVETHR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS CNISWEISQASHYFERHLEFEARTLSPGHT DIAVEWESNGQPENNYKTTPPVLDSDGSFFL WEEAPLLTLKQKQEWICLETLTPDTQYEFQ VSKLTVDKSRWQQGMVFSCSVMHEALHNHY VRVKPLQGEFTTWSPWSQPLAFRTKPAALG TQKSLSLSPG KD (SEQ ID NO: 4) (SEQ ID NO: 9) DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GGSSPP APTSSSTKKTQL hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP GGGSSG QLEHLLLDLQMILNGINNYKNPKL hIL2(R38A, EVKFNWYVDGVEVHNAKTKPREEQY GGSGP TAMLTAKFAMPKKATELKHLQCL F42A, ASTYRVVSVLTVLHQDWLNGKEYKC (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR Y45A, KVSNKALPAPIEKTISKAKGQPREP NO: 23) DLISNINVIVLELKGSETTFMCEY E62A, QVYTLPPCRDELTKNQVSLWCLVKG ADETATIVEFLNRWITFAQSIISTLT C125A) FYPSDSAVEWESNGQPENNYKTTPP (SEQ ID NO: 3) VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA263 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(R38A, ASTYRVVSVLTVLHQDWLNGKEYKC F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, QVYTLPPCRDELTKNQVSLWCLVKG E62A, FYPSDSAVEWESNGQPENNYKTTPP C125A) VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA278 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSGP DSGGFMLT hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [DSGGFMLT] EVKFNWYVDGVEVHNAKTKPREEQY NO: 33) NO: 25) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (C125A) KVSNKALPAPIEKTISKAKGQPREP QVYTLPPCRDELTKNQVSLWCLVKG FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA281 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSGP DSGGFMLT hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [DSGGFMLT] EVKFNWYVDGVEVHNAKTKPREEQY NO: 33) NO: 25) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (R38A, KVSNKALPAPIEKTISKAKGQPREP F42A, QVYTLPPCRDELTKNQVSLWCLVKG Y45A, FYPSDSAVEWESNGQPENNYKTTPP E62A, VIDSDGSFFLYSKITVDKSRWQQGN C125A) VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA440 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS AVNGTSQFTCFYNSRANISCVW hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ SQDGALQDTSCQVHAWPDRRR hCD122 EVHNAKTKPREEQYASTYRVVSVLTVLHQDW ID WNQTCELLPVSQASWACNLILG (C122S, LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: APDSQKLTTVDIVTLRVLCREGVR C168S) EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS 14) WRVMAIQDRCPFENLRLMAPIS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL LQWHVETHRSNISWEISQASHY VSKLTVDKSRWQQGMVFSCSVMHEALHNHY FERHLEFEARTLSPGHTWEEAPL TQKSLSLSPG LTLKQKQEWISLETLTPDTQYEFQ (SEQ ID NO: 9) VRVKPLQGEFTTWSPWSQPLAFR TKPAALGKD (SEQ ID NO: 5) DNA476 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK G NPMGSDPVNFKLLRWNG hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID NO: 325) [NPMGSD EVKFNWYVDGVEVHNAKTKPREEQY PVNFK ASTYRVVSVLTVLHQDWLNGKEYKC LLRWNG]- KVSNKALPAPIEKTISKAKGQPREP hIL2(F42S, QVYTLPPCRDELTKNQVSLWCLVKG E62S, FYPSDSAVEWESNGQPENNYKTTPP C125A) VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFP GGSSPP APTSSSTKKTQL mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED GGGSSG QLEHLLLDLQMILNGINNYKNPKL (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE GGSGP TAMLTAKFAMPKKATELKHLQCL hIL2 DYNSTLRVVSALPIQHQDWMSGKEF (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR (R38A, KCKVNNKDLGAPIERTISKPKGSVR NO: 23) DLISNINVIVLELKGSETTFMCEY F42A, APQVYVLPPCEEEMTKKQVTLWCMV ADETATIVEFLNRWITFAQSIISTLT Y45A, TQFMPEDIYVEWTNNGKTELNYKNT (SEQ ID NO: 3) E62A, EPVLDSQGSYFMYSKLRVEKKNWVE C125A) RNSYSCSWHEGLHNHHTTKSFSRTP G (SEQ ID NO: 280) DNA478 Knob: TIKPCPPCKCPAPNAAGGPSVFIFP GSGP DSGGFMLT mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ ID (SEQ ID (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE NO: 33) NO: 25) [VPLSLY] DYNSTLRVVSALPIQHQDWMSGKEF hIL2 KCKVNNKDLGAPIERTISKPKGSVR (R38A, APQVYVLPPCEEEMTKKQVTLWCMV F42A, TQFMPEDIYVEWTNNGKTELNYKNT Y45A, EPVLDSQGSYFMYSKLRVEKKNWVE E62A, RNSYSCSWHEGLHNHHTTKSFSRTP C125A) G (SEQ ID NO: 280) DNA479 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (LALAPG) DPDVQISWFVNNVEVHTAQTQTHRE DYNSTLRVVSALPIQHQDWMSGKEF KCKVNNKDLGAPIERTISKPKGSVR APQVCVLPPPEEEMTKKQVTLSCAV TDFMPEDIWEWTNNGKTELNYKNTE PVLDSDGSYFMVSKLRVEKKNWVER NSYSCSWHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQDGALQDT mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ SCQVHAWPDRRRWNQTCELLPVSQASWACN (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE ID LILGAPDSQKLTTVDIVTLRVLCREGVRWR hCD122 DYNSTLRVVSALPIQHQDWMSGKEF NO: VMAIQDFKPFENLRLMAPISLQVVHVETHR KCKVNNKDLGAPIERTISKPKGSVR 14) CNISWEISQASHYFERHLEFEARTLSPGHT APQVCVLPPPEEEMTKKQVTLSCAV WEEAPLLTLKQKQEWICLETLTPDTQYEFQ TDFMPEDIWEWTNNGKTELNYKNTE VRVKPLQGEFTTWSPWSQPLAFRTKPAALG PVLDSDGSYFMVSKLRVEKKNWVER KD (SEQ ID NO: 4) NSYSCSWHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) DNA516 FSSc EVQLLESGGGLVQPGGSLRLSCAASG GGS DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL FvVersion1- FTFSLFTMSWVRQAPGKGLEVVVSA MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV Hole: ISGSGGSTYYADSVKGRFTISRDNS EVHNAKTKPREEQYASTYRVVSVLTVLHQDW hFc(N297A)- KNTLYLQMNSLRAEDTAVYYCAKST LNGKEYKCKVSNKALPAPIEKTISKAKGQPR hCD122 HLYLFDYWGQGTLVTVSSGGGGSGG EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS GGSGGGGSEIVLTQSPGTLSLSPGE DIAVEWESNGQPENNYKTTPPVLDSDGSFFL RATLSCRASQSVSMPFLAWYQQKPG VSKLTVDKSRWQQGMVFSCSVMHEALHNHY QAPRLLIYGASSRATGIPDRFSGSG TQKSLSLSPG SGTDFTLTISRLEPEDFAVYYCQQM (SEQ ID NO: 9) RGRPPTFGQGTKVEIK (SEQ ID NO: 282) DNA520 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP HHHHHHHH mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE ID NoAnnotation DYNSTLRVVSALPIQHQDWMSGKEF NO: Found KCKVNNKDLGAPIERTISKPKGSVR 308) APQVCVLPPPEEEMTKKQVTLSCAV TDFMPEDIWEWTNNGKTELNYKNTE PVLDSDGSYFMVSKLRVEKKNWVER NSYSCSWHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) DNA521 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVNGTSQFTCFYNSRANISCVWSQDGALQDT mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ SCQVHAWPDRRRWNQTCELLPVSQASWACN (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE ID LILGAPDSQKLTTVDIVTLRVLCREGVRWR hCD122- DYNSTLRVVSALPIQHQDWMSGKEF NO: VMAIQDFKPFENLRLMAPISLQVVHVETHR NoAnnotation KCKVNNKDLGAPIERTISKPKGSVR 14) CNISWEISQASHYFERHLEFEARTLSPGHT Found APQVCVLPPPEEEMTKKQVTLSCAV WEEAPLLTLKQKQEWICLETLTPDTQYEFQ TDFMPEDIWEWTNNGKTELNYKNTE VRVKPLQGEFTTWSPWSQPLAFRTKPAALG PVLDSDGSYFMVSKLRVEKKNWVER KD (SEQ ID NO: 4) NSYSCSWHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) DNA522 Hole: TIKPCPPCKCPAPNAAGGPSVFIFP PGSGS AVKNCSHLECFYNSRANVSCMWSHEEALNV mFcIgG2a PKIKDVLMISLSPIVTCVVVDVSED (SEQ TTCHVHAKSNLRHWNKTCELTLVRQASWAC (LALAPG)- DPDVQISWFVNNVEVHTAQTQTHRE ID NLILGSFPESQSLTSVDLLDINWCWEEKGWR mCD122- DYNSTLRVVSALPIQHQDWMSGKEF NO: RVKTCDFHPFDNLRLVAPHSLQVLHIDTQR NoAnnotation KCKVNNKDLGAPIERTISKPKGSVR 14) CNISWKVSQVSHYIEPYLEFEARRRLLGHS Found APQVCVLPPPEEEMTKKQVTLSCAV WEDASVLSLKQRQQWLFLEMLIPSTSYEVQ TDFMPEDIWEWTNNGKTELNYKNTE VRVKAQRNNTGTWSPWSQPLTFRTRPADPM PVLDSDGSYFMVSKLRVEKKNWVER KE NSYSCSWHEGLHNHHTTKSFSRTPG (SEQ ID NO: 326) (SEQ ID NO: 281) DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS AVNGTSQFTCFYNSRANISCVWSQOGALQD hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ TSCQVHAWPDRRRWNGTCELLPVSQASWAC hCD122 EVHNAKTKPREEQYASTYRVVSVLTVLHQDW ID NLILGAPDSQKLTTVDIVTLRVLCREGVRWR (C168S) LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: VMAIGDFKPFENLRIMAPISLQVVHVETHR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS 14) CNISWEISQASHYFERHLEFEARTLSPGHT DIAVEWESNGQPENNYKTTPPVLDSDGSFFL WEEAPLLTLKQKQEWISLETLTPDTQYEFQ VSKLTVDKSRWQQGMVFSCSVMHEALHNHY yRVKPLQGEFTTWSPWSQPLAFRTKPAALGK TQKSLSLSPG D (SEQ ID NO: 327) (SEQ ID NO: 9) DNA530 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GGSSPP APTSSSTKKTQL mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE GGGSSG QLEHLLLDLQMILNGINNYKNPKL (DAPG)- VQFSWFVDDVEVHTAQTQPSEEQFN GGSGP TAMLTAKFAMPKKATELKHLQCL hIL2 STFRSVSELPIMHQDWLNGKEFKCR (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR (R38A, VNSAAFGAPIEKTISKTKGRPKAPQ NO: 23) DLISNINVIVLELKGSETTFMCEY F42A, VYTIPPPKEQMAKDKVSLTCMITDF ADETATIVEFLNRWITFAQSIISTLT Y45A, FPEDITVEWQWNGQPAENYDNTQPI (SEQ ID NO: 3) E62A, MOTDGSYFVYSDLNVQKSNWEAGNT C125A) FTCSVLHEGIHNHHTEKSLSHSPG (SEQ ID NO: 283) DNA531 Knob: VRSGCKPCICTVPEVSSVFIFPPKP GSPG VPLSLY mFcIgG1 KDVLTITLTPKVTCVVVAISKDDPE (SEQ (SEQ (DAPG)- VQFSWFVDDVEVHTAQTQPSEEQFN ID ID [VPLSLY] STFRSVSELPIMHQDWLNGKEFKCR NO: NO: hIL2 VNSAAFGAPIEKTISKTKGRPKAPQ 34) 28) (R38A, VYTIPPPKEQMAKDKVSLTCMITDF F42A, FPEDITVEWQWNGQPAENYDNTQPI Y45A, MOTDGSYFVYSDLNVQKSNWEAGNT E62A, FTCSVLHEGIHNHHTEKSLSHSPG C125A) (SEQ ID NO: 283) DNA532 Hole: VRSGCKPCICTVPEVSSVFIFPPKP mFcIgG1 KDVLTSTLTPKVTCVVVAISKDDPE (DAPG) VQFSWFVDDVEVHTAQTQPREEQFN STFRSVSELPIMHQDWINGKEFKCR VNSAAFGAPIEKTISKTKGRPKAPQ VYTIPPPKKQMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPI MKTDGSYFVYSKLNVQKSNWEAGNT FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) DNA533 Hole: VRSGCKPCICTVPEVSSVFIFPPKP PGSGS AVNGTSQFTCFYNSRANISCVWSQDGALQDT mFcIgG1 KDVLTSTLTPKVTCVVVAISKDDPE (SEQ SCQVHAWPDRRRWNQTCELLPVSQASWACN (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN ID LILGAPDSQKLTTVDIVTLRVLCREGVRWR hCD122 STFRSVSELPIMHQDWINGKEFKCR NO: VMAIQDFKPFENLRLMAPISLQVVHVETHR VNSAAFGAPIEKTISKTKGRPKAPQ 14) CNISWEISQASHYFERHLEFEARTLSPGHT VYTIPPPKKQMAKDKVSLTCMITDF WEEAPLLTLKQKQEWICLETLTPDTQYEFQ FPEDITVEWQWNGQPAENYKNTQPI VRVKPLQGEFTTWSPWSQPLAFRTKPAALG MKTDGSYFVYSKLNVQKSNWEAGNT KD (SEQ ID NO: 4) FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 284) DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKP AVKNCSHLECFYNSRANVSCMWSHEEALNV mFcIgG1 KDVLTSTLTPKVTCVVVAISKDDPE TTCHVHAKSNLRHWNKTCELTLVRQASWAC (DAPG)- VQFSWFVDDVEVHTAQTQPREEQFN NLILGSFPESQSLTSVDLLDINWCWEEKGWR mCD122 STFRSVSELPIMHQDWINGKEFKCR RVKTCDFHPFDNLRLVAPHSLQVLHIDTQR VNSAAFGAPIEKTISKTKGRPKAPQ CNISWKVSQVSHYIEPYLEFEARRRLLGHS VYTIPPPKKQMAKDKVSLTCMITDF WEDASVLSLKQRQQWLFLEMLIPSTSYEVQ FPEDITVEWQWNGQPAENYKNTQPI VRVKAQRNNTGTWSPWSQPLTFRTRPADPM MKTDGSYFVYSKLNVQKSNWEAGNT KE FTCSVLHEGLHNHHTEKSLSHSPG (SEQ ID NO: 326) (SEQ ID NO: 284) DNA542 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK APTSSSTKKTQL hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP QLEHLLLDLQMILNGINNYKNPKL hIL2(R38A, EVKFNWYVDGVEVHNAKTKPREEQY TAMLTAKFAMPKKATELKHLQCL F42A, ASTYRVVSVLTVLHQDWLNGKEYKC EEALKPLEEVLNLAQSKNFHLRPR Y45A, KVSNKALPAPIEKTISKAKGQPREP DLISNINVIVLELKGSETTFMCEY E62A, QVYTLPPCRDELTKNQVSLWCLVKG ADETATIVEFLNRWITFAQSIISTLT C125A) FYPSDSAVEWESNGQPENNYKTTPP (SEQ ID NO: 3) VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA543 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL GPPSG VPLSLY hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV SSPG (SEQ [VPLSLY] EVHNAKTKPREEQYASTYRVVSVLTVLHQDW (SEQ ID hCD122 LNGKEYKCKVSNKALPAPIEKTISKAKGQPR ID NO: EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS NO: 28) DIAVEWESNGQPENNYKTTPPVLDSDGSFFL 36) VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA544 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ (SEQ [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY ID ID hIL2(R38A, ASTYRVVSVLTVLHQDWLNGKEYKC NO: NO: F42A, KVSNKALPAPIEKTISKAKGQPREP 34) 28) Y4SA, E62A, QVYTLPPCRDELTKNQVSLWCLVKG L30F, R81D, FYPSDSAVEWESNGQPENNYKTTPP L85V, 186V, VIDSDGSFFLYSKITVDKSRWQQGN I92F, VFSCSVMHEALHNHYTQKSLSLSPG C125A) (SEQ ID NO: 12) DNA545 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GISSGLL APTSSSTKKTQL hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP SGRSSGP QLEHLLLDLQMILNGINNYKNPKL hIL2(R38A, EVKFNWYVDGVEVHNAKTKPREEQY (SEQ ID TAMLTAKFAMPKKATELKHLQCL F42A, ASTYRVVSVLTVLHQDWLNGKEYKC NO: 311) EEALKPLEEVLNLAQSKNFHLRPR Y45A, KVSNKALPAPIEKTISKAKGQPREP DLISNINVIVLELKGSETTFMCEY F62A, QVYTLPPCRDELTKNQVSLWCLVKG ADETATIVEFLNRWITFAQSIISTLT C125A) FYPSDSAVEWESNGQPENNYKTTPP (SEQ ID NO: 3) VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA546 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GGSSPP APTSSSTKKTQLQIEHLLLDLQMIINGINNY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP GGGSSG KNPKLTAMLTAKFAMPKKATELKHLQCLEE hIL2(R38A, EVKFNWYVDGVEVHNAKTKPREEQY GGSGP ALKPLEEVLNLAQSKNFHFDPRDVVSNINV F42A, ASTYRVVSVLTVLHQDWLNGKEYKC (SEQ ID FVLELKGSETTFMCEYADETATIVEFLNRW Y45A, E62A, KVSNKALPAPIEKTISKAKGQPREP NO: 23) ITFAQSIISTLT (SEQ ID NO: 328) L80F, R81D, QVYTLPPCRDELTKNQVSLWCLVKG L85V, 186V, FYPSDSAVEWESNGQPENNYKTTPP 192F VIDSDGSFFLYSKITVDKSRWQQGN C125A) VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA547 Hole: EPKSSDKTHTCPPCPAPELLGGPSV DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS hFcIgG1 FLFPPKPKDTLMISRTPEVTCVVVD MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ (N297A VSHEDPEVKFNWYVQGVEVHNAKTK EVHNAKTKPREEQYASTYRVVSVLTVLHQDW ID + EPKSS)- PREEQYASTYRVVSVLTVLHQDWLN LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: Hole: GKEYKCKVSNKALPAPIEKTISKAK EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS 14) hFc(N297A)- GQPREPQVCTLPPSRDELTKNQVSL DIAVEWESNGQPENNYKTTPPVLDSDGSFFL hCD122 SCAVKGFYPSDIAVEWESNGQPENN VSKLTVDKSRWQQGMVFSCSVMHEALHNHY YKTTPPVLDSDGSFFLVSKLTVDKS TQKSLSLSPG RWQQGNVFSCSVMHEALHNHYTQKS (SEQ ID NO: 9) LSLSPG (SEQ ID NO: 285) DNA548 Hole: AKTDKTHTCPPCPAPELLGGPSVFL DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS hFcIgG1 FPPKPKDTLMISRTPEVTCVVVDVS MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ (N297A HEDPEVKFNWYVDGVEVHNAKTKPR EVHNAKTKPREEQYASTYRVVSVLTVLHQDW ID + AKT)- EEQYASTYRWSVLTVLHQDWLNGKE LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: Hole: YKCKVSNKALPAPIEKTISKAKGQP EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS 14) hFc(N297A)- REPQVCTLPPSRDELTKNQVSLSCA DIAVEWESNGQPENNYKTTPPVLDSDGSFFL hCD122 VKGFYPSDIAVEWESNGQPENNYKT VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TPPVLDSDGSFFLVSKLTVDKSRWQ TQKSLSLSPG QGNVFSCSVMHEALHNHYTQKSLSL (SEQ ID NO: 9) SPG (SEQ ID NO: 286) DNA549 Hole: AKTEPKSSDKTHTCPPCPAPELLGGPSVFL EPKSSDKTHTCPPCPAPELLGGPSV DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFcIgG1 FPPKPKOTLMISRTPEVTCVVVDVSHEDPE FLFPPKPKDTLMISRTPEVTCVVVD MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (N297A + VKFNWYVDGVEVHNAKTKPREEQYASTYRV VSHEDPEVKFNWYVQGVEVHNAKTK EVHNAKTKPREEQYASTYRVVSVLTVLHQDW AKTEP VSVLTVLHQDWLNGKEYKCKVSNKALPAPI PREEQYASTYRVVSVLTVLHQDWLN LNGKEYKCKVSNKALPAPIEKTISKAKGQPR KSS)- EKTISKAKGQPREPQVCTLPPSRDELTKNQ GKEYKCKVSNKALPAPIEKTISKAK EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS Hole: VSLSCAVKGFYPSDIAVEWESNGQPENNYK GQPREPQVCTLPPSRDELTKNQVSL DIAVEWESNGQPENNYKTTPPVLDSDGSFFL hFc(N297A TTPPVLDSDGSFFLVSKLTVDKSRWQQGNV SCAVKGFYPSDIAVEWESNGQPENN VSKLTVDKSRWQQGMVFSCSVMHEALHNHY + EPKSS)- FSCSVMHEALHNHYTQKSLSLSPG YKTTPPVLDSDGSFFLVSKLTVDKS TQKSLSLSPG hFc(N297A)- (SEQ ID NO: 287) RWQQGNVFSCSVMHEALHNHYTQKS (SEQ ID NO: 9) hCD122 LSLSPG (SEQ ID NO: 285) DNA550 Knob: FPKSSDKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFclgG1 KPKDTLMISRTPEVTCVVVDVSHEDPEVKF (SEQ ID (SEQ ID (N297A NWYVDGVEVHNAKTKPREEQYASTYRVVSV NO: 34) NO: 28) + EPKSS)- LTVLHQOWLNGKEYKCKVSNKALPAPIEKT [VPLSLY]- ISKAKGQPREPQVYTLPPCRDELTKNQVSL hIL2 WCLVKGFYPSDIAVEWESNGQPENNYKTTP (R38A, FA2A, PVLDSDGSFFLYSKLTVDKSRYVQQGNVFS Y45A, CSVMHEALHNHYTQKSLSLSPG E62A, (SEQ ID NO: 288) C125A) DNA551 Knob: AKTDKTHTCPPCPAPELLGGPSVELFPPKP GSPG VPLSLY hFcIgG1 KDTLMISRTPEVTCVVVDVSHEDPEVKFNW (SEQ ID (SEQ ID (N297A YVDGVEVHNAKTKPREEQYASTYRVVSVLT NO: 34) NO: 28) + AKT)-[VPLSLY]- VLHQDWLNGKEYKCKVSNKALPAPIEKTIS hIL2 KAKGQPREPQVYTLPPCRDELTKNQVSLWC (R38A, F42A, LVKGFYPSDIAVEWESNGQPENNYKTTPPV Y45A, LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV E62A, MHEALHNHYTQKSLSLSPG C125A) (SEQ ID NO: 289) DNA552 Knob: AKTEPKSSDKTHTCPPCPAPELLGGPSVFLF GSPG VPLSLY hFcIgG1 PPKPKDTLMISRTPEVTCVVVDVSHEDPEV (SEQ ID (SEQ ID (N297A KFNVVYVDGVEVHNAKTKPREEQYASTYRV NO: 34) NO: 28) + AKTEPKSS) VSVLTVLHQDWLNGKEYKCKVSNKALPAPI Knob: EKTISKAKGQPREPQWTLPPCRDELTKNQV [VPLSLY]- SLWCLVKGFYPSDIAVEWESNGQPENNYKT hIL2 TPPVLDSDGSFFLYSKLTVDKSRVVQQGNV (R38A, F42A, FSCSVMHEALHNHYTQKSLSLSPG Y45A, (SEQ ID NO: 290) E62A, C125A) DNA553 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL GPPSG DSGGFMLT hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV SSPG (SEQ ID [DSGGFMLT]- EVHNAKTKPREEQYASTYRVVSVLTVLHQDW (SEQ ID NO: 25) hCD122 LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: 36) EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA554 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (E15R, L18C, KVSNKALPAPIEKTISKAKGQPREP D20R, QVYTLPPCRDELTKNQVSLWCLVKG R38A, FYPSDSAVEWESNGQPENNYKTTPP F42A, VIDSDGSFFLYSKITVDKSRWQQGN Y45A, VFSCSVMHEALHNHYTQKSLSLSPG E62A) (SEQ ID NO: 12) DNA563 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (E15R, L18C, KVSNKALPAPIEKTISKAKGQPREP D20R, QVYTLPPCRDELTKNQVSLWCLVKG R38A, FYPSDSAVEWESNGQPENNYKTTPP F42A, VIDSDGSFFLYSKITVDKSRWQQGN Y45A, VFSCSVMHEALHNHYTQKSLSLSPG E62A, (SEQ ID NO: 12) N88L) DNA565 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (E15R, L18C, KVSNKALPAPIEKTISKAKGQPREP D20R, QVYTLPPCRDELTKNQVSLWCLVKG R38A, FYPSDSAVEWESNGQPENNYKTTPP F42A, VIDSDGSFFLYSKITVDKSRWQQGN Y45A, VFSCSVMHEALHNHYTQKSLSLSPG E62A, (SEQ ID NO: 12) N88L) DNA566 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (E15R, L18C, KVSNKALPAPIEKTISKAKGQPREP R38A, QVYTLPPCRDELTKNQVSLWCLVKG F42A, FYPSDSAVEWESNGQPENNYKTTPP Y45A, VIDSDGSFFLYSKITVDKSRWQQGN E62A, VFSCSVMHEALHNHYTQKSLSLSPG N88L) (SEQ ID NO: 12) DNA567 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (L18C, KVSNKALPAPIEKTISKAKGQPREP D20R, QVYTLPPCRDELTKNQVSLWCLVKG R38A, FYPSDSAVEWESNGQPENNYKTTPP F42A, VIDSDGSFFLYSKITVDKSRWQQGN Y45A, VFSCSVMHEALHNHYTQKSLSLSPG E62A, (SEQ ID NO: 12) N88L) DNA568 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (E15F, KVSNKALPAPIEKTISKAKGQPREP L18C, QVYTLPPCRDELTKNQVSLWCLVKG D20R, FYPSDSAVEWESNGQPENNYKTTPP R38A, VIDSDGSFFLYSKITVDKSRWQQGN F42A, VFSCSVMHEALHNHYTQKSLSLSPG Y45A, (SEQ ID NO: 12) E62A, N88L) DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL PGSGS AVNGTSQFTCF hFc(N297A, MASRTPEVTCVVVDVSHEDPEVKFNWYVDG (SEQ ID YNSRANISCVW I253A)-hCD122 VEVHNAKTKPREEQYASTYRVVSVLTVLHQ NO: 14) SQDGALQDTSC DWLNGKEYKCKVSNKALPAPIEKTISKAKG QVHAWPDRRR QPREPQVCTIPPSRDELTKNQVSLSCAVKG WNQTCELLPVS FYPSDIAVEWESNGQPENNYKTTPPVLDSD QASWACNLILG GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA APDSQKLTTVDI LHNHYTQKSLSLSPG (SEQ ID NO: 10) VTLRVLCREGVR WRVMAIQDFK PFENLRLMAPIS LQVVHVETHRC NISWEISQASHY FERHLEFEARTL SPGHTWEEAPL LTLKQKQEWICL ETLTPDTQYEFQ VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPP PGSGS AVNGTSQFTCFYNSRANISCVW hFc(N297A, KPKDTLYITREPEVTCVVVDVSHED (SEQ ID SQDGALQDTSCQVHAWPDRRR M252Y, S254T, PEVKFNWYVDGVEVHNAKTKPREEQ NO: 14) WNQTCELLPVSQASWACNLILG T256E)- YASTYRVVSVLTVLHQDWLNGKEYK APDSQKLTTVDIVTLRVLCREGVR hCD122 CKVSNKALPAPIEKTISKAKGQPRE WRVMAIQDFKPFENLRLMAPIS PQVCTLPPSRDELTKNQVSLSCAVK LQVVHVETHRCNISWEISQASHY GFYPSDIAVEWESNGQPENNYKTTP FERHLEFEARTLSPGHTWEEAPL PVIDSDGSFFLVSKLTVDKSRWQQG LTLKQKQEWICLETLTPDTQYEFQ NVFSCSVMHEALHNHYTQKSLSLSP VRVKPLQGEFTTWSPWSQPLAFR G (SEQ ID NO: 292) TKPAALGKD (SEQ ID NO: 4) DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPPG APTSSSTKKTQL hFc(N297, KPKDTLMASRTPEVTCVVVDVSHED GGSSG QLEHLLLDLQMILNGINNYKNPKL I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ GGSGP TAMLTAKFAMPKKATELKHLQCL hIL2(R38A, YASTYRVVSVLTVLHQDWLNGKEYK (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR F42A, CKVSNKALPAPIEKTISKAKGQPRE NO: 23) DLISNINVIVLELKGSETTFMCEY Y45A, E62A, PQVYTLPPCRDELTKNQVSLWCLVK ADETATIVEFLNRWITFAQSIISTLT C125A) GFYPSDIAVEWESNGQPENNYKTTP (SEQ ID NO: 3) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) DNA578 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPPG APTSSSTKKTQL hFc(N297A, KPKDTLYITREPEVTCWVDVSHEDP GGSSG QLEHLLLDLQMILNGINNYKNPKL M252Y, S254T, EVKFNWYVDGVEVHNAKTKPREEQY GGSGP TAMLTAKFAMPKKATELKHLQCL T256E)- ASTYRWSVLTVLHQDWLNGKEYKCK (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR hIL2 VSNKALPAPIEKTISKAKGQPREPQ NO: 23) DLISNINVIVLELKGSETTFMCEY (R38A, F42A, VYTLPPCRDELTKNQVSLWCLVKGF ADETATIVEFLNRWITFAQSIISTLT Y45A, E62A, YPSDIAVEWESNGQPENNYKTTPPV (SEQ ID NO: 3) C125A) LDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 294) DNA579 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) [VPLSLY]- YASTYRVVSVLTVLHQDWLNGKEYK hIL2 CKVSNKALPAPIEKTISKAKGQPRE (R38A, F42A, PQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, GFYPSDIAVEWESNGQPENNYKTTP C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 13) DNA580 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY hFc(N297A, KPKDTLYITREPEVTCWVDVSHEDP (SEQ ID (SEQ ID M252Y, S254T, EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) T256E)- ASTYRWSVLTVLHQDWLNGKEYKCK [VPLSLY]- VSNKALPAPIEKTISKAKGQPREPQ hIL2 VYTLPPCRDELTKNQVSLWCLVKGF (R38A, F42A, YPSDIAVEWESNGQPENNYKTTPPV Y45A, E62A, LDSDGSFFLYSKLTVDKSRWQQGNV C125A) FSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 294) DNA581 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(L18C, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, KVSNKALPAPIEKTISKAKGQPREP F42A, Y45A, QVYTLPPCRDELTKNQVSLWCLVKG E62A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA582 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16Y, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, E62A, QVYTLPPCRDELTKNQVSLWCLVKG C125A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA583 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPISLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16E, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, E62A, QVYTLPPCRDELTKNQVSLWCLVKG C125A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA584 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2 ASTYRVVSVLTVLHQDWLNGKEYKC (D20L, R38A, KVSNKALPAPIEKTISKAKGQPREP F42A, Y45A, QVYTLPPCRDELTKNQVSLWCLVKG E62A, C125A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA585 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16Y, L18C, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, E62A) QVYTLPPCRDELTKNQVSLWCLVKG FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA586 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16E, L18C, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, E62A) QVYTLPPCRDELTKNQVSLWCLVKG FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA587 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(L18C, D20L, ASTYRVVSVLTVLHQDWLNGKEYKC R38A, F42A, KVSNKALPAPIEKTISKAKGQPREP Y45A, E62A) QVYTLPPCRDELTKNQVSLWCLVKG FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA588 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPLSLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16Y, L18C, ASTYRVVSVLTVLHQDWLNGKEYKC D20L, R38A, KVSNKALPAPIEKTISKAKGQPREP F42A, Y4SA, QVYTLPPCRDELTKNQVSLWCLVKG E62A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA589 Knob: DKTHTCPPCPAPELLGGPSVFLFPPK GSPG VPLSLY hFc(N297A)- PKDTLMISRTPEVTCVVVDVSHEDP (SEQ ID (SEQ ID [VPISLY]- EVKFNWYVDGVEVHNAKTKPREEQY NO: 34) NO: 28) hIL2(H16E, L18C, ASTYRVVSVLTVLHQDWLNGKEYKC D20L, R38A, KVSNKALPAPIEKTISKAKGQPREP F42A, Y4SA, QVYTLPPCRDELTKNQVSLWCLVKG E62A) FYPSDSAVEWESNGQPENNYKTTPP VIDSDGSFFLYSKITVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12) DNA603 Hole: ESKYGPPCPPCPAPEFLGGP PGSGS AVNGTSQFTCFYNSRANISCVW hFcIgG4- SVFLFPPKPKDTLMISRTPE (SEQ ID SQDGALQDTSCQVHAWPDRRR hCD122 VTCVVVDVSQEDPEVQFNWY NO: 14) WNQTCELLPVSQASWACNLILG VDGVEVHNAKTKPREEQFNS APDSQKLTTVDIVTLRVLCREGVR TYRVVSVLTVLHQDWLNGKE WRVMAIQDFKPFENLRLMAPIS YKCKVSNKGLPSSIEKTISK LQVVHVETHRCNISWEISQASHY AKGQPREPQVCTLPPSQEEM FERHLEFEARTLSPGHTWEEAPL TKNQVSLSCAVKGFYPSDIA LTLKQKQEWICLETLTPDTQYEFQ VEWESNGQPENNYKTTPPVL VRVKPLQGEFTTWSPWSQPLAFR DSDGSFFLYSRLTVDKSRWQ TKPAALGKD EGNVFSCSVMHEALHNHYTQ (SEQ ID NO: 4) KSLSLSLG (SEQ ID NO: 295) DNA604 Knob: ESKYGPPCPPCPAPEFLGGP GSSPPGG APTSSSTKKTQL hFc(N297A)- SVFLFPPKPKDTLMISRTPE GSSGG QLEHLLLDLQMILNGINNYKNPKL hIL2 VTCVVVDVSQEDPEVQFNWY GSGP TAMLTAKFAMPKKATELKHLQCL (R38A, VDGVEVHNAKTKPREEQFNS (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR F42A, TYRVVSVLTVLHQDWLNGKE NO: 23) DLISNINVIVLELKGSETTFMCEY Y45A, YKCKVSNKGLPSSIEKTISK ADETATIVEFLNRWITFAQSIISTLT E62A, AKGQPREPQVYTLPPSQEEM (SEQ ID NO: 3) C125A) TKNQVSLSWCLVKGFYPSDI AVEWESNGQPENNYKTTPPV LDSDGSFFLYSRLTVDKSRW QEGNVFSCSVMHEALHNHYT QKSLSLSLG (SEQ ID NO: 296) DNA605 Knob: hFc(N297A)- ESKYGPPCPPCPAPEFLGGP GSPG VPLSLY [VPLSLY]- SVFLFPPKPKDTLMISRTPE (SEQ ID (SEQ ID hIL2 VTCVVVDVSQEDPEVQFNWY NO: 34) NO: 2 (R38A, VDGVEVHNAKTKPREEQFNS 8) F42A, Y45A, TYRVVSVLTVLHQDWLNGKE E62A, YKCKVSNKGLPSSIEKTISK C125A) AKGQPREPQVYTLPPSQEEM TKNQVSLSWCLVKGFYPSDI AVEWESNGQPENNYKTTPPV LDSDGSFFLYSRLTVDKSRW QEGNVFSCSVMHEALHNHYT QKSLSLSLG (SEQ ID NO: 296) DNA606 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL GPPSGSSP RAAAVKSP hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ ID (SEQ ID [RAAAVKSP]- EVHNAKTKPREEQYASTYRVVSVLTVLHQDW NO: 37) NO: 27) hCD122 LNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA608 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSGSSP MPYDLYHP hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHEQ (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 37) NO: 24) [MPYDLYHP]- YASTYRVVSVLTVLHQDWLNGKEYK hCD122 CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFIVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) DNA609 Hole: DKTHTCPPCPAPELLGGPSVFLFPP GPPSG VPLSLY hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHEQ SSPG (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ (SEQ ID NO: 28) [VPLSLY]- YASTYRVVSVLTVLHQDWLNGKEYK NO: 36) hCD122 CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFIVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) DNA612 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL GPPSGSSP MPYDLYHP hFc(N297A, MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV (SEQ ID (SEQ ID I253A)- EVHNAKTKPREEQYASTYRVVSVLTVLHQDW NO: 37) NO: 24) [MPYDLYHP]- LNGKEYKCKVSNKALPAPIEKTISKAKGQPR hCD122 EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS (C122S, DIAVEWESNGQPENNYKTTPPVLDSDGSFFL C168S) VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA614 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL GPPSG DSGGFMLT hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDGV SSPG (SEQ ID [DSGGFMLT]- EVHNAKTKPREEQYASTYRVVSVLTVLHQDW (SEQ ID NO: 25) hCD122 LNGKEYKCKVSNKALPAPIEKTISKAKGQPR NO: 36) (C122S, EPQVCTLPPSRDELTKNQVSLSCAVKGFYPS C168S) DIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGMVFSCSVMHEALHNHY TQKSLSLSPG (SEQ ID NO: 9) DNA621 Hole: ESKYGPPCPPCPAPELLGGPSVFLF PSGSSPG VPLSLY hFcIgG4- PPKPKDTLMISRTPEVTCVVVDVSH (SEQ ID (SEQ ID [VPLSLY]- EDPEVKFNWYVDGVEVHNAKTKPRE NO: 313) NO: 28) hCD122 EQYASTRYRVVSVLTVLHQDWLNGK EYKCKVSNKGLPSSIEKTISKAKGQ PREPQVCTLPPSQEEMTKNQVSLSC AVKGFYPSDIAVEWESMGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRW QEGNVFSCSVMHEALHNHYTQKSLS LSLGGP (SEQ NO: 297) DNA623 Knob: DKTHTCPPCPAPELLGGPSVFLFPP GGSSPP MPYDLYHP hFc(N297A, KPKDTLMASRTPEVTCVVVDVSHED (SEQ ID (SEQ ID I253A)- PEVKFNWYVDGVEVHNAKTKPREEQ NO: 32) NO: 24) [MPYDLYHP]- YASTYRVVSVLTVLHQDWLNGKEYK hIL2(R38A, CKVSNKALPAPIEKTISKAKGQPRE F42A, PQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, GFYPSDIAVEWESNGQPENNYKTTP C125A) PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLS PG (SEQ ID NO: 13) DNA625 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297, KPKDTLMASRTPEVTCVVVDVSHEQ I253A) PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFIVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) DNA626 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIGg4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGPG (SEQ ID NO: 298) DNA669 Hole: DKTHTCPPCPAPELLGGPSVFLF PGSGS AVNGTSQFTCFYNSRANISCVW hFc- PPKPKDTLMISRTPEVTCVVVDV (SEQ ID SQDGALQDTSCQVHAWPDRRR hCD122 SHEDPEVKFNWYVDGVEVHNAKT NO: 14) WNQTCELLPVSQASWACNLILG KPREEQYNSTYRVVSVLWLHQDW APDSQKLTTVDIVTLRVLCREGVR LNGKEYKCKVSNKALPAPIEHIS WRVMAIQDFKPFENLRLMAPIS KAKGQPREPQVCTLPPSRDELTK LQVVHVETHRCNISWEISQASHY NQVSLSCAVKGFYPSDIAVEWES FERHLEFEARTLSPGHTWEEAPL NGQPENNYKTTPPVLDSDGSFFL LTLKQKQEWICLETLTPDTQYEFQ VSKLTVDKSRWQQGNVFSCSVMH VRVKPLQGEFTTWSPWSQPLAFR EALHNHYTQKSLSLSPG TKPAALGKD (SEQ ID NO: 8) (SEQ ID NO: 4) DNA670 Knob: hFc- DKTHTCPPCPAPELLGGPSVFLFPP GGSSPPG APTSSSTKKTQL hIL2 KPKDTLMISRTPEVTCVVVDVSHED GGSSG QLEHLLLDLQMILNGINNYKNPKL (R38A, F42A, PEVKFNWYVDGVEVHNAKTKPREEQ GGSGP TAMLTAKFAMPKKATELKHLQCL Y45A, E62A, YNSTYRVVSVLTVLHQDWLNGKEY (SEQ ID EEALKPLEEVLNLAQSKNFHLRPR C125A) KCKVSNKALPAPIEKTISKAKGQPR NO: 23) DLISNINVIVLELKGSETTFMCEY EPQVYTLPPCRDEL TKNQVSLWCL ADETATIVEFLNRWITFAQSIISTLT VKGFYPSDIAVEWESNGQPENNYKT (SEQ ID NO: 3) TPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSL SPG (SEQ ID NO: 11) DNA671 Knob: hFc- DKTHTCPPCPAPELLGGPSVFLFPP GSPG VPLSLY [VPLSLY]- KPKDTLMISRTPEVTCVVVDVSHED (SEQ ID (SEQ ID hIL2 PEVKFNWYVDGVEVHNAKTKPREEQ NO: 34) NO: 28) (R38A, F42A, YNSTYRVVSVLTVLHQDWLNGKEY Y45A, E62A, KCKVSNKALPAPIEKTISKAKGQPR C125A) EPQVYTLPPCRDEL TKNQVSLWCL VKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSL SPG (SEQ ID NO: 11) DNA672 Hole: DKTHTCPPCPAPELLGGPSVFLF GPPSGSSPG VPLSLY hFcIgG4- PPKPKDTLMISRTPEVTCVVVDV (SEQ ID (SEQ ID [VPLSLY]- SHEDPEVKFNWYVDGVEVHNAKT NO: 36) NO: 28) hCD122 KPREEQYNSTYRVVSVLWLHQDW LNGKEYKCKVSNKALPAPIEHIS KAKGQPREPQVCTLPPSRDELTK NQVSLSCAVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSPG (SEQ ID NO: 8) NAME NEW COMPONENT4 COMPONENT5 FULL NAMES SEQUENCE SEQUENCE SEQUENCE DNA158 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A) LMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYASTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG (SEQ ID NO: 9) DNA187 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH QBWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVWGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHBCNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWICLETLTPDTQYEPQVRVKPLQG EFTTWSPWSQFLAFRTKPAALGKD (SEQ ID NO: 38) DNA255 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD bIL2(R38A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH F42A, QDWLNGKEYKCKVSNKALPAPIEKTISKAK Y45A, E62A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK C125A) GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNAQSKNFHLRPRDLISN INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 51) DNA263 Knob: SGP(SEQ APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLT DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- ID NO: AMLTAKFAMPKKATELKHLQCLEEALKPLEEVLNLAQ LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- 23) SKNFHLRPRDLISNINVIVLELKGSETTFMCEYADET GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(R38A, ATIVEFLNRWITFAQSIISTLT QDWLNGKEYKCKVSNKALPAPIEKTISKAK F42A, (SEQ ID NO: 3) GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS C525A) DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSFGGSPGVPLSLYSGPA PTSSSTKKTQLQLEHLLLDLQMILNGINNY KNPKLTAMLTAKFAMPKKATELKHLQCLEE ALKPLEEVLNLAQSKNFHLRPRDLISNINV IVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT (SEQ ID NO: 49) DNA278 Knob: SGP (SEQ APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLT DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- ID NO: RMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQ LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [DSGGFMLT]- 23) SKNFHLRPRDLISNINVIVLELKGSETTFMCEYADET GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(C125A) ATIVEFLNRWITFAQSIISTLT QDWLNGKEYKCKVSNKALPAPIEKTISKAK (SEQ ID NO: 62) GQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGGSGPDSGGFMLTSG PAPTSSSTKKTQLQLEHLLLDLQMILNGIN NYKNPKLTRMLTSKFYMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNI NVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSIISTLT (SEQ ID NO: 357) DNA281 Knob: SGP(SEQ APTS8STKKTQLQLEHLLLDLQMILNGINNYKNPKLT DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- ID NO: AMLTAKFAMPKKATELKHLQCLEEALKPLEEYLNLAQ LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [DSGGFMLT]- 23) SKNFHLRPRDLISNINVIVLELKGSETTFMCEYADET GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(R38A, ATIVEFLNRWITFAQSIISTLT QDWLNGKEYKCKVSNKALPAPIEKTISKAK F42A, (SEQ ID NO: 3) GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, GFYPSDIAVEWSSNGQPENNYKTTPPVLDS C125A) DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALKNHYTQKSLSLSPGGSGPDSGGFMLTSG PAFTSSSTKKTQLQLEHLLLDLQMILNGIN NYKKPKLTAMLTAKFAMPKKATELKHLQCL EEALKPLEEVLNLAQSKNFHLRPRDLISNI NVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSIISTLT (SEQ ID NO: 48) DNA440 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD bCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH (C3l22S, QDWLNGKEYKCKVSNKALPAPIEKTISKAK C168S) GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWSSNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRSNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWISLETLTPDTQYEFQVRVKPLQG EFTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 39) DNA476 Knob: GP APTSSSTKKTQLQLEHLLLDLQMI DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT hFc(N297A)- LNGINNYKNPKLTRMLTSKFYMPK CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTY [NPMGSDP KATELKHLQCLEESLKPLEEVLNL RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK VNFKLLRVV AQSKNFHLRPRDLISNINVIVLEL GQPREPQVYT1PPCRDELTKNQVSLWCLVKGFYPSDIAVE NG]-hIL2 KGSETTFMCEYADETATIVEFLNR WESNGQPENNYKTTPPV1DSDGSFFLYSKLTVDKSRWQQG (F42S, WITFAQSIISTLT(SEQ ID NVFSCSVMHEALHNHYTQKSLSLSPG E62S, C1213A) NO: 74) (SEQ ID NO: 360) DNA477 Knob: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWEFNNVEVHTAQTQTHREDYNST (LALAPG)- LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP hIL2(R38A, KGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTDFMPEDIYV F42A, EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVE Y45A, E62A, RNSYSCSVVHEGLHNHHTTKSFSRTPGGGSSPPGGGSSGG C125A) GSGPAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKL TAMLTAKEAMPKKATELKHLQCLEEALKPLEEVLNLAQSK NFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVE FLNRWITFAQSIISTLT (SEQ ID NO: 361) DNA478 Knob: SGP APTSSSTKKTQL TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSP mFcIgG2a (SEQ ID QLEHLLLDLQMI IVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED (LALAPG)- NO: 29) LNGiNNYKNPKL YNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIE [VPLSLY]- TAMLTAKFAMP RTISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTD hIL2 KKATELKHLQCL FMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSK (R38A, EEALKPLEEVLN LRVEKKNWVERNSYSCSLLHEGLHNHHTTKSFSRTPGG F42A, LAQSKNFHLRPR SPGVPLSLYSGPAPTSSSTKKTQLQLEHLLLDLQMIL Y45A, DLISNINVIVLEL NGINNYKNPKLTAMLTAKFAMPKKATELKHLQCLEEA E62A, KGSETTFMCEY LKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS C125A) ADETATIVEFLN ETTFMCEYADETATIVEFLNRWITFAQSIISTLT RWITFAQSIISTL (SRQ ID NO: 362) T (SEQ ID NO: 3) DNA479 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDVLMISLSPIV mFcIgG2a TCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNST (LALAPG) LRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTISKP KGSVRAPQVCVLPPPEEEMTKKQVTLSCAVTDFMPEDIYV EWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVE RNSYSCVVHEGLHNHHTTKSFSRTPG (SEQ ID NO: 281) DNA480 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAPG)- NVEVHTAQTQTHREDYNSTLRVVSALPIQH hCD122 QDWMSGKEFKCKVNNKDLGAPIERTISKPK GSVRAPQVCVLPPPEEEMTKKQVTLSCAVT DFMPEDIYVEWTNNGCTELNYKNTEPVLDS DGSYFMVSKLRVEKKNWVERNSYSCSWHEG LKNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVVVSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQWHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 363) DNA516 F8ScFvVersion1- PGSGS AVNGTSQFTCFYNSRANISCVW EVQLLESGGGLVQPGGSLRISCAASGFTFSL Hole: (SEQ SQDGALQDTSCQVHAWPDRRR FTMSVVVRQAPGKGLEVVVSAISGSGGSTY hFc(N297A)- ID WNQTCELLPVSQASWACNLILG YADSVKGRFTISRDNSKNTYLQMNSLRAED hCD122 NO: APDSQKLTTVDIVTLRVLCREGVR TAVYYCAKSTHLYLFDYWGQGTLVTVSSGG 14) WRVMAIQDFKPFENLRLMAPIS GGSGGGGEIGGGGSEIVLTQSPGTLSISPG LQVVHVETHRCNISWEISQASHY ERATLSCRASQSVSMPFLAWYQQKPGQAPR FERHLEFEARTLSPGHTWEEAPL LLIYGASSRATGIPDRESGSGSGTDFTLTI LTLKQKQEWICLETLTPDTQYEFQ SRLEPEDFAVYYCQQMRGRPPTFGQGTKVE VRVKPLQGEFTTWSPWSQPLAFR IKGGSDKTHTCPPCPAPELLGGPSVFLFPP TKPAALGKD KPKDTLMISRTPEVTCVVVDVSHEDPEVKF (SEQ ID NO: 4) NWYVDGVEVHNAKTKPREEQYASTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVCTLPPSRDELTKNQVSL SCAVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGPGSGSAVNG TSQFTCFYNSRANISCVWSQDGALQDTSCQ VHAWPDRRRWNQTCELLPVSQASWACNLIL GAPDSQKLTTVDIVTLRVLCREGVRWRVMA IQDFKPFENLRLMAPISLQVVHVETHRCNI SWEISQASHYFERHLEFEARTLSPGHTWEE APLLTLKQKQEWICLETLTPDTQYEFQVRV KPLQGEFTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 364) DNA520 Hole: TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV mFcIgG2a LMLSLSPTVTCVVVDVSEDDPDVQISWFVN (LALAP NVEVHTAQTQTHREDYNSTLRVVSALPIQH G)- QDVVMSGKEFKCKVNNKDLGAPIERTISKP No KGSVRAPQVCVLPPPEEEMTKKQVTLSCAV AnnototationFound TDFMPEDIYVEWTNNGKTELNYKMTEPVLD SDGSYFMVSKLRVEKKNWVERNSYSCSVVH EGLHNHHTTKSFSRTPGHHHHHHHH (SEQ ID NO: 365) DNA521 Hole: GHHHH TIKPCPPCKCPAPNAAGGPSVFIFPPKIKDV hFcIgG2a HHHH LMISISPIVTCVVVDVSEDQPDVQISWFVN (LALAP (SEQ NVEVHTAQTQTHREDYNSTLRWSALPIQHQ G)- ID PWMSGKEFKCKVNNKDLGAPIERTISKPKG No NO: SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD AnnototationFound 334) FMPEDIYVEWTNNGKTELNYKNTEPVLDSD GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVNGTSQFTC FYNSRANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASVVACNLILGAPDS QKITTVDIVTLRVICREGVRWRVMAIQDFK PFENLRLMAPISLQWHVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP ILTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKDGHH HHHHHH (SEQ ID NO: 366) DNA522 Hole: GHHHH TIKPCPPCKCPAPNAAGGP5VFIFPPKIKDV mFcIgG2a HHHH LMISLSPIVTCVVVDVSEDDPDVQISWFVN (LALAP (SEQ NVEVHTAQTQTHREDYNSTLRWSALPIQHQ G)- ID DWMSGKEFKCKVNNKDLGAPIERTISKPKG No NO: SVRAPQVCVLPPPEEEMTKKQVTLSCAVTD AnnototationFound 334) FMPEDIYVEWTNNGKTELNYKNTEPVLDSD GSYFMVSKLRVEKKNWVERNSYSCSVVHEG LHNHHTTKSFSRTPGPGSGSAVKNCSHLEC FYNSRANVSCMWSHEEALNVTTCHVHAKSN LRHWNKTCELTLVRQASWACMLILGSFPES QSLTSVDLLDINVVCWEEKGWRRVKTCDFH PFDNLRLVAPHSLQVLHIDTQRCNISWKVS QVSHYIEPYLEFEARRRLLGHSWEDASVLS LKQRQQWLFLEMLIPSTSYEVQVRVKAQRN NTGTWSPWSQPLTFRTRPADPMKEGHHHHH HHH (SEQ ID NO: 367) DNA528 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYASTYRVVSVLTVLH (C168S) QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLV SKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGPGSGSAVNGTSQFTCFYNSRA NISCVWSQDGALQDTSCQVHAWPDRRRWNQ TCELLPVSQASWACNLILGAPDSQKLTTVD IVTLRVLCREGVRWRVMAIQDFKPFENLRL MAPISLQWHVETHRCNISWEISQASHYFER HLEFEARTLSPGHTWEEAPLLTLKQKQEWI SLFIITPDTQYEFQVRVKPLQGEFTTWSPW SQPLAFRTKPAALGKD (SEQ ID NO: 368) DNA530 Knob: VRSGCKPCICTVPEVSSVRFPPKPKDVLTI mFcIgG1 TLTPKVTCVVVAISKDDPEVQFSWFVDDVE (DAPG)- VHTAQTQPREEQFNSTFRSVSELPIMHQDW hIL2 LNGKEFKCRVNSAAFGAPIEKTISKTKGRP (R38A, KAPQVYTIPPPKEQMAKDKVSLTCMITDFF F42A, PEDITVEWQWNGQPAENYDNTQPIMDTDGS Y45A, YFVYSDLNVQKSNWEAGNTFTCSVLHEGLH E62A, NHHTEKSLSHSPGGGSSPPGGGSSGGGSGP C125S) APTSSSTKKTQLQLEHLLLDLQMILNGINN YKNPKLTAMLTAKFAMPKKATELKHLQCLE EALKPLEEVLNLAQSKNFHLRPRDLISNIN VIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSSISTLT (SEQ ID NO: 369) DNA531 Knob: SGP APTSSSTKKTQL VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 (SEQ QLEHLLLDLQMI ITLTPKVTCVVVAISKDOPEVQFSWFVDDV (DAPG)- ID LNGINNYKNPKL EVHTAQTQPREEQFNSTFRSVSELPIMHQD [VPLSLY] NO: TAMLTAKFAMP WLNGKEFKCRVNSMFGAPIEKTISKTKGRP hIL2 29) KKATELKHLQCL KAPQVYTIPPPKEQMAKDKVSLTCMITDFF (R38A, EEALKPLEEVLN PEDITVEWQWNGQPAENYDNTQPIMDTDGS F42A, LAQSKNFHLRPR YFVYSDLNVQKSNWEAGNTFTCSVLHEGLH Y45A, DLISNINVIVL NHHTEKSLSHSPGGSPGVPLSLYSGPAPTS E62A, ELKGSETTFMC SSTKKTQLQLEHLILDIQMILNGINNYKNP C125S) EYADETATIVEF KLTAMLTAKFAMPKKATELKHLQCLEEALK LNRWITFAQSII PLEEVLIMLAQSKNFHLRPRDLISNIVIVL STLT ELKGSETTFMCEYADETATIVEFLNRWSTF (SEQ ID AQSIISTLT (SEQ ID NO: 370) NO: 3) DNA532 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLH mFcIgG1 TLTPKVTCVVVAISKDDPEVQFSWFVDDVE (DAPG) VHTAQTQPREEQFNSTFRSVSELPIMHQDW LNGKEFKCRVNSAAFGAPIEKTISKTKGRP KAPQVYTIPPPKKQMAKDKVSLTCMITDFF PEDITVEWQWNGQPAENYKNTQPIMKTDGS YFWSKLNVQKSNWEAGNTFTCSVLHEGLHN HHTEKSLSHSPG (SEQ ID NO: 284) DNA533 Hole: VRSGCKPGCTVPGVSSVFIFPPKPKDVLTI mFcIgG1 TLTPKVTCVVVAISKDDPEVQFSWFVDDVE (DAP VHTAQTQPREEQFNSTFRSVSELPIMHQDW G)- LNGKEFKCRVNSAAFGAPIEKTISKTKGRP hCD122 KAPQVYTIPPPKKQPMAKDKVSLTCMITDF FPEDITVEWQWNGQPAENYKNTQPIMKTDG SYFVYSKLNVQKSNWEAGNTFTCSVLHEGL HNHHTEKSLSHSPGPGSGSAVNGTSQFTCF YNSRANISCVWSQPGALQPTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGAPDSQK LTTVDIVTLRVLCREGVRWRVMAIQDFKPF ENLRLMAPISLQVVHVETHRCNISWEISQAS HYFERHLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPLQGEFT TTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 371) DNA534 Hole: VRSGCKPCICTVPEVSSVFIFPPKPKDVLT mFcIgG1 ITLTPKVTCVWAISKDDPEVQFSWFV (DAP DDVEVHTAQTQPREEQFNSTFRSVSELPIM G)- HQDWLNGKEFKCRVNSAAFGAPIE mCD122 KTISKTKGRPKAPQVYTIPPPKKQMAKDKV SLTCMITDFFPEDITVEWQWNGQP AENYKNTQPIMKTDGSYFVYSKLNVQKSNW EAGNTFTCSVLHEGLHNHHTEKSL SHSPGPGSGSAVKNCSHLECFYNSRANVSC MWSHEEALNVTTCHVHAKSNLRH WNKTCELTLVRQASWACNLILGSFPESQSL TSVDLLOINWCWEEKGWRRVKTC DFHPFDNLRLVAPHSLQVLHIDTQRCNISW KVSQVSHYIEPYLEFEARRRLLGHS WEDASVLSLKQRQQVVLFLEMLIPSTSYEV QVRVKAQRNNTGTWSPWSQPLTFR TRPADPMKE (SEQ ID NO: 372) DNA542 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- MISRTPEVTCVVVDVSHEDPEVKFNWYVDG hIL2(R38A, VEVHNAKTKPREEQYASTYRVVSVLTVLHQ F42A; DWLNGKEYKCKVSNKALPAPIEKTISKAKG Y45A, QPREPQVYTLPPCRDELTKNQVSLWCLVKG E62A, FYPSDIAVEWESNGQPENNYKTTPPVLDSD C125A) GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGGSSGLLSGRSDQPSG PAPTSSSTKKTQLQLEHLLLDLQMILNGIN NYKNPKLTAMLTAKFAMPKKATELKHLQCL EEALKPLEEVLNLAQSKNFHLRPRDLISNI NVIVLELKGSETTFMCEYADETATIVEFLN RWITFAQSIISTLT (SEQ ID NO: 373) DNA543 Hole: GSGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWWDGV [VPLSLY]- ID SQDGALQDTSC EVHNAKTKPREEQYASTYRVVSVLWLHQDW hCD122 NO: QVHAWPDRRR LNGKEYKCKVSNKALPAPIEKTISKAKGQP 31) WNQTCELLPVS REPQVCTLPPSRDELTKNQVSLSCAVKGFY QASWACNLILG PSDIAVEWESNGQPENNYKTTPPVLDSDGS APDSQKLTTVDI FFLVSKLTVDKSRWQQGNVFSCSVMHEALH VTLRVLCREGVR NHYTQKSLSLSPGGPPSGSSPGVPLSLYGS WRVMAIQDFK QGGAVNGTSQFTCFYNSRANISCVWSQDGA PFENLRLMAPIS LQDTSCQVHAWPDRRRWNQTCELLPVSQAS LQVVHVETHRC WACNLILGAPDSQKLTTVDIVTLRVLCREG NISWEISQASHY VRWRVMAIQDFKPFENLRLMAPISLQVVHVE FERHLEFEARTL THRCNISWEISQASHYFERHLEFEARTISP SPGHTWEEAPL GHTWEEAPLLLIKQKQEWICLETITPDTQYE LTLKQKQEWICL FQVRVKPLQGEFTTWSPWSQPLAFRTKPAA ETLTPDTQYEFQ LGKD (SEQ ID NO: 42) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) DNA544 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ QLEHLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- ID LNGINNYKNPKL GVEVHNAHTKPREEQYASTYRVV5VLTVLH hIL2 NO: TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK (R38A, 29) KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, LAQSKNFHFDP DGSFFLYSKLTVOKSRWQQGNVFSCSVMHE E62A, RDWSNIMVFVL ALHNHYTQKSLSISPGGSPGVPLSLYSGPA L80F, SIKGSETTFMCE PTSSSTKKTQLQLEHLLLDLQMIING1NNY R81D, YADETATIVEFL KNPKLTAMLTAKFAMPKKATELKHLQCLEE L85V, NRWITFAQSII ALKPLEEVLNLAQSKNFHFDPRDWSNINVF I36V, STIT VLELKGSETTFMCEYADETATIVEFLNRWI I92F, (SEQ ID TFAQSIISTLT C125A) NO: 328) (SEQ ID NO: 375) DNA545 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc MISRTPEVTCVVVDVSHEDPEVKFNWYVDG (N297A)- VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2 PWLNGKEYKCKVSNKALPAPIEKHSKAKGQ (R38A, PRGPQVYTIPPCRDELTKNQVSLWCIVKGF F42A, YPSDIAVEWESNGQPENNYKTTPPVLDSDG Y45A, SFFLYSKLTVDKSRWQQGNVFSCSVMHEAL E62A, HNHYTQKSLSLSPGGISSGLLSGRSSGPAP C125A) TSSSTKKTQLQLEHLLLDLQMILNGINNYK NPKLTAMLTAKFAMPKKATELKHLQCLEEA LKPLEEVLNLAQSKNFHLRPRDLISNINVI VLELKGSETTFMCEYADETATIVEFLNRWI TFAQSIISTLT(SEQ ID NO: 376) DNA546 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LMISRTPEVTCVVVDVSHEDPEVKFNWYV (N297A)- DGVEVHNAKTKPREEQYASTYRWSVLTVLH hIL2 QDWINGKEYKCKVSNKALPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVQKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGG L30F, GSGPAPTSSSTKKTQLQLEHLLLDLQMILN R81D, GINNYKNPKLTAMLTAKFAMPKKATELKH I85V, LQCLEEALKPLEEVLNLAQSKNFHFDPRDV I86V, VSNINVFVLELKGSETTFMCEYADETATIV I32F, C125A) EFLNRWITFAQSHSTLT (SEQ ID NO: 377) DNA547 Hole: AVNGTSQFTCFYNSRANISCVW EPKSSDKTHTCPPCPAPELLGGPSV hFcIgG1 SQDGALQDTSCQVHAWPDRRR FLFPPKPKDTLMISRTPEVTCVVVD (N29 WNQTCELLPVSQASWACNLILG VSHEDPEVKFNWYVDGVEVHNAKTK 7A + EPKSS)- APDSQKLTTVDIVTLRVLCREGVR PREEQYASTYRVVSVLTVLHQDWLN Hole: WRVMAIQDFKPFENLRLMAPIS GKEYKCKVSNKALPAPIEKTISKAK hFc LQVVHVETHRCNISWEISQASHY GQPREPQVCLPPSRDELTKNQVSLS (N297A)- FERHLEFEARTLSPGHTWEEAPL CAVKGFYPSDIAVEWESNGQPENNY hCD122 LTLKQKQEWICLETLTPDTQYEFQ KTTPPVLDSDGSFFLVSKLTVCKSR VRVKPLQGEFTTWSPWSQPLAFR WQQGNVFSCSVMHEALHNHYTQKSL TKPAALGKD SLSPGPGSGSAVNGTSQFTCFYMSR (SEQ ID NO: 4) ANISCVWSQDGALQDTSCQVHAWPD RRRWNQTCELLPVSQASWACNLILG APDSQKLTTVDIVTLRVLCREGVRW RVMAIQDFKPFENLRLMAPISLQWH VETHRCNISWEISQASHYFERHLEF EARTLSPGHTWEEAPLLTLKQKQEW ICLETLTPDTQYEFQVRVKPLQGEF FTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 378) DNA548 Hole: AVNGTSQFTCFYNSRANISCVW AKTDKTHTCPPCPAPELLGGPSVFL hFcIgG1 SQDGALQDTSCQVHAWPDRRR FPPKPKDTLMISRTPEVTCVVVDVS (N29 WNQTCELLPVSQASWACNLILG HEDPEVKFNWYVDGVEVHNAKTKPR 7A + AK7)- APDSQKLTTVDIVTLRVLCREGVR EEQYASTYRVVSVLTVLHQDWLNGK Hole: WRVMAIQDFKPFENLRLMAPIS EYKCKVSNKALPAPIEKTISKAKGQ hFc LQVVHVETHRCNISWEISQASHY PREPQVCTLPPSRDELTKNQVSLSC (N297A)- FERHLEFEARTLSPGHTWEEAPL AVKGFYPSDIAVEWESNGQPENNYK hCD122 LTLKQKQEWICLETLTPDTQYEFQ TTPPVLDSDGSFFLVSKLTVDKSRW VRVKPLQGEFTTWSPWSQPLAFR QQGNVFSCSVMHEALHNHYTQKSLS TKPAALGKD LSPGPGSGSAVNGTSQFTCFYNSRA (SEQ ID NO: 4) NISCVWSQDGALQDTSCQVHAWPDR RRWNQTCELLPVSQASWACNLILGA PDSQKLTTVDIVTLRVLCREGVRWR VMAIQDFKPFENLRLMAPISLQVVH VETHRCNISWEISQASHYFERHLEF EARTLSPGHTWEEAPLLTLKQKQEW ICLETLTPDTQYEFQVRVKPLQGEF TTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 379) DNA549 Knob: PGSGS AVNGTSQFTCFYNSRANISCVW AKTEPKSSDKTHTCPPCPAPELLGG hFcIgG1 (SEQ SQDGALQDTSCQVHAWPDRRR PSVFLFPPKPKDTLMISRTPEVTCV (N29 ID WNQTCELLPVSQASWACNLILG VVDVSHEDPEVKFNWYVDGVEVHNA 7A +  NO: APDSQKLTTVDIVTLRVLCREGVR KTKPREEQYASTYRVVSVLTVLHQD AKTEPKSS)- 14) WRVMAIQDFKPFENLRLMAPIS WLNGKEYKCKVSNKALPAPIEKTIS hCD122 LQVVHVETHRCNISWEISQASHY KAKGQPREPQVCTLPPSRDEITKNQ FERHLEFEARTLSPGHTWEEAPL VSLSCAVKGFYPSDIAVEWESNGQP LTLKQKQEWICLETLTPDTQYEFQ ENNYKTTPPVLDSDGSFFLVSKLTV VRVKPLQGEFTTWSPWSQPLAFR DKSRWQQGNVFSCSVMHEALHNHYT TKPAALGKD QKSLSLSPGPGSGSAVNGTSQFTCF (SEQ ID NO: 4) YNSRANISCVWSQDGALQPTSCQVH AWPDRRRWNQTCELLPVSQASWACN LILGAPDSQKLTTVDIVTLRVLCRE GVRWRVMAIQDFKPFENLRLMAPIS LQWHVETHRCNISWEISQASHYFER HLEFEARTLSPGHTWEEAPLLTLKQ KQEWICLETLTPDTQYEFQVRVKPL QGEFTTWSPWSQPLAFRTKPAALGK D (SEQ ID NO: 380) DNA550 Knob: SGP APTSSSTKKTQL EPKSSDKTHTCPPCPAPELLGGPVF hFcIgG1 (SEQ QLEHLLLDLQMI LFPPKPKDTLMISRTPEVTCVVVDV (N29 ID LNGINNYKNPKL SHEDPEVKFNWY 7A + EPKSS)- NO: 29) TAMLTAKFAMP VDGVEVHNAKTKPREEQYASTFYRV hIL2 KKATELKHLQCL VSVLTVLHQDWLNGKEYKCKVSNKA (R38A, EEALKPLEEVLN LPAPIEKTISKAKGQPREPQVYTLP F42A, LAQSKNFHLRPR PCRDELTKNQVSLWCLVKGFYPSDI Y45A, DLISNINVIVLEL AVEWESNGQPENNYKTTPPVLDSDG E62A, KGSETTFMCEY SFFLYSKLTVDKSRWQQGNVFSCSV C125A) ADETATIVEFLN MHEALHNHYTQKSLSLSPGGSPGVP RWITFAQSIISTL LSLYSGPAPTSSSTKKTQLQLEHLL T LDLQMILNGINNYKNPKLTAMLTAK (SEQ ID FAMPKKATELKHLQCLEEALKPLEE NO: 3) VLNLAQSKNFHLRPRDLISNINVIV LELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 381) DNA551 Knob: SGP APTSSSTKKTQL AKTDKTHTCPPCPAPELLGGPSVFL hFcIgG1 (SEQ QLEHLLLDLQMI FPPKPKDTLMISRTPEVTCVVVDVS (N29 ID LNGINNYKNPKL HEDPEVKFNWYVDGVEVHNAKTRPR 7A +  NO: 29) TAMLTAKFAMP EEQYASTYRVVSVLTVLHQDWLNGK AKT)- KKATELKHLQCL EVKCKVSNKALPAPIEKTISKAKGQ [VPLSLY] EEALKPLEEVLN PREPQVYTLPPCRDELTKNQVSLWC hIL2 LAQSKNFHLRPR LVKGFYPSDIAVEWESNGQPENNYK (R38A, DLISNINVIVLEL TTPPVLDSDQSFFLYSKLTVDKSRW F42A, KGSETTFMCEY QQGIWFSCSVMHEALHNHYTQKSLS Y45A, ADETATIVEFLN LSPGGSPGVPLSLYSGPAPTSSSTK E62A, RWITFAQSIISTL KTQLQLEHLLLDLQMILNGINNYKN C125A) T PKLTAMLTAKFAMPKKATELKHLQC (SEQ ID LEEALKPLEEVLNLAQSKNFHLRPR NO: 3) DLISNINVIVLELKGSETTFMCEYA DETATIVEFLNRWITFAQSIISTLT (SEQ ID NO: 382) DNA552 Knob: SGP APTSSSTKKTQL AICTEPKSSDKTHTCPPCPAPELLG hFcIgG1 (SEQ QLEHLLLDLQMI GPSVFLFPPKPKDTLMISRTPEVTC (N29 ID LNGINNYKNPKL VVVDVSHEDPEVKFNWYVDGVEVHN 7A +  NO: 29) TAMLTAKFAMP AKTKPREEQYASTYRVVSVLTVLHQ AKTEPKSS)- KKATELKHLQCL DWLNGKEYKCKVSNKALPAPIEKLIS [VPLSLY] EEALKPLEEVLN KAKGQPREPQVYTLPPCRDELTKNQ hIL2 LAQSKNFHLRPR VSLWCLVKGFYPSDIAVEWESNGQP (E15R, DLISNINVIVLEL ENNYKTTPPVLDSDGSFFLYSKLTV L18C, KGSETTFMCEY DKSRWQQSNVFSCSVMHEALHNHYT D20R, ADETATIVEFLN QKSLSLSPGGSPGVPLSLYSGPAPT R38A, RWITFAQSIISTL SSSTKKTQLQLEHLLLDLQMILNGI F42A, T NNYKNPKLTAMLTAKFAMPKKATEL Y45A, (SEQ ID KHLQCLEEALKPLEEVLNLAQSKNF E62A, NO: 3) HLRPRDLISNINVIVLELKGSETTF N88L) MCEYADETATIVEFLNRWITFAQSI STLT(SEQ ID NO: 383) DNA553 Hole: SGGG AVNGTSQFTCFYNSRANISCVW DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ SQDGALQDTSCQVHAWPDRRR MISRTPEVTCVVVLWSHEDPEVKFNWYVDG [DSGGFMLT]- ID WNQTCELLPVSQASWACNLILG VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hCD122 NO: 30) APDSQKLTTVDIVTLRVLCREGVR DWLNGKEYKCKVSNKALPAPIEKTISKAKG WRVMAIQDFKPFENLRLMAPIS QPREPQVCTLPPSRDELTKNQVSLSCAVKG LQVVHVETHRCNISWEISQASHY FYPSDIAVEWESNGQPENNYKTTPPVLDSD FERHLEFEARTLSPGHTWEEAPL GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LTLKQKQEWICLETLTPDTQYEFQ LHNHYTQKSLSLSPGGPPSGSSPGDSGGFM VRVKPLQGEFTTWSPWSQPLAFR LTSGGGAVNGTSQFTCFYNSRANISCVWSQ TKPAALGKD DGALQDTSCQVHAWPDRRRWNQTCELLPVS (SEQ ID NO: 4) QASWACNLILGAPDSQKLTTVDIVTLRVLC REGVRWRVMAIQDFKPFENLRLMAPISLQV VHVETHRCNISWEISQASHYFERHLEFEAR TLSPGHTWEEAPLLTLKQKQEWICLETLTP DTQYEFQVRVKPLQGEFTTWSPWSQPLAFR TKPAALGKD (SEQ ID NO: 41) DNA554 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ QLRHLCLRLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- ID LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVITVLH hIL2 NO: 29) TAMLTAKFAMP QDWLNGKEYKCKV (E15R, L18C, KKATELKHLQCL SNKALPAPIEKTISKAKGQPREPQVYTLPP D20R, EEALKPLEEVIN CRDELTKNQVSLWCLVKGFYPSDIAVEWES R38A, LAQSKNFHLRPR NGQPENNYKTTPPVLDSDGSFFLYSKLTVD F42A, DLISNINVIVLEL KSRWQQGNVFSCSVMHEALHNHYTQKSLSL Y45A, KGSETTFMCEY SPGGSPGVPLSLYSGPAPTSSSTKKTQLQL E62A) ADETATIVEFLN RHLCLRLQMILNGINNYKNPKLTAMLTAKF RWITFCQSIISTL AMPKKATELKHLQCLEEALKPLEEVLNLAQ T SKNFHLRPRDLISNINVIVLELKGSETTFM (SEQ ID CEYADETATIVEFLNRWITFCQSIISTLT NO: 339) (SEQ ID NO: 385) DNA563 Knob: APTSSSTKKTQLQL DKTHTCPPCPAPELLGGPSVFLFPPK hFcIgG1 RHLCLSLQMILNGI PKDTLMISRTPEVTCVVVDVSHEDP (N297A) NNYKNPKLTAMLTA EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY]- KFAMPKKATELKH ASTYRVVSVLWLHQDWLNGKEYKCK hIL2 LQCLEEALKPLEEV VSNKALPAPIEKTISKAKGQPREPQ (R38A, LNLAQSKNFHLRPR VYTLPPCRDELTKNQVSLWCLVKGF F42A, DLISLINVIVLELK YPSDIAVEWESNGQPENNYKTTPPV Y45A, GSETTFMCEYADETA IDSDGSFFLYSKLWDKSRVYQQGNV E62A, TIVEFLNRWITFCQS FSCSVMHEALHNHYTQKSLSLSPGG C125A) IISTLT SPGVPLSLYSGPAPTSSSTKKTQLQ (SEQ ID LRMLCLRLQMILNGINNYKNPKLTA NO: 340) MLTAKFAMPKKATELKHLQCLEEAL KPLEEVLNLAQSKNFHLRPRDLISL INVIVLELKGSETTFMCEYAOETAT IVEFLNRWITFCQSIISTLT (SEQ ID NO: 386) DNA565 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPK hFc (SEQ QLLHLCLRLQMI PKDTLMISRTPEVTCVVVDVSHEDP (N297A) ID LNGINNYKNPKL EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY]- NO: 29) TAMLTAKFAMP ASTYRVVSVLWLHQDWLNGKEYKCK hIL2 KKATELKHLQCL VSNKALPAPIEKTISKAKGQPREPQ (E15R, EEALKPLEEVLN VCTLPPCRDELTKNQVSLWCLVKGF L18C, LAQSKNFHLRPR YPSDIAVEWESMGQPENNYKTTPPV D20R, DLISLINVIVLE LDSDGSFFLYSKLTVDKSRWQQGNV R38A, LKGSETTFMCEY FSCSVMHEALHNHYTQKSLSLSPGG F42A, ADETATIVEFLNR SPGVPLSLYSGPAPTSSSTKKTQLQ Y45A, WITFCQSIISTLT LLHLCLRLQMILNGINNYKNPKLTA E62A, (SEQ ID MLTAKFAMPKKATELKHLQCLEEAL N88L) NO: 341) KPLEEVLNLAQSKNFHLRPRDLISL INVIVLELKGSETTFMCEYADETAT IVEFLNRWITFCQSIISTLT (SEQ ID NO: 387) DNA566 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPK hFc (SEQ QLRHLCLDLQM PKDTLMISRTPEVTCVCCDVSHEDP (N297A)- ID ILNGINNYKNPK EVKFNWYVDGVEVHNAKTKPREEQY [VPLSLY] NO: 29) LTAMLTAKFAM ASTYRVVSVLTVLHQDWLNGKEYKC hIL2 PKKATELKHLQC KVSNKALPAPIEKTISKAKGQPREP (E15R, LEEALKPLEEVL QVYTLPPCRDELTKMQVSLWCLVKG L18C, NLAQSKNFHLR FYPSDIAVEWESNGQPENNYKTTPP R38A, PRDLISLINVIVL VLDSDGSFFLYSKLTVDKSRWQQGN F42A, ELKGSETTFMCE VFSCSVMHEALHNHYTQKSLSLSPG Y45A, YADETATIVEFL GSPGVPLSLYSGPAPTSSSTKKTQL E62A, NRWITFCQSIIS QLRHLCLDLQMILMGINNYKNPKLT N88L) TLT AMLTAKFAMPKKATELKHLQCLEEA (SEQ ID LKPLEEVLNWQSKNFHLRPRDLISL NO: 342) INVIVLELKGSETTFMCEYADETAT IVEFLNRVVITFCQSIISTLT (SEQ ID NO: 388) DNA565 Knob: APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFP hFc QLEHLCLRLQMI PKPKDTLMISRTPE (N297A) LNGINNYKNPKL VTCVVVDVSHEOPEVKFNWYVDGVE [VPLSLY]- TAMLTAKFAMP VHNAKTKPREEQYASTYRVVSVLTV hIL2 KKATELKHLQCL LHQDWLNGKEYKCKVSNKALPAPIE (L18C, EEALKPLEEVLN KTISKAKGQPREPQVYTLPPCRDEL D20R, LAQSKNFHLRPR TKMQVSLWCLVKGFYPSDIAVEWES R38A, DLISLINVIVLEL NGQPENNYKTTPPVLDSDGSFFLYS F42A, KGSETTFMCEYA KLTVDKSRWQQGNVFSCSVMHEALH Y45A, DETATIVEFINR NHYTQKSLSLSPGGSPGVPLSLYSG E62A, WITFCQSIISTLT PAPTSSSTKICTQLQLEHLCLRLQM N88L) (SEQ ID ILNGINNYKNPKLTAMLTAKFAMPK NO: 343) KATELKHLQCLEEALKPLEEVLNLA QSKNFHLRPRDLISLINVIVLELKG SETTFMCEYADETATIVEFLNRWIT FCQSIISTLT (SEQ ID NO: 389) DNA568 Knob: SGP APTSSSTKKT DKTHTCPPCPAPELLGGPSVFLFPPKPKDT HFc(N297A)- (SEQ QLQLFHLCLR LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- ID LQMILNGINN GVEVHNAKTKPREEQYASTYRWSVLTVLHQ hIL2(E15F, NO: 29) YKNPKLTAML DWLNGKEYKCKVSNKALPAPIEKTISKAKG L18C, D20R, TAKFAMPKKA QPREPQVYTIPPCRDEITKNQVSLWCIVKG R38A, F42A, TELKHLQCLE FYPSDIAVEWESNGQPENNYKTTPPVLDSD Y45A, E62A, EALKPLEEVLN GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA N88L) LAQSKNFHLRPR LHNHYTQKSLSLSPGGSPGVPLSLYSGPAP DLISLINVIVLE TSSSTKKTQLQLFHLCLRLQMILNGINNYK LKGSETTFMCEY NPKLTAMLTAKFAMPKKATELKHLQCLEEA ADETATIVEFLN LKPLEEVLNLAQSKNFHIRPRDLISLINVI RWITFCQSIIST VLELKGSETTFMCEYADETATIVEFLNRWI LT TFCQSIISTLT (SEQ ID NO: 390) (SEQ ID NO: 344) DNA575 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAIOKPREEQYASTYRVVSVLTVLH hCD122 QDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQPFK PFENLRIMAPISLQVVHVETHRCNISWEIS QASHYFERHLEFEARTLSPGHTWEEAPLLT LKQKQEWICLETLTPDTQYEFQVRVKPLQG EFTTVVSPVVSQPLAFRTKPAALGKD (SEQ ID NO: 43) DNA576 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LYITREPEVTCVVVDVSHEDPEVKFNWYVD (N297A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH M252Y, QDWLNGKEYKCKVSNKALPAPIEKTISKAK S254T, GQPREPQVCTLPPSRDELTKNQVSLSCAVK T256E)- GFYPSDIAVEWESNGQPENNYKTTPPVLDS hCD122 DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQVVHVETHRCNISWEISQ ASHYFERHLEFEARTISPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 392) DNA577 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, LMASRTPEVTCVVVDVSHEDPEVKFNWYVD I253A)- GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2 QDWLNGKEYKCKVSNKAIPAPIEKTISKAK (R38A, GQPREPQVYTLPPCRDELTKNQVSLWCLVK F42A, GFYPSDIAVEWESNGQPENNYKTTPPVLDS Y45A, DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG C125A) SGPAPTSSSTKKTQLQLEHLLLDLQMILNG INNYKNPKLTAMLTAKFAMPKKATELKHLQ CLEEALKPLEEVLNIAQSKNFHLRPRDIIS NINVIVLELKGSETTFMCEYADETATIVEF LNRWITFAQSIISTLT (SEQ ID NO: 393) DNA578 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc LYITREPEVTCVVVDVSHEDPEVKFNWYVD (N297A, GVEVHNAKTKPREEQYASTYRVVSVLTVLH M252Y, QDWLNGKEYKCKVSNKALPAPIEKTISKAK S254T, GQPREPQVCTLPPCRDELTKNQVSLWCLVK T256E)- GFYPSDIAVEWESNGQPENNYKTTPPVLDS hIL2 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE (R38A, ALHNHYTQKSLSLSPGGGSSPPGGGSSGGG F42A, SGPAPTSSSTKKTQLQLEHLILDLQMILNG Y45A, INNYKNPKLTAMLTAKFAMPKKATELKHLQ E62A, CEEALKPLEEVLNLAQSKNFHLRPRDLISN C125A) INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 394) DNA579 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297, (SEQ QLEHLLLDLQMI LMASRTPEVTCVVDVSHEDPEVKFNWYVDG I253A)- ID LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [VPLSLY]- NO: 29) TAMLTAKFAMP DWLNGKEYKCKVSNKALPAPIEKTISKAKG hIL2(R38A, KKATELKHLQCL QPREPQVYTLPPCRDELTKNQVSLWCAVKG F42A, EEALKPLEEVLN FYPSDIAVEWESNGQPE Y45A, LAQSKNFHLRPR NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ E62A, DLISNINVIVLEL QGNVFSCSVMHEALHNHYTQKSLSLSPGGS C125A) KGSETTFMCEY PGVPLSLYSGPAPTSSSTKKTQLQIEHLLL ADETATIVEFLN DLQMILNGINNYKNPKLTAMLTAKFAMPKK RWITFAQSIISTL ATELKHLQCLEEALKPLEEVLNLAQSKNFH T LRPRDLISNINVIVLELKGSETTFMCEYAD (SEQ ID ETATIVEFLNRWITFAQSIISTLT NO: 3) (SEQ ID NO: 50) DNA580 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A, (SEQ QLEHLLLDLQMI LYITREPEVTCVVVDVSHEDPEVKFNWYVD M252Y, ID LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH S2547, NO: 29) TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK T256E)- KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK [VPLSLY]- EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTPPVLD hIL2(R38A, LAQSKNFHLRPR SDGSFFLYSKLTVDKSRWQQGNVF F42A, DLISNINVIVLEL SCSVMHEALHNHYTQKSLSLSPGGSPGVPL Y45A, KGSETTFMCEY SLYSGPAPTSSSTKKTQLQLEHLLLDLQMI E62A, ADETATIVEFLN LNGINNYKNPKITAMLTAKFAMPKKATELK C125A) RWITFAQSIISTL HLQCLEEALKPLEEVLNLAQSKNFHLRPRD T LISNINVIVLELKGSETTFMCEYADETATI (SEQ ID VEFLNRWITFAQSIISTLT NO: 3) (SEQ ID NO: 396) DNA581 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLCLDLQM LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) ILNGINNYKNPK GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(L18C, L7AMLTAKFAM QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, PKKATELKHLQC GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A) LEEALKPLEEVL GFYPSDIAVEWESNGQPENNYKTTPPVLDS NLAQSKNFHLR DGSFFLY PRDLISNINVIVL SKLTVDKSRWQQGNVFSCSVMHEALKNHYT ELKGSETTFMCE QKSLSLSPGGSPGVPLSLYSGPAFTSSSTK YADETATIVEFL KTQLQLEHLCLDLQMILNGINNYKNPKLTA NRWITFCQSHST MLTAKFAMPKKATELKHIQCIEEALKPLEE LT VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID NO: 365) SETTFMCEYADETATIVEFLNRWITFCQSI ISTLT (SEQ ID NO: 397) DNA582 SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT (SEQ ID QLEYLLLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS LAQSKNFHLRPR DGSFFLY DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSISLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQLEYLLLDLQMILNGINNYKNPKLTA RWITFAQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID NO: 346) SETTFMCEYADETATIVEFLNRWITFAQSH STLT (SEQ ID NO: 398) DNA583 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELLLDLQMI LMISRTPEVTCVVVDVS [VPLSLY]- NO: 29) LNGINNYKNPKL HEDPEVKFNWYVDGVEVHNAKTKPREEQYA hIL2(H16E, TAMLTAKFAMP STYRVVSVLTVLHQDWLNGKEYKCKVSNKA R38A, F42A, KKATELKHLQCL LPAPIEKTISKAKGQPREPQVYTLPPCRDE Y45A, E52A, EEALKPLEEVIN LTKNQVSLW Cl25A) LAQSKNFHLRPR CLVKGFYPSDIAVEWESNGQPENNYIOTPP DLISNINVIVLEL VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS KGSETTFMCEY VMHEALHNHYTQKSLSLSPGGSPGVPLSLY ADETATIVEFLN SGPAPTSSSTKKTQLQLEELLLDLQMILNG RWITFAQSIISTL INNYKNPKLTAMLTAKFAMPKKATELKHLQ T CLEEALKPLEEVLNLAQSKNFHLRPRDLISN (SEQ ID NO: 347) INVIVLELKGSETTFMCEYADETATIVEFL NRWITFAQSIISTLT (SEQ ID NO: 399) DNA584 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLLLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2,(D20L, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E62A, EEALKPLEEVIN GFYPSDIAVEWESNGQPENNYKTTPPVLDS C125A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLLLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFAQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFAQSIISTLT (SEQ ID NO: 400) 348) DNA585 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLDLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGiNNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(H16Y, TAMLTAKFAMP QDWLNGKEYKCKVSNKALPAPIEKTISKAK R38A, F42A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKNQVSLWCLVK Y45A, E52A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS Cl25A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEYLCLDLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCEYADETATIVEFLNRW (SEQ ID NO: ITFCQSIISTLT (SEQ ID NO: 401) 349) DNA586 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLDLQMI LMISRTPEVTCVVVDVSHEOPEV [VPLSLY]- NO: 29) LNGINNYKNPKL KFNWYVDGVEVHNAKTKPREEQYASTYRVV hIL2(H16E, TAMLTAKFAMP SVLTVLHQDVVLNGKEYKCKVSNKALPAPI L18C, R38A, KKATELKHLQCL EKTISKAKGQPREPQVYTLPPCRDELTKNQ F42A, Y45A, EEALKPLEEVLN VSLWCLVKGFYPSDIAVEWESNGQPEN E62A) LAQSKNFHLRPR NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ DLISNINVIVLEL GNVFSCSVMHEALHNHYTQKSLSLSPGGSP KGSETTFMCEY GVPLSLYSGPAPTSSSTKKTQLQLEELCLD ADETATIVEFLN LQMILNGINNYKNPKLTAMLTAKFAMPKKA RWITFCQSIISTL TELKHLQCLEEALKPLEEVLNLAQSKNFHL (SEQ ID NO: RPRDLISNINVIVLELKGSETTFMCEYADE 350) TATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 402) DNA587 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEHLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAKTKPREEQYASTYRVVSVLTVLH hIL2(L18C, TAMLTAKFAMP QPWLNGKEYKCKVSNKALPAPIEKTISKAK D20L, R38A, KKATELKHLQCL GQPREPQVYTLPPCRDELTKMQVSLWCLVK F42A, Y45A, EEALKPLEEVLN GFYPSDIAVEWESMGQPENNYKTTPPVLDS E62A) LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEHLCLLLQMILNGINNY ADETATIVEFLN KNPKLTAMLTAKFAMPKKATELKHLQCLEE RWITFCQSIISTL ALKPLEEVLNLAQSKNFHLRPRDLISNINV T IVLELKGSETTFMCBYADETATIVEFLNRW (SEQ ID NO: 351) ITFCQSIISTLT (SEQ ID NO: 403) DNA588 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEYLCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [VPLSLY]- NO: 29) LNGINNYKNPKL GVEVHNAICTKPREEQYASTYRVVSVLTVL hIL2(H16Y, TAMLTAKFAMP HQDWLNGKEYKCKVSNKALPAPIEKTISKA L18C, KKATELKHLQCL KGQPREPQVYTLPPCRDELTKNQVSLWCLV D20L, R38A, EEALKPLEEVLN KGFYPSDIAVEWESNGQPENNYKTTPPVLD F42A, Y45A, LAQSKNFHLRPR SDGSFFLY E62A) DLISNINVIVLEL SKLTVDKSRWQQGNVFSCSVMHEALHNHYT KGSETTFMCEY QKSLSLSPGGSPGVPLSLYSGPAPTSSSTK ADETATIVEFLN KTQLQIEYLCLLLQMILNGINNYKNPKLTA RWITFCQSIISTL MLTAKFAMPKKATELKHLQCLEEALKPLEE T VLNLAQSKNFHLRPRDLISNINVIVLELKG (SEQ ID SETTFMCEYADETATIVEFLNRWITFCQSI NO: 352) ISTLT (SEQ ID NO: 404) DNA589 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID QLEELCLLLQMI LMISRTPEVTCVVVDVSHEDPEVKFNWWDG [VPLSLY]- NO: 29) LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hIL2(H16E, TAMLTAKFAMP DWLNGKEVKCKVSNKALPAPIFKTISKAKG L18C, KKATELKHLQCL QPRFPQVYTLPPCRDELTKNQVSIAVCLVK D20L, R38A, EEALKPLEEVLN GFYPSDIAVEWESNGQPENNYKTTPPVLDS F42A, Y45A, LAQSKNFHLRPR DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE E62A) DLISNINVIVLEL ALHNHYTQKSLSLSPGGSPGVPLSLYSGPA KGSETTFMCEY PTSSSTKKTQLQLEELCLLLQMILNGINNY ADETATIVEFLN KNPKLT RWITFCQSIISTL AMLTAKFAMPKKATELKHLQCLEEALKPLE T (SEQ ID NO: EVLNLAQSKNFHLRPRDLISNINVIVLELK 353) GSETTFMCEYADETATIVEFLNRWITFCQS IISTLT (SEQ ID NO: 405) DNA603 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4- DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hCD122 VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSL GPGSGSAVNGTSQFTCFYNSRANISCVWSQ DGALQDTSCQVHAWPDRRRWNQTCELLPVS QASWACNLILGAPDSQKLTTVDIVTLRVLC REGVRWRVMAIQDFKPFENLRLMAPISLQW HVETHRCNISW EISQASHYFERHLEFEARTLSPGHTWEEAP LLTLKQKQEWICLETLTPDTQYEFQVRVKP LQGEFTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 406) DNA604 Knob: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK IgG4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY hFc- VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hIL2(R38A, LHQDWLNGKEYKCKVSNKGLPSSIEKTISK F42A, Y45A, AKGQPREPQVYTLPPCQEEMTKNQVSLWCL E62A, C125A) VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGGGSSPPGGGSSG GGSGPAPTSSSTKKTQLQLEHLLLDLQMIL NGINNYKNPKLTAMLTAKFAMPKKATELKH LQCLEEALKPLEEVLNLAQSKNFHLRPRDL ISNINVIVLELKGSETTFMCEYADETATIV EFLNRWITFAQSIISTLT (SEQ ID NO: 407) DNA605 Knob: SGP APTSSSTKKTQL ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIgG4-hIL2- (SEQ ID QLEHLLLDLQMI DTLMISRTPEVTCVVVDVSQEDPEVQFNWY [VPLSLY]- NO: 29) LNGINNYKNPKL VDGVEVHNAKTKPREEQFNSTYRVVSVLTV hIL2(R38A, TAMLTAKFAMP LHQDWLMGKEYKCKVSNKGLPSSIEKTISK F42A, Y45A, KKATELKHLQCL AKGQPREPQVYTLPPCQEEMTKNQVSLWCL E62A, C125A) EEALKPLEEVLN VKGFYPSDIAVEWESMGQPENNYKTTPPVL LAQSKNFHLRPR DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM DLISNINVIVL HEALHNHYTQKSLSLSLGGSPGVPLSLYSG ELKGSETTFMC PAPTSSSTKKTQLQLEHLLLDLQMILNGIN EYADETATIVEF NYKNPKLTAMLTAKFAMPKKATELKHLQCL LNRWITFAQSII EEALKPLEEVLNLAQSKNFHLRPRDLISNI STLT NVIVLELKGSETTFMCEYAOETATIVEFLN (SEQ ID RWITFAQSIISTLT (SEQ ID NO: 408) NO: 3) DNA606 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ YNSRANISCVW MISRTPEYTCVVVDVSHEDPEVKFNWYVDG [RAAAVKSP] ID SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hCD122 NO: QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG 30) WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESMGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPRAAAVKS WRVMAIQDFK PSGGGAVNGTSQFTCFYNSRANISCVLVSQ PFENLRLMAPIS OGALQDTSCQVHAWPDRRRWNQTCELLPVS LQVVHVETHRC QASWACNLILGAPDSQKLTTVDIVTLRVLC NISWEISQASHY REGVRWRVMAIQDFKPFENLRLMAPISLQV FERHLEFEARTL VHVETHRCNISWEISQASHYFERHLEFEAR SPGHTWEEAPL TLSPGHTWEEAPLLTLKQKQEWICLETLTP LTLKQKQEWICL DTQYEFQVRVKPLQGEFITWSPWSQPLAFR ETLTPDTQYEFQ TKPAALGKD (SEQ ID NO: 409) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) DNA608 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A, (SEQ YNSRANISCVW MASRTPEVTCVVVDVSHEDPEVKFNWYVDG I253A)- ID SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [MPYDLYHP]- NO: QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG hCD122 30) WNQTCELLPVS OPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPMPYDLYH WRVMAIQDFK PSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQVVHVETHRC ASWACNLILGAPDSQKLTTVDIVTLRVLCRE NISWEISQASHY GVRWRVMAIQDFKPFENLRLMAPISLQVVH FERHLEFEARTL VETHRCNISWEISQASHYFERHLEFEARTL SPGHTWEEAPL SPGHTWEEAPLLTLKQKQEWICLETLTPDT LTLKQKQEWICL QYEFQVRVKPLQGEFTTWSPWSQPLAFRTK ETLTPDTQYEFQ PAALGKD (SEQ ID NO: 410) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) DNA609 Hole: GSGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A, (SEQ YNSRANISCVW MASRTPEVTCVVVDVSHEDPEVKFNWWDGV I253A)- ID SQDGALQDTSC EVHNAKTKPREEQYASTYRVVSVLTVLHQD [VPLSLY]- NO: QVHAWPDRRR WLNGKEYKCKVSNKALPAPIEKTISKAKGQ hCD122 31) WNQTCELLPVS PREPQVCTLPPSRDELTKNQVSLSCAVKGF QASWACNLILG YPSDIAVEVVESNGQPENNYKTTPPVLDSD APDSQKLTTVDI 6SFFLVSKLTVDKSRWQQGNVFSCSVMHEAL VTLRVLCREGVR HNHYTQKSLSLSPGGPPSGSSPGVPLSLYG WRVMAIQDFK SGGGAVNGTSQFTCFYNSRANISCVWSQDG PFENLRLMAPIS ALQDTSCQVHAWPDRRRWNQTC LQVVHVETHRC ELLPVSQASWACNLILGAPDSQKLTTVDIV NISWEISQASHY TLRVLCREGVRWRVMAIQDFKPFENLRLMA FERHLEFEARTL PISLQVVHVETHRCNISWEISQASHYFERH SPGHTWEEAPL LEFEARTLSPGHTWEEAPLLTLKQKQEWIC LTLKQKQEWICL LETLTPDTQYEFQVRVKPLQGEFTTWSPWS ETLTPDTQYEFQ QPLAFRTKPAALGKD VRVKPLQGEFTT (SEQ ID NO: 411) WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) DNA612 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297A)- (SEQ ID YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWYVDG [MPYDLYHP]- NO: 30) SQDGALQDTSC VEVHNAKTKPREEQYASTYRVVSVLTVLHQ hCD122 QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG (C122S, WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG C168S) QASWACNLILG FYPSQIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPMPYDLYH WRVMAIQDRC PSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQWHVETHRS ASWACIMLILGAPDSQKLTTVDIVTLRVLC NISWEISQASHY REGVRWRVMAIQDFKPFENLRLMAPISLQV FERHLEFEARTL VHVETHRSNISWEISQASHYFERHLEFEAR SPGHTWEEAPL TISPGHTWEEAPLLTIKQKQEWISLETLTP LTLKQKQEWISL DTQYEFQVRVKPLQGEFTTWSPWSQPLAFR ETLTPDTQYEFQ TKPAALGKD (SEQ ID NO: 40) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 5) ANA614 Hole: SGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc(N297A)- (SEQ ID YNSRANISCVW LMISRTPEVTCVVVDVSHEDPEVKFNWYVD [DSGGMLT]- NO: 30) SQDGALQDTSC GVEVHNAKTKPREEQYASTYRVVSVLTVLH hCD122 QVHAWPDRRR QDWLNGKEYKCKVSNKALPAPIEKTISKAK (C122S, WNQTCELLPVS GQPREPQVCTLPPSRDELTKNQVSLSCAVK C168S) QASWACNLILG GFYPSQIAVEWESNGQPENNYKTTPPVLDS APDSQKLTTVDI DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE VTLRVLCREGVR ALHNHYTQKSLSLSPGGPPSGSSPGDSGGF WRVMAIQDRC MLTSGGGAVNGTSGFTCFYNSRANISCVWS PFENLRLMAPIS QDGALQDTSCQVHAWPDRRRWNQTCELLPV LQWHVETHRS SQASWACNLILGAPDSQKLTTVDIVTLRVL NISWEISQASHY CREGVRWRVMAIQDFKPFENLRLMAPISLQ FERHLEFEARTL VVHVETHRSNISWEISQASHYFERHLEFEA SPGHTWEEAPL RTLSPGHTWEEAPLLTLKQKQEWISLETIT LTLKQKQEWISL PDTQYEFQVRVKPLQGEFTTWSPWSQPLAF ETLTPDTQYEFQ RTKPAALGKD (SEQ ID NO: 413) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 5) DNA623 Knob: SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDTL hFc(N297, (SEQ QLEHLLLDLQMI MASRTPEVTCVVVDVSHEDPEVKFNWYVDG I253A)- ID LNGINNYKNPKL VEVHNAKTKPREEQYASTYRVVSVLTVLHQ [MPYDLYHP] NO: TAMLTAKFAMP PWLNGKEYKCKVSNKALPAPIEKTISKAKG hIL2 29) KKATELKHLQCL QPREEQVYTLPPCRDELTKNQVSLWCLVKG (R38A, EEALKPLEEVLN FYPSDIAVEWESNGQPENNYKTTPPVLDSD F42A, LAQSKNFHLRPR GSFFLYSKLTVDKSRWQQGNVFSCSVMHEA Y45A, DLISNINVIVL LHNHYTOKSLSLSPGGGSSPPMPYDLYHPS E62A, ELKGSETTFMC GPAPTSSSTKKTQLQLEHLLLDLQMILNGI C125A) EYADETATIVEF NNYKNPKLTAMLTAKFAMPKKATELKHLQC LNRWITFAQSII LEEALXPLEEVLNLAQSKNFHLRPRDLISN STLT INVIVLELKGSETTFMCEYADETATIVEFL (SEQ ID NRWITFAQSIISTLT NO: 3) (SEQ ID NO: 415) DNA625 Hole: DKTHTCPPCPAPELLGGPSVFLFPP hFc(N297, KPKDTLMASRTPEVTCVVVDVSHEQ I253A) PEVKFNWYVDGVEVHNAKTKPREEQ YASTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFIVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 10) DNA626 Hole: ESKYGPPCPPCPAPEFLGGPSVFLFPPKPK hFcIGg4 DTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVCTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVM HEALHNHYTQKSLSLSLGPG (SEQ ID NO: 298) DNA669 Hole: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc- LMISRTPEVTCVVVDVSHEDPEVKFNWYVD hCD122 GVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWINGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHMHYTQKSLSLSPGPGSGSAVNGTSQFT CFYNSRANISCVWSQDGALQDTSCQVHAWP DRRRWNQTCELLPVSQASWACNLILGAPDS QKLTTVDIVTLRVLCREGVRWRVMAIQDFK PFENLRLMAPISLQWHVETHRCNISWEISQ ASHYFERHLEFEARTLSPGHTWEEAPLLTL KQKQEWICLETLTPDTQYEFQVRVKPLQGE FTTWSPWSQPLAFRTKPAALGKD (SEQ ID NO: 422) DNA670 Knob: DKTHTCPPCPAPELLGGPSVFLFPPKPKDT hFc- LMISRTPEVTCWVDVSHEDPEVKFNWYVDG hIL2(R38A, VEVHNAKTKPREEQYNSTYRWSVLTVLHQD F42A, Y45A, WLNGKEYKCKVSNKALPAPIEKTISKAKGQ E62A, C125A) PREPQWTLPPCRDELTKNQVSLWCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGGGSSPPGGGSSGGGSGP APTSSSTKKTQLQLEHLLLDLQMILNGINN YKNPKLTAMLTAKFAMPKKATELKHLQCLE EALKPLEEVLNLAQSKNFHLRPRDLISNIN VIVLELKGSETTFMCEYADETATIVEFLNR WITFAQSIISTLT (SEQ ID NO: 423) DNA671 Knob: hFc- SGP APTSSSTKKTQL DKTHTCPPCPAPELLGGPSVFLFPPKPKDT [VPLSLY]- (SEQ ID QLEHLLLDLQMI IMISRTPEVTCVVVDVSHEDPEVKFNWYV hIL2 NO: 29) LNGINNYKNPKL DGVEVHNAKTKPREEQYNSTYRVVSV (R38A, F42A, TAMLTAKFAMP LTVLHQDWLNGKEYKCKVSNKALPAPIEKT Y45A, E62A, KKATELKHLQCL ISKAKGQPREPQVYTLPPCRDELTKNQVSL C125A) EEALKPLEEVLN WCLVKGFYPSDIAVEWESNGQPENNYKTTP LAQSKNFHLRPR PVLCSDGSFFLYSKLTVDKSRWQQGNVFSC DLISNINVIVLEL SVMHEALHNHYTQKSLSLSPGSSPGVPLSL KGSETTFMCEY YSGPAPTSSSTKKTQLQLEHLLLDLQMILN ADETATIVEFLN GINNYKNPKLTAMLTAKFAMPKKATELKHL RWITFAQSIISTL QCIEEALKPLEEVLNLAQSKNFHIRPRDLI T SNINVIVLELKGSETTFMCEYADETATIVE (SEQ ID FLNRWITFAQSRSTLT NO: 3) (SEQ ID NO: 424) DNA672 Hole: hFc- GSGGG AVNGTSQFTCF DKTHTCPPCPAPELLGGPSVFIFPPKPKDTL [VPLSLY]- (SEQ YNSRANISCVW MISRTPEVTCVVVDVSHEDPEVKFNWYVDG hCD122 ID SQDGALQDTSC VEVHNAKTKPREEQYNSTYRVVSVLTVLHQ NO: QVHAWPDRRR DWLNGKEYKCKVSNKALPAPIEKTISKAKG 31) WNQTCELLPVS QPREPQVCTLPPSRDELTKNQVSLSCAVKG QASWACNLILG FYPSDIAVEWESNGQPENNYKTTPPVLDSD APDSQKLTTVDI GSFFLVSKLTVDKSRWQQGNVFSCSVMHEA VTLRVLCREGVR LHNHYTQKSLSLSPGGPPSGSSPGVPLSLY WRVMAIQDFK GSGGGAVNGTSQFTCFYNSRANISCVWSQD PFENLRLMAPIS GALQDTSCQVHAWPDRRRWNQTCELLPVSQ LQVVHVETHRC ASWACNLILGAPDSQKLTTVDIVTIRVLCR NISWEISQASHY EGVRWRVMAIQDFKPFENLRLMAPISLQVV FERHLEFEARTL HVETHRCNISWEISQASHYFERHLEFEART SPGHTWEEAPL LSPGHTWEEAPLITIKQKQEWSCIETITPD LTLKQKQEWICL TQYEFQVRVKPLQGEFTTWSPWSQPLAFRT ETLTPDTQYEFQ KPAALGKD (SEQ ID NO: 425) VRVKPLQGEFTT WSPWSQPLAFR TKPAALGKD (SEQ ID NO: 4) 

1. A polypeptide drug construct comprising (i) a therapeutic moiety; (ii) a carrier moiety and (iii) a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
 2. A polypeptide drug construct according to claim 1, wherein the proteolytically cleavable peptide (CP) is flanked on both sides by a spacer domain (SD1 and SD2) as shown in formula: SD1-CP-SD2. 3.-5. (canceled)
 6. A polypeptide drug construct according to claim 2, wherein the first spacer domain (SD1) and/or second spacer domain (SD2) is between 3 and 6 amino acids in length. 7.-15. (canceled)
 16. A polypeptide drug construct according to claim 1, wherein the proteolytically cleavable peptide linker is covalently bonded directly to the therapeutic moiety. 17.-19. (canceled)
 20. A polypeptide drug construct according to claim 1, wherein the polypeptide drug construct comprises more than one polypeptide chain. 21.-23. (canceled)
 24. A polypeptide drug construct according to claim 1, further comprising a masking moiety. 25.-26. (canceled)
 27. A polypeptide drug construct according to claim 1, wherein the polypeptide drug construct comprises a half-life extension moiety. 28.-31. (canceled)
 32. A masked cytokine comprising: a) a first polypeptide chain comprising a masking moiety linked to a first half-life extension moiety via a first linker; and b) a second polypeptide chain comprising a cytokine moiety thereof linked to a second half-life extension moiety via a second linker, wherein the first half-life extension moiety is associated with the second half-life extension moiety, and wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
 33. A masked cytokine according to claim 32, wherein the first polypeptide chain comprises: N′HL1-L1-MM C′ and the second polypeptide chain comprises: N′HL2-L2-C C′ where HL1 is the first half life extension domain, L1 is the first linker, MM is the masking moiety, HL2 is the second half life extension domain, L2 is the second linker, and C is the cytokine moiety, wherein the first half-life extension moiety is associated with the second half-life extension moiety, and wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. 34.-35. (canceled)
 36. A masked cytokine comprising a polypeptide chain comprising formula: N′HL-L2-C-L1-MM C′ where HL is the half-life extension domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety, wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
 37. A masked cytokine comprising a polypeptide chain comprising formula: N′HL-L2-MM-L1-C C′ where HL is the half-life extension domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety thereof, wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
 38. A masked cytokine according to claim 32, wherein the proteolytically cleavable peptide (CP) is flanked on both sides by a spacer domain (SD1 and SD2) as shown in formula: SD1-CP-SD2. 39.-51. (canceled)
 52. A masked cytokine according to claim 36, wherein the second linker is a cleavable or non-cleavable linker. 53.-56. (canceled)
 57. A masked cytokine according to claim 36, wherein the half-life extension domain comprises a first half life extension domain and a second half life extension domain. 58.-69. (canceled)
 70. A masked cytokine according to claim 32, wherein the cytokine moiety is an IL-2 cytokine moiety. 71.-83. (canceled)
 84. A masked cytokine according to claim 32, wherein the cytokine moiety is an IL-12 cytokine moiety. 85.-115. (canceled)
 116. A masked cytokine according to claim 32, wherein the cytokine moiety is an IL-15 cytokine moiety. 117.-154. (canceled)
 155. A cleavage product comprising an active therapeutic moiety, preparable by proteolytic cleavage of the proteolytically cleavable linker in a polypeptide drug construct according to claim
 1. 156.-162. (canceled)
 163. A host cell comprising a nucleic acid encoding a masked cytokine of claim
 32. 164.-182. (canceled)
 183. A method of treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of a polypeptide drug construct according to claim
 1. 184.-203. (canceled) 